

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A01H 1/00, C07H 21/04, C07K 14/00, C12N 5/04, 5/10, C12P 19/34, C12Q 1/68</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/30083 (43) International Publication Date: 16 July 1998 (16.07.98)</p>
<p>(21) International Application Number: PCT/US98/00615 (22) International Filing Date: 9 January 1998 (09.01.98) (30) Priority Data: 08/781,734 10 January 1997 (10.01.97) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US). (72) Inventors: SHEN, Kathy; 44228 Country Club Drive, El Macero, CA 95618 (US). MEYERS, Blake; 904 Drake Drive, Davis, CA 95616 (US). MICHELMORE, Richard, W.; 36757 Russel Boulevard, Davis, CA 95616 (US). (74) Agents: EINHORN, Gregory, P. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).</p>	<p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>	
<p>(54) Title: RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS (57) Abstract The present invention provides RG nucleic acids and proteins which confer disease resistance to plants. The nucleic acids can be used to produce transgenic plants resistant to pests. Antibodies to proteins of the invention are also provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LR	Liberia	SD	Sudan		
DK	Denmark			SE	Sweden		
EE	Estonia			SG	Singapore		

RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS

5

The present application is a continuation-in-part application ("CIP") of U.S. Patent Application Serial No. ("USSN") 08/781,734, filed January 10, 1997. The
10 aforementioned application is explicitly incorporated herein by reference in its entirety and for all purposes.

This invention was made with Government support under Grant Nos. 92-37300-7547 and 95-37300-1571, awarded by the United States Department of Agriculture.
15 The Government has certain rights in this invention.

FIELD OF THE INVENTION

The present invention relates generally to plant molecular biology. In particular, it relates to nucleic acids and methods for conferring pest resistance in plants.
20 particularly lettuce.

BACKGROUND OF THE INVENTION

Recently, several resistance genes have been cloned by several groups from several plants. Many of these genes are sequence related. The derived amino acid
25 sequences of the most common class, *RPS2*, *RPM1* (bacterial resistances in *Arabidopsis* (Mindrinos *et al.* *Cell* 78:1089-1099 (1994)); Bent *et al.* *Science* 265:1856-1860 (1994); Grant *et al.*, *Science* 269:843-846 (1995)), *L6* (fungal resistance in flax; Lawrence, *et al.*, *The Plant Cell* 7:1195-1206 (1995)), and *N*, (virus resistance in tobacco; Whitham, *et al.*, *Cell* 78:1101-1115 (1994); and U.S. Patent No. 5,571,706), all contain leucine-rich
30 repeats (LRR) and nucleotide binding sites (NBS).

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

LRR domains can mediate protein-protein interactions and are found in a variety of proteins involved in signal transduction, cell adhesion and various other functions. LRRs are leucine rich regions often comprising 20-30 amino acid repeats where leucine and other aliphatic residues occur periodically. LRRs can function extracellularly or intracellularly.

Since the onset of civilization, plant diseases have had catastrophic effects on crops and the well-being of the human population. Plant diseases continue to effect enormous human and economic costs. An increasing human population and decreasing amounts of arable land make all approaches to preventing and treating plant pathogen destruction critical. The ability to control and enhance a plant's protective responses against pathogens would be of enormous benefit. Tissue-specific and temporal control of mechanisms responsible for plant cell death would also be of great practical and economic value. The present invention fulfills these and other needs.

What is needed in the art are plant disease resistance genes and means to create transgenic disease resistance plants, particularly in lettuce. Further, what is needed in the art is a means to DNA fingerprint cultivars and germplasm with respect to their disease resistance haplotypes for use in plant breeding programs. The present invention provides these and other advantages.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acid constructs. These constructs comprise an RG (resistance gene) polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and an RG4 polypeptide. RG1, RG2, RG3, RG4, and the like, represent individual "RG families." Each "RG family," as defined herein, is a group of polypeptide sequences that have at least 60% amino acid sequence identity. Individual members of an RG family, *i.e.*, individual species of the genus, typically map to the same genomic locus. The invention provides for constructs comprising nucleotides encoding the RG families of the

invention, which can include sequences encoding a leucine rich region (LRR), and/or a nucleotide binding site (NBS), or both.

The invention provides for an isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence
5 identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide. In alternative embodiments, the nucleic acid construct comprises an RG polynucleotide which encodes an RG polypeptide comprising an leucine rich region (LRR), or, an RG polypeptide comprising a nucleotide binding site
10 (NBS). The nucleic acid construct can comprise a polynucleotide which is a full length gene. In another embodiment, the nucleic acid construct encodes a fusion protein.

In one embodiment, the nucleic acid construct comprises a sequence encoding an RG1 polypeptide. The RG1 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 and
15 SEQ ID NO:137 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

In another embodiment, the nucleic acid construct comprises a sequence encoding an RG2 polypeptide. The RG2 polypeptide can be encoded by a polynucleotide
20 sequence selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87
25 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N);
30 SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In other embodiments, the nucleic acid construct comprises a RG3 sequence (SEQ ID NO:68) encoding an RG3 polypeptide (SEQ ID NO:138) (RG3). In other embodiments, the nucleic acid construct comprises an RG4 sequence (SEQ ID NO:69) encoding an RG4 polypeptide (SEQ ID NO:139) (RG4).

5 In other embodiments, the nucleic acid construct comprises a RG5 sequence (SEQ ID NO:134) encoding an RG5 polypeptide (SEQ ID NO:135). The RG5 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

The invention also provides for a nucleic acid construct which comprises an RG7 sequence encoding an RG7 polypeptide. The RG7 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.

10 In further embodiments, the nucleic acid construct can further comprise a promoter operably linked to the RG polynucleotide. In alternative embodiments, the promoter can be a plant promoter; a disease resistance promoter; a lettuce promoter; a constitutive promoter; an inducible promoter; or, a tissue-specific promoter. The nucleic acid construct can comprise a promoter sequence from an RG gene linked to a heterologous polynucleotide.

The invention also provides for a transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide. The expression cassette can comprise a plant promoter or a viral promoter; the plant promoter can be a heterologous promoter. In one embodiment, the transgenic plant is lettuce. In alternative embodiments, the transgenic plant comprises an expression cassette which includes an RG polynucleotide selected from the group consisting of SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO: 3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J); SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104

(RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W); SEQ ID NO:68 (RG3); SEQ ID NO:69 (RG4); SEQ ID NO:134 (RG5); or SEQ ID NO:136 (RG7).

The invention provide for a transgenic plant comprising an expression cassette comprising an RG polynucleotide which can encode an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W); an RG4 polypeptide as set forth by SEQ ID NO:72; an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135; or, an RG7 polypeptide.

The invention also provides for a method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence. In this method, the plant can be a lettuce plant; and, the RG polynucleotide can encode an RG polypeptide selected from the group consisting of an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID

NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:72; SEQ ID NO:74; SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W). In this method, the promoter can be a plant disease resistance promoter, a tissue-specific promoter, a constitutive promoter, or an inducible promoter.

The invention also provides for a method of detecting RG resistance genes in a nucleic acid sample, the method comprising: contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and, wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample. In this method, the RG polynucleotide can be an RG1 polynucleotide, an RG2 polynucleotide, an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide. In this method, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide, and, the RG resistance gene can be amplified by the polymerase chain reaction. In one embodiment, the RG polynucleotide is labeled.

The invention further provides for an RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification, the figures and claims.

5 All publications, patents and patent applications cited herein are hereby expressly incorporated by reference for all purposes.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to families of RG genes, particularly from *Lactuca sativa*. Nucleic acid sequences of the present invention can be used to confer resistance in
10 plants to a variety of pests including viruses, fungi, nematodes, insects, and bacteria. Sequences from within the RG genes can be used to fingerprint cultivars or germplasm for the presence of desired resistance genes. Promoters of RG genes can be used to drive heterologous gene expression under conditions in which RG genes are expressed. Further, the present invention provides RG proteins and antibodies specifically reactive to RG
15 proteins. Antibodies to RG proteins can be used to detect the type and amount of RG protein expressed in a plant sample.

The present invention has use over a broad range of types of plants, including species from the genera *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*,
20 *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Zea*, *Avena*, *Hordeum*, *Secale*,
25 *Triticum*, and, *Sorghum*. In particularly preferred embodiments, species from the family *Compositae* and in particular the genus *Lactuca* are employed such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

The nucleic acids of the present invention can be used in marker-aided selection. Marker-aided selection does not require the complete sequence of the gene or
30 precise knowledge of which sequence confers which specificity. Instead, partial sequences can be used as hybridization probes or as the basis for oligonucleotide primers to amplify nucleic acid, e.g., by PCR. Partial sequences can be used in other methods, such as to

follow the segregation of chromosome segments containing resistance genes in plants. Because the RG marker is the gene itself, there can be negligible recombination between the marker and the resistance phenotype. Thus, RG polynucleotides of the present invention provide an optimal means to DNA fingerprint cultivars and wild germplasm with respect to their disease resistance haplotypes. This can be used to indicate which germplasm accessions and cultivars carry the same resistance genes. At present, selection of plants (e.g., lettuce) for resistance to some diseases is slow and difficult. But linked markers allow indirect selection for such resistance genes. Moreover, RG markers also allow resistance genes to be identified and combined in a manner that would not otherwise be possible. Numerous accessions have been identified that provide resistance to all isolates of downy mildew (*Bremia lactucae*). However, without molecular markers it is impossible to combine such resistances from different sources. The nucleic acid sequences of the invention provide for a fast and convenient means to identify and combine resistances from different sources. The RG markers of the invention can also be used to identify recombinants that have new combinations of resistance genes in *cis* on the same chromosome.

In addition, RG markers may allow the identification of the Mendelian factors determining traits, such as field resistance to downy mildew. Once such markers have been identified, they will greatly increase the ease with which field resistance can be transferred between lines and combined with other resistances.

In another application, primers to RG sequences can be also designed to amplify sequences that are conserved in multiple RG family members. This gives genetic information on multiple RG family members. Alternatively, one or more primers can be made to sequences unique to a single resistance gene genus or a single RG specie. This allows an analysis of individual family groups (an RG genus) or an individual family member (a specie). Primers made to individual RGs at the edge of each cluster can be used to select for recombinants within the cluster. This minimizes the amount of linkage drag during introgression. Classical and molecular genetics has shown that pest resistance genes tend to be clustered in the genome. Pest resistance loci comprise arrays of genes and exhibit a variety of complex haplotypes rather than being simple alternate allelic forms. Pest resistance is conferred by families, or genuses, of related RG sequences, individual members, or species, of which have evolved to have a different specificity.

Oligonucleotide primers can be designed that amplify members from multiple haplotypes, or genuses, or amplify only members of one genus, or only amplify an individual specie. This will provide codominant information and allow heterozygotes to be distinguished from homozygotes.

5 Further, comparison of RG sequences will allow a determination of which sequences are critical for resistance and will ultimately lead to engineering resistance genes with new specificities. Resistance gene sequences were not previously available for lettuce. Marker-aided selection will greatly increase the precision and speed of breeding for disease resistance. Transgenic approaches will allow pyramiding of resistance genes
10 into a single Mendelian unit, transfer between sexually-incompatible species, substitute for conventional backcrossing procedures, and allow expression of other genes in parallel with resistance genes.

The RG polynucleotides also have utility in the construction of disease resistant transgenic plants. This avoids lengthy and sometimes difficult backcrossing
15 programs currently necessary for introgression of resistance. It is also possible to transfer resistance polynucleotides between sexually-incompatible species, thereby greatly increasing the germplasm pool that can be used as a source of resistance genes. Cloning of multiple RG sequences in a single cassette will allow pyramiding of genes for resistance against multiple isolates of a single pathogen such as downy mildew or against multiple
20 pathogens. Once introduced, such a cassette can be manipulated by classical breeding methods as a single Mendelian unit.

Transgenic plants of the present invention can also be constructed using an RG promoter. The promoter sequences from RG sequences of the invention can be used with RG genes or heterologous genes. Thus, RG promoters can be used to express a
25 variety of genes in the same temporal and spatial patterns and at similar levels to resistance genes.

Nucleic acids of the Invention and Their Preparation

RG Polynucleotide Families

30 The present invention provides isolated nucleic acid constructs which comprise an RG polynucleotide. In alternative embodiments, the RG polynucleotide is at least 18 nucleotides in length, typically at least 20, 25, or 30 nucleotides in length, more

typically at least 100 nucleotides in length, generally at least 200 nucleotides in length, preferably at least 300 nucleotides in length, more preferably at least 400 nucleotides in length, and most preferably at least 500 nucleotides in length.

In particularly preferred embodiments, the RG polynucleotide encodes a RG protein which confers resistance to plant pests. This RG protein can be longer, equivalent, or shorter than the RG protein encoded by an RG gene. In various embodiments, an RG polynucleotide can hybridize under stringent conditions to members of an RG family (an RG genus); *e.g.*, it can hybridize to a member of the RG1 RG family, such as an RG1 polynucleotide selected from the group consisting of: SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO: 3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J).

In other embodiments, the polynucleotide can also hybridize under stringent conditions to a member of the RG2 family; such as an RG2 polynucleotide selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In alternative embodiments, each RG2 gene can also include an AC15 sequence which hybridizes under stringent conditions to a polynucleotide selected from the group consisting of: SEQ ID NO:56 (AC15-2A); SEQ ID NO:57 (AC15-2B); SEQ ID NO:58 (AC15-2C); SEQ ID NO:59 (AC15-2D); SEQ ID NO:60 (AC15-2E); SEQ ID NO:61 (AC15-2G); SEQ ID NO:62 (AC15-2H); SEQ ID NO:63 (AC15-2I); SEQ ID

NO:64 (AC15-2J); SEQ ID NO:65 (AC15-2L); SEQ ID NO:66 (AC15-2N); SEQ ID NO:67 (AC15-2O).

In other embodiments, an RG polynucleotide can hybridize under stringent conditions to an RG3 (SEQ ID NO:68), an RG4 (SEQ ID NO:69), and RG5 (SEQ ID NO:135), and an RG7 (SEQ ID NO:137), RG family member.

The present invention further provides nucleic acid constructs which comprise an RG polynucleotide which encodes RG polypeptides from various RG families; such as an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and RG4 polypeptide, and RG5 polypeptide, and an RG7 polypeptide.

Exemplary RG1 polypeptides have the sequences shown in SEQ ID NO:2 (RG1A), SEQ ID NO:4 (RG1B), SEQ ID NO:6 (RG1C), SEQ ID NO:8 (RG1D), SEQ ID NO:10 (RG1E), SEQ ID NO:12 (RG1F), SEQ ID NO:14 (RG1G), SEQ ID NO:16 (RG1H), SEQ ID NO:20 (RG1J). Exemplary RG2 polypeptides have the sequences shown in SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

An exemplary RG3 polypeptide has the sequence shown in SEQ ID NO:138. An exemplary RG4 polypeptide has the sequence shown in SEQ ID NO:139. RG polynucleotides will have at least 60% identity, more typically at least 65% identity, generally at least 70% identity, and preferably at least 75% identity, more preferably at least 80% identity, and most preferably at least 85%, 90%, or 95% identity at the deduced amino acid level. The regions where substantial identity is assessed can be inclusive or exclusive of the nucleotide binding site or the leucine rich region.

Vectors and Transcriptional Control Elements

The invention, providing methods and reagents for making novel species and genres of RG nucleic acids described herein, further provides methods and reagents for expressing these nucleic acids using novel expression cassettes, vectors, transgenic plants and animals, using constitutive and inducible transcriptional and translational *cis-* (e.g., promoters and enhancers) and *trans-*acting control elements.

The expression of natural, recombinant or synthetic plant disease resistance polypeptide-encoding or other (*i.e.*, antisense, ribozyme) nucleic acids can be achieved by operably linking the coding region a promoter (that can be plant-specific or not, constitutive or inducible), incorporating the construct into an expression cassette (such as an expression vector), and introducing the resultant construct into an *in vitro* reaction system or a suitable host cell or organism. Synthetic procedures may also be used. Typical expression systems contain, in addition to coding or antisense sequence, transcription and translation terminators, polyadenylation sequences, transcription and translation initiation sequences, and promoters useful for transcribing DNA into RNA. The expression systems optionally at least one independent terminator sequence, sequences permitting replication of the cassette *in vivo*, e.g., plants, eukaryotes, or prokaryotes, or a combination thereof, (e.g., shuttle vectors) and selection markers for the selected expression system, e.g., plant, prokaryotic or eukaryotic systems. To ensure proper polypeptide expression under varying conditions, a polyadenylation region at the 3'-end of the coding region can be included (see Li (1997) *Plant Physiol.* 115:321-325, for a review of the polyadenylation of RNA in plants). The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA (e.g., using *Agrobacterium tumefaciens* T-DNA replacement vectors, see e.g., Thykjaer (1997) *Plant Mol Biol.* 35:523-530; using a plasmid containing a gene of interest flanked by *Agrobacterium* T-DNA border repeat sequences; Hansen (1997) "T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes," *Proc. Natl. Acad. Sci. USA* 94:11726-11730.

To identify the promoters, the 5' portions of the clones described here are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further

upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) N G (see, *e.g.*, Messing, in *Genetic Engineering in Plants*, pp. 221-227, Kosage, Meredith and Hollaender, eds. 1983). If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the RG coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from viral genes, such as T-DNA.

The nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are transiently expressed in cells using, for example, episomal expression systems (*e.g.*, cauliflower mosaic virus (CaMV) viral RNA is generated in the nucleus by transcription of an episomal minichromosome containing supercoiled DNA, Covey (1990) *Proc. Natl. Acad. Sci. USA* 87:1633-1637). Alternatively, coding sequences can be inserted into the host cell genome becoming an integral part of the host chromosomal DNA.

Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode biocide resistance, such as antibiotic resistance, particularly resistance to chloramphenicol, kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta, to permit selection of those cells transformed with the desired DNA sequences, see for example, Blondelet-Rouault (1997) *Gene* 190:315-317; Aubrecht (1997) *J. Pharmacol. Exp. Ther.* 281:992-997. Because selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*. See also, Mengiste (1997) "High-efficiency transformation of *Arabidopsis thaliana* with a selectable marker gene regulated by the T-DNA 1' promoter," *Plant J.* 12:945-948, showing that the 1' promoter is an attractive alternative to the cauliflower mosaic virus (CaMV) 35S promoter for the generation of T-DNA insertion lines, the 1' promoter may be especially beneficial for the secondary transformation of transgenic strains containing the 35S promoter to exclude homology-mediated gene silencing.

The endogenous promoters from the RG genes of the present invention can be used to direct expression of the genes. These promoters can also be used to direct expression of heterologous structural genes. The promoters can be used, for example, in recombinant expression cassettes to drive expression of genes conferring resistance to any number of pathogens or pests, including fungi, bacteria, and the like.

Constitutive Promoters

In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a promoter fragment can be employed to direct expression of the desired gene in all tissues of a plant or animal. Promoters that drive expression continuously under physiological conditions are referred to as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include those from viruses which infect plants, such as the cauliflower mosaic virus (CaMV) 35S transcription initiation region; the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*; the promoter of the tobacco mosaic virus; and, other transcription initiation regions from various plant genes known to those of skill. See also Holtorf (1995) "Comparison of different constitutive and inducible promoters for the overexpression of transgenes in *Arabidopsis thaliana*," *Plant Mol. Biol.* 29:637-646.

Inducible Promoters

Alternatively, a plant promoter may direct expression of the plant disease resistance nucleic acid of the invention under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include pathogenic attack, anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters. For example, the invention incorporates the drought-inducible promoter of maize (Busk (1997) *supra*); the cold, drought, and high salt inducible promoter from potato (Kirch (1997) *Plant Mol. Biol.* 33:897-909).

Embodiments of the invention also incorporate use of plant promoters which are inducible upon injury or infection to express the invention's plant disease resistance (RG) polypeptides. Various embodiments include use of, e.g., the promoter for a tobacco (*Nicotiana tabacum*) sesquiterpene cyclase gene (EAS4 promoter), which is expressed in wounded leaves, roots, and stem tissues, and upon infection with microbial pathogens (Yin

(1997) *Plant Physiol.* 115(2):437-451); the ORF13 promoter from *Agrobacterium rhizogenes* 8196, which is wound inducible in a limited area adjacent to the wound site (Hansen (1997) *Mol. Gen. Genet.* 254:337-343); the Shpx6b gene promoter, which is a plant peroxidase gene promoter induced by microbial pathogens (demonstrated using a fungal pathogen, see Curtis (1997) *Mol. Plant Microbe Interact.* 10:326-338); the wound-inducible gene promoter wun1, derived from potato (Siebertz (1989) *Plant Cell* 1:961-968); the wound-inducible *Agrobacterium pmas* gene (mannopine synthesis gene) promoter (Guevara-Garcia (1993) *Plant J.* 4:495-505).

Alternatively, plant promoters which are inducible upon exposure to plant hormones, such as auxins, are used to express the nucleic acids of the invention. For example, the invention can use the auxin-response elements E1 promoter fragment (AuxREs) in the soybean (*Glycine max L.*) (Liu (1997) *Plant Physiol.* 115:397-407); the auxin-responsive Arabidopsis GST6 promoter (also responsive to salicylic acid and hydrogen peroxide) (Chen (1996) *Plant J.* 10: 955-966); the auxin-inducible parC promoter from tobacco (Sakai (1996) 37:906-913); a plant biotin response element (Streit (1997) *Mol. Plant Microbe Interact.* 10:933-937); and, the promoter responsive to the stress hormone abscisic acid (Sheen (1996) *Science* 274:1900-1902).

Plant promoters which are inducible upon exposure to chemicals reagents which can be applied to the plant, such as herbicides or antibiotics, are also used to express the nucleic acids of the invention. For example, the maize In2-2 promoter, activated by benzenesulfonamide herbicide safeners, can be used (De Veylder (1997) *Plant Cell Physiol.* 38:568-577); application of different herbicide safeners induces distinct gene expression patterns, including expression in the root, hydathodes, and the shoot apical meristem. Coding sequence can be under the control of, *e.g.*, a tetracycline-inducible promoter, *e.g.*, as described with transgenic tobacco plants containing the *Avena sativa L.* (oat) arginine decarboxylase gene (Masgrau (1997) *Plant J.* 11:465-473); or, a salicylic acid-responsive element (Stange (1997) *Plant J.* 11:1315-1324. Using chemically- (*e.g.*, hormone- or pesticide-) induced promoters, harvesting of fruits and plant parts would be greatly facilitated. A chemical which can be applied to the transgenic plant in the field and induce expression of a polypeptide of the invention throughout all or most of the plant would make an environmentally safe defoliant or herbicide. Thus, the invention also provides for transgenic plants containing an inducible gene encoding for the RG

polypeptides of the invention whose host range is limited to target plant species, such as weeds or crops before, during or after harvesting.

Abcission promoters are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. In some embodiments, when a plant disease resistant polypeptide-encoding nucleic acid is under the control of such a promoter, rapid cell death, induced by expression of the invention's polypeptide, can accelerate and/or accentuate abcission, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like. Induction of rapid cell death at this time would accelerate separation of the fruit from the plant, greatly augmenting harvesting procedures. See, *e.g.*, Kalaitzis (1997) *Plant Physiol.* 113:1303-1308, discussing tomato leaf and flower abcission; Payton (1996) *Plant Mol. Biol.* 31:1227-1231, discussing ethylene receptor expression regulation during fruit ripening, flower senescence and abcission; Koehler (1996) *Plant Mol. Biol.* 31:595-606, discussing the gene promoter for a bean abcission cellulase; Kalaitzis (1995) *Plant Mol. Biol.* 28: 647-656, discussing cloning of a tomato polygalacturonase expressed in abcission; del Campillo (1996) *Plant Physiol.* 111:813-820, discussing pedicel breakstrength and cellulase gene expression during tomato flower abcission.

Tissue-Specific Promoters

Tissue specific promoters are transcriptional control elements that are only active in particular cells or tissues. Plant promoters which are active only in specific tissues or at specific times during plant development are used to express the nucleic acids of the invention. Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves, roots, fruit, seeds, ovules, pollen, pistils, or flowers. Such promoters are referred to as "tissue specific". The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

For example, a seed-specific promoter directs expression in seed tissues. Such promoters may be, for example, ovule-specific, embryo-specific, endosperm-specific, integument-specific, seed coat-specific, or some combination thereof. A leaf-specific promoter has been identified in maize, Busk (1997) *Plant J.* 11:1285-1295. The ORF13 promoter from *Agrobacterium rhizogenes* exhibits high activity in roots (Hansen (1997) *supra*). A maize pollen-specific promoter has been identified in maize (Guerrero (1990)

Mol. Gen. Genet. 224:161-168). A tomato promoter active during fruit ripening, senescence and abscission of leaves and, to a lesser extent, of flowers can be used (Blume (1997) *Plant J.* 12:731-746). A pistil specific promoter has been identified in the potato (*Solanum tuberosum* L.) SK2 gene, encoding a pistil-specific basic endochitinase (Ficker (1997) *Plant Mol. Biol.* 35:425-431). The Blec4 gene from pea (*Pisum sativum* cv. Alaska) is active in epidermal tissue of vegetative and floral shoot apices of transgenic alfalfa, making it a useful tool to target the expression of foreign genes to the epidermal layer of actively growing shoots. The activity of the Blec4 promoter in the epidermis of the shoot apex makes it particularly suitable for genetically engineering defense against insects and diseases that attack the growing shoot apex (Mandaci (1997) *Plant Mol Biol.* 34:961-965).

The invention also provides for use of tissue-specific plant promoters include a promoter from the ovule-specific *BEL1* gene described in Reiser (1995) *Cell* 83:735-742, GenBank No. U39944. Suitable seed specific promoters are derived from the following genes: *MAC1* from maize, Sheridan (1996) *Genetics* 142:1009-1020; *Cat3* from maize, GenBank No. L05934, Abler (1993) *Plant Mol. Biol.* 22:10131-1038; the gene encoding oleosin 18kD from maize, GenBank No. J05212, Lee (1994) *Plant Mol. Biol.* 26:1981-1987; *viviparous-1* from *Arabidopsis*, Genbank No. U93215; the gene encoding oleosin from *Arabidopsis*, Genbank No. Z17657; *Atmyc1* from *Arabidopsis*, Urao (1996) *Plant Mol. Biol.* 32:571-576; the 2s seed storage protein gene family from *Arabidopsis*, Conceicao (1994) *Plant* 5:493-505; the gene encoding oleosin 20kD from *Brassica napus*, GenBank No. M63985; *napA* from *Brassica napus*, GenBank No. J02798, Josefsson (1987) *JBL* 26:12196-1301; the napin gene family from *Brassica napus*, Sjobahl (1995) *Planta* 197:264-271; the gene encoding the 2S storage protein from *Brassica napus*, Dasgupta (1993) *Gene* 133:301-302; the genes encoding oleosin a, Genbank No. U09118, and, oleosin B, Genbank No. U09119, from soybean; and, the gene encoding low molecular weight sulphur rich protein from soybean, Choi (1995) *Mol Gen, Genet.* 246:266-268. The tissue specific E8 promoter from tomato is particularly useful for directing gene expression so that a desired gene product is located in fruits. Other suitable promoters include those from genes encoding embryonic storage proteins.

One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues other than the target tissue. Thus, as

used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue, but may also lead to some expression in other tissues as well.

The invention also provides for use of tissue-specific promoters derived from viruses which can include, *e.g.*, the tobamovirus subgenomic promoter (Kumagai
5 (1995) *Proc. Natl. Acad. Sci. USA* 92:1679-1683; the rice tungro bacilliform virus (RTBV), which replicates only in phloem cells in infected rice plants, with its promoter which drives strong phloem-specific reporter gene expression; the cassava vein mosaic virus (CVMV) promoter, with highest activity in vascular elements, in leaf mesophyll cells, and in root tips (Verdaguer (1996) *Plant Mol. Biol.* 31:1129-1139).

10 In some embodiments, the nucleic acid construct will comprise a promoter functional in a specific plant cell, such as in a species of *Lactuca*, operably linked to an RG polynucleotide. Promoters useful in these embodiments include RG promoters. In additional embodiments, the nucleic acid construct will comprise a RG promoter operably linked to a heterologous polynucleotide. The heterologous polynucleotide is chosen to
15 provide a plant with a desired phenotype. For example, the heterologous polynucleotide can be a structural gene which encodes a polypeptide which imparts a desired resistance phenotype. Alternatively, the heterologous polynucleotide may be a regulatory gene which might play a role in transcriptional and/or translational control to suppress, enhance, or otherwise modify the transcription and/or expression of an endogenous gene within the
20 plant. The heterologous polynucleotide of the nucleic acid construct of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics.

Modifying and Inhibiting RG Gene Expression

25 The invention also provides for RG nucleic acid sequences which are complementary to the RG polypeptide-encoding sequences of the invention; *i.e.*, antisense RG nucleic acids. Antisense technology can be conveniently used to modify gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be
30 transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, *e.g.*,

Sheehy (1988) *Proc. Nat. Acad. Sci. USA* 85:8805-8809; Hiatt et al., U.S. Patent No. 4,801,340.

Antisense sequences are capable of inhibiting the transport, splicing or transcription of RG-encoding genes. The inhibition can be effected through the targeting of genomic DNA or messenger RNA. The transcription or function of targeted nucleic acid can be inhibited, *e.g.*, by hybridization and/or cleavage. One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind RG gene or message, in either case preventing or inhibiting the production or function of RG. The association can be through sequence specific hybridization. Such inhibitory nucleic acid sequences can, for example, be used to completely inhibit a plant disease resistance response. Another useful class of inhibitors includes oligonucleotides which cause inactivation or cleavage of RG message. The oligonucleotide can have enzyme activity which causes such cleavage, such as ribozymes. The oligonucleotide can be chemically modified or conjugated to an enzyme or composition capable of cleaving the complementary nucleic acid. One may screen a pool of many different such oligonucleotides for those with the desired activity.

Antisense Oligonucleotides

The invention provides for with antisense oligonucleotides capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such RG oligonucleotides using the novel reagents of the invention. In some situations, naturally occurring nucleic acids used as antisense oligonucleotides may need to be relatively long (18 to 40 nucleotides) and present at high concentrations. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2-aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197; *Antisense Therapeutics*, ed. Agrawal (Humana Press, Totowa, N.J., 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate,

phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described herein.

Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense RG sequences of the invention (for general background information, see, *e.g.*, Gold (1995) *J. of Biol. Chem.* 270:13581-13584).

Inhibitory Ribozymes

The invention provides for with ribozymes capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing ribozymes and selecting the RG-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such RG ribozymes using the novel reagents of the invention. Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence, or, preventing transport of the message from the nucleus to the cytoplasm. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of any plant gene. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described, *e.g.*, in Haseioff (1988) *Nature* 334:585-591.

In some circumstances, the enzymatic nature of a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid

molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single
5 ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio
10 of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.

The enzymatic ribozyme RNA molecule can be formed in a hammerhead
15 motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) *Aids Research and Human Retroviruses* 8:183; hairpin motifs by Hampel (1989) *Biochemistry* 28:4929, and Hampel (1990) *Nuc. Acids Res.* 18:299; the hepatitis delta virus motif by Perrotta (1992) *Biochemistry* 31:16;
20 the RNaseP motif by Guerrier-Takada (1983) *Cell* 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target
25 gene RNA regions, and has nucleotide sequence within or surrounding that substrate binding site which imparts an RNA cleaving activity to the molecule.

Sense Supression

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method
30 to modulate expression of endogenous genes see, Napoli et al., *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323.

Cloning of RG Polypeptides

Synthesis and/or cloning of RG polynucleotides and isolated nucleic acid constructs of the present invention are provided by methods well known to those of ordinary skill in the art. Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989).

The isolation of RG genes may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as roots and a cDNA library which contains the RG gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which RG genes or homologs are expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned RG gene such as the genes disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species.

Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%.

Alternatively, the RG nucleic acids of the invention can be amplified from nucleic acid samples using a variety of amplification techniques, such as polymerase chain reaction (PCR) technology, to amplify the sequences of the RG and related genes directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.

Oligonucleotides can be used to identify and detect additional RG families and RG family species using a variety of hybridization techniques and conditions. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, *ed.* Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), *ed.* Innis, Academic Press, Inc., N.Y. (Innis)), ligase chain reaction (LCR) (Wu (1989) *Genomics* 4:560; Landegren (1988) *Science* 241:1077; Barringer (1990) *Gene* 89:117); transcription amplification (Kwoh (1989) *Proc. Natl. Acad. Sci. USA* 86:1173); and, self-sustained sequence replication (Guatelli (1990) *Proc. Natl. Acad. Sci. USA*, 87:1874); Q Beta replicase amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA, Cangene, Mississauga, Ontario); see Berger (1987) *Methods Enzymol.* 152:307-316, Sambrook, and Ausubel, as well as Mullis (1987) U.S. Patent Nos. 4,683,195 and 4,683,202; Arnheim (1990) *C&EN* 36-47; Lomell *J. Clin. Chem.*, 35:1826 (1989); Van Brunt, *Biotechnology*, 8:291-294 (1990); Wu (1989) *Gene* 4:560; Sooknanan (1995) *Biotechnology* 13:563-564. Methods for cloning *in vitro* amplified nucleic acids are described in Wallace, U.S. Pat. No. 5,426,039.

The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium as described earlier.

In some preferred embodiments, members of this class of pest resistance genes can be identified by their ability to be amplified by PCR primers based on the sequences disclosed here. Appropriate primers and probes for identifying RG sequences

from plant tissues are generated from comparisons of the sequences provided herein. See, e.g., Table 1. For a general overview of PCR see *PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990), incorporated herein by reference.

5 Briefly, the first step of each cycle of the PCR involves the separation of the nucleic acid duplex formed by the primer extension. Once the strands are separated, the next step in PCR involves hybridizing the separated strands with primers that flank the target sequence. The primers are then extended to form complementary copies of the target strands. For successful PCR amplification, the primers are designed so that the
10 position at which each primer hybridizes along a duplex sequence is such that an extension product synthesized from one primer, when separated from the template (complement), serves as a template for the extension of the other primer. The cycle of denaturation, hybridization, and extension is repeated as many times as necessary to obtain the desired amount of amplified nucleic acid.

15 In the preferred embodiment of the PCR process, strand separation is achieved by heating the reaction to a sufficiently high temperature for an sufficient time to cause the denaturation of the duplex but not to cause an irreversible denaturation of the polymerase (see U.S. Patent No. 4,965,188). Template-dependent extension of primers in PCR is catalyzed by a polymerizing agent in the presence of adequate amounts of four
20 deoxyribonucleotide triphosphates (typically dATP, dGTP, dCTP, and dTTP) in a reaction medium comprised of the appropriate salts, metal cations, and pH buffering system. Suitable polymerizing agents are enzymes known to catalyze template-dependent DNA synthesis.

25 Polynucleotides may also be synthesized by well-known techniques as described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer
30 sequence.

RG Proteins

The present invention further provides isolated RG proteins encoded by the RG polynucleotides disclosed herein. One of skill will recognize that the nucleic acid encoding a functional RG protein need not have a sequence identical to the exemplified genes disclosed here. For example, because of codon degeneracy a large number of nucleic acid sequences can encode the same polypeptide. In addition, the polypeptides encoded by the RG genes, like other proteins, have different domains which perform different functions. Thus, the RG gene sequences need not be full length, so long as the desired functional domain of the protein is expressed.

The resistance proteins are at least 25 amino acid residues in length. Typically, the RG proteins are at least 50 amino acid residues, generally at least 100, preferably at least 150, more preferably at least 200 amino acids in length. In particularly preferred embodiments, the RG proteins are of sufficient length to provide resistance to pests when expressed in the desired plants. Generally then, the RG proteins will be the length encoded by an RG gene of the present invention. However, those of ordinary skill will appreciate that minor deletions, substitutions, or additions to an RG protein will typically yield a protein with pest resistance characteristics similar or identical to that of the full length sequence. Thus, full-length RG proteins modified by 1, 2, 3, 4, or 5 deletions, substitutions, or additions, generally provide an effective degree of pest resistance relative to the full-length protein.

The RG proteins which provide pest resistance will typically comprise at least one of an LRR or an NBS. Preferably, both are present. LRR and/or NBS regions present in the RG proteins of the present invention can be provided by RG genes of the present invention. In some embodiments, the LRR and/or NBS regions are obtained from other pest resistance genes. See, e.g., Yu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11751-11756 (1996); Bent *et al.*, *Science*, 265: 1856-1860 (1994).

Modified protein chains can also be readily designed utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. Modification can also include swapping domains from the proteins of the invention with related domains from other pest resistance genes.

Pests that can be targeted by RG genes and proteins of the present invention include such bacterial pests as *Erwinia carotovora* and *Pseudomonas marginalis*. Fungal pests which can be targeted by the present invention include *Bremia lactucae*, *Marssonina panattoniana*, *Rhizoctonia solani*, *Olpidium brassicae*, root aphid, *Sclerotinia sclerotiorum* and *S. minor*, and *Botrytis cinerea* which causes gray mold. RG genes also provide resistance to viral diseases such as lettuce and turnip mosaic viruses.

Fusion Proteins

RG polypeptides can also be expressed as recombinant proteins with one or more additional polypeptide domains linked thereto to facilitate protein detection, purification, or other applications. Such detection and purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and plant disease resistant polypeptide may be useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding a plant disease resistant polypeptide of the invention and nucleic acid sequence encoding six histidine residues followed by thioredoxin and an enterokinase cleavage site (*e.g.*, see Williams (1995) *Biochemistry* 34:1787-1797). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described, see *e.g.*, Kroll (1993) *DNA Cell. Biol.*, 12:441-53.

Antibodies Reactive to RG Polypeptides and Immunological Assays

The present invention also provides antibodies which specifically react with RG proteins of the present invention under immunologically reactive conditions. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. "Immunologically reactive conditions" includes reference to conditions which allow an antibody, generated to a particular epitope of an antigen, to bind to that

epitope to a detectably greater degree than the antibody binds to substantially all other epitopes, generally at least two times above background binding, preferably at least five times above background. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols.

"Antibody" includes reference to an immunoglobulin molecule obtained by *in vitro* or *in vivo* generation of the humoral response, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies), and recombinant single chain Fv fragments (scFv). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab', F(ab')₂, Fab, Fv, rIgG, and, inverted IgG). See, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL). An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.* (1989) *Science* 246:1275-1281; and Ward, *et al.* (1989) *Nature* 341:544-546; and Vaughan *et al.* (1996) *Nature Biotechnology*, 14:309-314.

Many methods of making antibodies are known to persons of skill. A number of immunogens are used to produce antibodies specifically reactive to an isolated RG protein of the present invention under immunologically reactive conditions. An isolated recombinant, synthetic, or native RG protein of the present invention is the preferred immunogens (antigen) for the production of monoclonal or polyclonal antibodies.

The RG protein is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies can be generated for subsequent use in immunoassays to measure the presence and quantity of the RG protein. Methods of producing monoclonal or polyclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY.

Frequently, the RG proteins and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide

variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

The antibodies of the present invention can be used to screen plants for the expression of RG proteins of the present invention. The antibodies of this invention are also used for affinity chromatography in isolating RG protein.

10 The present invention further provides RG polypeptides that specifically bind, under immunologically reactive conditions, to an antibody generated against a defined immunogen, such as an immunogen consisting of the RG polypeptides of the present invention. Immunogens will generally be at least 10 contiguous amino acids from an RG polypeptide of the present invention. Optionally, immunogens can be from regions
15 exclusive of the NBS and/or LRR regions of the RG polypeptides. Nucleic acids which encode such cross-reactive RG polypeptides are also provided by the present invention. The RG polypeptides can be isolated from any number plants as discussed earlier. Preferred are species from the family *Compositae* and in particular the genus *Lactuca* such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

20 "Specifically binds" includes reference to the preferential association of a ligand, in whole or part, with a particular target molecule (i.e., "binding partner" or "binding moiety") relative to compositions lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a ligand and a non-target molecule. Nevertheless, specific binding, may be distinguished as mediated
25 through specific recognition of the target molecule. Typically specific binding results in a much stronger association between the ligand and the target molecule than between the ligand and non-target molecule. Specific binding by an antibody to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. The affinity constant of the antibody binding site for its cognate monovalent antigen is at
30 least 10^7 , usually at least 10^8 , preferably at least 10^9 , more preferably at least 10^{10} , and most preferably at least 10^{11} liters/mole. A variety of immunoassay formats are appropriate for selecting antibodies specifically reactive with a particular protein. For

example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically reactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific reactivity. The antibody may be polyclonal but preferably is monoclonal. Generally, antibodies cross-reactive to such proteins as RPS2, RPM1 (bacterial resistances in Arabidopsis), L6 (fungal resistance in flax), PRF (resistance to *Pseudomonas syringae* in tomato), and *N*, (virus resistance in tobacco), are removed by immunoabsorbtion.

Immunoassays in the competitive binding format are typically used for cross-reactivity determinations. For example, an immunogenic RG polypeptide is immobilized to a solid support. Polypeptides added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above polypeptides to compete with the binding of the antisera to the immobilized RG polypeptide is compared to the immunogenic RG polypeptide. The percent cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with such proteins as RPS2, RPM1, L6, PRF, and *N*, are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorbtion with these non-RG resistance proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay to compare a second "target" polypeptide to the immunogenic polypeptide. In order to make this comparison, the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the antisera to the immobilized protein is determined using standard techniques. If the amount of the target polypeptide required is less than twice the amount of the immunogenic polypeptide that is required, then the target polypeptide is said to specifically bind to an antibody generated to the immunogenic protein. As a final determination of specificity, the pooled antisera is fully immunosorbed with the immunogenic polypeptide until no binding to the polypeptide used in the immunosorbtion is detectable. The fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If no reactivity is observed, then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

Production of transgenic plants of the invention

Isolated nucleic acid constructs prepared as described herein can be introduced into plants according techniques known in the art. In some embodiments, the introduced nucleic acid is used to provide RG gene expression and therefore pest resistance in desired plants. In some embodiments, RG promoters are used to drive expression of desired heterologous genes in plants. Finally, in some embodiments, the constructs can be used to suppress expression of a target endogenous gene, including RG genes.

To use isolated RG sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al. Ann. Rev. Genet.* 22:421-477 (1988).

A DNA sequence coding for the desired RG polypeptide, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a recombinant expression cassette which can be introduced into the desired plant. An expression cassette will typically comprise the RG polynucleotide operably linked to transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the RG gene in the intended tissues of the transformed plant.

Such DNA constructs may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment and microinjection of plant cell protoplasts or embryogenic callus, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.

Transformation techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. Embo J.* 3:2717-2722 (1984).

Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al. Nature* 327:70-73 (1987).

Agrobacterium tumefaciens-mediated transformation techniques are well
5 described in the scientific literature. See, for example Horsch *et al. Science* 233:496-498
(1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA* 80:4803 (1983). Although
Agrobacterium is useful primarily in dicots, certain monocots can be transformed by
Agrobacterium. For instance, *Agrobacterium* transformation of rice is described by Hiei *et*
al. Plant J. 6:271-282 (1994). A particularly preferred means of transforming lettuce is
10 described in Michelmore *et al., Plant Cell Reports*, 6:439-442 (1987).

Transformed plant cells which are derived by any of the above
transformation techniques can be cultured to regenerate a whole plant which possesses the
transformed genotype and thus the desired RG-controlled phenotype. Such regeneration
techniques rely on manipulation of certain phytohormones in a tissue culture growth
15 medium, typically relying on a biocide and/or herbicide marker which has been introduced
together with the RG nucleotide sequences. Plant regeneration from cultured protoplasts is
described in Evans *et al., Protoplasts Isolation and Culture, Handbook of Plant Cell*
Culture, pp. 124-176, Macmillan Publishing Company, New York, 1983; and Binding,
Regeneration of Plants, Plant Protoplasts, pp. 21-73, CRC Press, Boca Raton, 1985.
20 Regeneration can also be obtained from plant callus, explants, organs, or parts thereof.
Such regeneration techniques are described generally in Klee *et al. Ann. Rev. of Plant*
Phys. 38:467-486 (1987).

The methods of the present invention are particularly useful for
incorporating the RG polynucleotides into transformed plants in ways and under
25 circumstances which are not found naturally. In particular, the RG polypeptides may be
expressed at times or in quantities which are not characteristic of natural plants.

One of skill will recognize that after the expression cassette is stably
incorporated in transgenic plants and confirmed to be operable, it can be introduced into
other plants by sexual crossing. Any of a number of standard breeding techniques can be
30 used, depending upon the species to be crossed.

Detection of RG Resistance Genes

The present invention further provides methods for detecting RG resistance genes in a nucleic acid sample suspected of comprising an RG resistance gene. The means by which the RG resistance gene is detected is not a critical aspect of the invention. For example, RG resistance genes can be detected by the presence of amplicons using RG resistance gene specific primers. Additionally, RG resistance genes can be detected by assaying for specific hybridization of an RG polynucleotide to an RG resistance gene. In some embodiments, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

In a typical detection method, the nucleic acid sample is contacted with an RG polynucleotide to form a hybridization complex. The hybridization complex may be detected directly (e.g., in Southern or northern blots), or indirectly (e.g., by subsequent primer extension during PCR amplification). The RG polynucleotide hybridizes under stringent conditions to an RG polynucleotide of the invention. Formation of the hybridization complex is directly or indirectly used to indicate the presence of the RG resistance gene in the nucleic acid sample.

Detection of the hybridization complex can be achieved using any number of well known methods. For example, the nucleic acid sample, or a portion thereof, may be assayed by hybridization formats including but not limited to, solution phase, solid phase, mixed phase, or *in situ* hybridization assays. Briefly, in solution (or liquid) phase hybridizations, both the target nucleic acid and the probe or primer are free to interact in the reaction mixture. In solid phase hybridization assays, probes or primers are typically linked to a solid support where they are available for hybridization with target nucleic acid in solution. In mixed phase, nucleic acid intermediates in solution hybridize to target nucleic acids in solution as well as to a nucleic acid linked to a solid support. In *in situ* hybridization, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the various hybridization assay formats: Singer *et al.*, *Biotechniques* 4(3):230-250 (1986); Haase *et al.*, *Methods in Virology*, Vol. VII, pp. 189-226 (1984); Wilkinson, "The theory and practice of *in situ* hybridization" In: *In situ Hybridization*, Ed. D.G. Wilkinson. IRL Press, Oxford University Press, Oxford; and *Nucleic Acid Hybridization: A Practical Approach*, Ed. Hames, B.D. and Higgins, S.J., IRL Press (1987).

The effect of the modification of RG gene expression can be measured by detection of increases or decreases in mRNA levels using, for instance, Northern blots. In addition, the phenotypic effects of gene expression can be detected by measuring nematode, fungal, bacterial, viral, or other pest resistance in plants. Suitable assays for determining pest resistance are well known. Michelmore and Crute, *Trans. Br. mycol. Soc.*, 79(3): 542-546 (1982).

The means by which hybridization complexes are detected is not a critical aspect of the present invention and can be accomplished by any number of methods currently known or later developed. RG polynucleotides can be labeled by any one of several methods typically used to detect the presence of hybridized nucleic acids. One common method of detection is the use of autoradiography using probes labeled with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P , or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, stability, and half lives of the selected isotopes. Other labels include ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. Alternatively, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents or enzymes. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation. Labeling the RG polynucleotide is readily achieved such as by the use of labeled PCR primers.

The choice of label dictates the manner in which the label is bound to the probe. Radioactive probes are typically made using commercially available nucleotides containing the desired radioactive isotope. The radioactive nucleotides can be incorporated into probes, for example, by using DNA synthesizers, by nick translation with DNA polymerase I, by tailing radioactive DNA bases to the 3' end of probes with terminal deoxynucleotidyl transferase, by treating single-stranded M13 plasmids having specific inserts with the Klenow fragment of DNA polymerase in the presence of radioactive deoxynucleotides, dNTP, by transcribing from RNA templates using reverse transcriptase in the presence of radioactive deoxynucleotides, dNTP, or by transcribing RNA from vectors containing specific RNA viral promoters (e.g., SP6 promoter) using the corresponding RNA polymerase (e.g., SP6 RNA polymerase) in the presence of radioactive ribonucleotides rNTP.

The probes can be labeled using radioactive nucleotides in which the isotope resides as a part of the nucleotide molecule, or in which the radioactive component is attached to the nucleotide via a terminal hydroxyl group that has been esterified to a radioactive component such as inorganic acids, *e.g.*, ³²P phosphate or ¹⁴C organic acids, or esterified to provide a linking group to the label. Base analogs having nucleophilic linking groups, such as primary amino groups, can also be linked to a label.

Non-radioactive probes are often labeled by indirect means. For example, a ligand molecule is covalently bound to the probe. The ligand then binds to an anti-ligand molecule which is either inherently detectable or covalently bound to a detectable signal system, such as an enzyme, a fluorophore, or a chemiluminescent compound. Enzymes of interest as labels will primarily be hydrolases, such as phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescers include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol. Ligands and anti-ligands may be varied widely. Where a ligand has a natural anti-ligand, namely ligands such as biotin, thyroxine, and cortisol, it can be used in conjunction with its labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

Probes can also be labeled by direct conjugation with a label. For example, cloned DNA probes have been coupled directly to horseradish peroxidase or alkaline phosphatase, (Renz, M., and Kurz, K. (1984) A Colorimetric Method for DNA Hybridization. *Nucl. Acids Res.* 12: 3435-3444) and synthetic oligonucleotides have been coupled directly with alkaline phosphatase (Jablonski, E., *et al.* (1986) Preparation of Oligodeoxynucleotide-Alkaline Phosphatase Conjugates and Their Use as Hybridization Probes. *Nuc. Acids. Res.* 14: 6115-6128; and Li P., *et al.* (1987) Enzyme-linked Synthetic Oligonucleotide probes: Non-Radioactive Detection of Enterotoxigenic *Escherichia Coli* in Faeca Specimens. *Nucl. Acids Res.* 15:5275-5287).

Definitions

Units, prefixes, and symbols can be denoted in their SI accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation, respectively. The

headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

5 As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

10 As used herein, "pest" includes, but is not limited to, viruses, fungi, nematodes, insects, and bacteria.

 As used herein, "heterologous" is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form.

15 As used herein, "RG gene," alternatively referred to as "RLG gene," is a gene encoding resistance to plant pests, such as viruses, fungi, nematodes, insects, and bacteria, and which hybridizes under stringent conditions and/or has at least 60% sequence identity at the deduced amino acid level to the exemplified sequences provided herein. RG genes encode "RG polypeptides," alternatively referred to as "RLG polypeptides," which can comprise LRR motifs and/or NBS motifs. The RG polypeptides encoded by RG genes have at least 55% or 60% sequence identity, typically at least 65% sequence identity, preferably at least 70% sequence identity, often at least 75% sequence identity, more preferably at least 80% sequence identity, and most preferably at least 90% sequence identity at the deduced amino acid level relative to the exemplary RG sequences provided herein. The term "RG family" or "RG family genus" or "genus" includes reference to a group of RG polypeptide sequence species that have at least 60% amino acid sequence identity, and, the nucleic acids encoding these polypeptides. The individual species of a genus, i.e., the members of a family, typically are genetically mapped to the same locus.

20 As used herein, "RG polynucleotide" includes reference to a contiguous sequence from an RG gene of at least 18, 20, 25, 30, 40, or 50 nucleotides in length, up to

at least about 100 or at least about 200 nucleotides in length. In some embodiments, the polynucleotide is preferably at least 100 nucleotides in length, more preferably at least 200 nucleotides in length, most preferably at least 500 nucleotides in length. Thus, RG polynucleotide may be a RG gene or a subsequence thereof.

5 As used herein, "isolated," when referring to a molecule or composition, such as, for example, an RG polypeptide or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (*e.g.*, RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, an RG polypeptide or nucleic acid is considered isolated
10 when it has been isolated from any other component with which it is naturally associated, *e.g.*, cell membrane, as in a cell extract. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-
15 PAGE) or high performance liquid chromatography (HPLC).

 The term "nucleic acid" or "nucleic acid molecule" or "nucleic acid sequence" refers to a deoxyribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides which have similar or
20 improved binding properties, for the purposes desired, as the reference nucleic acid. The term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester,
25 sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see *Oligonucleotides and Analogues, a Practical Approach*, edited by F. Eckstein, IRL Press at Oxford University Press (1991); *Antisense Strategies*, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and Applications* (1993, CRC Press). PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described in WO
30

97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197. Other synthetic backbones encompassed by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) *Biochemistry* 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

The term "exogenous nucleic acid" refers to a nucleic acid that has been isolated, synthesized, cloned, ligated, excised in conjunction with another nucleic acid, in a manner that is not found in nature, and/or introduced into and/or expressed in a cell or cellular environment other than or at levels or forms different than the cell or cellular environment in which said nucleic acid or protein is found in nature. The term encompasses both nucleic acids originally obtained from a different organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed. invention.

The term "recombinant," when used with reference to a cell, or to the nucleic acid, protein or vector refers to a material, or a material corresponding to the natural or native form of the material, that has been modified by the introduction of a new moiety or alteration of an existing moiety, or is identical thereto but produced or derived from synthetic materials. For example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise expressed at a different level, typically, under-expressed or not expressed at all. The term "recombinant means" encompasses all means of expressing, *i.e.*, transcription or translation of, an isolated and/or cloned nucleic acid *in vitro* or *in vivo*. For example, the term "recombinant means" encompasses techniques where a recombinant nucleic acid, such as a cDNA encoding a protein, is inserted into an expression vector, the vector is introduced into a cell and the cell expresses the protein. "Recombinant means" also encompass the ligation of nucleic acids having coding or promoter sequences from different sources into one vector for expression of a fusion protein, constitutive expression of a protein, or inducible expression of a protein, such as the plant disease resistant, or RG. polypeptides of the invention.

The term "specifically hybridizes" refers to a nucleic acid that hybridizes, duplexes or binds to a particular target DNA or RNA sequence. The target sequences can be present in a preparation of total cellular DNA or RNA. Proper annealing conditions depend, for example, upon a nucleic acid's, such as a probe's length, base composition, and the number of mismatches and their position on the probe, and can be readily
5 determined empirically providing the appropriate reagents are available. For discussions of nucleic acid probe design and annealing conditions, see, *e.g.*, Sambrook and Ausubel.

The terms "stringent hybridization," "stringent conditions," or "specific hybridization conditions" refers to conditions under which an oligonucleotide (when used, for example, as a probe or primer) will hybridize to its target subsequence, such as an RG
10 nucleic acid in an expression vector of the invention but not to a non-RG sequence. Stringent conditions are sequence-dependent. Thus, in one set of stringent conditions an oligonucleotide probe will hybridize to only one specie of the genus of RG nucleic acids of the invention. In another set of stringent conditions (less stringent) an oligonucleotide
15 probe will hybridize to all species of the invention's genus but not to non-RG nucleic acids. Longer sequences hybridize specifically at higher temperatures. Stringent conditions are selected to be about 5⁰C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium (if
20 the target sequences are present in excess, at T_m , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, *i.e.*, about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30⁰C for short probes
25 (*e.g.*, 10 to 50 nucleotides) and at least about 60⁰C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Often, high stringency wash conditions preceded by low stringency wash conditions to remove background probe signal. An example of medium stringency wash conditions for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at
30 45⁰C for 15 minutes (see Sambrook for a description of SSC buffer). An example low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4-6x SSC at 40⁰C for 15 minutes. a signal to noise ratio of 2x (or higher) than that observed for an unrelated

probe in the particular hybridization assay indicates detection of a "specific hybridization." Nucleic acids which do not hybridize to each other under stringent conditions can still be substantially identical if the polypeptides which they encode are substantially identical. This can occur, *e.g.*, when a nucleic acid is created that encodes for conservative
5 substitutions. Stringent hybridization and stringent hybridization wash conditions are different under different environmental parameters, such as for Southern and Northern hybridizations. An extensive guide to the hybridization of nucleic acids is found in, *e.g.*, Sambrook, Tijssen (1993) *supra*.

As used herein "operably linked" includes reference to a functional linkage
10 between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

15 In the expression of transgenes one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to a sequence of the gene from which it was derived. As explained herein, these variants are specifically covered by this term.

In the case where the inserted polynucleotide sequence is transcribed and
20 translated to produce a functional RG polypeptide, one of skill will recognize that because of codon degeneracy, a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the term "RG polynucleotide sequence". In addition, the term specifically includes those full length sequences substantially identical (determined as described herein) with an RG gene sequence which
25 encode proteins that retain the function of the RG protein. Thus, in the case of RG genes disclosed here, the term includes variant polynucleotide sequences which have substantial identity with the sequences disclosed here and which encode proteins capable of conferring resistance to nematodes, bacteria, viruses, fungi, insects or other pests on a transgenic plant comprising the sequence.

30 Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence, as described below. The term

"complementary to" is used herein to mean that the complementary sequence is identical to all or a specified contiguous portion of a reference polynucleotide sequence.

The terms "sequence identity," "sequence similarity" and "homology" refer to when two sequences, such as the nucleic acid and amino acid sequences or the polypeptides of the invention, when optimally aligned, as with, for example, the programs PILEUP, BLAST, GAP, FASTA or BESTFIT (see discussion, *supra*). "Percentage amino acid/nucleic acid sequence identity" refers to a comparison of the sequences of two polypeptides/nucleic acids which, when optimally aligned, have approximately the designated percentage of the same amino acids/nucleic acids, respectively. For example, "60% sequence identity" and "60% homology" refer to a comparison of the sequences of two RG nucleic acids or polypeptides which, when optimally aligned, have 60% identity. For example, in one embodiment, nucleic acids encoding RG polypeptides of the invention comprise a sequence with at least 50% nucleic acid sequence identity to SEQ ID NO:1. In other embodiments, the RG polypeptides of the invention are encoded by nucleic acids comprising a sequence with at least 50% sequence identity to SEQ ID NO:1, or, are encoded by nucleic acids comprising SEQ ID NO:1, or, have at least 60% amino acid sequence identity to the polypeptide of SEQ ID NO:2.

"Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 55% or 60% sequence identity, generally at least 65%, preferably at least 70%, often at least 75%, more preferably at least 80% and most preferably at least 90%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding

identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 55% or 60%, preferably at least 70%, more preferably at least 80%, and most preferably at least 95%. Polypeptides having "sequence similarity" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under appropriate conditions. Appropriate conditions can be high or low stringency and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C to about 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent wash conditions are those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 50°C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

Nucleic acids of the invention can be identified from a cDNA or genomic library prepared according to standard procedures and the nucleic acids disclosed here used as a probe. Thus, for example, stringent hybridization conditions will typically include at least one low stringency wash using 0.3 molar salt (*e.g.*, 2X SSC) at 65°C. The washes

are preferably followed by one or more subsequent washes using 0.03 molar salt (e.g., 0.2X SSC) at 50°C, usually 60°C, or more usually 65°C. Nucleic acid probes used to identify the nucleic acids are preferably at least 100 nucleotides in length.

As used herein, "nucleotide binding site" or "nucleotide binding domain" ("NBS") includes reference to highly conserved nucleotide-, *i.e.*, ATP/GTP-, binding domains, typically included in the "kinase domain" of kinase polypeptides, such as a kinase-1a, kinase 2, or a kinase 3a motif, as described herein. For example, the tobacco N and Arabidopsis RPS2 genes, among several recently cloned disease-resistance genes, share highly conserved NBS sequence. Kinase NBS subdomains further consist of three subdomain motifs: the P-loop, kinase-2, and kinase-3a subdomains (Yu (1996) *Proc. Acad. Sci. USA* 93:11751-11756). As discussed in detail herein, examples include the Arabidopsis RPP5 gene (Parker (1997) *supra*), the *A. thaliana* RPS2 gene (Mindrinos (1997) *supra*), and the flax L6 rust resistance gene (Lawrence (1995) *supra*) which all encode proteins containing an NBS; and Mindrinos (1994) *Cell* 78:1089-1099; and Shen (1993) *FEBS* 335:380-385. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can identify members having NBS domains, including any of the genus of NBS-containing plant disease resistant polypeptides of the invention.

As used herein, "leucine rich region" ("LRR") includes reference to a region that has a leucine content of at least 20% leucine or isoleucine, or 30% of the aliphatic residues: leucine, isoleucine, methionine, valine, and phenylalanine, and arranged with approximate repeated periodicity. The length of the repeat may vary in length but is generally about 20 to 30 amino acids. An LRR-containing polypeptide typically will have the canonical 24 amino acid leucine-rich repeat (LRR) sequence, which is present in different proteins that mediates molecular recognition and/or interaction processes; as described in Bent (1994) *Science* 265:1856-1860; Parker (1997) *Plant Cell*. 9:879-894; Hong (1997) *Plant Physiol.* 113:1203-1212; Schmitz (1997) *Nucleic Acids Res.* 25:756-763; Hipskind (1996) *Mol. Plant Microbe Interact.* 9:819-825; Tornero (1996) *Plant J.* 10:315-330; Dixon (1996) *Cell* 84:451-459; Jones (1994) *Science* 266:789-793; Lawrence (1995) *Plant Cell* 7:1195-1206; Song (1995) *Science* 270:1804-1806; as discussed in further detail *supra*. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can

identify polypeptides having LRR domains, including any member of the genus of LRR-containing RG polypeptides of the invention.

The term "promoter" refers to a region or sequence determinants located upstream or downstream from the start of transcription and which are involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating and/or regulating transcription in plant cells; see also discussion on plant promoters, *supra*.

The term "constitutive promoter" refers to a promoter that initiates and helps control transcription in all tissues. Promoters that drive expression continuously under physiological conditions are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation; see also detailed discussion, *supra*.

The term "inducible promoter" refers to a promoter which directs transcription under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters; see also detailed discussion, *supra*.

The term "abscission-induced promoter" or "abscission promoter" refers to a class of promoters which are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. When the plant disease resistant polypeptide-encoding nucleic acid is under the control of an abscission promoter, rapid cell death, induced by expression of the invention's polypeptide, accelerates and/or accentuates abscission of the plant part, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like; see also detailed discussion, *supra*.

The term "tissue-specific promoter" refers to a class of transcriptional control elements that are only active in particular cells or tissues. Examples of plant promoters under developmental control include promoters that initiate transcription only (or primarily only) in certain tissues, such as roots, leaves, fruit, ovules, seeds, pollen, pistils, or flowers; see also detailed discussion, *supra*.

As used herein "recombinant" includes reference to a cell, or nucleic acid, or vector, that has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid to a form not native to that cell, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

As used herein, a "recombinant expression cassette" or "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed, and a promoter.

As used herein, "transgenic plant" includes reference to a plant modified by introduction of a heterologous polynucleotide. Generally, the heterologous polynucleotide is an RG structural or regulatory gene or subsequences thereof.

As used herein, "hybridization complex" includes reference to a duplex nucleic acid sequence formed by selective hybridization of two single-stranded nucleic acids with each other.

As used herein, "amplified" includes reference to an increase in the molarity of a specified sequence. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR). A wide variety of cloning methods, host cells, and *in vitro* amplification methodologies are well-known to persons of skill.

As used herein, "nucleic acid sample" includes reference to a specimen suspected of comprising RG resistance genes. Such specimens are generally derived, directly or indirectly, from lettuce tissue.

The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens, such as a genus or subgenus of polypeptides of the invention, as described *supra*.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

5

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1

10

Example 1 describes the use of PCR to amplify RG genes from lettuce.

Multiple primers with low degeneracy, particularly at the 3' end, were designed based on the sequences of two known resistance genes from tobacco and flax.

DNA Templates

15

Lettuce genomic DNA was extracted from cultivar Diana and a mutant line derived from cultivar Diana using a standard CTAB protocol. To generate cDNA templates, RNA was isolated from cultivar Diana and the mutant following standard procedures; first strand cDNA was synthesized using Superscript reverse transcriptase from 1 Φ g total RNA as specified by the manufacturer (Life Technologies). BAC (bacterial artificial chromosome) clones from the *Dm3* region were isolated from a BAC library of over 53,000 clones using marker AC15 that was known to be closely linked to *Dm3*. Bacterial plasmids containing clones of *L6* and *RPS2* were used as positive controls.

20

PCR with degenerate oligonucleotide primers

25

Oligonucleotide primers were designed based on conserved motifs in the nucleotide binding sites (NBS) of *L6*, *RPS2*, and *N*. Eight primers were made corresponding to the GVGKTT motif in the sense direction; each had 64-fold degeneracy. Six primers were made to the GLPLAL motif in the anti-sense direction; with either 16 or 256-fold degeneracy (Table 1).

30

Oligonucleotides included 14-mer adaptors of (CUA)₄ at the 5' end of the sense primers and (CAU)₄ at the 5' end of the antisense primers to allow rapid cloning of the PCR products into pAMP1 (Life Technologies).

5 PCR amplification was performed in 50 Φ l reaction volume with 1 Φ M of each of a pair of sense and antisense primers. The templates were denatured by heating to 94EC for 2 min. This was followed by 35 cycles of 30 sec at 94EC, 1 min at 50EC, 2 min at 72EC, with a single final extension of 5 min at 72EC. 25 ng of genomic DNA or cDNA was used. BAC clones as templates required less. The final dNTP concentration was 0.2 mM; MgCl₂ was 1.5 mM.

Forty-eight combinations of sense and antisense primers were tested on a panel of nine templates consisting of two genomic DNA samples, two cDNA preparations, three BAC clones and plasmids containing *L6* and *RPS2* as positive controls.

10 Amplification from *L6* and *RPS2* resulted in fragments of 516 and 513 repectively. Seven combinations of primers resulted in fragments of approximately this size with multiple templates (Table 2). Primers that gave RLG products were: PLOOPAA, PLOOPAG, PLOOPGA, PLOOPGG, PLOOPAC, GLPL3, GLPL4.

15

20

(Intentionally left blank)

25

Table 1

DEGENERATE PRIMER SEQUENCES for NBS PCR

Sense primers based on GVGKTT amino acid sequence from L6, N and rps2 PLOOP motif:

PLOOPAG 5' GGN GTN GGN AAA ACG AC 3'

PLOOPAA 5' GGN GTN GGN AAA ACA AC 3'

PLOOPAT 5' GGN GTN GGN AAA ACT AC 3'

PLOOPAC 5' GGN GTN GGN AAA ACC AC 3'

PLOOPGG 5' GGN GTN GGN AAG ACG AC 3'

PLOOPGA 5' GGN GTN GGN AAG ACA AC 3'

PLOOPGT 5' GGN GTN GGN AAG ACT AC 3'

PLOOPGC 5' GGN GTN GGN AAG ACC AC 3'

Antisense primers based on GLPLAL amino acid sequence:

GLPL1 5' AGN GCN AGN GGN AGG CC 3'

GLPL2 5' AGN GCN AGN GGN AGA CC 3'

GLPL3 5' AGN GCN AGN GGN AGT CC 3'

GLPL4 5' AGN GCN AGN GGN AGC CC 3'

GLPL5 5' AAN GCC AAN GGC AAA CC 3'

GLPL6 5' AAN GCC AAN GGC AAT CC 3'

TABLE 2. Characteristics of RLGs isolated from lettuce.

	Template	Primers	Number ^a	Size ^b (bp)	Copy number ^c	Dm linkage
5	RLG1	genomic DNA	PLOOPGA+GLPL6	6/6	522	DM4,
	cDNA	PLOOPGA+GLPL6	1/5		DM13	
	genomic DNA	PLOOPAA+GLPL6	5/5			
	cDNA	PLOOPAA+GLPL6	1/1			
RLG2	BACH8	PLOOPGG+GLPL3	3/3	510	DM1, Dm3	
RLG3	gemonic DNA	PLOOPGA+GLPL4	3/6	461	Dm5 Dm8	
10	RLG4	genomic DNA	PLOOPGA+GLPL4	1/6	524	

^a Number of RLG sequences out of total number of clones sequenced.

^b Size of fragment amplified from the nucleotide binding domain.

^c Estimated copy number from genomic Southern blot analysis and numbers of clones in the BAC library.

15

Example 2

Example 2 describes the genetic analysis used to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes.

20

Bulked segregant analysis was performed to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes. DNA from individuals were pooled for each susceptible and resistant bulk. Amplified products were then mapped by RFLP analysis from our intraspecific mapping population. Resistances from four clusters of resistance genes as well as over six hundred markers have now been mapped on this population. Linkage analysis was done using JIONMAP or MAPMAKER mapping programs. Due to a suppression of recombination in the *Dm3* region, sequences were mapped relative to *Dm3* using a panel of deletion mutants that provided greater genetic resolution than the mapping population (Anderson *et al.* 1996). All blots were washed twice at 63EC in 2x SSC/1% SDS for 20 min, followed by one wash at 63EC in 1x SSC/0.1% SDS for 10 or 30 min.

25
30

Most of the RLG sequences were analyzed by bulked segregant analysis (BSA) using pools of resistant and susceptible individuals for each of the four clusters of resistance genes. In genomic Southern analyses, all the RLGs revealed numerous fragments of varying intensity. The numbers of bands was highly dependent of the stringency of hybridization. BSA demonstrated that RLG1 was linked to the *Dm4,7* and *Dm13* clusters. Segregation analysis confirmed this linkage.

RLG2 was derived from BAC H8 that was known to be from the *Dm3* region. BSA with RLG2 demonstrated that the polymorphic bands that distinguished the parents of our mapping population mapped to the *Dm1,Dm3* cluster. Several bands absolutely cosegregated with *Dm1* or *Dm3*. To provide finer genetic resolution, RLG2 was also mapped using a panel of *Dm3* deletion mutants. A number of fragments were missing in largest deletion mutant demonstrating that several RLG2 family members are physically located very close to *Dm3*. No fragment was missing in all deletion mutants; however, this is not unexpected as there is extensive duplication within the region.

15

Example 3

Example 3 describes the screening of a bacterial artificial chromosome library.

Over 53,000 BAC clones containing lettuce genomic DNA were screened with two of the amplified products. High density filters each containing 1536 clones were hybridized to ³²P labelled probes. Filters were washed at 65EC with 40 mM Na₂PO₄/0.1% SDS for 5 min followed by 20 min in the same solution.

To isolate additional RLG sequences we screened our genomic BAC library. Clones were identified that hybridized to RLG1 and RLG2. Nearly all the clones that hybridized to RLG2 also hybridized to marker AC15 that had already been shown by deletion mutant analysis to be clustered around *Dm3*. This provided further evidence for clustering of RLG2 sequences.

Using primers conserved within each family, part of the NBS was amplified from each unique BAC clone and sequenced. This revealed that members within each family varied from 64% identical at the deduced amino acid level. The most divergent members only weakly cross-hybridized to each other. Currently, RLG sequences are

30

considered to be part of the same family of sequences if they are at least 55% identical at the deduced amino acid level and map to the same region of the chromosome.

Example 4:

5 Example 4 describes the cloning, identification, sequencing and characterization of RG polynucleotide sequences; including use of RG sequences from plasmid and PCR products.

 Doubled stranded plasmid DNA clones and PCR products were sequenced using an ABI377 automated sequencer and fluorescently labelled di-deoxy terminators. Sequences were assembled using Sequencher (Genecodes), DNASTar (DNASTar) and Genetics Computer Group (GCG, Madison, WI) software. Database searches were performed using BLASTX and FASTA (GCG) algorithms.

 Sequences flanking the NBS region for RLG2 and for some of RLG1 were obtained by a series of IPCR and the products sequenced directly. IPCR worked less well for RLG1. Therefore RLG1 was subcloned from a BAC clone into pBSK (Stratagene) and the double stranded plasmid sequenced by long range sequencing.

 Initially, a total of 30 clones were sequenced. Three of these seven primer combinations yielded sequences that comprised continuous open reading frames with sequence identity to the NBS of known resistance genes. Seven out of 10 clones amplified from genomic DNA with the primer pair PLOOPGA/GLP6 were 522 bp long; they were identical to each other and named RLG1. All six clones amplified from genomic DNA or cDNA using the primers PLOOPAA/GLP6 were similar/the same as RLG1. All three clones sequenced from BAC clone H8 were 510 bp long, identical to each other but different from RLG1 and were therefore designated RLG2. The 11 clones sequenced from four other primer combinations had no similarity to any NBS motifs and therefore were not studied further. Therefore, sequencing resulted in the identification of clones containing NBS motifs representing four RLG sequences.

 Comparison of the deduced amino acid sequences of RLG1 and RLG2 to those of known resistance genes revealed that RLG1 and RLG2 are as similar to each other as they are to resistance genes from other species and that this is the same level of identity shown between the known resistance genes (Table 3). The percent identity (upper quadrant) and percent identity (lower quadrant) were determined using the MEGALIGN

routine of the DNASTAR package. Identity refers to the proportion of identical amino acids; identity refers to the proportion of identical and similar amino acids and takes into account substitutions of amino acids with similar chemical characteristics. RG1 and RG2 are as similar to each other and to cloned resistance genes as cloned resistance genes from a variety of species are to each other. L6, resistance to *Melampsora lini* in flax (Lawrence *et al.*, 1995). *N*, resistance to tobacco mosaic virus in tobacco (Whitham *et al.*, 1994). *PRF*, required for resistance to *Pseudomonas syringae* in tomato. *RPS2*, resistance to *Pseudomonas syringae* in *Arabidopsis thaliana* (Bent *et al.*, 1994; Mindrinos *et al.*, 1994). *RPM1*, resistance to *Pseudomonas syringae* pv. *maculicola* in *A. thaliana* (Grant *et al.*, 1995). The initial RG1 and RG2, sequences were amplified from lettuce using degenerate primers.

Table 3

IDENTITIES OF

RESISTANCE GENE HOMOLOGUES

		RG1	RG2	RG3	RG4	N gene	RPS2
Lettuce	RG1	***	22.7	15.0	29.2	25.4	23.8
Lettuce	RG2		***	32.2	21.6	22.7	33.0
Lettuce	RG3			***	17.2	15.0	32.8
Lettuce	RG4				***	44.3	22.7
Tobacco	N gene					***	21.6
<i>Arabidopsis</i>	RPS2						***

The regions homologous to the primers are included in this analysis as the genomic sequences for RLG1 and RLG2 were determined by IPCR. Interestingly, the genomic sequences for RLG1 exactly matched that of the primers used.

To obtain further evidence that we had amplified resistance genes, we amplified the regions flanking the NBSs of RLG1a and RLG2a by IPCR of BAC clones. These products were then directly sequenced without cloning to minimize the introduction of PCR artifacts. Sequence analysis of the 5' regions failed to detect any homology to known resistance genes. However, the sequence of the 3' region contained leucine-rich

repeats (LRRs). When this sequence was used to search GENBANK using BLASTX, it detected identity to the *Arabidopsis* resistance gene, *RPS2*. This region does not contain as regular LRRs as in some resistance genes; however, the repeat structure seems to be consistent with that of the flax resistance gene, *L6*. Therefore, the presence of an LRR region is further evidence that the sequences we amplified using degenerate oligonucleotide primers are probably resistance genes.

The sequences of the IPCR products also provided the genomic sequences of the regions complementary to the sequences of the degenerate oligonucleotide primers. The genomic sequences for RLG1 were identical to one of the primers in the mixture. The RLG sequences are resistance genes as supported by three criteria: the presence of multiple sequence motifs characteristic of resistance genes, genetic cosegregation with known resistance genes, and their existence as clustered multi-gene families. The presence of LRR regions in a similar position relative to the NBS as in cloned resistance genes provides stronger evidence than relying solely sequence similarity between NBS regions. The clustering of RLG sequences at the same position as the known clusters of resistance genes make them strong candidates for encoding resistance genes. The hybridization patterns and genetic distribution of the RLG sequences are similar to that of cloned resistance genes in other species. Most of these hybridize to small multigene families and preliminary genetic evidence indicates that they are clustered in the genome. Therefore, the degenerate primers that we designed from other resistance genes seemed to have been specific enough to amplify resistance genes rather than P-loop containing proteins in general.

25

(intentionally left blank)

30

SEQ ID NO: 1

FLGLA
[Strand]

1	ATCGTAAACCGTTGTCACGAG	ANCGCTGTCCTCCTTCATC	TTTGTTCATATGTCATATTC	TCATNNAATMTGCCACATNT
81	AATTTTGTGGTTATTTTAAA	TTAATTTTATTCACATGT	CATTTTATGAGTTTTCAT	TTTATTTGAGTTTCACATAAT
161	ATTTAAATGTAATAACAATA	AATGCATATTTATTTTCTT	TAAATAAACGCATATAATAT	ATAGATTTAAAAATCATATAAT
241	ACATAGGTTAAACTCATAATA	ATACATATGTTTCATCCCAG	TTTATTTATATGTCATCCTC	TTAATTTTATTTATTTAT
321	TTATTAGAGTAGATGATCTT	TGTGATATTAATAATTAAT	TTGTTCAAATTTAAAATTA	TTAATAATCCCACAAATTTGA
401	ATAAAATTAATAAAATGGN	CCCACCAATAGTCCATCACT	TTTTCAGCTCAACAATATCG	TGAGTATTCCTCTCGTTTC
481	CACCCTAATCAATATTTCCA	CGAATGACAGACTCTACG	GGFTTCTGAAATTTGGCTC	CGACACTGTTTCATTGAAGGA
561	GATAATAAATCAAAATGGAGC	TGCTCCAATGTTTCATTGCTG	ATGAAAGGTGAAATTTGTATGT	GAAGANAATGTCACGGATCN
641	ATCTCCATCCGGAACCCACC	ACATTATCAGTGTACCACCA	AACCACCTCAAACCGVGGAA	GTAGRRAKCWRKAAAGTCA
721	TGAAGAATAGATTTATTTTG	TCCTCATGGGCTGACTGAGG	AGCGGGTTFAGTTCATCAT	TTTCMTTGANCAAGAATTA
801	TCGGTCCATCGAATTTTAC	ATCGACAAAGAAGTTTCACT	TCGCAATGTTTGTAAACA	ATTTTTAATCTTTTTATCTT
881	TTCGTTGAAACTCCTCAATT	GCACTTGCAACTTGCAACT	TTTGGCCCAACAATTTGTG	GTGGCGTTAATTTAATCCA
961	CATATTCCTCGTAACAATA	ATTCAAATCGATCTCTGTTC	ATCCAATTCATCAACATCTC	TTGATAATTTGAAATCAATTC
1041	CGCTTCATCCATTTCTCCCA	CATCTATACTATAATTCCTG	CCTCTATCATATAAACCAGAT	GGCTGAAATCGTCTTCTG
1121	CCTCTTTGACAGTGGTGT	GAAAAGCTGGCATTTGAAGC	CTTGAAGAAGATTTGTCCT	CCAAAAGAATTTGAATCTGAG
1201	CTTAAGAAATGAAGGAGAC	ATTAGACCAAATCCAAGATC	TGCTTAACAGATGCTTCCAG	AAGGAAGTAACTAATGAAGC
1281	CGTTAAAGATGGCTGAAATG	ATCTCCAACATTTGGCTTAT	GACATAGACGACCTACTTGA	TGATTTTGCAACTGAAGCTG
1361	TTCAACGTTAGTTGACCGAG	GAGGGTGGAGCCTCCTCCAG	TATGGTAAGAAAATAATCC	CAAGTTGTTCCCAAGTTTC
1441	TCACAAAGTAATAGGATGCA	TGCCAAGTTAGATGATATG	CCACCAGGTTACRAGAATCTG	GTAGAGGCAAAAATAATCT
1521	TGGTTTAAAGTGTGATAACAT	ATGAAAAGCCAAAATTGAA	AGGTATGAGCGCTTCTGGT	AGATGAAAGCGGTTACTGTCG
1601	GACGTTAAGATGATAAGAAA	AAATTECTGGAGAAGCTGTT	GGGGGATAAAGATGAATCAG	GGAGTCAAACCTTCAGCATC
1681	GTGCCCATAGTTGGTATGGG	TGGAGTTGGTAAAACAATC	TAGCTAGACTTTTGTATGAT	GAAAAGAAAGTGAAGGATCA
1761	CTTCGAACCTCAGGCTTGGG	TTTGTGTTCTGATGAGTTC	AGTGTTCCTCAATATAAGCAG	AGTTATTTATCAATCTGTGA
1841	CTGGGAAAAGAAGGATTTT	GAAGACTTAAATCTGCTTCA	AGAAGCTCTTAAAGAGAAAAC	TTAGGAACCAGCTATTTCTA
1921	ATAGTTTTGGATGATGTTG	GTCTGAAAGCTATGTTGAT	GGGAGAAAATAGTGGGCCCA	TTCTTGGCGGGTCTCCCTG
2001	AAGTAGATAATCATGACAAA	CTCGGAAGGACAAATGCTC	AGAAAAGCTGGGCTTTTCTCA	TCAAGACCTCTGGAGGGTTC
2081	TATCACAAAGATGATGCTTTG	TCPTTGTGTTGCTCAACACCG	ATTTGGTGTACCAAACCTTTG	ATTCAACCTCAACCTAAGG
2161	CCACATGGAGAACTGTTTGT	GAAGAAATGTTGATGGCTTAC	CTCTAGCTTAAAGAACACTT	GGAAGGTTATTAAGGACAAA
2241	AACAGACGAGGAAACATGGA	AGGAGCTGTTGGATAGTGG	ATATGAGGTTAGGAAAGAG	CGATGAGATTTGTTCCGGCTC
2321	TTAGACTAAGCTGAAATGAT	CTTTCGCCCTTTGGAAGCT	RTTFTTTGCTATVTCCTCCT	TGTTTTCCCAAGCTATGAG
2401	TTTGACAAGGAGGATTTGAT	TCTATTTGTTGATGGCAGAG	GGTTTTTTCRCCAACCACT	AYAACAAGTCAAAGCAAGG
2481	KTTGGGCTCTGAAATTTTTR	AAGAGTTTGTGCAAGRTCR	TTTTTTCAACATGCTCTTAA	TRRCAATCTSTGTTTGTGA
2561	TGCATGACCTAATGAAATGAT	TTGGCTACATTTGTTGCTGG	AGAATTTTTTTCAAGGTTAG	ACATAGAGATGAAGAAGGAA
2641	TTTAGGATGSAATCTTTGGA	RAAGCACCGMCATATGTCAT	TTGTATGTGAGRATFACATA	GGTTACAAAARGTTCCGAGCC
2721	ATTTAGAGGAGCTAAAATTT	TGAGAACATTTTTCAGATTG	TCGTTGGGGTGGTAGAAGA	TTGGAAGATGTTTTACTTAT
2801	CAAACAAGGCTTTGAAATGAC	WTACTTTCARGAATTAACAT	GTTAAGGGTCTTRAKTTTGA	TTTRTCTTAYAATAASYRAG
2881	GTACCARAATCTGTSGGTAG	TATGAASCATTTGCCGTATC	TTAATCTATCWGRAACTTWA	ATCACMCAATTTACCGGAWA
2961	TKTCTGCAATCTTTATAATT	TACARACCTGATTTGTTCT	GGCTGTGAMTATTTAGTTAA	KTTGCCCAARACCTTCTCAA
3041	ASCTTAAAAATTTGCCASCAT	TTTGACATGAGGRTACTCC	KAANTTRAARAACATGCCCT	TARGGATTTGGGARTTGA
3121	ARTCTCAAACTCTCTTPTMG	TAACATTTGCCATAGCAATAA	CCGAGCTTAAAGAACTTTCAM	AAAAAGGTTWAATGARTTA
3201	TATTGGCGGGCTGGGAAAAA	TGGAATAATGCMGTGGATGC	ACGTTAAGCGAACTTGTCTC	AAAAAGGTTWAATGARTTA
3281	NAAACTGGRTTGGGGGTGA	TPAATTTAATGTTTCCGAA	ATGGGAACACTTGAAAAGA	AGTCTCTCAATGAAGTATGC
3361	CTCATAAATGGTACTCTANAA	AAAACCCANAATATGCTTA	TAGGGGTTATAGAGTTTCCA	AAATGGGTTGGTTNCACTAA
3441	GGGTTTTCTGAACTAGAGAT	GTGTTCAATGGTGTATGAAA	AGANTGTTTTACGTAGTTTC	ATCAATCAACAAAGTGGGAAA
3521	TAGATGATATTTTCAGGGCY	TACTGATGAGATGTTGGAGAG	GTATGATAGGGTTCCTTTGGG	GCGGTAGAAGAAATAAGCAT
3601	CCATCTTGTAAATGAAATAA	GATATTTGTTGGAAATCAGAA	GCAGAGGCAAGTAAGGTTCT	TATGAATTTAAAGAAGTTGG
3681	ATTTAGGTTGAATGTAATAA	TTGGTGAATTTAGGGGAGAA	AAAGGAGGATAATCATATAA	TTAATAGTTGGGAGCAGCCTA
3761	ACATCTTTTAGGAGGTTGAA	TGTTAGGAGATGTAACAGCT	TGGAGCATTTGCAGGTGTCCA	GATAGCATGGAGAAATTTGTA
3841	TATGCAATGTTGRTTCAAA	TAACATCTGCTCTCCTCCCA	ACAGGAGGAGGACAGAAGAT	CAAGTCACTTACCATCACTG
3921	ATTCRAGAAGCTTTCCGAA	GAGGAGTTGGGAGGACGAGA	GAGGACAAGAGTCTTATAA	ACTCAAAAATGCAGATGCTT
4001	GAATCTGTAGATATACGTAA	TTGGCCAAATCTGAAATCTA	TCAGTGAATTTGAGTTGCTTC	ATTCACCTGAACAGATTTATA
4081	TATATCAAATGTCGAGTR	TGGAGTCAATTTCCGACCAT	GAGTTGCCAAATCTCACCTC	CTTAACAGATCGAAGGAGAG
4161	GACAGCGATTTTCGTACGAA	CGGTTACGATTCGACTGGCC	GTCGTTTT	

SEQ ID NO: 2

RLG1B

[Strand]

```

1   AACCGTTCGT ACCGAAATCG CTGTCCTCTC CTTCTGTAA TATAATGATA AGAAAAATA TGATTAAAGG
71  TTFAAAATCCA AAATCCATTA TTCCACCGGT GATATGATGC ACTAGCTGTA GTATGCAAAA ACAGTATTAT
141 AAATGCTAAC CAAAACAGCA GCTAAGAAAC AATATAAATA ATGGTTTGAA TCGTCCTTTC TCCGTACAQT
211 CATTTCTTCC AAATCCCTAT CATTCATACA TACAAGTGCT CCCATATTAG GTTTTCACTA TAAGCAATGG
281 CTGAAATCCT TGGTTCGCG TTCTTTGCGG TGTTCCTTGA AAAGCTTGCT TCTGAAGCCT TGAAGAGGGT
351 TGCTTGCTCC AAAGTAATTG ACAAGGAGCT CGAGAAATTG AATAGCTCAT GAATCAATAT AAAAGCTCTG
421 CTCAATGATG CTTCTCAGAA GGAATAAGT AAGGAAGCTG TTAAGAATG GTTGAATGCT CTTCAACATT
491 TGCTTACGA CATAGATGAT CTACTTGGCG ATTTGGCAAC CAAAGCTATC CATCGTAAGT TCTCTGAGGA
561 ATACGGGGCC ACCATCAACA AGGTACGAAA GTTAATTCCA TCTTGTTCCT CTAGTTTGTG AAGTACTAAG
631 ATGCGCAACA AGATACATAA TATTACCAGC AAGTTACAAG AACTATTAGA AGAGAGAAAT AATCTTGGAT
701 TATGTGAAT TGGTGAANGC CGAAAACCTC GAAATAGAAA ATCAGAGACC TCTNVTGCTAG ATCCATCTAG
771 TATTGTTGGA CGCACAGATG ATAAGGAAGC GTTGCCTCTC AAGCTATATG AACCATGTGA TAGAACTTT
841 AGCATCTTGC CNATAGTTGG TATGGGTGGG TPAGATAAGA CCACTTTAGG TAGACTTTTG TATGATNAAA
911 TGCAAGTGA GATCACTTC GAACCAAGG CGTGGGTTTG TGTTCCTGAT GAGTTTGATA TCTTCGGTAT
981 AAGCAAAACC ATTTTCGAAT CGATAGAGGG GGGAAACCAA GAGTTTAAGG ATTTAAATCT CCTTCAGGTG
1051 GCTTFAAGG AGAAAACTC AAAGAAACGA TTCTTGTGTG TTCTTGATGA TGTATGGAGC GAGAGCTATA
1121 CTGATTGGGA AATCTAGAA CGTCCATTTC TAGCAGGAGC ACCAGGAAGT AAAGTAATCA TCACAACCCG
1191 CAAGTTGTCG TTGCTAAACC AATTGGGTCA TGATCAACCA TACCAATTGT CTGATTTGTC ACATGACAA
1261 GCTCTAATCT TATTTGTGCA ACACGCATTT GGTGTAAATA GCTTTGATTC ACATCCGATA CTTAAACCAC
1331 ATGGTGAAGG TATTGTTGAA AAATGTGATG GTTTGCCATT GGCTTTGATT GCACCTGGGA GGTATTGAG
1401 GACAAAAGA GATGAGGAAG AATGGAAGGA ACTATTGAAT AGTGAGATAT GGAGGTTAGG AAAGAGAGAT
1471 GAGATTAATC CGGTCTTAG ACTAAGCTAT AATGATCTTT CTGCCCTTTT GAAGCAGTTG TTTGCATATT
1541 GCTCCTTGT CCCCAAAGAC TATGTGTTCA ACAAGGAGAA GTTGATTTTA TTATGGATGG CAGAAGGGTT
1611 TTTGCACAAT GAAAATACAA ACAAGTCAAT GGAACGCTTA GMTCTGAAT ATTTTGACGA CTTGTGTGCA
1681 AGGTCTTTT TTCAACATGC ACTCGATGAC AAATCGTGT TGTGGTGA CAACCTCATG AATGACTTGG
1751 CCACATCTGT TGCTGGAGAT TATTTTTTAA GATTAGACAT TGAATGAAA AAGGAAGCTT TGGAAAAATA
1821 CCGACATAG TCATTTGTTT GTGAGAGTTA CATGGTTTAC AAAAGGTTCC AACCATTTAA AGGAGCTAAA
1891 AAATTGAGAA CTTTCTTAGC AATGCCTGTT GGGATGATAA AAAGTTGGAC AACATTTTAC TTATCAATA
1961 AAGTCTTGA TGACTTACTT CACGAATTAC CATTGTGTAG AGTCTAAGT TTGAGTTATC TTAGCATCAA
2031 GGAGGTACCT GAAATAATAG GCAATTTGAA AACTTGCAG TATCTTAATT TATCACACAC GAGTATCACA
2101 CATTTACCAG AAAATGTCTG CAATCTTTAC AACTTACAAA CATTGATCCT TTGTGGCTGT TGTTTTATA
2171 CCAAGTTTCC CAACAACCTC TTAAAGCTTA GAAATTTACG GCATTTGGAC ATTAGCGATA CTCCCGGTTT
2241 GAAGAAAGAT TCCTCGGGGA TTGGTGAATT GAAGAACCTA CACACYCTCT CCAAGCTCAT TATTGGAGGT
2311 GAAAATGAGC TAAACGAGCT TAAGAACTTA CAAAATCTCC ATG

```


RLG1b - Diana
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTTCTGAT GAGTTTGATA TCITCAATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAABAG
211 AGAAGATCTC AAAGAAAAGa TTTCTTCTTG TICTTIGATGA TGTTTGGAGT GAAAGCTATA CCGATTGGGA
281 AATTNTAGAA CGCCCATTTT TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTIGTC ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGGAGG
491 TATTGTTGAA AAATGTGATG GATTGCCATT GGCATTGTCTG ACATGATGAT GATG
```

SEQ ID 137

SEQ ID NO: 3

RIGLC
[Strand]

```

1   TCCCCTGCAA CGTNTATCAT TCAGAAGGNC CCAAAGACCA NAGATNTGTT TAANGNTGNT TINCAGAAGG
71  AAGTAATTGA TGAAGCTGTN AAAAGATGGC TGAATTGATNT CCAACAATTG GCTTACGACA CTGANGACNA
141 ACTTGATGAT NTCGCAACAG AAGCTATTCA TCGTGAGTTG ATCCGTGAAA CTGGAGCTTC CNCCAGCATG
211 GTAAGAAAGC TAATCCCAAG TTGTTGCACA AGTTTCTCAC AAAGTAATAG GATGCATGCC AGGTTAGATG
281 ATATTGCCCG TAAGTNACAA GAACTGGTAG AGCCGAAAAA TAATCTTGGT TTAAGTGIGA TAACATACGA
351 AAAACCCAAA ATTGAAAGAG ATGAGGCGTN TTTGGTAGAT GCAAGTGGTA TCATIGGACG TGAAGATGAT
421 AAGAAAAAAT TGCTTCAGAA GCTGTTGGGG GATACTEATG AATCAAGTAG TCAAAACTTC AACATCGTGC
491 CCATAGTTGG TATGGGTGGG GTAGGTAAAA CAACTCTAGC TAGACTTTTG TATGATGAAA AAAAAGTGAA
561 GGATCACITC GAACTCAGGG TTTGGGTTTG TGTTTCIGAT GAGTTCAGTG TTCCAATAT AAGCAGAGTT
631 ATCTATCAAT CTGTGACTGG TGAAAACAAA GAATTTGCAG ATTTAAATCT GCTTCAAGAA GCCCTTAAAG
701 AGAAACTTCA GAACRAACTA TTTCTAATAG TTTTAGATGA TGTATGGTCT GAAAGCTATG GTGATTGGGA
771 GAAATTAGTG GGCCCATTTT ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTACTCG GAAGGAGCAA
841 TTACTCAAAC AGCTGGGTTT TTCTCATGAA GACCCCTTGC ATAGTATAGA CTCCCTGCAA CGTCTATCAC
911 AAGAAGATGC TTTGTCTTTG TTTTCTCAAC ACGCATTTGG TGTACCTAAC TTTGATTCAC ATCCAACACT
981 AAGGCCATAT GGGGACAGT TTGTGAAAAA ATGTGGGGA TTGCCTTTGG CCTTGT

```

SEQ ID NO:4

FLG1D

[Strand]

```

1   CNTACCTTC TACGAGATCG CTGTCCCTCC TCGATCTGCT TAACGATGCT TCCCAGAAGG AAGTNACTAA
71  TGAAGCOGTT AAAAGATGGC TGAATGATCT CCAACATTTC GCTTATGACA TANACGACCT ACTTGATGAT
141 CTTCACACAS AAAGCTATTC NTCSTGAGTT GACCGANGAA GGTGGAGCCT CCACCAGTAT GGTAAGAAAA
211 CTAATCCCAA GTTGTTCAC AAGTTTCICA CAAAGTTATA GGATGCATGC CAAGTTAGAT GATATTGCCA
281 CCAGGTTACA AGAACTGGTA GAGGCAAAAA ATAATCTTGG TTTAAGTGTG ATAACATATG AAAAGCCCAA
351 AATTCGAAAG TATGAGGCAT CTTTGGTAGA CGAAAGTGGT ATTTTGGGAC GTTNAGATGA TNAGAAAAAA
421 TTGATGGAGA AGCTGTGGGA GGATAAAGAT GAATCCGGAG TCNAACTTC AGCATCCTGC CCATAATTGG
491 TATGGGTGGA GTTGGCNAAA CAACTCTAGC TAGACTCTTG TTTGATGAAA AGACAGTGAA GGATCACTTC
561 GAACTCAGGG CTGGGGTTTG TGTTCCTGAT GAATTCAGTA TTCTCAACAT AAGCAAAGTT ATCTATCAAT
631 CTGTGACCCG GGAARAAGAA GAGTTTGAAG ACTTAAATCT GCTTCAAGAA GCTCTTAGAG GGAAACTACA
701 AAACAAACTA TTCTAATAG TTTTGGATGA TGTATGGTCG GAAAGCTATG GTGATTGGGA GAAATTAGTG
771 GGCCCTTTTC ATGCTGGGAC TTCGGAAGT AGAATAATCA TGACTIONCG GAAGGAGCAA TTACTIONAAC
841 AGTTGGSTTT TTCTCATCAA GACCCTCTGC GTTGTATAGA CTCCCTGCAA CGTCTATCAC AAGATGATGC
911 TTTGTCTTTG TTTGCTCAAC ACCGATTGG TGWCCA

```

RLGLE
[Strand]

```
1   TCTAGCTAGA CTTTGTATG ACGAGATGCA AGAGAAGGAT CACTTCGAAC TCAAGGCGTG GGTITGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAAGAAT
141 TTAAGGACTT AAATCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTCAAAG AAACGATTC TACTTGTTC
211 TGATGATGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT CTGGAACGCC CATTTCITGC AGGGCAGCC
281 GGAAGTAAAA TTATCATGAC GACCCGGAAG CAGTCATTC TAACCAAAC CGGTTACAAG CAACCTTACA
351 ACCTTCCGT TTTGTACAT GACAGTGCTC TCTCTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CGATTCCAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCT
```

SEQ ID NO:5

RLG1F
[Strand]

```

1   ATTTTCNGCT CNAACAAAN AAAAGCAATG GCTGAAATCT TTCTTTGNGC ATTCTAGACC AGTATTCTTT
71  GAAAAAGNTGG CTTCTGAAGC CTTGAAGAAG ATCGCTCGCT TCCATCGGAT TGATTCTGAG CTCAAGAAAC
141 TGAAGAGGTC ATTAATCCAG ATCAGATCTG TGCTTAATGA TGCTTCTGAG AAGGAAATAA GTGATGAAQC
211 TGTTAAAGAA TGGCTGAATG GTCTCCAACA TTTGTCTTAC GACATAGACG ACCTACTTGA TGATTTGCCA
281 ACCGAAACTA TGCATCGTGA GTTGACCCAC GGATCTGGAG CCTCCACCAG CTTGTAAGAA AGATAATCCC
351 AACTTGTGTG ACAGATTTCT CACTAAGTAG TAAGATGCGT AACCAAGTTAG ATAATATTAC CATCAAGTTA
421 CAAGAAGTGG TAGAGGAAAA AGATAATCTT GGCTTAAGTG TGAAGGTGA AAGCCCAAAA CATACCAACA
491 GAAGATTACA GACCTCTTTG GTAGATGCAT CTAGCATTAT TGGTCGTGAA GGTGATAAGG ATGCAATGCT
561 CCATAAGCTG CTGGAGGATG AACCAAGTGA TAGAACTTTT AGCATCGTGC CAATAGTTGG TATGGGTGGT
631 GTGGGTAAGA CGACTCTAGC TAGACTTTTG TATGACGAGA TGCAAGAGAA GGATCACTTC GAACTCAAGG
701 CGTGGGTTTG TGTTCCTGAT GAGTTTGATA TCTTCAATAT AAGCAAAGTT ATCTTCCAAT CGATAGGTGG
771 TGGARACCAA GAATTTAAGG ACTTAAATCT CCTTCAAGTA GCTGTAAAAG AGAAGATTTC AAAGAAACGA
841 TTTCTTNTTG TTCTGGATGA TGTTTGGAGT GAAAGCTATA CAGAATGGGA AATTCFAGCA CGTCCATTTT
911 TTCCAGGGGC ACCAGGAAGT AAGATTATCA TGACGACCCG GAAGTTGTGG TTGCTAACCA AACTCGGTTA
981 CAATCAACCT TACAACCTTT CSGTTTTGTC ACATGATAAT GCTVTGTCTT TATTCTGTCA GCAYGCATTG
1051 GGTGAAGATA ACTTCGATTC ACATCCAACA CTTAAACCCAC ASGGTGAAG TATTGTGTA AAATGTGACG
1121 GTTTACCATT GGCCTTTRATT GCACCTGGGA GRTTGTGTA GACAAAAACA GATGAGGAAG AATGGAARGA
1191 AGTGTGAAT AGTGAATAT GGGGTCAGG AAAGGGAGAT GAGATTGTTC CGGCTCTTAA ACTAAGCTAC
1261 AATGATCTCT CTGCTCTTT GAAGAAGTTG TTTGCATACT GCTCCTTGTT CCCAAAAGAC TATGTGTTCG
1331 ATAAGGAGGA GTTGATTTTG TTGTGGATGG CAGAAGGGTT TTTGCACCAA TCAACCACAA CCAAGTCBAT
1401 GGAACGCTTG GGHCATGAAG GTTTTIGATGA ATTGTGTGCA AGATCATTTT TTCAACATGC CCCTGATGCC
1471 AAATCGATGT TTGTGATGCA TGACCTGATG AATGACTTGG CHACATCTGT TGCTGGAGAT TTTTPTTCAA
1541 GGATGGACAT TGAGATGAAG AARGAATTA GGAAGGAAGC TTTGSAAAAG YAYCGCCATA TGTCAWTTGT
1611 TTGTGAKGAT TACATGGTKK ACAAAGGTT CRAGCCATTS ACAAGGAGCT AG
    
```

SEQ ID NO: 6

RLG1G
[Strand]

```
1  GTGAAGGATC  ACTTCGAACT  CAGGGCTTGG  GTTTGTGTTT  CTGATGAATT  TAATATCCTC  AATATAAGCA
71  AAGTAATTTA  TCAATCTGTA  ACCGGGGAAA  AAAAGGAGTT  TGAAGACTTA  AATCTGCTTC  AAGAAGCTCT
141 TAAAGAAAAA  CTTTGAATC  AGTTATTCT  AATAGTTCG  GATGATGTGT  GGTCTGAAAG  CTATCGTGAT
211 TGGGAGAAAT  TAGTGGGCC  ATTTTTTCG  GGGTCTCCG  GAAGTATGAT  TATCATGACA  ACTCGGAAG
281 AGCAATGCC  AAGAAAGCTG  GGTTCCTC  ATCAAGACC  TTTGCAAGGT  CTATCACATG  ACGATGCITT
351 GTCTTGTIT  GCTCAACACG  CATTTGGTGT  ACCA
```

SEQ ID NO:7

RLGH

[Strand]

```
1   TCTAGCTAGA CTTTGTATG AGGAAATGCA AGGGAAGGAT CACTTCGAAC TCAAGGCGTG GGTATGRTT
71  TCTGATGAGT TTGATATCTT CAATATAAGC AAAATTATCT TACAATCGAT AGGTGGTGGG AACCAAGAAT
141 TTACGGACTT AAACCTGCTT CAAGTAGCTT TAAAAGAGAA GATCTCAAG AAAAGATTTC TTCTTGTCT
211 TGATGATGTT TGGAGTAAA GCTATACCGA TTGGGAAATT CTAGAACGCC CATTTCCTGC AGGGGCRCTT
281 GGAAGTAAGA TTATTATCAC CACCCGGAAG CTGTCATTGT TAAACAACT CGTTTACAAT CAACCTTACA
351 ACCTTTCGGT TTGTTCACAT GAGAATGCTT TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CAATTCACAT CCAACACTTA AACCACATGG CGAAGGTATT GTTGAAAAAT GTGAT
```

SEQ ID NO: 8

RLGI
[Strand]

```
1  TCTAGCTAGA CTTGTGTATG ATGAGATGCA AGAGAAGGAT CACTTTGAAC TCAAGGCCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAGAAT
141 TTAAGGACTT AAACCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTTAAAG AAACGATTTC TTCTGTTCCT
211 TGACGACGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT NTGGAACGCC CATTTCCTGC AGGGGCAGCC
281 GGAAGTAAAA TTATCATGAC AACCCGAAAG CAGTCATTGC TAACCAACT CGGTACAAG CAACCTTACA
351 ACCTTCCCGT TTTGTCACAT GACAGTGCTC TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGGTAAGT
421 CGATTACAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCTGGATT GCCATGGCA
491 TTGTCGACA
```

SEQ ID NO. 9

RLGLJ
[Strand]

```
1 TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71 GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTCCTGAT GAGTTTGATA TCTTCAATAT AAGCAAATTT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAAG
211 AGAAGATcTC AAAGAAAAGa TTCTCTCTG TTCTTGATGA TGTTGGAGT GAAAGCTATA CCGATIGGGA
281 AATINTAGAA CGCCCATTC TTGCAGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAACA AACTCGGTA CAATCAACCT TACAACCTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGaAGG
491 TATIGTTGAA AAATGTGATG GaTTGCCATT GGCATTGTG ACATGATGAT GATG
```

SEQ ID NO: 10

RLGIA aa.

IVTVRTR?LSLLHLLSYVIFS?I?PH?ILWLF.INFYSTCHFMSFSILLSFT.YLNVITINAYLFFFK.THIIYR
LKSUNT.VKLI.YICSSPVYLYVSSLIYLLFIY.SR.SL.Y.KFNLFKI.NY..SHNLNKIKKNGPTISPSLFQINIV
SILLRFHPNQYFQRM TDSYGVSEFAFRHCSLKEIINQMELLOCSLLMKGELYVK?MSAI?LHPEPTLSV
YHQTTQNGGSR?T?KS.RIDYFCPHGLTEERV.FIIFL.?KNYRSIEFLHRQRSFTSQCFVKQFLIFLSFR.NS
SIATCNLQLLGPOICGGR.FNPHIHCKQ.FKSISVHPIHQHLLIIEIHHASSISSTSIYSLLSY.TMAEIVLS
AFLTUVFEKLA?EALKKIVRSKRIESELKKLKETLDQIQDLLNDASQKEVTNEAVKRWLNDLQHLAYDID
DLLDD?ATEAV?RELTEEGGASSSMVRKLPSCCTSFSQSNRMHAKLDDIATRLQELVEAKNNLGLSVI
TYEKP KIERYEASLVDES GTVGREDDKKKLEKLLGDKDESGSQNFSVPIVGMGGVGTTLARLLYDEK
KVKDHFELRAWVCVSDEFSVPNISRVIYQSVTGEKKEFEDLNLLOEALKEKLRNQLFLIVLDDVWSESY
GDWEKLVGPFLAGSPGSRIMTTRKEQLLRKLGFSHQDPLEGLSQDDALSFAQHAFGVVPNFD SHPTLR
PHGELFVKKCDGLPLALRTLGRLLRKTDEEQWKELLDSEIWRLGKSDEIVPALRLSYNDLSA?LKLFA
YCSLFPKDYEFDKEELLLWMAEGFLHQPT?NKSKQRLGLEYP?ELLSRSFFQHAPN?KSLFVMHDLMDND
LATFVAGEFFSRLDIE:MKKEFRM?SLEKHRHMSFVCE?YIGYK?FEPFRGAKNLR TFLALS VGVVEDWK
MFYLSNKV LND?LQDLPLLRVL?LI?L?I??VP??V GSM?HLRYLNLS?T?ITHLPE??CNLYNLQTLIV
SGC?YLV?LPKTF?LKNL?HFDMR?TP?LKNMPL?IGELK?LQTLF?NIGIAITELKNL?NLHGK?CIGG
LGKMENAVGCTLSELVSKKV?..??NW??G..I.CFPKWEHLKKKSSMK.CLIMVL?KKP?IMSIGGIEFPN
WVGLSRVSETRDVFMVYEK?CFT.FHQSPSGK.MIFSG?TDEMWRGMIG?LGAVEEISIHSCNEIRYLWE
SEAEASKVLMNLKLDLGECEENLVSLGEKKEDNHNINSGSSLTSFRRLNVWRCNSLEHCRCPPDSMENLY
MHMCDS?TSVSFPTGGGQKIKSLTITDCKKLEEEELGGRERTRVLINSKMQMLESVDIRNWPNLKSISEL
SCFIHLNRLYISNCPS?ESFPDHELPNL TSLD RRRRGQRFSYERLRFDWPSF

SEQ ID NO:11

RLGIB a.a.

NRSYENRCPLLPVI...EKI.LKV.IQNPLFHR.YDALAVVCKNSIINANQNSS.ETI.IMV.IVLSPTYTHFFQIPII
HTYKCSHIRFSLAMAEILGSAFFAVFFEKLASEALKRVACSKVIDKELEKLNSS.INIKALLNDASQKEIS
KEAVKEWLNALQHLPYDIDDLGDLATKAIHRKFSEEYGATINKVRKLIPOCFSSLSSTKMRNKIHNITS
KLQELLEERNLGLCEIGESRKLNRKSETS?LDPSSIVGRTDDKEALLKLYEPCDRNFSILPIVGMGGL
DKTTLGRLLYD?MQVKDHFELKAWVCVSDDEFDIFGISKTFESIEGGNQEFKDLNLLQVALKEKISKKRFL
VLDDVWSESYTDWEILERPFLAGAPGSKVIITTRKLSLLNQLGHDQPYQLSDLSHDNALSIFCQHAFG
VNSFDSPILKPHGEGIVEKCDGLPLALIALGRLLRTRKDEEWEKELNSEIWRGKRDEIIP?LRLSYND
LSASLKQLFAYCSLFPKDYVFNKEKLILLWMAEGFLHNENTNKSMERL?LEYFDDLLSRFFQHALDDKS
LFVVHDLMNDLATS VAGDYFLRLDIEMKKEALEKYRHMSFVCESYMVYKRFEPFKGAKKLRTFLAMPV
GMIKSWTTFYLSNKVLDLLHELPLLRVLSLSYLSIKEVPEIIGNLKHRLRYLNLSTHSITHLPENVCNLYN
LQTLILCGCCFITKFPNNFLKLRNLRHLDISDTPGLKMKSSGIGELKNLHTLSKLIIGGENRLNELKNLQNL
H

SEQ ID NO:12

RLG 1 c a a.

SRAT?IIQK?PKT?D?F????QKEVIDEAVKRWLID?QQLAYDT?D?LDD?ATEAIHRELIRETGAS?S
MVRKLIPSCCTSFSQSNRMHARLDDIAAK?QELVEAKNNLGLSVITYEKPKIERDEA?LVDASGIIGRED
DKKKLLQKLLGDTYESSSQNFNIVPIVGMGGVGKTTLARLLYDEKKVKDHFELRVWVCVSDEFSVPNIS
RVIIQSVTGENKEFADLNLQEQALKEKLQNKLFVIVLDDVWSESYGDWEKLVGPFHAGTSGSRIIMTTR
KEQLLKQLGFSHEDPLHSIDSLQRLSQEDALSLFSQHAFGVPNFDSHPTLRPYGEQFVKKCGGLPLAL

SEQ ID NO:13

RLG ID

?T?LRDRCPSSICLTMLPRRK?LMKPLKDG.MISNIWLMT?TTYLMILQ?KAI??ELT?EGGASTSMVRK
LIPSCCTSFSQSYRMHAKLDDIATRLQELVEAKNNLGLSVITYEKPKIERYEASLVDESGIFGR?DD?KK
LMEKLLDKDESGVKLQHLPIIGMGGVG?TLARLLFDEKTVKDFELRAWVCVSDEFSILNISKVIYQS
VTGEKKEFEDLNLLQEALRGKLNKFLIVLDDVWSESYGDWEKLVGPFHAGTSGSRIIMTTRKEQLLK
QLGFHQDPLRCIDSLQRLSQDDALSIFAQHAFG?

SEQ ID NO: 14

RLGIE

LARLLYDEMQEKDHFELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKISKKRFLLVLD
DWSESYADWEILERPFLAGAAGSKIIMTTRKQSLTKLGYKQPYNLSVLSHDSALSFCQHALGEDNF
DSHPTLKPHEGIVEKCA

SEQ ID NO: 15

RLGIF

FSA?NK?KQWLKSFF?HSRPVFFEK?ASEALKKIARFHRIDSELKCLKRSLIQIRSVLNDASEKEISDEA
VKEWLNLGLQHLSYDIDDLDDLATETMHRELTTDLEPPPACKKDNPTCCTDFSLSSKMRNKLDNITIKL
QELVEEKDNLGLSVKGESPKHTNRRLQTSLVDAASSIIGREGDKDALLHKLLEDEPSDRNFSIVPIVGMGG
VGKTTLARLLYDEMQEKFELKAWVCVSDEFDIFNISKVIFQSIGGG?QEFKDLNLLQVAVKEKISKKR
FL?VLDDVWSESYTEWEILARPFLAGAPGSKIIMTTRKLSLLTKLGYNQPYNLSVLSHDNALSFCQHA
LGEDNFDSHPTLKP?GESIVEKCDGLPLALIALGRLL?TKTDEEEWKEVLNSEIWGSGKGDÉIVPALKLS
YNDLSASLKKLFAYCSLFPKDYVFDKEELJLLWMAEGFLHQSTTSKSMERLGHEGFDELLSRFFQHAPD
AKSMFVMHDLMNDLATS VAGDFFSRMDIEMKKEFFRKEAL?K?RHMS?VC?DYMV?KRF?P?TRS.

SEQ ID NO: 16

RLGIG

VKDFELRAWVCVSDEFNILNISKVIYQSVTGEKKEFEDLNLLQEALKEKLNQFLVLDVWSESYR
DWEKLVGPPFFSGSPGSMIIMTTRKEQLPRKLGFPHQDPLQGLSHDDALSIFAQHAFGVP

SEQ ID NO: 17

RLG 1 H

LARLLYEEMQGKDHFKAWWCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLQVALKEKISKKRFLLVLD
DVWSESYTDWEILERPFLAGAPGSKIITTRKLSLLNKLGYNPYNLSVLSHENALSIFCQHALGEDNFN
SHPTLKPHGEGIVEKCD

SEQ ID NO: 18

RLGI I

LARLVYDEMQEKDHFELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKILKKRFLLVLD
DVWSESYADWEI?ERPFLAGAAGSKIIMTTRKQSLTKLGYKQPYNLSVLSHDSALSFCQHALGEGNF
DSHPTLKPHEGIVEKCAGLPLALST

SEQ ID NO: 19

RLG 15

EFGVGKTTLARLLYEEMQGGKDFELKAWVCVSDEFDIFNISKIILQSIGGGNQEFDTLNLRLVALKEKISK
KRFLLVLDDVWSESYTDWEI?ERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSLFCQH
ALGEDNFNSHPTLKPHG?GIVEKCDGLPLALS

SEQ ID NO: 20

SEQ ID NO: 21
RLG 2A

1 TTNACACCAT AAATTCNA CCTGNGGGGA CAAAAACCTA AAAATGGTCC ATAATGCNCA AATCAGNAAG
71 GTTGANAAG CTCTAAGTTT TINACCTCCA NCTGATGCNC NNTCCNTA AAGTTCANAT CCAAGCTTGC
141 CCTCCAACCTC TANCNCTTC AATGGCACCT CCTTCTCTC AAAAGCACAC AAGAACACTT TCAAGCTCAA
211 CCACACTCAC ACAAGCTCTA GAACNAGGGT TAGGGCACAT TTAGGGTTTT GCTCTCTGGA AATGGTGTCT
281 AAAAGTGAGG CCATAATGTT CCTTATATAA GGCTCACTCC CACAATTAGG CTTTCAATCT GAACGTANTA
351 CGCCAGTGT ACACATAGGT ACGCCCAACG TACTCGGTAG TCTCCGGTC AANAATACAC TCATGAGTAC
421 GCGCAACGTA CTTTCCCTTA CGCCAGCGT ACTCAAAAGC CAAACATCT TTTCAAGGAC TAATTTTGAC
491 AACCTGAGGA AAGAAAAGGA TCAAAGANAT ATACTTGAAT TCCGGGATGT TACAATGAAG TTGANACTT
561 GGCTAAAAA TTAATTTGGT TGTGGAAGCC GTTGGCTGAG CAAGCAACAA GGGTAAAAAT CGTAATCTAC
631 AAATGGTGT ATTTTCTATT TCTTCTTATT ATTTTACTTG ATTTACGGGT AGTTTTTTTT TCTTACAAAA
701 AATATTAAG TTGATAAAGT ATAGCCACTA AAATTGACTT TTTCCAAAAC ATAAATGTC AAATGGTGT
771 TATGTATCAT GTTGTATTAN ATAATGAATA TGATGATNCT GTTCTATTTA ANCCGAAAAA ATTATCTAAT
841 GATTTTATAT TGGAAAACAA AGTTGTGATT TTTNGCATAA TATAATCAA TCCNCTTTTG TNGGGAGGT
911 GGATAAATGT GGTAAATTTA NAACAAGTGT TTTNACNTG AAGGGTNGG AAAGTTGAA AAAAGTTAA
981 ATGATAAAT GTTTACACAA ATGTTGTATC CGACTGAATA TNAATTTAA GGATNATTGT ATTAATTTGT
1051 TGATATATAG TAAGCATAAA TATTTAGAAT TGTGACTTAA ATTTATAAGT TATNCAACT GGATTGAAAC
1121 ATTTTGTATA TANATFAGGA ATGAAAATGA GCAACCCTAA CACTTATC TTTGGTAGTT TGGTTATTAT
1191 ATTTTATATA NAATATAGAA NCATCCCTTT ATTTTAAACC CATATTTGG ACGGACTTGA ATAAATGGGA
1261 AAAATGTACC TTGCTATTTA GCACAAAAA ATTATAAAA TGTACATTC TATTTAGCAC AAACAAAAA
1331 AAAAACTTA TCCTTTTGGC ATTAGGTCAC AAAGAAATAT AAAATGGGAA ATGTGTTGCT ATTTAATGCA
1401 CTAAAAAGAA CTATTTTGGC TTTATTAAAC CCGGTAACC AATAGAAAAA TGGAAATGTA TTGCTATTTA
1471 GCATGAAAAA AAATAACTTT CCATTTTTTG CATCCGGTCA CAATAATAGA AAAATGAAAG TACGTTGCTA
1541 TTTAGCGAAA CTAACCTTCT TTTTCTTTTT TGCCATCGTA TCATAAAAA TAGACTAAAA TACGTTAGTT
1611 TTACATTTTT AATACATTTA AATGCTAAT CCACATGTTA TTCTATAAAA AGGGAAATGT AATTTACTTA
1681 TTCTTTGATT CTTTGGCTTC TTTTGTAGTAC CCAAAACATC CCTCTATCCA TCTATTCCAA CTAAAAATAAT
1751 GAAAACATA TTCCCTCCAT TGTAGGGATG TTATAAATTT TGAATTTGT TTTATGCAA AAAGTGTTTT
1821 TTGTTAACTA GATTAACGAG ATTCATTTTT GAGGTCCCTA TATGCTCAA AAATAGCAA TGAGAAATTT
1891 GTGCAAGCCA AGTTCTTTAA CATGGAATAT GAGGTCCCTA TATGCTCAA AAATAGCAA TGAGAAATTT
1961 TTTAAATTTG ATCCCATATA AAGAAAATTT GTTAATGTTT GTTTTAAAT TGGTCAATGT GTCCACCGGA
2031 TGAGCAATAA ACTAGTTTAT AAGGGTAAAC CGTGGGTTG GTGGGCCCAT TTATCTTTAT TATTTCTAAA
2101 AGTCAGAAAT AAGTAAAAA AATTATAAGA TAAATACCAT AAGGATAAAA AATCATTTTA TTTGGACCAA
2171 AGACCAAGT TGTAAAGGGG CIGTTTGT TTTTGTGAA GAGCTGTGCA ACCACTTTTG TCTGCGCCG
2241 ACAGACACG TCGACACATA TCCCTCGCA GAGTGTGT TTTTGAAG TCGCCAGACC AAAAAACGT
2311 CTGCGCAGG TCATCTGGC GCATATATGT GTCACGTCT TCAAGGTCT TCAGACTCA TTTTAAACCA
2381 AAAAAAAA GACCACCGGT TTTTTTTTT TTTTNTCT TTCTCTGTA GCTGAAAATG CATTTTTAAT
2451 CTTTATGACA TGAATTAAG TTTGAAAAAT TAATTTATTT CAACAGCTGT AGACGTTAAA AACAAACAGT
2521 CTTCTTTG TCGACTGGG ACATTTGGTC CACCTCTCT ACCCGAGAGA CTTGCGAGT TGGTCCCGAG
2591 ACTGACAGCA TTTTGGCTTC AAATAAACAA ACATCACCTA ATTTGACTAC ACCACCGGA CCTCCAATGT
2661 AACAAAAAA AGGTTGAAAC AAAGTTGCTT ATTTCTCCAT ATCCAGGGG CATTTATGTA AGAGTTATCT
2731 AAAATTTAGT TCGGTAGATC AGTTCTACA TTTTAAACCG GTAAAGTGT TGTGTGACG CGCGCACCTG
2801 AAAGTTTGA ANGTAACTTC CAACTGAAN CAANAATCGA TATGAAGTAT CAAGTTAGAG GTTCAATTTG
2871 TGAAGGAAT AGCTGGAGGT TGGGGAATCG AGCTTCCACT ATTAAGGTAA AATCCATAAC CCTAAAATGT
2941 GGTACGCTCA TATATCAAA TGGGTGTTTT GTTGAATGAA AAAAGCATG TCAAAAAACC AGTGTAGGC
3011 ACGGTATATG ACATATTTAT AGTTACTGAT AACAAATTTAT GATAATTTTG GGTTTACGTA AGTTAGGATT
3081 CGTACTTCAA CCAAAATGTA TAGTTTTTGT GAGTCTATCT ATGTATTTGG GGAATCATAT TAGCAACGGG
3151 ATGTACTAG TAATTCGAAA AAGTCTTTTA AATAATTTTT CTGTTTATA TTTATGATA GTTTTAGCGA
3221 CATCTAATAT TAAATAGAAT GTATCTGATA TTGAATTAAT GTCTTAAATG TGAACATAGA CCTTTTCCAT
3291 TACTAATGC CTAATTTATA GTTCTAATC AATAAATTTT AATTTCTGTT TTATGCTTCT AAGACAATA
3361 AAATCCATGA TTTACCTTTA AATATTAACA AAAATGACCA TAAATAAATA AAAATFAGG ATACCAAAAC
3431 CCCCCGCCAT GCCCAATGTC TAAATATCT TAGATCTTTT GCTTTTCCCT CTTTCTCTTG TTAGCTTATT
3501 ATTTCTGAGA GTTTGAGAGA GTTTCATACA AGAAAATTTT AAGAAGAAAG CAAAGGTCCA GGTATTTCT
3571 TTTCTAAT ATGTATTAAC TTACAAGCAT TTTTACACG ATCCATGTTT TTTTGTGTAT GTTTTCAA
3641 TTGAAACTAG ATTTGGACTT TTGCCCTTGA TGATTCATAA GATAATGCAAT GGAGTTGAGA TGTGTAAGA
3711 AAAGTGTGA ATAGAAAGAG CAAGTGAATC CAGATATAGT ATTTGTAATA TATGATGATG AGATAGAGAT
3781 ATGTTAAAAC TGGCTAGAAA ATTTGTTTTAA TTTGAAATTT AGGTGTTTGA ATTTGAAAGA TACCAAGCTA
3851 AFAACTAAT AGTTATGCTA AATAGTTATA AAGAACAACA AACTCGTAGT TTTTCTTCA TGAATTTCAA
3921 CCTCTCTGTA CCAAACTAAA TTATAACAAA ATTTGAATATC ATTTCTGCA ATCAATTTTA ACTTTTGTTA
3991 TTATCTCAT GTCTAAAAT GCCACAAGT TATTTTCTA GTCATATGG ATTATGAAAG GACTATTTTT
4061 ACCAATZACA TCTTACTTT ATGGCCAAAG CTAATACAAT CCGACTAAAC TAAAGGATTC TAGGATGCAAT

SEQ ID NO: 21
RLG ZA cont.

4131 ATAGTTTGGCT CCCCATTAT AGATTTCAT CTAATTTGTC TATTGTACTA ATTTAGGTCC CACCACAAGT
4201 AAATTCCTGA AATGGAATGC GTTAATGCCA TTCTTAAACC AGTTGTGCGAG ACTCTCATGG TACCCGTTAA
4271 GAAACACATA GGGTACCTCA TTTCTGCGAG GCAATATATG AGGGAATGG GTATCAAAAT GAGGGGATTG
4341 AATGCTACAA GACTTGGTGT CGAAGAGCAC GTGAACCCGA ACATAAGCAA CCAGCTTGAG GTTCCAGCCC
4411 AAGTCAGGGG TTGTTTGAA GAAGTAGGAA AGATCAATGC AAAAGTGGAA AATTTCCCTA CCGATGTTGG
4481 CAGTTGTTTC AATCTTAAGG TTAGACACCG GGTCCGAAAG AGAGCCTCCA AGATAATGA GGACATCGAC
4551 AGTGTCTATGA GAGAACACTC TATCATCATI TGGAAATGATC ATTCCATICC TTTAGGAAGA ATTGATTTCA
4621 CGAAAGCATC CACCTCAATA CCATCAACCG ATCATCATGA TGAGTTCCAG TCAAGAGAGC AAACTTTTAC
4691 AGAAGCACTA AACGCACTCG ATCCTAACCA CAAATCCCAC ATGATAGCCT TATGGGGAAT GGGCGGAGTG
4761 GGAAGACCGA CAATGATGCA TCGGCTCAA AAGGTTGTA AAGAAAAGAA AATGTTTAAAT TTTATAATTG
4831 AGCGGTTGT AGGGGAAAA ACAGACCCCA TTGCTATTCA ATCAGCTGTA GCAGATTACC TAGGTATAGA
4901 GCTCAATGAA AAAACTAAAC CAGCAAGAAC TGAGAAGCTT CCGAAAATGGT TTGTGGACAA TTCTGGTGGT
4971 AAGAAGATCC TAGTCATACT CGACGATGTA TGGCAGTTTG TGGATCTGAA TGATATTGGT TTAAGTCCIT
5041 TACCAATCA AGGTGTCGAC TTCAAGGTGT TGTTGACATC ACGAGACAAA GATGTTTGA CATGAGATGG
5111 AGCTGAGTT AATCAACTT TAAATGTA AATGTTAATA GAAACAGAAG CACAAAGTTT ATTCCACCAA
5181 TTTATAGAAA TTTCCGATGA TGTGATCCCT GAGCTCCATA ATATAGGAGT GAATATTGTA AGGAAGTGTG
5251 GGGTCTTACC CATTGCCATA AAAACCATGG CGTGTACTCT TAGAGGAAAA AGCAAGGATG CATGGAAGAA
5321 TGCACCTTCT CGTTTAGAGC ACTATGACAT TGAAAATATT GTTAAATGGAG TTTTTAAAAT GAGTTACGAC
5391 AATCTCCAAAG ATGAGGAGAC TAAATCCACC TTTTGTCTTT GTGGAATGTA TCCCGAARAC TTTGATATT
5461 TTACCCGAGG GTTGGTGAGG TATGGATGGG GGTGAAATT ATTTAAAAA NIGTATACTA TAGGAGAAGC
5531 AAGAACCAGG CTCAACACAT GCATTGAGCG GCTCATTCT ACAAATTTGT TGATGGAAGT TGATGATGTT
5601 AGGTGCATCA AGATGCATGA TCTTGTTCGT GCTTTTGTGTT TGGATATGTA TTCTAAAGTC GAGCATGCTT
5671 CCATTGTCAA CCATAGTAAT AACTAGAGT GGCATGCAGA TAATATGCAC GACTCTTGT AAGACTTTT
5741 ATTAACATCG AAGGATATGT CTAAGTTTCC TCACAGACCTG AAGTTTCCAA ACCTCTCCAT TTTGAACTT
5811 ATGCAATGAA ATATATCAAT GAGGTTTCCC AAAAATTTT ATGAAGAAAT GGAGAAGCTT GAGGTATAT
5881 CCTATGATAA AATGAAATAT CCATTGCTTC CCTCATCACC TCAATGTTCC GTCAACCTTC CGGTGTTTCA
5951 TCTACATAAA TGCTCGTTAG TGATGTTTGA CTGCTCTTGT ATTTGGAATC TTCTCGAATCT AGAAGTCTT
6021 AGCTTGTCTG ATCTGCCAT TGACCCGTTG CCTTCCCAA TCGGAAAGTT GAAGAAGCTA AGGCTACTGG
6091 ATTTGACGAA TTGTTATGCT GTTCGTATAG ATAATGGTGT CTTAAAAAA TTGGTCAAAC TGGAGGAGCT
6161 CTATATGACA GTGGTTGATC GAGGTCGAAA GGGGATTAGC CTCACAGATG ATAACCTGCAA GAGATGGCA
6231 GAGGTTCAA AAGATATTTA TGCAATGAA CTTGAGTTCT TTGAAAACGA TGCTCAACCA AAGATATGT
6301 CATTTGAGAA GCTACAACGA TTCCAGATCT CAGTGGGGCG CTATTTATAT GGAGATTCCA TAAAGATGAG
6371 GCACCTGAT GAAAACACAT TGAAGTTGGT TCTTGA AAAA GCGTGAATTAT TGGAACTCG AATGAACGAG
6441 TTGTTAAGA AAACAGAGGT GTTATGTTTA AGTGTGGGAG ATATGAATGA TCTTGAAGAT ATTGAGGTTA
6511 AGTCATCTTC ACAACTTCTT CAATCTTCTT CGTTCAACAA TTTAAGAGTC CTGTGCTTT CAAAGTGTGC
6581 AGAGTTGAAA CACTTCTTCA CACCTGGTGT TGCAAAACACT TTAAAAAAGC TTGAGCATCT TGAAGTTTAC
6651 AAATGTGATA ATATGGAAGA ACTCATACTG AGCAGGGGTA GTGAAGAAGA GACGATPACA TTCCCAAGC
6721 TGAAGTTTIT ATCTTTTGTG GGGCTACCAA AGCTATCGGG TTTGTGCGAT AATGTCAAAA TAATGTAGCT
6791 ACCCAACTC ATGGAGTTGG AACTTGACGA CATTCCAGGT TTCACAAGCA TATATCCCAT GAAAAAGTTT
6861 GAAACATTTA GTTTGTTGAA GGAAGAGGTA AATATAAAT TTTAATGCTA ATACATTACA AAGGATCTTT
6931 TCAGTTAAAT CTTTCAAAAT ATATTGTAAT TTGATTTGAT GGGGTATTAT TGTGAGATGG GACTATTAAT
7001 AAATGATTTAT CTTGCAGGTT CTGATTTCTA AGTTPAGAGAA ACTGCATGTT AGTATGATGT GGAATCTGAA
7071 GGAGATATGG CCTTGCBAAT TPAATATGAG TGAGGAAGTT AAGTTCAGAG AGATTAAAGT GAGTAACTGT
7141 GATAAGCTTG TGAATTTGTT TCCGCACAAG CCCATATCTC TGCTGCATCA TCTTGAAGAG CTTAAAGTCA
7211 AGAATTTGTTG TTCCATTGAA TCGTTATTCA ACATCCATTT GGAATGTTGT GGTGCAACTG GAGATGAATA
7281 CAACAACAGT GGTGPAAGAA TTATTTAAAGT GATCAGTTGT GATAAGCTTG TGAATCTCTT TCCACACAAT
7351 CCCATGCTCA TACTGCATCA TCTTGAAGAG CTTGAAGTCT AGAATTTGTTG TTCCATTGAA TCGTTATTCA
7421 ACATTGACTT GGATTTGCTG GGTGCAATTG GGAAGAAGA CAACAGCATC AGCTTAAGAA ACATCAAAGT
7491 GGAGAAATTTA GGAAGCTTAA GANAGGTGTG GAGGATAAAA GGTGGAGATA ACTCTCGTCC CTTGTTTCA
7561 GGCCTTCAAT CTGTTGAAAG CATAAGGGTT ACNAAATGTTN AGAAGTTTGA AAATGTATTC ACACCTACCA
7631 CCACAAGATTT TAATCTGGGG GCACCTTTTGG AGATTTCAAT AGATGACTGC GGAGAAAACA GGGGAAATGA
7701 CGAATCGGAA GAGAGTAGCC ATGAGCAAGA GCAGGTAAGG ATTTCAATTT CACTGTCTTA ATTAATGAT
7771 AAGCTCTCTG TTTTGAATA AAAAAGGGAC AAACCATTTT ATGACTTAAAT CTGACTTAAAT AAGTCATGTA
7841 TAAGATGACT CAACTCTTTT TTATTTATAA AATGACTACA AAATATTTT TTTTATTAGA GATCATGAT
7911 AAATGTGACT AATTTTTCAT CACTAACTT TAGTTGATAA ATCTTTATAA ATGTCACTAG TTACTTTTCA
7981 TFAAAATAAC AAATTTAATA AATTAATCAC AAAAAGCATC AACTAAAAA ATCCCAACAC CCGTAAATAT
8051 TFAAAATAAA AGGATTTAAC ATCTAATACG AACAAATTTT TTCTAAACA TGATTTGGAC CAAATATCAC
8121 CAGCAACTCA AGTTTGAAT CGATTCAGCT TAAAATTTGA CCAGCATAAT TAGATAGATG AGAGTTGAAG
8191 CTAAAGTGCC TATATAAGTT CGTTTCTTGA TTTTCTTGA TCTTGATAGC AAGTTGAATG ATTTTCTTCT

RLG 2A cont.

8261 TC AAAATTGA TAAAAATCTA CATTATAAAG AGACTAGCTT GAAAAAAAAT GGTCTAGGTG GGTCTMGGGT
8331 TCTGGTAGAT GAAGATGGAA GGGGAGAGTA TGATTTTCAA GACACAACAC ATCCTTCATT TTATTTTATT
8401 ATTATATATA TTATTTTTTG ATATCTTGCT CATATTTGTT ACAGATATGT GAGGTCTATT AATCTTTTTA
8471 AATATATAAA AAAATAAATA ACATAAATGA GAAAATTAAT TAAAGAATAA ATTAATAAGG GCACAATAGT
8541 CTTTTTAGGT AAGACAAGGA CCAAAACAGC AACAAAAATA AACAGTAGGG ACCATCCGAT TTAAAAAAA
8611 TAATTAGGGA CCAAAAACAT AAATTCCCCC AAACCATAGG GACCATTCTT GTAATTTACT CTACTTTTTC
8681 GTTTTGTTC TATTTGGGTA ACTATTTTTT TTGTACACAT CTAGGTAACG AACTTGTGTA AGTGTTCCTA
8751 TTTAGGATGT GACCTACTAC AACCGATCAT AATAGTCATA TGTGAACACT TCCAACAAC TTTACTTTA
8821 GGTGTGTACA AAAAAACAAT AGTTACCATG ATGTGAACAT ACTGAAAAAT TAATTACCTT AGCAAGTTAT
8891 TTTCCCATTT AGGTTGTATG GAAACAGTTC CGTGAGACCG TGACTTGGAT GGTAGATAAA TTTAGTAAAC
8961 TTAACCCCTT AATTAACCTA CCTTTTTCTT ATTAACCTCA TTTC AACCTA AATTCGTATT CTGTGTGAA
9031 AGTAAGTTGC ATCTTTATTT TTGTATTATC TTGTGTGATA GGATCCTTAG CATCTTTTAA TAATTTATTT
9101 GAAGGTGAAA GATCCAAC TA TTTTAAATCT GTTGGCATTT TCCATCATTT GCAACTGTTT CTGTGAAAAA
9171 AAATACCTAA AATCAAATA ACCATTTTCA AATCCAAAAT TATAAGAGAG AATTTGTAAT GGACATGGAA
9241 TCATAAAATCA TTAACACAGT TCAGTAAACA AGTTGCTAAT TACATTTCTT GCTGTGCAGA TTAGAAATCT
9311 ATCAGAGAAA GAGACATTAC AAGAAGCCAC TGACAGTATT TCTAATGTTG TATTCCTATC CTGTCTCATG
9381 CACTCTTTTC ATAACCTCCA GAAACTTATA TTGAACAGAG TTAAGGAGT GGAGGTGGTG TTTGAGATAG
9451 AGAGTGAGAG TCCAACAAGT AGAGAATGG TAACAACCTA CCATAACCAA CAACRACCTA TTATACTTCC
9521 CAACCTCCAG GAATTGATTC TATGGAATAT GGACAACATG AGTCAATGTT GGAAGTGCAG CAACTGGAA
9591 AAATCTTTCA CTCTTCCAAA ACAACAATCA GAATCCCCAT TCCACAACCT CACAACCATA AAAATTTATG
9661 ATTGCAAAAG CATTAAGTAC TTGTTTTGCG CTCATCATGG AGAACTTCTT TCCAACCTAA AGCATATCAA
9731 GATAAGAGAG TGTGATGGTA TTGGAGAAGT TGTTTCAAAC AGAGATGATG AGGATGAAGA AATGACTACA
9801 TTTACTCTTA CCCACACAAC CACCACCTTG TTCCCTAGTC TTGATTTCTT CACTCTAAGT TTCCCTGGAGA
9871 ATCTGAAGTG TATTGGTGGG GGTGGTGCCA AGGATGAAGG GAGCAATGAA ATATCTTTCA ATAATACCAC
9941 TGCAACTACT GCTGTCTCTG ATCAATTTGA GGTATGCTTT GTACATATTC AATTTATTTAT TTAATTTCTT
10011 TTTTTATTTG CAATATTTCTA TAAATAATAC ATTTTATACC CACTATACTA AGATAATAAT TACCTAGAGG
10081 GATGGAATGCT ATGACACAGC TGCTACACTT CAGAAACTCT AGTAAGGGCA GTTATGGAAG TTCAATAAAA
10151 TGATAATGGC ATCTTTTGAT GGGTAATATA GGCAATTTAA GTTTTATTTT TGTAAAGCA GTATTTAGCA
10221 AGTACTGGCC AGTAGGAGAG GAGAATATCA CCTTTTGIGA AAATCTGGTC ATTTGTACCCA GAATTTAGTT
10291 AAATGTRACA TTTTAGATAT CAGGGTCTAT CAGGTGACAG ATATTGTAGA ATAGAACAAT ATATAATATC
10361 ACCCAAAACT ATTTTTTCTA AGGTTATTTCT GTTAAATATG TGCTTTCTTG TTTTCAINGA ATINGCATTC
10431 GTATATTTTA GGTGTTAAAG TGATTTTNTC TTCAATAAAT CCCGAAATTA ATTAATAAAA AAAAAACAAA
10501 AGTACA TTTT TGATGTGGAG AGCACTGGTA TCACITTAGTA TATAAAAAGC TTGATTTTGA ATTAACITTC
10571 TTATACAAAA GTTGTGATA TAGTTTAATT AGTTTTACAT CATTTTTCCA TGTGGTGTG CAGTTGTCTG
10641 AAGCAAGTGG TGTTCCTTGG AGCTTATGCC AATACGCTAG AGAGATGAGA ATAGAATTTCT GCAATGCATT
10711 GTCAAGTGTG ATTCATGTT ATGCAGCAGG ACAAATGCAA AAGCTGAAGG AGAGGACAGC GATTTCTCGTA
10781 CGAACGGTTA CGATTCGACT GGCCGTCGTT TTACA

SEQ ID NO: 21

RLGIA a.a.

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVVEEHVNRNINISNQLVPAQV
 RGWFEEVGGKINAKVENFPSDVGSCFNKVRHGVGKRASKIIEDIDSVMREHSIIIWNDHSIPLGRIDSTK
 ASTSIPSTDHHDDEFQSREQTFTEALNALDPNHKSHMIALWGMGGVGKTTMMHRLKVVKEKMFNFII
 EAVVGEKTDPIAIQSAVADYLGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLS
 PLPNQGVDFKVLVTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIGVNIVRK
 CGGLPIAIKTMACTLRGKSKDAWKNAALLRLEHYDIENIVNGVFKMSYDNLQDEETKSTFLCGMYPE?FD
 ILTEELVRYGWGLKLFKK?YTIGEARTRLNTCIERLIHTNLLMEVDDVRCIKMHDLVRAFVLDMYSKVEH
 ASIVNHSNTLEWHADNMHDSCKRSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFKPNFYEEEMKLE
 VISYDKMKYPLLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDRLPSTIGLKKLR
 LLDLTNCYGVRIDNGVLKLVKLEELYMTVVDGRGRKAISLTDDNCKEMAERSKDIYALELEFFENDAQPK
 NMSFEKLRQFQISVGRYLYGDSIKSRHSYENTLKLVLKGELEARMNELFKKTEVLCLSVGMNDLEDIE
 VKSSQLLQSSSFNNLRVLVSKCAELKHFFTPGVANTLKKLEHLEVYKCDNMEELJRSRGSEEEITTFP
 KLFSLCGLPKLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLLEEVLIPKLEKLVSSM
 WNLKEIWPCEFNMSSEEVKFREIKVSNCDKLVNLFPHKPISSLHHLEELKVKNCGSIESLFNIHLDCVGAT
 GDEYNNSGVRIIKVISCDKLVNLFPHNPMSILHLEEELEVENCGSIESLFNIDLDCAGAIGQEDNSISLRNI
 KVENLGKLR?VWRIKGGDNSRPLVHGFQSVESIRVTKC?KFRNVFTPTTTNFNLGALLEISIDDCGENR
 GNDESEESSHEQEIEILSEKETLQEATDSISNVVFPSCLMHSFHNLQKLILNRVKGVEVFEIESESPTS
 RELVTTHHNQQQPIILPNLQELILWNMDNMSHWKCSNWNKFFTLPKQSESPFHNLTTIKIMYCKSIKY
 LFSPLMAELLSNLKHIRECDGIGEVVSNRDEDEEMTTFTSTHTTTTLFPSLDSLTLSFLENLKCIGGG
 GAKDEGSNEISFNNTTATTAVLDQFEVCFVHIQLFI.

SEQ ID NO:22

RLG 2B

SEQ ID NO: 23

```

1  AGTTTTTTTTT TTTCCCAATA TCCATTTATA TCGGATTTAT TTCTGAAATA ATTTTATCAA AACGCAGGAA
71  ACAATGTAGA ATAATACTGG TATAATTAAT TATATAAAGT TATTAGGCTG AAATCTTGAG GCTACTATAA
141  TTTAATATATC ATAATTTGAA AATCATCAAA TTGTATTTCCA TGATATATTA TGTATCAGA TAATTAATAA
211  TATGTGAGCC ACACAAATCC ACATCATCAG ACACCCACC TTATTGTCGG CTACCTCACC ACTTGCATGA
281  TCCCGACATC TTCCCAACCC CACCGACGAC TTGGGGTCTC CTTAATATAT CAATTATTTT CTGTAAAGTAT
351  TTATTTGTGT AAATGTGTAA TGTCATTTTA CCTTTTTTCT AATATATACA GAAACATAAA TTTTAAATGA
421  AATTCACCTG CGTTTCATTC TTGCATTAAT AAAAAAGACT GTACTGTTGT CAATATTTTA CTTATAACCT
491  GATTAATTA TTAAGCGTA ATTGCATAAT TTGCATTAGG TTGTAATTTT GTGTTTTATA GGGAGGGTGA
561  GGGTCACCGG GAATCAAAGC ACTTATGTAA AAGCAGGGGA AATACAAAA ATTTACTCGA AACAATTTT
631  ATTCATTTTA AGTGAGATAA TAAATGTCCTG ATTAGATTAT GAGAAGTAGG AGATTTAAGT GATATATCCC
701  ATTTAAAGA AATTGCATTA TTAATTTTGG ATCTCTTGAT GATGACAAAA TTAECTCGTG ACAGGTATATA
771  TATCATATAC AAAATGAGTG GCTATGCTTT CGCTTTCCAA AAAGCAATTA TAGTTTACT ACACCTACAA
841  ATTTTAAAG GGGTTAAACA TATCAAAAAT CTGTATAAGT AATTATATAA ATATGCATTT AACCCCTATA
911  AGAAAATGCT ACTAAGCTTG GACCATCTCA GAATTACAAT CATACCCCTC CCCTCAAAA AGATTGCTAT
981  ATATCATGTC ATTTGGCATT CATTCTTTT TCACAATTCA TAGTTCTATT CTCAAAAAAT TCGAGTTCTC
1051  GTATTTGTAA GGAAGATCAG AAGAGACTGT TCACACAGGT ACCTCTTTT ATTTATIGAT TCACATTCAT
1121  ATATGTTATT GTTTTCTTGC TTAATGGTTF CGTCAGTCTA ACTGCGCTTG CTGATTTAAA TTTCTTCACT
1191  TTCTTCCACG GATTTTTTAA ATATTAGTTT TGTAATGAA CAATTGGTGA AGGAAAGAAA CATGGGAGTC
1261  TTTTCTAAG TAAACCTAGA TACTTAGGTT ATAAGGGTAT ATGCTAAAAT GAACATATGCC CATTCACTT
1331  TGCCTTTTCT TTTACTTTTT AGTTTTTAGA ATCCAAGTTT TCATATGTAT CTCGATGTGT GAGAAGAATA
1401  GGCATTAAGAA AGGTTAAAGGA CGTACATAAA ATTGATTAAT TAGTGAATGT TCTTTGATAT CATTATTTTT
1471  ACTCTCATAA AAAGCATATA GATCAACAC AAATGTCTAC TTGTTAGTGT AACAACCTCG ACTTAATAAT
1541  GTTAATAATC AAGATTCTCT TGATTCAAC TATTTTCTAA CCGAACAAGC TCACTAAAAA CTCATATTCG
1611  TTTGAGTCTG AGTGGTTTAT ATTTGGGTT TTACATTTAA TTTTTTGTGC ATGAATGTGA AAATAGACTG
1681  CTTATTGATT CTTTGTGTTT CATTGAGTTG ATTTTCATTA TTACTACCTT ACAAATGCT CAGTGATAGA
1751  TTTCATTA TTTGCTAATT CGGTTGCTTC TAAATATGTA GGAGCTACTA AAAGCAAAA TATCCGAGCA
1821  TGTCCGACCC AACGGGGATT GCTGGTGCCA TTATTAACCC AATTGCTCAG ACGGCTTGG TTCCCGTTAC
1891  GGACCAATGA GGCTACATGA TTTCTTGCAG AAAATATGTG AGGGTCATGC AGATGAAAT GACAGAGTTG
1961  AATACCTCAA GAATCAGTGT AGAGGAACAC ATTAGCCGGA ACACAAGAAA TCATCTTCAG TTCCATCTCA
2031  AACTAAGGAA TGTTGGACC AAGTAGAAGG GATCAGAGCA AATGTGGAAT ACTTTCCGAT TGATGTATC
2101  ACTTGTGTTA GTCTCAGGAT CAGGCACAAG CTTGGACAGA AAGCNITCAA GATAACTGAG CAGATTGAAA
2171  GTCTAAGCAG ACAACTCTCC CTGATCAGTT GGACTGATGA TCCAGTCTYT CTAGGAAGAG TTGGTTCATC
2241  GAATGCTACC ACCTCTGCAT CATTAAAGTA TGATTTCCCA TCAAGAGAGA AAACITTTAC ACAAGCACTA
2311  ATAGCACTCG AACCCAAACCA AAAATTCCAC ATGGTAGCCT TGTGTGGGAT GGGTGGAGTG GGGAAAGACTA
2381  GAATGATGCA AAGGCTGAAG AAGGCTGHTG AAGAAAAGAA ATTTGTTAAT TATATTGTTG GGGCAGTTAT
2451  AKGGGAAG ACGGACCCCT TTGCCATTA AGAAGCTATA GCAGATTACC TCGGTATACA ACTCAATGAA
2521  AAAAATCAGC CAGCAAGAGC TGATAAGCTT CGTGAATGTT TCAAAAAGAA TTCCAGATGA GGTAAAGACTA
2591  AGTTCTCTAT AGTACTTGAC GATGTTTGGC AATTAGTTGA TCTTGAAGAT ATTTGGGTTAA GTCTTTTCC
2661  AAATCAAGST GTCCACTTCA AGGTCTTGTG GACATCAGCA GACTCACAAG TTTGCACTAT GATGGGGTTT
2731  GAAGCTAATT CAATTATTAA CGTGGCCCTT CTAACITGAAG CAGAAGCTCA AAGTCTGTTC CAACAATTTG
2801  TAGAACTTTC TGAGCCCGAG CTCCAGAAGA TAGGAGAGGA TATCGTRAAG AAGTGTTCGG GTCTACCTAT
2871  TGCCATAAAA ACCATGGCAT GTWCTCTTAG AAATAAAGA AAGGATGCAT GGAAGGATGC ACTTTCCGGC
2941  ATAGAGCACT ATGACATICA CAATGTTGCG CCCAAAGTCT TTGAAAAGAG CTACCACAAT CTCCAAGAAG
3011  AGGAGACTAA ATCCACTTTT TTAATGTGTG GTTTGTTTCC CGAAGACTTC GATATTCTTA CTGAGGAGTT
3081  GATGAGGTAT GGATGGGGCT TGAAGCTATT TGATAGAGTT TATACGATTA GAGAAGCAAG AACCCAGGCTC
3151  AACACCTGCA TTGAGCGACT GGTGCAGACA AATTTGTTAA TTGAAAAGTGA TGATGTTGGG TGTGTCAAGA
3221  TGATGATCT GGTCCGTGCT TTTGTTTTGG GTATGTTTTT TGAAGTCGAG CATGCTTCTA TTGTCAACCA
3291  TGGTAAATAT CCTGGGTGGC CTGATGAAAA TGATATGATC GTGCACCTTT GCAAAAAGAA TTTTATTAACA
3361  TGCAAGGGTA TGATGAGAT TCCAGTAGAC CTCAAGTTTC CTAAGCTAAC TTTAAAAGAA GATTTTGAAG CTTATGCAITG
3431  GAGATGAGTC GCTAAGGTTT CCTCAAGACT TTTATGAAG AATGGAAAAG CTCCATGTTA TATCATACGA
3501  TAAAAAGAA TACCATATGC TTCCPTTGGC ACCTCGATGC TCCACCAACA TTCCGGTGTCT TCATCTCACT
3571  GAATGTTTAT TAAAGATGTT TGATGCTCT TCTATCGGAA ATCTATCGAA TCTGGAAGTG CTGAGCTTTG
3641  CAAATCTTCA CATTGAAATG TTACCTTCCA CAGTCAGAAA TTTAAAAGAA CTAAGGTTAC TTGATCTGAG
3711  ATTTTGTGAT GGTCTCOGTA TAGAACAGG TGCTTGAAA AGTTTTGTCA AACTTGAAGA ATTTTATATT
3781  GGAGATGAT CTGGGTTTTAT AGATGATAAC TGCAATGAGA TGGCAGAGCG TTCTTACAAC CTTTCTGCAIT
3851  TAGAATTCG GTTCTTTAAT AACAAAGGCTG AAGTGAAAAA TATGTCATTT GAGAATCTTG AACGATTTCA
3921  GATCTCAGTG GGATGCTCTT TTGATGAAAA TATCAATATG AGTAGCCACT CATACGAAAA CATGTTGCAA
3991  TTGGTGAACA ACAAAGGTGA TGTATTAGAC TCTAAAACCTA ATGGGTTATT TTTGAAAAA GAGGTGCTTT
4061  TTTTAAAGTGT GCATGGCATG AATGATCTTG AAGATGTTGA GGTGAAGTCG ACACATCCTA CTCAGTCTCT

```


RLG 2B (cont.)

SEQ ID NO: 23

4131 TTCATCTGCG AATTTAAAAG TCTTATTAT TTCAAAGTGT GTAGAGTTGA GATACCTTTT CAAACTCAAT
4201 CTTGCAAAACA CTTTGTCAAG ACTTGAGCAT CTAGAAGTTT GTGAATGTGA GAATATGGAA GAACCTCATAC
4271 ATACTGGAAT TGGGGTGTGT GGAGAAGAGA CAATPACTTT CCCTAAGCTG AAGTTTTTAT CTTTGAGTCA
4341 ACTACCGAAG TTATCAAGTT TGTGCCATAA TGTCACATA ATTGGGCTAC CACATCTCGT AGACTTGATA
4411 CTTAAGGGCA TTCCAGGTTT CACAGTCATT TATCCGCAGA ACAAGTTGCG AACATCTAGT TTGTTGAAGG
4481 AAGGGSTAGA TATATGTTCT TTATGTTAAT ACAATTTAAA TAATATTTTC AACCAAATTT TCATAATATA
4551 TCTGTAATTT GATTGTATGA TGTGTATTG TTTTATATG GCTATTAAGG GATGATTATT TTGCAGGTTG
4621 TGATTCCGTA GTTTGGAGACA CTTCAAATG ATGACATGGA GAACTTAGAA GAAATATGGC CTTGTGAATC
4691 TAGTGGAGGT GAGAAAGTTA AGTTGAGAGC GATTRAAGTG AGTAGCTGTG ATAAGCTTGT GAATCTATTT
4761 CCGCGCAATC CCATGTCTCT GTTGCAATCAT CTTGAAGAGC TTACAGTCCA GAATTCGGGT TCCATTGAGT
4831 CGTTATCTCA CATTGACTTG GATTGTGTCG GTGCAATTGG AGAAGAAGAC AACAAGAGCC TCTTAAGAAG
4901 CATCAACGTG GAGAATTTAG GGAAGCTAAG AGAGGTGTGG AGGATAAAAAG GTCCAGATAA CTCTGATCTC
4971 ATCAACGGTT TTCAAGCTGT TGAAGCATA AAGATTGAAA AATGTAAGAG GTTTAGAAAT ATATTCACAC
5041 CTATCACCCG CAATTTTTAT CTGGAGGCAC TTTTGGAGAT TCAGATAGAA GGTTCGGGAG GAAATCAGGA
5111 ATCAGAGAGAG CAGGTAACGC TTTCAATTTT ACTTTCTTAA TTAATTAAGG ACTAAGCTCC TGTTTTTTGA
5181 ATAAATAAGA GTTGGGATGA CTAACCTTGG GCATCACAAT TGCAACAAAA TGTTCACAAAC CATGAAACGT
5251 TCAAACCATT TCTTGAATTA AGGTTTCAAT ACAAGTCATT TAAAAATATG GCTTAAATTT TTTTTATATT
5321 TATGTATCAA CATGATTTTT CATTAGAGAT CATTATTATA ATAGTAAGTT TAAAGCAATT TAAATCAGAA
5391 CTAATCTCAA CTTTAGCTAA TAAATCGTTA TAAATGTAAT TAATTAATTT TTAGTGAAT AAGCAACGGA
5461 TTTAATAAGT TAACAACCTA AATGTCATTT CCTAACAAAA AAAAATTTGG TTCAGAAAAA CCGCAATTCA
5531 AGATAACTAA AATAAAAATA TTTGACATTC ACTAAGAGCA TTTTTTTTTC TAAATATGAT TGCAAATGAA
5601 TAAAACCTAA ATTTATACAG AAAATTCITTT TATATATGTT ATACAAAAAT TACAAAATGA AATTTGATAT
5671 GTTAATAAAC GGTTTATAAT TCTGGTATCA CAAAGGGATA TATAATAAAA TATTTATTTT TGTAGTCATT
5741 TGTAAITGTA CTAGTTTTATA ACCCGTGGGA ACCATGAGTT CTAATAATTAG TTAACITTTT ATAATAAAAA
5811 TTTATAATTA TTATTTATTT TAAATAAAT ATTAATTAAG AGATAATPCA AAAATTTAAA GTTTATATAA
5881 CTTCAAAATT AACATATAAT TAGAAAAAT ATGATCATAA CTTCTGCACT CTCTTTGTAT AAATGCAGAG
5951 AAGCTATTAG TATATTCTA ATCAAGTCCA AACCTAATGA AGCCTATATA ATTTTGTGAA AACCTAATTA
6021 GCATTAGGTT TTAAGAGTCA CCAAATCAA AGAATAATCC AATGCTTTCA TTACCCTAT CAGGAAATTC GTTAAATFAA
6091 TTTCTTAGT TTAATGAAA TGAAAACAAA CATTCAAAT AATTTGTTGCT TATTAACCA AAGACCCATT
6161 ACTTGGCCAA GAGTTTAAACA AAAAAAATT ACAITTCATGT ATCATTTATC ATGACTAGAT ATATATGAAC
6231 ATGAAGGGAG TTTTATAGA AATATAATC ATAGATATTC AACATAACTT CAGGAAATTC CTCAAAATFAA
6301 CCAAGTTATT CAAGAAATTA CATCCAAGTC AACCAAAGAG AAGTTTAGCC TAGCATGGCT AAACCTAAGA
6371 AACTAAATA AGGATTAGAA GTACCAACA TGTAGTAAGA ATCACAGTAA AAGATGATGT TGTCTTGTAT
6441 GTTCTCTAA GTTCTTCAAG TCTCCAGTTG CTCTTAATAA TGCAAAGGAG AGCCATTAAA TTTCTTGTGA
6511 TTGATCCCTT CAAAAGCTGC ACCAACCTCC CTTAAATAAC ACTCAAAGCA AAAATGACAA AATGCCCTGA
6581 AGGACCCAT ATGGGTGCCCT TGCGGGGTG GAGCTGCATA CGAAAGGTTCT TTGGTCTTTG TGAGGGTGTG
6651 GTTGTGGGG ATAGCTTGTG GCATGCTTCC GCGGGTTC CAACATGTC CACAGGTGAT GCATGGTGTG
6721 TGCGTCTTG AGTTTTGAGC CTCCGATGCT TAGTCCACTT GGCCCAATTC GAGTCCAATC AGCTTATAAC
6791 CCATTTTTCT TCAAGTTATC TTCAAGTTAA GCCCAATTTG GCTTCTCAA ATCATCCATA ACTTCACAGA
6861 ATGGCCCGTT CATCTTAATC CCGGATGCAC AATTATTCTC CCGTCTTCAT TTTAAGCAAG ATACCACTTT
6931 CTTCAATGCTT CATCCATCAA TAGTACACTT CATGTATCAT CTCTACTAGT TATTTAGTCC ACAAACTCTT
7001 GTTGTCTCC AAATTTAAT ATCTCATTAA GTTCCCGTT CCGCTACTTT CCTTAAAAT TGAATTAAG
7071 CTCAGAGAAA TATTAAGTAC CCGAAATGTT CATAAAATTA ACAAAGGA AAATGCATGA AGATTAACATA
7141 AATGATGAAC GAAATATGCT AAAATAGACT ATAAAATGAA GTAAAATAAAA TGAATTTATC GCACCTCCGAC
7211 CACCCCTATG CTTTGTAGTC CACCCACCTT TCATTCCTTG TACCAATATG GATGGAAC ATCATTAAT
7281 AAGCCAAAA GCTAACATAT AAGGGTTTAG TGACAAAGGT AAGTACTAAA GATGAAAATA ATCCATTTTT
7351 CTTGTTTTTA CACAACACAC ACATAGGGGC AGACGTAGGA TTTCAAAGTA CAGATTGTTG GTGGCACATA
7421 AGTGTGCTG GTGACATTTT TTTTCTTTT TTACGTTGTT GCACAACAGT AGGAAAAACG AAAAATTCGA
7491 AATTTTTTAC AATTTGCTT AAAAAAACA GGGGTTGTTG GTGCCACTAT GGCAACAAAA TGTGAACCTC
7561 CTFACGGCG CACACACACA CACACACATA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA AAGAAAGAAA
7631 GAGAGAGAGA GTTTGGGATG TGATACTTCT TTTAGGAAAA TGGAGTTATA TCTTTGATAT TGTATTTTTT
7701 TAATGTAATT TATNTATTTA ATCATTTTAG TTTATAAGTT NTATTTATIN GGNATGAAA AAAAAAGTCT
7771 TTTATACATT GGATTTAACA TAAAAATCCA ACAAATTTAA TCAAAAAGAC CAAACATGTG GACAATATG
7841 TATATAATTA ATTCACAATA GTCTTTAGGA ATAGTATTAT ATATATAATT AATCTCAAT GGTCTTAGGA
7911 ATAGTAAGTT CTTATATTTT AAACCTTTTC CACAATCTTT TGCTTACTTT GACTTTTTC CTCTTAACCT
7981 TTACATATAT ATATATATTA AAGCGCAAAG GTCATAGGAA TATAATATTT TCTATTATTC TACGTTTTGC
8051 CACAAAAGTT TGAACACTTT GCCACTTTTT GTCCCTCTTT AACCTTTTCA ATGTTTTGCG ACAAAAGTTC
8121 CAAAACCTTG CCACTTTGAT CATTCTCAA CTTTTACCG CATTAGTTG TGGAGTTGGC AGTTTTGGTC
8191 CCTCAACTT CGATATTCT TACTGCTAGC CAAAAGGGT TCCAGAGTTT CACTTTTTG GTCCCTGACA

RLG2B cont.

8261 GTAACCAAAT GTGAGATGTC AAATTTTTGC CACATTAGTT TGTGGAGTTG TCCCTTTTGG TCCCCCACA
8331 TTCGATATTC TACTATACGA TCCTATTTTT CTCAAATAAC AACACGTATA TTTCATC:CT AATTTGGAAAA
8401 AGAGTTTTAA AA:AAATAAC GACTAGG::: G:GC:GAGTT TTTTTT:ACA AGTTTGTATC AAATCATATC
8471 AAAATTTAAG GTGGAAACGGT GACCACATTA ACCGAAATG TAATTTATTC TTGATTTTG ATAATTTTITA
8541 ATATTTTTGTT GTGATCTATG TTTTTAAAAG TAAACAACAA AGAACATAAT CCAAACCCTT AAATTTGCAAG
8611 TCICGCCCAA TTTCTCTATC ACTAGTCCTC ACTTACGATG GCGTTACGTC GCTCTCTCAC TGCTTACAAC
8681 CCTTTGTTGC TACTCATTAC AATAACGAAA AGTTGAATAT CCATATATTT ATTTGGATGT GGAATTTGAC
8751 GAATCTCTGC AAAATTTTGA TTTTGTGATG GGATTTGAGT AGAAGTTTGG GCAGAACGGG AATGATGGTC
8821 TGCAAGTGGT TATAAACTTG ATTCTGAGTT ATTACTATAT ATGTAGCCCTC TTTACAACGA CCAAGGTTTC
8891 TTCAGGTAC CATTTGATCT TTTTAGAAGT TAGTTTTCTG AAACACCCTG ATTTGGATCA AATATCACCA
8961 ACAACTCTTA AAAACTTGAT TAATCAATTT TTTCTTTCAT CTTGATAACA AGTGGAAATGA TTTTCTACTT
9031 AGATTRAAGT GAAAAAAG GTCCATGTGC GTCTGGTGA TCTGGTAAAT GAAGATGGAA GGGAGAGCTG
9101 ACTTTAAAGA CACAAACAG TCACCATATC TCTTATTTTA TTTTAAATTT GCTTTTGGTG TATTTTCTTT
9171 TTTCTTATTT CTTTCTTTCT TGATCTCCAG ATGGTATGTG GTGTGGATAA TTTACACCTA GAGATTGGGA
9241 ACGATGGGAA GGGGTCTGTG ATTTATGGCT GGCCGAGTTT TACTTATTA CTCAATTTCA ACCTAAATTC
9311 TGATTTCTGT TTGAAAAATA GTTGCATCTT TATTTTGTGA TTATCTTGTG GCATAGGATC CTTAGCATCT
9381 TTTAATAATT TATTTGAAGG TGAAAGATCC AACTATTTTT TAGCTGTGG CATTTTCCAT CATTITGCAAC
9451 TGTTTCTTGA AAAAAAATA CCTAAAATA AAATAACCAT TTTCAAATCC AAAATTATA GAGAGAATTG
9521 TAAATGGACA TGGAAATATA AATCATTAAC ACAGTTTCAAGT AAACAAGTTG CTAATTACAT TTTCTGCTGT
9591 GCAGATTGAA ATTCTATCAG AGAAAGAGAC ATTACAAGAA GCCACTGGCA GTATTTCAA TCTTGTATTC
9661 CCATCCCTGC TCATGCATC TTTTCATAAC CTCCTGTGTC TTACATTTGA TAATTATGAA GGAGTGGAGG
9731 TGGTATTTGA GATAGAGAGT GAGAGTCCAA CATGTAGAGA ATTTGGTAACA ACTCCGAATA ACCAACAACA
9801 GCCTATTTATA CTTCCTTACC TCCAGGATTT GTATCTAAGG AATATGGACA ACACGAGTCA TGTGTGGGAG
9871 TGCAGCAACT GGAATAAATT CTTCACCTTT CCAAAACAAC AATCAGAATC CCCATTCCAC AACCTCACAA
9941 CCATAAATAT TCTTAAATGC AAAAGCATTTA AGTACTTGTG TTCGCTCTC ATGGCAGAAC TTTCTTCCAA
10011 CCTAAAGGAT ATCCGGATAA GTGAGTGTGA TGGTATTAAG GAAGTTGTTT CAAACAGAGA TGATGAGGAT
10081 GAAGAAATGA CTACATTTAC ATCTACCCAC ACAACCACCA CTTTGTTTCC TAGTCTTGTAT TCTCTCACTC
10151 TAAGTTTCTT GGAGAATCTG AAGTGTATTG GTGGAAGTGG TGCCAAGGAT GAGGGGAGCA ATGAAATATC
10221 TTTCAATAAT ACCACTGCAA CTACTGCTGT TCTTGATCAA TTTGAAGTAT GCTTTGTACA TATTCCATTA
10291 TTTATTTAAT TTCTTTTTT ATTTGCAATA TTCTATAAAT AATACATTTT ATACCCACTA TACTAAGATA
10361 ATAATTTCTT AGAGGSATGG ATGCTATGAC ACAGCTGCTA CACTTCAGAA ACTCTARTAA GGGCAGTTAT
10431 GGAAGTTCAA TAAAAATGATA ATGGCATCTT TTGATGGGTA ATATAGGCAA TTTAAGTTTT ATTTCTGTTA
10501 AAGCAGTATT TAGCAAGTAC TGGCCAGTAG GAGAGGAGAA TATCACCTTT TGTGAAAATC TGGTCATTTG
10571 ACCCAGATT TAGTTAAATG TAACATTTTA GATATTAGGG GTTATCAGGT GACAGATATT GTAGAATAGA
10641 ACAATATGTA ATATTACCCA AAACATTTTT TTCTAAGGTT GCCTGTATA ATATGTGCTT TCTTGATTTT
10711 ATTGAATTTG CATTCCTATA TTTTAGGTGG TAAAGTGATT GTCTCTTCAA TAAATCCCGA AATTTTTTAA
10781 TTAATAAAAA AAAAAACAAA AGTAAATTTT TGATATGGAG AGCACTGGTA TCATTTAGTA TATAAAAAAC
10851 AGATTTTGAA TTAAGTTTCT TATATAAAAG CTGTGTATAT AGTTTAAATTA GTTTTACATC ATTTTTCCAT
10921 GTGGTGTGTC AGTTGTCTGA AGCAGGTGGT GTTTCTTGGG GCTTATGCCA ATACGCTAGA GAGATAAAAA
10991 TAGGCAACTG CCATGCATTG TCAAGTGTGA TTCCATGTTA TGCAGCAGTA CAAATGCAGA AAGCTT

SEQ ID NO: 23

RLG2 B a.u.

MSDPTGIAGAIINPIAQTALVPVTDHVGVMISCRKYVRVMQMKMTELNTSRISVEEHISRNTRNHLQIP
SQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITEQIESLTRQLSLISWTD DPV?LGRVG
SMNASTSASLSDDFPSREKTFQALIALEPNQKFHMVALCGMGGVGKTRMMQRLKKA?EEKLFFNYIV
GAVI?EKTDPFAIQEAIADYLG IQLNEKTKPARADKLREWFKNSDGGKTKFLIVLDDVWQLVDLEDIGL
SPFPNQGVDKVLVLLTSRDSQVCTMMGVEANSIINVGLLTEAEAQSLFQQFVETSEPELQKIGEDIVRKC
CGLPIAIKTMAC?LRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQEEETKSTFLMCGLFPEDFDI
PTEELMRYGWGLKLFDRVYTI REARTRLNTCIERLVQTNLLIESDDVGCVKMHDLVRAFVLGMFSEVEH
ASIVNHGNMPGWPDENMIVHSCKRISLTCKGMIEIPVDLKF PKLTILKLMHGDKSLRFPQDFYEGMEKL
HVISYDKMKYPLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVL SFANSHIEWLPSTVRNLKKL
RLDLRFCDGLRIEQGVKSFVKLEEFYIGDASGFIDDNCNEMAERSYNLSALEFAFFNKA EVKNMSFE
NLERFKISVGC SFDENINMSSH SYENMLQLVTNKG DVLD SKLNGFLFKTEVLF LSVHGMNDLEDVEVKS
THPTQSSSFCNLKVLII SKCVELRYL FKLNLANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLF
LSLSQLPKLSSLCHNVNII GLPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEGVVIPKLETLOIDD MENLEE
IWPCELSGGEKVKLRAIKVSSCDKLVNLFPRNPMSLLHHLEELTVENCGSIESLFNIDLDCVGAIGEEDN
KSLLR SINVENLGKLRVWRIK GADNSDLINGFQAVESIKIEKCKRFRNIFT PITANFYLEALLEIQIEGCG
GNHESEEQVTL SISLS

SEQ ID NO: 24

RL62A
 RL62B
 RL62C
 RL62D
 RL62E
 RL62F
 RL62G
 RL62H
 RL62I
 RL62J
 RL62K
 RL62L
 RL62M

AAATCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG
 210 220 230 240 250 260 270 280 290 300
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 293
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 300
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 292
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 270
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 295
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 300
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 289
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 287
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 281
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 265
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 299
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 245
 AATTCAGATCGAGGTAAAGCAATTAAGTCTCCCTGTAATACTTACAGCAATGTTTGGCGAGTGTGTTGAGATGATTTGGTTTAAAGTCCCTTTCCCAANTCAAG 274

GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA
 310 320 330 340 350 360 370 380 390 400
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 393
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 400
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 392
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 370
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 395
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 400
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 389
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 367
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 381
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 365
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 399
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 345
 GTGTCCGACTTTCAGGTCCTGTTGAGCACTTCCACGAGACTCCACAATGTTTCCGACTGTGATGGCGCTTGAAGCTTAATTCATTCATTAATGTGGGACTTCTAATAGA 374

410
 420
 430
 440
 450
 460
 470
 480
 490
 500
 510
 520
 530
 540
 550
 560
 570
 580
 590
 600

RLG2A
 RLG2B
 RLG2C
 RLG2D
 RLG2E
 RLG2F
 RLG2G
 RLG2H
 RLG2I
 RLG2J
 RLG2K
 RLG2L
 RLG2M

510
 520
 530
 540
 550
 560
 570
 580
 590
 600

RLG2A
 RLG2B
 RLG2C
 RLG2D
 RLG2E
 RLG2F
 RLG2G
 RLG2H
 RLG2I
 RLG2J
 RLG2K
 RLG2L
 RLG2M

RLG2A
 RLG2B
 RLG2C
 RLG2D
 RLG2E
 RLG2F
 RLG2G
 RLG2H
 RLG2I
 RLG2J
 RLG2K
 RLG2L
 RLG2M

GACATTGGTAGTGTG-----TTGCCCCCTGAAAGTTTTTAAACCGAGCTTCGACCACTCCACAGCGAGAGACTAAATCTATTTTATTTATGTTGTTGTTGT
 610 620 630 640 650 660 670 680 690 700
 GACATTGCAAAATA-----TTGTTTAAATCCGAGTTTAAATGAGTTTACGACCACTCCAGAGACTAAATCCACCCTTTTTCCTTTGCGAAATGT 680
 GACATTCCACAAATG-----TTGCCCCCAAAAGTCTTTGAAACCGAGCTTACGACCACTCCAGAGAGAGAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 678
 GACATTGGTAAATG-----TTGCTACTGCGAGTTTTTAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 670
 GACATTGGTAAATG-----TTGCTACTGCGAGTTTTTAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 648
 GACATTAGCAGTGT-----TTGCCCCCAAAAGTCTTTGAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 673
 GACATTCAAAAGTGT-----TTGTTGCTTAAAGTCTTTGAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 678
 AAGNATGSETAGTAGAGAGTGTGCGTGAAGTTTTTAAATGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 688
 AAGNATGSETAGTAGAGAGTGTGCGTGAAGTTTTTAAATGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 688
 AAGNATGSETAGTAGAGAGTGTGCGTGAAGTTTTTAAATGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 666
 AAGNATGSETAGTAGAGAGTGTGCGTGAAGTTTTTAAATGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 680
 GACATTGACACAA-----TTGCCCCCAAAAGTCTTTGAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 664
 GACATTGACACAA-----TTGCCCCCAAAAGTCTTTGAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 677
 GACATTCCACAAATG-----TTGCCCCCAAAAGTCTTTGAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 623
 GACATTCCACAAATG-----TTGCCCCCAAAAGTCTTTGAAACCGAGCTTACGACCACTCCAGAGACTAAATCCACCCTTTTATGTTGTTGTTGT 652

RLG2A
 RLG2B
 RLG2C
 RLG2D
 RLG2E
 RLG2F
 RLG2G
 RLG2H
 RLG2I
 RLG2J
 RLG2K
 RLG2L
 RLG2M

TTCCCTGAGAGACTTTTGATATTCCTACTGAGCGAGTTTCATGAGGTATGCGAGCTTCCGAGCTTCCGAAATTTTGTGATGAGTTTATCTACTATTAGAGAGCGCAAGAAACAG
 710 720 730 740 750 760 770 780 790 800
 ATCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 780
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 778
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 770
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 748
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 773
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 778
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 788
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 766
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 780
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 764
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 777
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 723
 TTCCCGAAGACTTTTGTATTTCTTACCGAGAGTTGCTGAGGTAATGGAATGGAATTTTAAAGAGTGTACTATTAGGAGCGCAAGAAACAG 752

RLG2A	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2B	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2C	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2D	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2E	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2F	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2G	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2H	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2I	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2J	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2K	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2L	1210	1230	1240	1250	1260	1270	1280	1290	1300
RLG2M	1210	1230	1240	1250	1260	1270	1280	1290	1300

RLG2A	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2B	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2C	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2D	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2E	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2F	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2G	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2H	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2I	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2J	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2K	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2L	1310	1330	1340	1350	1360	1370	1380	1390	1400
RLG2M	1310	1330	1340	1350	1360	1370	1380	1390	1400

SER ID NO:

GETT-----LRSVVEKGFNIVIVGKGTDPFAIQAVADYLIQELKSTPARADKLRMFKASDGRKMKFLVLDVWQSVLDELIGLSPFNQG 100 100
 10 20 30 40 50 60 70 80 90
 RLG2A protein CRTTHMRLKVVKQKRNFIIEAVGKETPIAIGSADVIGIENKTPARTKDKRMVFNNSGQ--KKTIVTIDVWQFVDIANDIGLSPFNQG 98-41
 RLG2B protein OKTHMRLKAAEKELFNIVGAVIKETKINFAIQEALNDYLIQELNEKTPARADKLRMFKNSLQKTKLVLWLVWQVLDLDELIGLSPFNQG 100-42
 RLG2C protein NTRX--AKAEVAKKKEEFGYIIEAVIGESIDPFAIQAVADYLIQELKSTPARADKLRMFKNSDGRKMKFLVLDVWQSVLDELIGLSPFNQG 98-43
 RLG2D protein EVAK--KX-----RK--FGYIIEAVIKETKINFAIQEALNDYLIQELKSTPARADKLRMFKNSDGRKMKFLVLDVWQSVLDELIGLSPFNQG 90-44
 RLG2E protein GRND--KVEEVAKENRMHVMVAVIGKTDPLAIGSADVIGIENKTPARADKLRMFKNSDGRKMKFLVLDVWQSVLDELIGLSPFNQG 99-45
 RLG2F protein LEDTHMRLKVVKQKRNFIIEAVGKETPIAIGSADVIGIENKTPARTKDKRMVFNNSGQ--KKTIVTIDVWQFVDIANDIGLSPFNQG 100-46
 RLG2G protein GRHDD--EELKVVGGQKSFNIIIVQVIGKTNPIAIGSADVIGIENKTPARTKDKRMVFNNSGQ--KKTIVTIDVWQFVDIANDIGLSPFNQG 97-47
 RLG2H protein -----KEVVERKKNFSTIVQVIGKTNPIAIGSADVIGIENKTPARTKDKRMVFNNSGQ--KKTIVTIDVWQFVDIANDIGLSPFNQG 89-48
 RLG2I protein CKAS-----WKVEVQKTNFIIVQVIGKTNPIAIGSADVIGIENKTPARTKDKRMVFNNSGQ--KKTIVTIDVWQFVDIANDIGLSPFNQG 89-49
 RLG2J protein ERGR-----GAKTFTIIVLWIKETKINFAIQEALNDYLIQELKSTPARADKLRMFKNSDGRKMKFLVLDVWQSVLDELIGLSPFNQG 89-50
 RLG2K protein LEDTHMRLKVVKQKRNFIIEAVGKETPIAIGSADVIGIENKTPARADKLRMFKNSDGRKMKFLVLDVWQSVLDELIGLSPFNQG 100-51
 RLG2L protein -----FSYVAVIGKTDPLAIGSADVIGIENKTPARADKLRMFKNSDGRKMKFLVLDVWQSVLDELIGLSPFNQG 82-52
 RLG2H protein AEE-----AAEKKLFNIVGAVIGKTDPLAIGSADVIGIENKTPARADKLRMFKNSDGRKMKFLVLDVWQSVLDELIGLSPFNQG 92-53

VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 110
 110 120 130 140 150 160 170 180 190 200
 RLG2A protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 196
 RLG2B protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 193
 RLG2C protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 193
 RLG2D protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 185
 RLG2E protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 193
 RLG2F protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 197
 RLG2G protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 194
 RLG2H protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 189
 RLG2I protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 195
 RLG2J protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 177
 RLG2K protein VDFKVLTSRDSHVCTVWGVVANSILNVGLLIEAQAOSLFFQGFVETS--E---PELQKIGEDIVRKCQGLPIAINTKACTLRNKRKQAKWDALSRIEYD 187

IGS--VAPKVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 210 220 230 240 250 260 270 280 290 300
 RIQ2A protein, IIRN--LVNGVFKMRYNRQHQEIKGVTIJAAGYVHVFHIIIEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 294
 RIQ2B protein IIRN--VAPKVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 291
 RIQ2C protein IGN--VATAVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 291
 RIQ2D protein IGN--VATAVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 283
 RIQ2E protein ISS--VAPKVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 291
 RIQ2F protein IQS--VWPKVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 293
 RIQ2G protein IGSEEWREVFKISYRHQDEVTKSIFELCNLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 297
 RIQ2H protein IGSEEWREVFKISYRHQDEVTKSIFELCNLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 289
 RIQ2I protein IGSEEWREVFKISYRHQDEVTKSIFELCNLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 294
 RIQ2J protein IGSEEWREVFKISYRHQDEVTKSIFELCNLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 289
 RIQ2K protein IET--LAHVVFQMSYRNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 293
 RIQ2L protein IXX--VAPKVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 275
 RIQ2H protein IUN--VAPKVFETSYNQLQDEETKSIFLMCGLFPEDFDIPTEELMRYGGLKLPDRVYIIEARNRLMNTCIEERLVQTNLLIESDDVGCYVRRMIDLVRAPVL 285

GMFSEVEHASTVNHGN--MPGMPEND-IVHSCRRISLITCKGSEF PVDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 310 320 330 340 350 360 370 380 390 400
 RLG2A protein DYSKVEIASIVNHGN--TLEWHADN--MIDSCRRISLITCKGSEF PVDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 390
 RLG2B protein GMFSEVEHASTVNHGN--MPGMPENDIVHSCRRISLITCKGHEIHPVDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 391
 RLG2C protein GMFSEVEHASTVNHGN--MPGMPENDIVHSCRRISLITCKGHEIHPVDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 389
 RLG2D protein GMFSEVEHASTVNHGN--MPGMPENDIVHSCRRISLITCKGHEIHPVDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 381
 RLG2E protein VHFSEVEHASTVNHGN--HLMGPENY--MTDSCRRISLITCKGSEF PGDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 387
 RLG2F protein GMFSEVEHASTVNHGN--HPEWTEHD--MTDSCRRISLITCKGSEF PGDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 389
 RLG2G protein HIFSEVQIASIVNHGN--VSEMLEDNH--SIYSCRRISLITCKGSEF PKDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 394
 RLG2H protein HIFSEVQIASIVNHGN--VSEMLEDNH--SIYSCRRISLITCKGSEF PKDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 386
 RLG2I protein HIFSEVQIASIVNHGN--VSEMLEDNH--SIYSCRRISLITCKGSEF PKDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 391
 RLG2J protein HIFSEVQIASIVNHGN--VSEMLEDNH--SIYSCRRISLITCKGSEF PKDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 386
 RLG2K protein DTFNRFKHSLVNHGCGHGMPEIN--DMSASSCRRI SLITCKGSEF PFDVAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 392
 RLG2L protein GMFSEVEHASTVNHGN--MHGMPEND--MNSDSCRRISLITCKGSEF PVDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 371
 RLG2H protein GMFSEVEHASTVNHGN--MPGMPENDIVHSCRRISLITCKGHEIHPVDLAF PNLITLKLHGDKSLRFPDFYEGHEKLVQVISTYRKHYPLLPSSPQCS 383

```
-----
TNLRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG
410 420 430 440 450 460 470 480 490
RLG2A protein VHLRVLHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 479
RLG2B protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 481
RLG2C protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 488
RLG2D protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 471
RLG2E protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 477
RLG2F protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 488
RLG2G protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 472
RLG2H protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 480
RLG2I protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 479
RLG2J protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 478
RLG2K protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 465
RLG2M protein TNIRVLIHLRGCSTLRFDCSSIGNLNLEVLSEFANSGETEMLPSTIGNLKKLRLLDLTNCYGLRITENGVLNANVKKLEELYIGNANG-PG 480
-----
```

SEQ ID NO:

10 20 30 40 50 60 70 80 90 100
 TGTGAGCCGCTGACTTGGATGGTAGTAATAATTAGTAACTTAACC-CCTTC--AATTAACCTACCTTTTCTTAATTAACCTCAATTTCAAGCTAAATTCCTG → 54
 110 120 130 140 150 160 170 180 190 200
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 187
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 186
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 188
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 187
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 176
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 164
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 152
 ATCTCTGTTCGAAAATBAAGTT-GCATCTTTATTTT-TG--TATTATCTGTTCATAGCATCCT-TAGCATCTTTTAAATTAATTTATTT-----GAAGGTG 187
 ---TCT-----AATAA-TGCCATCTTAAATTAATAAAGTATTAAATTTCTTCCATACGACCGTATAACACTCTCTTAATTAATTTATTT-----GAAGGTG 168

- AC15-2A
- AC15-2B
- AC15-2C
- AC15-2D
- AC15-2E
- AC15-2G
- AC15-2H
- AC15-2I
- AC15-2J
- AC15-2L
- AC15-2N
- AC15-2O

- AC15-2A
- AC15-2B
- AC15-2C
- AC15-2D
- AC15-2E
- AC15-2H
- AC15-2I
- AC15-2J
- AC15-2L
- AC15-2N
- AC15-2O

SEQ ID NO:

779
777
777
788
721
781
738
722
784
699
778
763

810 820
TAAGTACTTGTGTTTCACCTCTCAGG -56
TAAGTACTTGTGTTTCACCTCTCAGG -57
TAGGTACTTGTGTTTCACCTCTCAGG -58
TAGGTACTTGTGTTTCACCTCTCAGG -59
TAAGTACTTGTGTTTCACCTCTCAGGA -60
TAAGTACTTGTGTTTCACCTCTCAGGA -61
TAAGTACTTGTGTTTCACCTCTCAGC -62
TAAGTACTTGTGTTTCACCTCTCAG -63
TAAGTACTTGTGTTTCACCTCTCAG -64
TAAGTACTTGTGTTTCACCTCTCAG -65
TAAGTACTTGTGTTTCACCTCTCAGGA -66
TAAGTACTTGTGTTTCACCTCTCAGG -67

AC15-2A
AC15-2B
AC15-2C
AC15-2D
AC15-2E
AC15-2G
AC15-2H
AC15-2I
AC15-2J
AC15-2L
AC15-2N
AC15-2O

()

SEQ ID NO:68

RLG3 (real RLG3)

[Strand]

```
1  AATGGCAAAA GAAGTCGGAG CAAGAGCTAA GTTAGAGCAT CTATTGACG TCATTATCAT GGTAGATGTC
71  ACTCAAGCAC CCAACAAGAA CACAATTCAA AGTAGTATTT CAGAACAGTT GGGATTAATA CTGCAAGAAG
141 AGAGCTTGTT GGTAAAGACA CCTAGGGTAA GTGCGAGGTT AAAAAAGCTT ACAAGGGTGC TGGTGATATT
211 AGACGATATA TGGTCAAGGC TTGACATGGA GGAAGCTGGG ATTCCCTTTG GATCAGATAG ACAACACCAC
281 GGCTGCAAAA TCTTGTGAC TTCAAGAAGT ATTAGTGCTT GTAACCGAT GAGAGCTGAT AGAATCTTTA
351 AAATACGAGA AATGCCACTG AATGAAGCAT GGCTTCTTTT CGAAAGAACA GCTAAAAAAG CTCCGAATCT
421 GCATCAAGTA GCAAGAGATA TCGTGGAGGA GTGTGTTGGG C
```

RLG4
SEQ ID NO:69

```
1 GAATTCGGTG TTGGTAAGAC AACTCTTGCC TCTTCTGTTT ATGATGAAAT CTCTAGCAAG TTIGATGGTT
71 GCTGCTTTCT AAAAATATCT GGGAGGAATC AAGTAATAAA GACGGTATAG AAAGATIGCA AGAAAAATC
141 ATTTGTGATG TTTTGAACA AGAGCAAGTG GCGGTAGGGA GAGTTGAAGA AGGAAAGCGC ATGATAAAGG
211 ATAGGTTACA ACATAGAAG GTATTGATTG TGCTTGATGA TGTGACAAC GTTGAGCAGC TAGCTAGAAC
281 AGTTGGCTGG ATCACATGAT TGGTTTGSTG AAGGTAGCCG CATAATAATC ACAACTAGAG ATGAACATGT
351 ATTAATTGCA CACAAAGTAG ATGTGATACA CAATATAAGC TTGTTAAACA ACGATGAAGC TATGCATCTC
421 TTCIGCAAGC AAGCACCACG GGGTCACAAA CGTATACAAG ATTATGAGCA ACTTTTAAAA CATGTGGTTT
491 CTTATGCTGG TGGGCTTCCA CTAGCACTGT CGAC
```

SEQ. ID NO: 70
RLGI-E169
[Strand]

1 ATCGTAACCG TTCGTACGAG ANCGCTGTCC CTCCTTCATC TTTTGTGATA TGTCATATTC TCATNNATTV
71 TGCCACATCT AATTTTGTGG TTATTTTAAA TTAATTTTTA TTCCACATGT CATTTTATGA GTTTTCTAT
141 TTTATTGAGT TTCACATAAT ATTTAAATGT AATAACAATA AATGCATATT TATTTTCTTT TAAATAAACG
211 CATATAATAT ATAGATTAAT ATCATATAAT ACATAGGTTA AACTCATATA ATACATATGT TCATCCOCAG
281 TTTATTTATA TGTCATATCC TTAATTTATT TATTTATTAT TTATTAGAGT AGATGATCTT TGTGATATTA
351 AAAATTTAAT TTGTTCAAAA TTTAAAATTA TTAATAATCC CACAATTIGA ATAAAATTAA AAAAAATGGN
421 CCCACCATTA GTCCATCACT TTTTCAGCTC ATCAATATCG TGAGTATTTCT CCTTCGTTTC CACCCTAATC
491 AATATTTCCA GCGAATGACA GACTCCTACG GCGTTTCTGA ATTTGCGTTC CGACACTGTT CATTTGAAGGA
561 GATAATAAAT CAAATGGAGC TGCTCCAATG TTCATTGCTG ATGAAAAGTG AATTGTATGT GAAGANAATG
631 TCAGCGATCN ATCTCCATCC GGAACCCACC ACATATTCAG TGTACCACCA AACCCACTCA AACGGYGGAA
701 GTAGRRAKAC WRKAAAGTCA TGAAGARTAG ATTTATTTTG TCCTCATGGG CTGACTGAGG AGCGGTTTA
771 GTTCATCACT TTCTTTTGAN CAAAGAATTA TCGGTCCATC GAATTTTAC ATCGACAAG AGTTTCACT
841 TCGCAATGTT TTGTTAACA ATTTTAAATC TTTTATCTT TCGTTGAAA CTCCCTCAAT GCAACTTGCA
911 ACTTGCACCT TTGGGCCCA CAAATTTGTG GTGGGCGTTA ATTTAATCCA CATATTCACT GTAACAATA
981 ATTCAAATCG ATCTCTGTTC ATCCAATFCA TCAACATCTC TTGATAATTG AAATCATFCA CGCTTCATCC
1051 ATTTCAATCCA CATCTATACT ATATCTCTCT CTCTTATCAT ATTTAAACGAT GGCTGAAATC GTCTTTCTG
1121 CCTTCTTGAC AGTGGTGTIT GAAAGAGCTGG CATYTGAAAG CTTGAAGAAG ATTTGTTGCT CCAAAGAAT
1191 TGAATCTGAG CTTAGAAAT TGAAGGAGAC ATTAGACCAA ATCCAAGATC TGCTTAACGA TGCTTCCAG
1261 AAGGAAGTAA CTAATGAAGC CGTTAAAGA TGGCTGAATG ATCTCCAACA GTTGCCTTAT GACATAGACG
1331 ACCTACTTGA TGATYTTGCA ACTGAAGCTG TTCAWCGTGA GTTGAACCGAG GAGGGTGGAG CCTTCTCCAG
1401 TATGGTAAGA AAACATATCC CAAGTTGTG CACAAGTTTC TCACAAGTA ATAGGATGCA TGCCAAGTTA
1471 GATGATATTT CCACCAGGTT ACAAGAAGCTG GTAGAGCCAA AAAATAATCT TGGTTAAGT GTGATAACT
1541 ATGAAAAGCC AAAAATTGAA AGGTATGAGG CGCTTTGGT AGATGAAAGC GGTACTGTCC GACTGAAGA
1611 TGATAAGAAA AAATTCCTGG AGAAGCTGTT GGGGGATAAA GATGAATCAG GGAGTCAAAA CTTCAGCATC
1681 GTGCCATAAG TTGGTATGGG TGGAGTTGST AAAACAATC TAGCTAGACT TTTGTATGAT GAAAAGAAAG
1751 TGAAGGATCA CTTGCAACTC AGGGCTTGGG TTTGTGTTTC TGATGAGTTC AGTGTTCOCA ATATAAGCAG
1821 AGTTATTTAT CAATCTGTGA CTGGGAAAAA GAAGGAGTTT GAAGACTTAA ATCTGCTTCA AGAAGCTCTT
1891 AAAGAGAAAAC TPAGGAACCA GCTATTTCTA ATAGTTTIGG ATGATGTGTG GTCTGAAAGC TATGGTGAT
1961 GGGAGAAAAT AGTGGGCCCA TTCCCTTGGG GGTCTCCCTG AAGTGAATA ATCATGACAA CTGGGAAGGA
2031 GCAATTCCTC AGAAAGCTGG GCTTTTCTCA TCAAGACCOCT CTGGAGGATC TATCACAAGA TGATGCTTTG
2101 TCTTTGTGTT CTCAACAGCG ATTTGGTGTG CCAAACTTTG ATTCACATCC AACACTAAGG CCACATGGAG
2171 AACGTGTTGT GAAGAAATGT GATGGCTTAC CTCTAGCTTT AAGAACACTT GGAAGGTTAT TAAGGACAAA
2241 AACAGACGAG GAACAATGGA AGGAGCTGTT GGATAGTGAG ATATGGAGGT TAGGAAAGAG CGATGAGATT
2311 GTTCCGGCTC TTAGACTAAG CTACAATGAT CTTTCTGCGW CTTTGAAGCT RTTTRTTGCA TAYTGCTCT
2381 TGTTTCCCAJ GGACTATGAG TTTGACAAGG AGGAGTTGAT TCTATGTGG ATGGCAGAG GGTTTTTCGA
2451 CCAACCAACT AYAAACAAGT CAAAGCAAGC KTTGGGCTT GAATATTTTR AAGAGTTRTT GTCAAGRTCR
2521 TTTTTCACAC ATGCTCCCTAA TRRCAAAATCS TTTTGTGTA TGCAAGCTT AATGAATGAT TTGGCTACAT
2591 TTGTTGGCTG AGAATTTTTT TCAAGGTTAG ACATAGAGAT GAAGAAGGAA TTTAGGATGS AATCTTTGGA
2661 RAAGCAGCGI CATATGTGAT TTGTATGTGA GRATTACATA GGTACAAAAA RSTTGGAGCC ATTTAGAGGA
2731 GCTAAAAATTT TGAGAACATT TTTAGCATTG TCTGTGGGG TTGTAGAAGA TTGGAAGATG TTTTACTTAT
2801 CAAACAAGGT CTGTAAGTAC WTACTTCARG ATTTACCATT GTTAAAGGTC CTRAKTTTGA TTRRTCTTAY
2871 AATAASYRAG GTACCARAAK TCGTSGGTAG TATGAASCAC TTCCGGTATC TTAATCTATC WGRAACTTWA
2941 ATCACACAT TACCQGAWA TKTCTGCAAT CTTTATAATT TACARACCOCT GATGTGKTCT GGCTGTGAMT
3011 ATTTAGTTAA KTTGCCCAAR ACCTTCTCAA ASCTTAAAAA TTTGCASCAT TTTGACATGA GGGRTACTCC
3081 KAAKTTTAAAR AACATGCCCT TARGGATTGG TGARTTGAATA ARTCTACAAA CTCTCTTYNG TAACATTGGC
3151 ATAGCAATAA CCGAGCTTAA GAACCTGCM AYCTTCCATG GGAARTTTG TATTTGGGGG CTGGAAAAA
3221 TGGAAAAATC NHTTGGATCC ACGTTAAGCG AACTTGTCTC A: AAAAAGGT TWAATGART ANAACTGGR
3291 WTKGGGGCTG ATRAATTTAA TGTTTTCCGA AATGGGAACA CTTGAAAAAA NAAGGTCCCT AATGAATTGA
3361 ATGCTCAZA ATGSTAYTCY AAMWAARRRY YWTRWAT TWKAWRRK KGKTTYATRR TKTTHYRAW
3431 WAGRGTKTR KARGTAGSTT TCATCCAATC ACCCAAGTGG GAAAATAGAT GATATTTTCA GGCYACTG
3501 ATGAGATGTT GAGAGGTATG ATAGGGTNTC TTGGGGCGGT AGAAGAAATA AGCATCCATT CTGTAAATGA
3571 AATAAGATA YTGTTGGAAAT CAGAAGCAGA GGCAAGTAAG GTTCTTATGA ATTTAAGAA GTTGGATTA
3641 GGTGAATGTT AAAATTTGGT GAGTTTGGG GAGAAAAAGG AGGATAATCA TAATATTAAT ATGGGAGCA
3711 CCCTAACATC TTTTGGAGG TTGAATGTAT GGAGATGTA CAGCTTGGAG CATTTGAGGT GTCCAGATG
3781 CATGGAGAA TTTTATATGC ACATGTGTGA TTCAATNACA TCCGCTCTCT TCCCAACAGG AGGAGGACAG
3851 AAGATCAAGT CACTTACCAT CACTGATTCC AAGAAGCTTT CGGAAGAGGA GTTGGGAGG CGAGAGGACAG
3921 CAAGAGTCTT TATAACTCA AAAATGCGAGA TGCTTGAATC AGTATGATATA GGTAAITGGC CAACTTGA
3991 ATCTATCACT GAATTGAGTT GCTTCATTCA CCTGAACAGA TTATATATAT CAAACTGTCC GAGTRTGGAG
4061 TCATTTCTCT ACCATGAGTT GCCAAATCTC ACCTCTTAA CAGATCGAAG GAGAGGACAG CGATTTTCTT

RLGI-E169
[Strand]

4131 ACGAACGGTT ACGATTCCGAC TGGCCGTCGT TTT

SEQ ID NO: 70

Further Characterization of RG2 Family Members:

Further sequencing of cloned RG2 polynucleotide sequences, as discussed above, identified additional RG2 species, listed below. Additionally, further sequencing of the 5' sections of RG2 sequences listed above resulted in modified and/or new sequence information, also listed below. The AC15 sequences found in the 3' sections of RG2 family have not changed.

Listed below are: four full length species, RG2A, RG2B, RG2C and RG2S; two near complete, but with a gap in the largest intron, RG2D and RG2J; three nearly complete RG2 gene sequences, RG2K, RG2N, and RG2O. The deduced translation products (polypeptides) encoded by these RG2 species are listed below. The polynucleotide sequences do not contain any gaps (as with some of the polynucleotide sequences), because all of the gaps in the sequences are in introns, *i.e.*, there are no gaps in exon, or coding, sequences.

They include: an RG2A polynucleotide sequence (SEQ ID NO:87) and its deduced polypeptide sequence (SEQ ID NO:88); an RG2B polynucleotide sequence (SEQ ID NO:89) and its deduced polypeptide sequence (SEQ ID NO:90); an RG2C polynucleotide sequence (SEQ ID NO:91) and its deduced polypeptide sequence (SEQ ID NO:92); an RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94), and its deduced polypeptide sequence (SEQ ID NO:95); an RG2E polynucleotide sequence (SEQ ID NO:96) and its deduced polypeptide sequence (SEQ ID NO:97); an RG2F polynucleotide sequence (SEQ ID NO:98) and its deduced polypeptide sequence (SEQ ID NO:99); an RG2G polynucleotide sequence (SEQ ID NO:100) and its deduced polypeptide sequence (SEQ ID NO:101); an RG2H polynucleotide sequence (SEQ ID NO:102) and its deduced polypeptide sequence (SEQ ID NO:103); an RG2I polynucleotide sequence (SEQ ID NO:104) and its deduced polypeptide sequence (SEQ ID NO:105); an RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107), and its deduced polypeptide sequence (SEQ ID NO:108); an RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110), and its deduced polypeptide sequence (SEQ ID NO:111); an RG2L polynucleotide sequence (SEQ ID NO:112) and its deduced polypeptide sequence (SEQ ID NO:113); an RG2M polynucleotide sequence (SEQ ID NO:114) and its deduced polypeptide sequence (SEQ ID NO:115); an RG2N polynucleotide sequence (SEQ ID NO:116) and its deduced polypeptide sequence (SEQ ID NO:117); an RG2O

polynucleotide sequence (SEQ ID NO:118) and its deduced polypeptide sequence (SEQ ID NO:119); an RG2P polynucleotide sequence (SEQ ID NO:120) and its deduced polypeptide sequence (SEQ ID NO:121); an RG2Q polynucleotide sequence (SEQ ID NO:122) and its deduced polypeptide sequence (SEQ ID NO:123); RG2S polynucleotide sequence (SEQ ID NO:124) and its deduced polypeptide sequence (SEQ ID NO:125); an RG2T polynucleotide sequence (SEQ ID NO:126) and its deduced polypeptide sequence (SEQ ID NO:127); an RG2U polynucleotide sequence (SEQ ID NO:128) and its deduced polypeptide sequence (SEQ ID NO:129); and RG2V polynucleotide sequence (SEQ ID NO:130) and its deduced polypeptide sequence (SEQ ID NO:131); and, an RG2W polynucleotide sequence (SEQ ID NO:132) and its deduced polypeptide sequence (SEQ ID NO:133).

Characterization of New RG Family Groups and RG Species:

Further BAC insert characterization and sequencing, as discussed above, identified new RG polynucleotide sequences. The new sequences were characterized as belonging to new RG families; designated RG5 and RG7. These RG polynucleotides sequences, and their predicted translation products (the polypeptides which are encoded by these sequences) are summarized and listed below.

Identified and listed below is an RG5 family member, designated as the RG5 polynucleotide sequence set forth in SEQ ID NO:134, and its deduced polypeptide sequence (SEQ ID NO:135). This sequence contains an NBS region sequence.

Also identified and listed below is an RG7 family member, designated as the RG7 polynucleotide sequence set forth in SEQ ID NO:136. No deduced polypeptide sequence is given for the new RG7 family member as this sequence appears to be a pseudogene.

RG2A polynucleotide sequence (SEQ ID NO:87)

AAAGTTCATATCCAAGCTTGCCCTCCAACCTAGCTCCTTCAATGGCACC
TCCTTCTCTTCAAAAGCACACAAGAACAACCTTCAAGCTCAACCACACTCA
30 CACAAGCTCTAGAACGAGGGTTAGGGCACATTTAGGGTTTTGCTCTCTGG
AAATGGTGTCTAAAAGTGAGGCCATAATGTTCCCTTATATAAGGCTCACTC
CCACAATTAGGCTTTCAATCTGAACGTANTACGCCAGTGACTACTATGG
TACGCCCAACGTAACGTTAGTCTCCGCGTCAANAATACTCATGAGTA

CGCGCAACGTACTTTCCCTTACGCCAGCGTACTCAAAGCCAAACATTC
TTTTCAAGGACTAATTTTGACAACTTGAGGAAAGAAAAGGATCAAAGANA
TATACTTGAATTCCGGGATGTTACAATGAAGTTGANACCTTGGCTAAAAA
ATTAAATTGGTTGTGGAAGCCGTTGGCTGAGCAAGCAACAAGGGTAAAT
5 TCGTAATCTACAAATGGTGTTATTTTCTATTTCTTCTTATTATTTACTT
GATTTACGGGTAGTTTTTTTTTCTTACAAAAAATATTAAGTTGATAAAG
TATAGCCACTAAAATTGACTTTTTCCAAAACATAATGTCAAATGGTGCCT
ATATGTATCATGTTGTATTANATAATGAATATGATGATNCTGTTCTATTT
AANCCGAAAAAATTATCTAATGATTTTATATTGGAAAACAAAGTTGTGAT
10 TTTTNGCATAATATAATCAAATCCNCTTTTGTNTGGGAGGTGGATAAATG
TGGTAAATTTANAACAAGTGTTTTNACNTTGAAGGGTNTGGAAAGGTTGA
AAAAAGTTAAAATGATAAAATGTTTACACAAATGTTGTATCCGACTGAAT
ATNATGTTTAAAGGATNATTGTATTAATTTGTTGATATATAGTAAGCATAA
ATATTTAGAATTGTGACTTAAATTTATAAGTTATNCNAACTGGATTGAAA
15 CATTTTTGATATANATTAGGAATGAAAATGAGCAACCCTAACATACTTAT
CTTTGGTAGTTTGGTTATTATATTTTTATTANAATATAGAANCATCCCTT
TATTTTAAACCCATATTGTGGACGGACTTGAATAAATGGGAAAAATGTAC
CTTGCTATTTAGCACAAAAAATTATAAAAATGTACATTGCTATTTAGCA
CAAACAAAAAATAAATACTTATCCTTTTTGCATTAGGTCACAAAGAAATA
20 TAAAATGGGAAATGTGTTGCTATTTAATGCACTAAAAGAACTATTTTGC
CTTTATTAACCGGGTAAACCAATAGAAAAATGGAAGTACATTGTCATTT
AGCATGAAAAAATAAATTTCCATTTTTTGCATCCGGTCACAATAATAG
AAAAATGAAAGTACGTTGCTATTTAGCGAACTAACTCCTTTTTTCTTT
TTGGCATCGTATCATAAAATATAGACTAAAATACGTTAGTTTTACATTTT
25 TAATACATTGAAATGTCTAATCCACATGTTATTCTATAAAAAGGGAAATG
TAAATTTACTTATTCTTTGATTCTTTGGCTTCTTTTTAGTACCCAAAACAT
CCCTCTATCCATCTATTTCCAATAAATAATGAAAATAATTTCTTCCA
TTGTAGGGATGTTATAAATTTGTAATTGTTTTTATGCAAAAAAGTGTTT
TTTGTTAACTAGATTAACGAGATTCATTTTTTCAGCATTTTAGGAGAAGTT
30 CATCCATCTTTGGATATGAAGTGCAAGCCAAGTTCTTTAACATGGAATA
TGAGGTCCTATATGCTCAAAAAATAGCAAATGAGAAATTTTTTAAATTG
GATCCCCATAAAAGAAAATTTGTTAATGGTTGTTTTAATATTGGTCAATG
TGTCCACCGGATGAGCATAATACTAGTTTATAAGGGGTAAAGGTGGGTTT
GGTGGGCCCATTTATCTTTATTATTTCTAAAAGTCAGAATTAAGTAAAAA
35 AAATTATAAGATAAATACCATAAAGGATAAAAAATCATTTTATTTGGACCA
AAGACCAAAGTTGTTAAGGGGCTGTTTGTTTTTTTTTGTGAAGAGCTGTGC
AACCCTTTTGTCTGCGCCGCACAGACAACGTGCAGACATATGCCCTCGC
AGAGTGTTTGTTTTTTGAAGTGCGCAGACCAAAAAAACGTCTGCGCGAG
GTCATCCTGGCGCATATATGTGTCCTGTTCAAAGGTCTTCAGACCTC
40 ATTTTAAACCAAAAAAAGACCACCGGTTTTTTTTTTTTTTTTNTTC
TTTCTTGTAGCTGAAAATGCATTTTAAATCTTTATGACATGAAATTA
GTTTGAATAAATTTATTTCAACAGCTGTAGACGTTAAAAACAACAG
TCTTCTTGTGACACTGTGGACATTTGGTCCACCTCTTCTACCGCAGAG

ACTTGCAGATGTGGTCCGCAGACTGCAGACATTTTGGCTTCAAATAAACA
AACATCACCTAATTTGACTACACCACACGGACCTCCAATGTAACAAAAAA
AAGGTTGAAACAAAGTTGCCTATTTCTCCATATCCAGGGGCCATTTATGT
AAGAGTTATCTAAATTTTAGTTCGGTAGATCAGTTCTCACATTTTAACCG
5 GGTAAAGTGTATGTGTGTACGCGCGCACCTGAAAGGTTTGAANGTAACTT
CCAACTGAANCAANAATCGATATGAAGTATCAAGTTAGAGGTTCAATTG
GTG.AAGGAATCAGCTGGAGGTTGGGGAATCGAGCTTCCACTATTAAGGTA
AAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCGTGTTT
TGTTGAATGAAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGGTATAT
10 GAC.ATATTTATAGTTACTGATAACAAATTATGATAATTTTGGGTTTACGT
AAGTTAGGATTCGTACTTCAACCAAATGTAATAGTTTTTGTGAGTCTATC
TATGTATTTGGGGAATCACATTAGCAACGGGATTGTAAGTAAATTCGAA
AAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTTTAGCG
ACATCTAATATTAATAGAATGTATCTGATATTGAATTAATGTCCTTAAT
15 GTG.AACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTTCTAAT
CAATAAATTTAATTTCTGTTTTATGCTTCTAAGACAATAAAAAATCCATG
ATTTACCTTTAAATATTAACAAAAATGACCATAAATAAATAAAAAATTAG
GAT.ACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGATGCTTT
TGCTTTTCCCTCTTTTCCCTTGTTAGTCTATTATTCTGGAGAGTTTGAGAG
20 AGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTATTCTC
TTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTTACACGATCCATGGT
TTTTTGTGTATGTTTTTCAAATTGAAACTAGATTGGGACTTTTGCCCTTG
ATG.ATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAGTGGTG
AAT.AGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATGATGAT
25 GAG.ATAGAGATATGTTAAAACCTGGCTAGAAAATTGTTTTAATTTGAAATT
TAGGTTGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTTATGCT
AAATAGTTATAAAGAACAACAACTCGTAGTTTTTTTTTCATGATTTTCA
ACCTCTTCGTACCAAATAATTATAACAAAATTGAATATCATTCTCTGC
AATCAATTTTAACTTTTGTTATTATCATCATGTCTAAAATTGCCACAAGT
30 TTATTTTCATAGTCATATTGGATTATGAAAGGACTATTTTACCAATTAC
ATCTTTACTTTATGGCCAAAGCTAATAACAATCCGACTAACTAAAGGATT
CTAGGATGCATATAGTTTGCTCCCCGATTATAGATTCTATCTAATTTGT
CTATTGTAATAATTTAGGTGCCACCACAAGTAAATTCCTGAAATGGATGT
CGTTAATGCCATTCTTAAACCAGTTGTGCGAGACTCTCATGGTACCCGTTA
35 AGAAACACATAGGGTACCTCATTTCCTGCAGGCAATATATGAGGGAAATG
GGT.ATCAAATGAGGGGATTGAATGCTACAAGACTTGGTGTGCGAAGAGCA
CGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAAGTCAGGG
GTTGGTTTGAAGAAGTAGGAAAGATCAATGCAAAGTGGAAAATTTCCCT
AGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGGTCGGAAA
40 GAG.AGCCTCCAAGATAATTGAGGACATCGACAGTGTCATGAGAGAACACT
CTATCATCATTTGGAATGATCATTCCATTCTTTAGGAAGAATTGATTCC
ACG.AAAGCATCCACCTCAATACCATCAACCGATCATCATGATGAGTTCCA
GTC.AAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGATCCTAACC

ACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGGGAAGACG
ACAATGATGCATCGGCTCAAAAAGGTTGTGAAAGAAAAGAAAATGTTAA
TTTTATAATTGAGGCGGTTGTAGGGGAAAAAACAGACCCCATGCTATTC
AATCAGCTGTAGCAGATTACCTAGGTATAGAGCTCAATGAAAAACTAAA
5 CCAGCAAGAACTGAGAAGCTTCGGAAATGGTTTGTGGACAATTCTGGTGG
TAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTGGATCTGA
ATGATATTGGTTAAGTCCTTTACCAAATCAAGGTGTCGACTTCAAGGTG
TTGTTGACATCACGAGACAAAGATGTTTGCCTGAGATGGGAGCTGAAGT
TAATTCAACTTTTAAATGTGAAAATGTTAATAGAAACAGAAGCACAAAGTT
10 TATCCACCAATTTATAGAAATTCGGATGATGTTGATCCTGAGCTCCAT
AATATAGGAGTGAATATTGTAAGGAAGTGTGGGGGTCTACCCATTGCCAT
AAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCATGGAAGA
ATGCACTTCTTCGTTTAGAGCACTATGACATTGAAAATATTGTTAATGGA
GTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTAAATCCAC
15 CTTTTTGCTTTGTGGAATGTATCCCGAAGACTTTGATATTCTTACCGAGG
AGTTGGTGAGGTATGGATGGGGGTGAAATTATTTAAAAAAGTGTATACT
ATAGGAGAAGCAAGAACCAGGCTCAACACATGCATTGAGCGGCTCATTCA
TAC.AAATTTGTTGATGGAAGTTGATGATGTTAGGTGCATCAAGATGCATG
ATCTTGTTTCGTGCTTTTGTGTTTGGATATGTATTCTAAAGTCGAGCATGCT
20 TCCATTGTCAACCATAGTAATACACTAGAGTGGCATGCAGATAAATATGCA
CGACTCTTGTA AAAAGACTTTTCATTAACATGCAAGGGTATGTCTAAGTTTC
CTACAGACCTGAAGTTTCCAAACCTCTCCATTTTGAACTTATGCATGAA
GAT.ATATCATTGAGGTTTCCAAAAACTTTTATGAAGAAATGGAGAAGCT
TGAGGTTATATCCTATGATAAAAATGAAATATCCATTGCTTCCCTCATCAC
25 CTC.AATGTTCCGTCAACCTTCGCGTGTTTCATCTACATAAATGCTCGTTA
GTGATGTTTGACTGCTCTTGTATTGGAAATCTGTGCAATCTAGAAGTGCT
TAGCTTTGCTGATTCTGCCATTGACCGTTGCCTTCCACAATCGGAAAGT
TGA.AGAAGCTAAGGCTACTGGATTTGACGAATTGTTATGGTGTTCGTATA
GAT.AATGGTGTCTTAAAAAAATTGGTCAAACCTGGAGGAGCTCTATATGAC
30 AGTGGTTGATCGAGGTCGAAAGGCGATTAGCCTCACAGATGATAACTGCA
AGG.AGATGGCAGAGCGTTCAAAAGATATTTATGCATTAGA ACTTGAGTTC
TTTGAAAACGATGCTCAACCAAAGAATATGTCATTTGAGAAGCTACAACG
ATTCCAGATCTCAGTGGGGCGCTATTTATATGGAGATTCCATAAAGAGTA
GGC.ACTCGTATGAAAACACATTGAAGTTGGTTCTTGAAAAGGTGAATTA
35 TTGGAAGCTCGAATGAACGAGTTGTTTAAAGAAAACAGAGGTGTTATGTTT
AAGTGTGGGAGATATGAATGATCTTGAAGATATTGAGGTAAAGTCATCCT
CAC.AACTTCTTCAATCTTCTTCGTTCAACAATTTAAGAGTCCTTGTCGTT
TCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTGTGCAAAACAC
TTT.AAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGATAAATATGGAAG
40 AACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTACATCCCCAAG
CTG.AAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGGGTTTGTGCGA
TAA.TGTCAAATAATTGAGCTACCACAACCTCATGGAGTTGGA ACTTGACG
ACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTTTGAAACATTT

AGTTTGTGAAGGAAGAGGTAATATAAATTTTTAATGCTAATACATTAC
AAAGGATCTTTTCAGTTAAATCTTTCAAAATATATTGTAATTTGATTGTA
TGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTATCTTGCAGGT
TCTGATTCCCTAAGTTAGAGAACTGCATGTTAGTAGTATGTGGAATCTGA
5 AGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGTTAAGTTCAGA
GAGATTAAGTGAGTAACTGTGATAAGCTTGTGAATTTGTTTCCGCACAA
GCCCATATCTCTGCTGCATCATCTTGAAGAGCTTAAAGTCAAGAATTGTG
GTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGTTGGTGCAACT
GGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAGTGATCAGTTG
10 TGATAAGCTTGTGAATCTCTTCCACACAATCCCATGTCTATACTGCATC
ATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCATTGAATCGTTATTC
AACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAGACAACAGCAT
CAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAAGCTAAGAGAGGTGT
GGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTCATGGCTTTCAA
15 TCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAAGTTTAGAAATGTATT
CACACCTACCACCACAAATTTTAATCTGGGGGCACCTTTTGGAGATTTCAA
TAGATGACTGCGGAGAAAACAGGGGAAATGACGAATCGGAAGAGAGTAGC
CATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTGTCTTAATTAATGAT
TAAGCTCCTGCTTTTTGAATAAAAAAGGGACAAACCATTTTCATGACTTAA
20 TGTAGCAATACAAGTCATGTATAAGAGTGACCAACTCTTTTTTATTATA
AAATGACTACAAAATATTTTTTTTTCATTAGAGATCATGTATAAATGTGAC
TAATTTTTTCATCACCTAACTTTAGTTGATAAATCTTTATAAATGTCACTA
GTTACTTTTTCAGTAAAATAACAAATTTAATAAATTATCAACAAAAAGCAT
CAACTAAAAAATCCCACAACCCGTAATAATTTAAAATAAAAGGATTTAA
25 CATCTAATACGAACAATTTTTTTTCTAAACATGATTTGGACCAAATATCA
CCAGCAACTCAAGTTTGGAAATCGATTCAGCTTAAAACCTGACCAGCATAA
TTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATATAAGTTCGTTTCATC
TTTTTTCTTGATCTTGATAGCAAGTTGAATGATTTTCTTCTTCAAATTG
ATAAAAATCTACATTATAAAGAGACTAGCTTGAAAAAAATGGTCTAGGT
30 GGGTCTTGGGTTCTGGTAGATGAAGATGGAAGGGGAGAGTAGATTTCAA
GACACAACACATCCTTCATTTTATTTATTATTATTATTATTTTTTG
ATACTTGCTCATATTTGTTACAGATATGTGAGGTCTATTAATCTTTTTA
AATATATAAAAAAATAAATAACATAAATGAGAAAATTAATAAAGAATAA
ATT.AATAAGGGCACAATAGTCTTTTTTAGGTAAGACAAGGACCAAACACGC
35 AAC.AAAAATAAACAGTAGGGACCATCCGATTTAAAAAAAATAATTAGGGA
CCAAAAACATAAATCCCCCAACCATAGGGACCATTCATGTAATTTACT
CTTACTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTTTTTGTACACAT
CTAGGTAACGAACCTGTTGAAGTGTCCCATTTAGGATGTGACCTACTAC
AACCGATCATAATAGTCATATGTGAACACTTCCAACAACCTTATTACTTA
40 GGTGTGTACAAAAAACAATAGTTACCATGATGTGAACATACTGAAAAAT
TAATTACCTTAGCAAGTTATTTCCCATTTAGGTTGTATGGAAACAGTTC
CGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCCTTC
AATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGATT

CTTGTTTGAAAGTAAGTTGCATCTTTATTTTGTATTATCTTGTTGCATA
GGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAAAGATCCAACATA
TTTTTAATCTGTTGGCATTTCATCATTGCAACTGTTTCTTGAAAAA
AAATACCTAAAATCAAATAACCATTTTCAAATCCAAAATTATAAGAGAG
5 AATTGTAATGGACATGGAATCATAAATCATTAACACAGTTCAGTAAACA
AGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAA
GAGACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATC
CTGTCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAG
TTAAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGT
10 AGAGAATTGGTAACAACCTACCATAACCAACAACAACCTATTATACTTCC
CAACCTCCAGGAATTGATTCTATGGAATATGGACAACATGAGTCATGTGT
GGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATCA
GAATCCCCATTCCACAACCTCACAACCATAAAAATTATGTATTGCAAAAG
CATTAAAGTACTTGTGTTTCGCCTCTCATGGCAGAACTTCTTCCAACCTAA
15 AGC.ATATCAAGATAAGAGAGTGTGATGGTATTGGAGAAGTTGTTTCAAAC
AGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAAC
CACCCTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCCTGGAGA
ATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAA
ATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGA
20 GGT.ATGCTTTGTACATATTCAATTATTTATTTAATTTCCTTTTTTATTG
CAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAAT
TACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCT
AGT.AAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGAT
GGGTAATATAGGCAATTTAAGTTTATTTCTGTAAAGCAGTATTTAGCA
25 AGT.ACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTC
ATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGTCAT
CAGGTGACAGATATTGTAGAATAGAACAATATATAATATCACCCAAAAC
ATTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGTTTTTCATNGA
ATTNGCATTTCGTATATTTTAGGTGTTAAAGTGATTTTNTCTTCAATAAAT
30 CCCGAAATTAATTAACAAAAAACAACAAAGTACATTTTGTATGTGGAG
AGCACTGGTATCACTTAGTATATAAAAAGCTTGATTTTGAATTAACCTTC
TTATACAAAAGTTGTGTATATAGTTAATTAGTTTTACATCATTTTTCCA
TGTGGTGTGTCAGTTGTCTGAAGCAGGTGGTGTGTTCTTGAGCTTATGCC
AAT.ACGCTAGAGAGATGAGAATAGAATTCTGCAATGCATTGTCAAGTGTA
35 ATTCCATGTTATGCAGCAGGACAAATGCAAAAAGCTTCAAGTGCTGACAGT
AAGTGATTGCAAAGGGATGAAGGAGGTATTTGAACTCAATTAAGGAGGA
GCAGCAACAAAAACAACAAGAGTGGTGCAGGTGAGGAAGGAATTCCAAGA
GTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATTGGAAATCAG
CTTTTGTGGGGTTTGGAACATATATTACATTCTCTGCACTTGAAAGCC
40 TGAGACAGCTCCAAGAGTTAAAGATAACATTTTGCTACGGAATGAAAGTG
ATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGTAAACAACAACAAC
AAC.AACAATAACGAAGGGGGCATCATCATCATCTTCTTCATCTTCTA
AGGAGGTTGTGGTCTTTCCTCGTCTCAAATCCATTGAACTAAATGATGTA

CCAGAGCTGGTAGGATTCTTCTTGGGGAAGAATGAGTTCCGGTTGCCTTC
ATTGGAAGAAGTTACCATCAAGTATTGCTCAAAAATGATGGTGTTCAG
CTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACACAGAATTAGGC
AGACATGCTCTTGATCAAGAATCTGGCCTTAACTTTCATCAGGTATATAT
5 ATTTCTTTAATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAG
TAA.ATTTACTTCAAACACATTCACTGGTTTCAGTCTAAGTTTATGTTG
TTCTAGGAAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTT
CAGTGGAAAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGG
CTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATTATTATTCTGATTT
10 GCTTGTTCCTTATCATTTTTTCTTAGCCTCTGGAACAGCTAGAAACCCT
TTT.AATCTTTTGATTTTCAATGACAAAATTTTTCTGTACTACATTTGA
TTGTGTTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCT
TTTGATTGTTATTTTCATATCATGTTAGTCACTTGAATCAAGCTTTTCTA
TTTTCAACCAGGGCAAAGGTCAAAGTAACCTACTTTATGAGATCAAAA
15 ACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACC
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC
AGC.ACATATATGACATTTCAAAGTTTTTGTGTTGACATATATATGCCTCT
GGCGTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTG
ACACCTTGGGCCCTGTAACCTCAGAAGGGACAACCTGTTCTTTTCATAAC
20 TTG.ATCGAATTATATATGGAATTTAATGATGCTGTAAAAAGATTATTC
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTCATGTGACTT
ATTGTAATTGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG
AGAAATGGAAATAGTGGAAATTGGTTTTGATGAATCGTCACAAACAACCTAC
CACTACTCTTGTCAATCTTCCAAACCTCAGAGAAATGAAGTTATGGTATC
25 TAA.ATTGCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG
TTTCCAAACCTAACAAGAGTCGATATATGGGGATGTGATAGGTTAGAACA
TGT.ATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAC
GCATATGGAACTGCAGTCAGATAGAGGTCGTGATTGTTTCAGGATGCAGAT
GTTTGTGTAGAAGAAGACAAAGAGAAAGAATCTGATGGCAAGACGAATAA
30 GGAGATACTTGTGTTACCTCGTCTAAAGTCCTTGATATTAACACCTTC
CAWGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTTCATCCCATTA
TTGGATACYTTGGAAATCTACRAATGCCAGCAATAACCACCTTCACCAA
GGGAAATTCRCTACTCCACAGCTAAAAGAAATTGAAACAMATTTTGGCT
TCTTTTATGCTGCAGGGGAAAAGACATCAACTCCTCTATTATAAAGATC
35 AAACAACAGGTAACCAGATCTTTGTTGCTTNNATAATTCTTAAACNACA
TNTGAAAAGCTTCATGCAAGTTTTTTTTNGTTATATNGTCAAAAACCGCAA
CCT.ACATTTTCAGCTTTANATTTATGTACTTTATGCAGGATTTCAAACAA
GACTCTGATTAATGTGAAGTGAATATTAAGGTAATATATTTTCATGT
TCCTAGTNGCCTATTAATTAAGGCCTTTTAGTTCGNGATTTTTGGATGT
40 ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTGGTTG
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA
TATGAAGGACATTAAGAACATGGATGCTCTGAAGATGTTGGGAACACA

RG2A deduced polypeptide sequence (SEQ ID NO:88)

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVN
 RNISNQLEVPAQVRGWFEVVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDI
 DSVMREHSIIWNDHSIPLGRIDSTKASTSIPSTDHHDEFQSREQTFTEALNALDPNHK
 5 SHMIALWGMGGVGGKTTMMHRLKVKVKEKMFNFIEAVVGEKTDPIAIQSAVADY
 LGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLSPLPNQGV
 DFKVLLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIG
 VNIVRKCGGLPIAIKTMACTLRGKSKDAWKNALLRLEHYDIENIVNGVFKMSYDNL
 QDEETKSTFLLCGMYPEDFDILTEELVRYGWGLKLFKKVYTIGEARTRLNTCIERLI
 10 HTNLLMEVDDVRCIKMHDLVRAFVLDMYSKVEHASIVNHSNTLEWHADNMHDSC
 KRLSLTCKGMSKFPDLDLKFPLNSILKLMHEDISLRFKPNFYEEMEKLEVISYDKMKY
 PLLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDRLPSTIGKLK
 KLRLLDLTNCYGVRIDNGVLKLVKLEELYMTVVDRGRKAISLTDDNCKEMAERS
 KDIYALELEFFENDAQPKNMSFEKLRFOISVGRYLYGDSIKSRHSYENTLKLVLK
 15 GELLEARMNELFKKTEVLCLSVGDMNDLEDIEVKSSSLLQSSSFNNLRVLVSKC
 AELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEETITFPKLFSLCGLP
 KLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLKKEEVLIPKLEKLVSS
 MWNLKEIWPCEFNMSSEEVKFREIKVSNCDKLVNLFPHKPSILLHHLEELKVKNCGSI
 ESLFNIHLDCVGATGDEYNNSGVRIKVISCDKLVNLFPHNPMSILHHLEEELEVEN
 20 GSIESLFNIDLDCAGAIGQEDNSISLRNIKVENLGKLREVWRIKGGDNSRPLVHGFQS
 VESIRVTCKCKFRNVFTPTTTNFNLGALLEISIDDCGENRGNDESEESSHEQEIEILS
 EKETLQEATDSISNVVFPSCLMHSFHNLQKLILNRVKGVEVVFEIESESPTSRELVT
 HHNQQPPIILPNLQELILWNMDNMSHVWKCNSWNKFFTLPKQQSES PFHNLTIKI
 MYCKSIKYLFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTT
 25 LFPSLDSLTLFLENLKCIGGGGAKDEGSNEISFNNTTATTA VLDQFELSEAGGVSW
 SLCQYAREMRIEFCNALSSVIPCYAAGQMQLQVLTVSDCKGMKEVFETQLRRSSN
 KNNKSGAGEEGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESRLQELKITFC
 YGMKVIVKKEEDEYGEQ.TTTTTITKGASSSSSSSSSKEVVVFPRLKSIELNDVPELV
 GFFLGKNEFRLPSLEEVTIKYCSKMMVFAAGGSTAPQLKYIHTELGRHALDQESGL
 30 NFHQTSFQSLYGDTLGPVTSSEGTTCSEFHNLIELYMEFNDAVKKIIPSELLQLQKLEK
 IHVTYCNWVEEVFETALEAAGRNGNSGIGFDESSQTTTTTLVNLPNLREMKLWYL
 NCLRYIWKSNQWTAFFPNLTRVDIWGCDRLEHVFTSSMVGSLQLQELRIWNCSQ
 IEVVIVQDADVCVEEDKKEKESDGKTNKEILVLPRLKSLILKHLPCCLKGFSLGKEDFSF
 PLLDTLEIYKCPAITFTFKGNSTTPQLKEIETHFGFFYAAGEKDINSSIIKIKQQDFKQ
 35 DSD.CEVNIK

RG2B polynucleotide sequence (SEQ ID NO:89)

TTTTTTAAGATCAGGGATTCAAATTCAGCCCTAGTGATTACAATTGTGTG
 TAAACTTTCCCATACCTTCACATTATTGTAAGTATACTTTCTCAGTTTCT
 40 CTCTTGGAAGCTTCCTTGGTATTTAACTCGTGTCTAATATTTAACTCT
 GATAGTTATTTGGCCAATCTACTATCTGCATGTCCGGTTATTGAATCCG
 AAGGCACTGGAATCTTGGATTCCATTCCGTTGTGTGTTTGGTTGCCAAAT

GAACGGAATTGAATTATGTAAGATTCCTTCAAAAATCCATGTTTAGGTATA
TCGTTGTTTCTTGGGATGGATGGTAAAGAACGGAATTTCTCCTGTTTCATT
TTTTAATGAAAGACCAAATTGACCTTATAAACCTGTAAAAAAATTACAT
TCCAGTTTTCTTAACAAACTGAAAATGGTAAAGGAGTGTGATTGAATTCC
5 AATCTGTTTCCTGTCCAAAACACGTGACGGAATATTACAATTCCTTCAAA
TTTCATTTTCTTAAATTGTTATTCCTTTCTTACAAAAACAAGGTAAACG
AAACACCCGCTTACTTAATCATACTCCTACATGATGTAATGAAAAGGT
ATAAATGGTATTTTATTACAGGGATGAGTCACCATGGTCATGAAAGAAT
CATTAAACCGCCCTTACCCAATTCATGTTTGCCCCTAAAATATGATTTAAA
10 GTAATATTGGCTTATGGGATTCAAGTTGACTTTTTTTGTGGCGAAGAAATA
ATGAAAATCTTCATTTCTAAAGTGTCTTCTACCACTGACATTTTCTAAGA
AAGAACTTGCTAGAAGAAGGTGGGTGTTTAGTCTTTTACTCTTTAAAT
GTGAAGACTGTTGAGTTATTATTATTTTGGCAACTATGGACAACCTTG
TTTAGTTTTTTTTTTTCCCAATATCCATTTATATGCGATTTATTTCTGA
15 AATAATTTTATCAAAAACGCAGGAAACAATGTAGAATAATACTGGTATAAT
TAATTATATAAAGTTATTAGGCTGAAATCTTGAGGCTACTATAATTTAAT
TATCATAATTTGAAAATCATCAAATTGTATTCCATGTATATTTATGTTAT
CAGATAATTAATAATATGTGAGCCACACAAATCCACATCATCAGACACCC
CACCTTATTGTCGGCTACCTCACCACTTGCATGATCCCGACATCTTCCCA
20 ACCCCACCGACGACTTGGGGTCTCCTTAATATATCAATTATTTTCTGTAA
GTATTTATTTGTGTAATGTGTAATGTCATTTTACCTTTTTTCTAATATA
TACAGAAACATAAATTTTAAATGAAATTCAACTGCGTTTCATTCTTGCAT
TAAAAAAAAGACTGTACTGTTGTCAATATTTTACTTATAACCTGATTAA
TTAATTAAGCGTAATTGCATAATTTGCATTAGGTTGTAATTTTGTGTTT
25 TATAGGGAGGGTGAGGGTCACCGGGAATCAAAGCACTTATGTAAGCAG
GGAAATACAAAAAATTTACTCGAAACAAATTTTATTCAATTTAAGTGAGA
TAATAATGTTCTGATTAGATTATGAGAACTAGGAGATTTAAGTGATATAT
CCCATTTAAAAGAAATGCAATTATTAATTTTGGATCTCTTGATGATGACA
AAATTAACCTCGTGACAGGTTATATATCATATACAAAATGAGTGGCTATGC
30 TTTCGCTTTCCAAAAGCAATTATAGTTATACTACACCTACAAATTTTAA
AAGGGGTAAACATATCAAAATACTTGATAAGTAATTATATAAATATGCA
TTT.AACCCTCTAAAGAAAATGCTACTAAGCTTGGACCATCTCAGAATTAC
AATCATACCCTTCCCCTCAAAAAGATTTCGTATATATCATGTCATTTGGC
ATTCATTTCTTTTTCACAAATTCATAGTTCTATTCTCAAAAAATTCGAGTT
35 CTCGTATTTGTAAGGAAGATCAGAAGAGACTGTTACACAGGTA CTCTCT
TTT.ATTTATTGATTCACATTCATATATGTTATTGTTTTCTTGCTTAATGG
TTTCGTCAGTCTAACTGCGCTTGCTGATTTAAATTTCTTCACTTTCTTCC
ACGGATTTTTTAAATATTAGTTTTGTGAATGAACAATTGGTGAAGGAAAG
AAACATGGGAGTCTTTTCTAAAGTAAACCTAGATACTTAGGTTATAAGGG
40 TAT.ATGCTAAAATGAACTATGCCATTACCTTTGCCTTTTCTTTTACTT
TTTAGTTTTTAGAATCCAAGTTTTTCATATGTATCTCGATGTGTGAGAAGA
ATAGGCATTAGAAAGGTAAAGGACGTACATAAAAATTGATTAATTAGTGAA
TGTTCTTTGATATCATTATTTTACTCTCATAAAAAGCATATAGATCAAA

CAC.AAATTGCTACTTGTTAGTGTAACAACCTCGACTTAATAATGTTAATA
ATC.AAGATTCTCTTGATTTCAACTATTTTCTAACCGAACAAGCTCACTAA
AAACTCATATTGCTTTGAGTCTGAGTGGTTTATATTTGGGGTTTTACATT
TAAATTTTTGTGCATGAATGTGAAAATAGACTGCTTATTGATTCTTTGTG
5 TTTCATTGAGTTGATTTTCATTATTACTACCTTACAAATTGCTCAGTGAT
AGATTTCCATTAATTTGCTAATTCGGTTGCTTCTAAATATGTAGGAGCTA
CTAAAAGCAAAAATATCGAGCAATGTCGGACCCAACGGGGATTGCTGGTG
CCATTATTAACCCAATTGCTCAGACGGCCTTGGTCCCGTTACGGACCAT
GTAGGCTACATGATTTCCCTGCAGAAAATATGTGAGGGTCATGCAGATGAA
10 AATGACAGAGTTGAATACCTCAAGAATCAGTGTAGAGGAACACATTAGCC
GGAACACAAGAAATCATCTTCAGATTCCATCTCAAACCTAAGGAATGGTTG
GACCAAGTAGAAGGGATCAGAGCAAATGTGGAAAACCTTCCGATTGATGT
CATCACTTGTGTAGTCTCAGGATCAGGCACAAGCTTGGACAGAAAAGCCT
TCAAGATAACTGAGCAGATTGAAAGTCTAACGAGACAACCTCTCCCTGATC
15 AGTTGGACTGATGATCCAGTTCCTCTAGGAAGAGTTGGTTCATGAATGC
ATCCACCTCTGCATCATTAAAGTGATGATTTCCCATCAAGAGAGAAAACCTT
TTACACAAGCACTAAAAGCACTCGAACCCAACCAAAAATTCACATGGTA
GCCTTGTGTGGGATGGGTGGAGTGGGGAAGACTAGAATGATGCAAAGGCT
GAAGAAGGCTGCTGAAGAAAAGAAATTGTTTAATTATATTGTTGGGGCAG
20 TTATAGGGGAAAAGACGGACCCCTTTGCCATTCAAGAAGCTATAGCAGAT
TACCTCGGTATACAACTCAATGAAAAAACTAAGCCAGCAAGAGCTGATAA
GCTTCGTGAATGGTTCAAAAAGAATTCAGATGGAGGTAAGACTAAGTTCC
TCATAGTACTTGACGATGTTTGGCAATTAGTTGATCTTGAAGATATTGGG
TTAAGTCCTTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTGACATC
25 ACGAGACTCACAAGTTTGCATATGATGGGGGTTGAAGCTAATTCAATTA
TTAACGTGGGCCTTCTAACTGAAGCAGAAGCTCAAAGTCTGTTCCAACAA
TTTGTAGAACTTCTGAGCCCGAGCTCCAGAAGATAGGAGAGGATATCGT
AAGGAAGTGTGCGGTCTACCTATTGCCATAAAAACCATGGCATGTACTC
TTAGAAATAAAAAGAAAGGATGCATGGAAGGATGCACTTTCGCGCATAGAG
30 CACTATGACATTCACAATGTTGCGCCCAAAGTCTTTGAAACGAGCTACCA
CAATCTCCAAGAAGAGGAGACTAAATCCACTTTTTTAATGTGTGGTTTGT
TTCCCGAAGACTTCGATATTCCTACTGAGGAGTTGATGAGGTATGGATGG
GGCTTGAAGCTATTTGATAGAGTTTATACGATTAGAGAAGCAAGAACCAG
GCTCAACACCTGCATTGAGCGACTGGTGCAGACAAATTTGTTAATTGAAA
35 GTGATGATGTTGGGTGTGTCAAGATGCATGATCTGGTCCGTGCTTTTGT
TTGGGTATGTTTTCTGAAGTCGAGCATGCTTCTATTGTCAACCATGGTAA
TATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACCTTGCAAAA
GAAATTCATTAACATGCAAGGGTATGATTGAGATTCCAGTAGACCTCAAG
TTTCCTAAACTAACGATTTTGAACCTTATGCATGGAGATAAGTCGCTAAG
40 GTTTCCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCATGTTATATCAT
ACGATAAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCGATGCTCCACC
AACATTCGGGTGCTTCATCTCACTGAATGTTTATTAAAGATGTTTGATTG
CTCTTCTATCGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCAAATT

CTCACATTGAATGGTTACCTTCCACAGTCAGAAATTTAAAGAAGCTAAGG
TTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAACAGGGTGTCTT
GAAAAGTTTTGTCAAACCTGAAGAATTTTATATTGGAGATGCATCTGGGT
TTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTTACAACCTTTCT
5 GCATTAGAATTCGCGTCTTTAATAACAAGGCTGAAGTGAAAAATATGTC
ATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGCTCTTTTGATG
AAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCAATTGGTG
ACCAACAAAGGTGATGTATTAGACTCTAAACTTAATGGGTTATTTTTGAA
AACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAGATG
10 TTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAATTA
AAAGTTCCTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAAAC
CAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTGAAT
GTGAGAATATGGAAGAACTCATACATACTGGAATTGGGGGTTGTGGAGAA
GAGACAATTACTTTCCCTAAGCTGAAGTTTTTATCTTTGAGTCAACTACC
15 GAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACCACATC
TCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTTATCCG
CAGAACAAGTTGCGAACATCTAGTTTGTGGAAGGAAGGGGTAGATATATG
TTCTTTATGTTAATAACAATTTAAATAATATTTTCAACCAAATTTTCATAA
TATATCTGTAATTTGATTGTATGATGTATTGTTTATATGTGGCTATT
20 AAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGACACTTCAA
ATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTTAGTGG
AGGTGAGAAAGTTAAGTTGAGAGCGATTAAAGTGAGTAGCTGTGATAAGC
TTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTTGAA
GAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACATTGA
25 CTTGGATTGTGTCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCTTAA
GAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGGATA
AAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTTGAAAG
CATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTATCA
CCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGTTGC
30 GGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCAATTTCACTTTC
TTAATTAATTAAGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGTGGG
ATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCATGAA
ACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAAAAA
TATGGCTTAAATTTTTTTTATATTTATGTATCAACATGATTTTTTCATTAG
35 AGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATCAGAATAAAT
CTAACTTTAGCTAATAAATCGTTATAAATGTAATAAATTACTTTTTAGTG
AAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCCCTAAC
AAAAAAACTATTTGGTTCAGAAAAACCGTAATTCAAGATAACTAAAATA
AAAATATTTGACATTCACTAAGAGCATTTTTTTTTTCTAAATATGATTGCA
40 AATGAATAAAACTTAAATTTATACAGAAAATTCTTTTATATATGTTATAC
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG
GTATCACAAAGGGATATATAATAAAATATTATTTTCTGTAGTCATTTGTA
ATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTAA

ACTTTCATAATAAAAAATTTATAATTATTATTTATTTTAAATAAATTATTA
ATTAAGAGATATATCAAAAATTTAAAGTTATTATAACTTCAAATTTAACA
TATAATTAGAAAATATATGATCATAACTTTCTGCAACTCTTCTTTTGTAT
TAAAATGACCAGAGAAGCTCTTAGTATATTTCTAATCAAAGTCTCAAAMC
5 TAATGAAGCATATAATTTGTGAAAATCAATTAGCATTAGGTTTTAAGAGT
CACCAAATTCAAAGAATAATCCAATGCTTTCATTACCACTATGGAGAAAA
TATTTTCTTAGTTTTAAATGAAATGAAAACAAACATTCAAACAAATTGTTG
CTTATTAACCAAAGACCCATTACTTAGCCAAGAGTTTAAACAAAAA
10 TTACATTCATGTATCATTATTCATGACTAGATATATATGAACATGAAGGG
AGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTCAGGGAAT
TCCTCAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACCAAAG
AGAAGTTTAGCCTAGCATGGCTAAACTCAAGAACTAAAATAAGGATTAG
AAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTTGTTCTTG
ATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAATGCAAAGG
15 AGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCACCAACCT
CCCTTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTGAAGGACC
CTATGTGGGTGCCTTGCGCGGGTGGAGCTGCATACGAAAGGTCTTTGGTC
TTTGTGAGGGTGATGTTGTGCGGGATAGCTTGTGCGATGCTTCCGCGCGG
TTCACGCACATGTGCACAGGTGATGCATGGTGTGTGCGTTCCTTGAGTTTT
20 GAGCCTCCGATGCTTAGTCCACTTGGCCCAATTCGAGTCCAATCAGCTTA
TAACCCATTTTTCTTCAAGTTATCTTCAAGTTAAGCCCAATTTGCCTTCT
CCAAATCATCCATAACTTCACAGAATCGCCGTTTCATCTTAATCCCGGAT
GCACAATTATTCTCCCGTCTTCATTTTAAGCAAGATAACCACCTTCTTCAT
GCTTCATCCATCAATAGTACACTTCATGTATCATCTCTACTAGTTATTTA
25 GTCCACAATCCTTGTTGTCTCCAAATTTAATTATCTCATTTAGTTCCCG
TTCCGCTAGTTTCCTTAAATTTGCAATTAAGCTCAGAGAAATATTAAGT
ACCCGAAATGGTCATAAAAATAACAAAAAGGAAAATATGCATGAAGATTAA
CTAAATGATGAACGAAATATGCTAAAATAGACTATAAAAATGAAGTAAATA
AAATGAAATTATCGCACTCCGACCACCCTTATAGGCTTGTAGTCCACCCA
30 CCCTTCATTCCTTGTAACCAATATGGGATGGAAACATCATTAAATTAAGCCA
AAAAGCTAACATATAAGGGTTTAGTGACAAAGGTAAGTACTAAAGATGAA
AATAATCCATTTTTCTTGTATATACACAACACACACATAGGGGCAGACGT
AGGATTTCAAAGTACAGATTGTTGGTGGCACATAAGTGTGCTGGTGACA
TTTTTTTTTTTTTTTACGTAGTGGCACAAACAGTAGGAAAAACGAAAAAT
35 TCGAAATTTTTTACAATTTGTCTAAAAAAAACAGTGGTTGTTGGTGCCAC
TATGGACACCAAAGTTGAACTGCCCCACGCGCGCACACACACACACACA
CATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAAAGAAAGAGAGAGA
GAGAGTTTGGGATGTGATACTTCTTTTAGGAAAATGGAGTTATATCTTTG
ATATTGTATTTTTTTAATGTAATTTATATATTTAATCATTTTTAGTTTATA
40 AGTTTTATTTATTTTGATATGAAAAAAAAGTCTTTTATACATTGGATTT
AACATAAAAATCCAACAATATTAATCAAAAAGACCAMACATGTGGACAMW
TATGTATATAAWTAATTCACAATAGTCTTTAGGAATAGNATTATATATAT
AATTAATTCTCAATGGTCTTAGGAATAGTAAGTTCTTATATTTCAAACCT

TNGCCACAATTCTTTGKTTACTTGWGACACTTYCCTCTCTCTAATTATATA
TATATATATATATATATATATATATATATACACACACACACACACACTAG
ATGTGTGCCCGCGCAAAGCAGTGACGTNNNGGAGAANAACCTTTCTTAAGCA
TAAATAATTATTATATTTTTTTATTGGGTATTATATAATAAAAAAATTACAA
5 CTTTTAAATAAAATATTTATGTTTATACTTTATATTTATATTGCTTGTAT
ACTATTAATATAATAAATTAATATTTATGTCTAATTTATGAAATGTAAAT
TAATTTAAATACATGAATTTAATATTTTTAAATTTTCAGTTTGCTTCAA
ATTGAGTTTCTTAATTATTTTTTTTAAATTCANGTATTCAAACCTTTGGTA
AGTATTAAGAATTATTTATGCATAATTGATTTATACAAAAAATTTGTA
10 ACTTATACATCTTAAATTTCAAGATATAACTAACATGTTTTACAATATAT
AT
TAAAGCGCAAAGGTCATAGGAATAGAATATTTTCTATTATTCTACGTTTT
GCCACAAAAGTTTGAACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTT
CAATGTTTTGCGACAAAAGTTCCAAAACCTTTGCCACTTTGATCATTCCCTC
15 AACTTTTCACCGCAATTAGTTTGTGGAGTTGGCAGTTTTGATCCCCCTAA
CTTCGATATTCTCTACTGCTAGCCAAAAAGGGTTCCAGAGTTTCACACTT
TTGGTCCCTGACAGTAACCAAATGTGAGATGTCAAATTTTTGCCACATTA
GTTTGTGGAGTTGTCCCTTTTGGTCCCCCACATTTCGATATTCTANTATA
CGACCTTATTTTTNTCAAATAACAACACGTATATTTAATTACCAATTATA
20 GAAATAGATATCAAATAAAGTATTTGTAACACTGTGTAAGAACGGTGCTA
CTATAGGTAAAAATAAACATTTCAAAGTACGATATCCTAATTGAAAAAAG
AGTTTTAAAAAAATAACGACTAGGGGCGAGTTTTTTTTTACAAGTTTGTAT
CAAATCATATCAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAAT
GTAATTTATTCTTTGATTTTGATAATTTTTAATATTTTGTGTGATCTAT
25 GTATTTAAAAGTAAACAACAAGAACATAATCCAAAACCCTAAATTGCAA
GTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGT
CGCTCTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAA
AAGTTGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGT
CAAATTTTGTATTTTGTGATGGATTTGAGTAGAAGTTTGGGCAGAACGG
30 GAATGATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATA
TATGTAGCCTCTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATC
TTTTTAGAAGTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACC
AACAACTCTTAAAAACTTGATTAATCAATTGTTTTCTTCATCTTGATAAC
AAGTGAATGATTTTCTACTTAGATTAACCTTGAAAAAAAAGGTCCATGTG
35 CGTCTGGTGGATCTGGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAG
ACACAAACACGTCACCATATCTCTTATTTTATTTTAAATTTGCTTTTGGT
GATTTTTCTTTTTCTTATTTCTTTCTTTGATCTCCAGATGGTATGT
GGTGTGGATAATTTACACCTAGAGATTGGGAACGATGGGAAGGGGTCTGT
GATTTATGGCTGGCCGAGTTTTACTTATTAACCTCAATTTCAACCTAAATT
40 CTGATTCCTTGTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGT
TGCATAGGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATC
CAACTATTTTTTAGCTGTTGGCATTTCATCATTGCAACTGTTTCTTG
AAAAAAAATACCTAAAATAAAAATAACCATTTTCAAATCCAAAATTATA

AGAGAGAATTGTAAATGGACATGGAATCATAAATCATTAAACACAGTTCAG
TAAACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCA
GAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATCTTGTATT
CCCATCCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGG
5 ATAATTATGAAGGAGTGGAGGTGGTATTTGAGATAGAGAGTGAGAGTCCA
ACATGTAGAGAATTGGTAACAACCTCGCAATAACCAACAACAGCCTATTAT
ACTTCCCTACCTCCAGGATTTGTATCTAAGGAATATGGACAACACGAGTC
ATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAA
CAATCAGAATCCCCATTCCACAACCTCACACCATAAATATTCTTAAATG
10 CAAAAGCATTAAAGTACTTGTTTTCGCCCTCATGGCAGAACTTCTTTCCA
ACCTAAAGGATATCCGGATAAGTGAGTGTGATGGTATTAAGAAGTTGTT
TCAAACAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCA
CACACCACCCTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCC
TGGAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGC
15 AATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCA
ATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCCTTTTT
TATTTGCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGAT
AAT.AATTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTCAGA
AACTCTAGTAAGGGCAGTTATGGAAGTTCATAAAAATGATAATGGCATCT
20 TTTGATGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTAT
TTAGCAAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAAT
CTGGTCATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGG
GGACATCAGGTGACAGATATTGTAGAATAGAACAATATATAATATTACCC
AAAACTATTTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGATTT
25 CATTGAATTTGCATTCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCA
ATAAATCCCGAAATTAATTAAAAAAGAAAAAAACAAAAGTAAATTTTTGA
TATGGAGAGCACTGGTATCATTAGTATATAAAAAAACTAGATTTTGAAT
TAAGTTTCTTATATAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCA
TTTTTCCATGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTGGAG
30 TTTATGCCAATACGCTAGAGAGATARAATAGKTGGATGCTATGCATTGT
CAAGTGTGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTG
CTGAGAATAGAGTCTTGTGATGGCATGAAGGAGGTATTTGAAACTCAATT
AGGGACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGCGAGGAAGGAA
TTCCAAGAGTAAATAACAATGTTATTATGCTTCCAATCTAAAGATATTA
35 AGT.ATTGGAAATTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACT
TGAAAGCCTGAGACAGCTCCAAGAGTTAAAGATAAAAATTTTGCTACGGAA
TGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACA
ACAACAACAACAACGAAGGGGCATCTTCTTCTTCTTCTTCTTCTTCTTCTC
TTCTTCTTCTAAGAAGGTGTGGTCTTTCCCTGTCTAAAGTCCATTGTAT
40 TGGTCAATCTACCAGAGCTGGTAGGATTTCTTCTGGGGATGAATGAGTTC
CGGTTGCCTTCATTAGATAAACTTAAGATCAAGAAATGCCCAAAAATGAT
GGTGTTCACAGCTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACA
CAAGATTAGGCAAACATACTTTGATCAAGAATCTGGCCTTAACTTTCAT

CAGGTATATATATATTTCTTTAATTGGCATCATCTAATTAAGAAAGATAT
CATTCCCTGCCAAGTAAATTTACTTCAAACACATTCACACTGGTTTCAGTC
TAAGTTTATGTTGTTCTAAGAAGGCCAAAATGGGAAAGCAAGATAGGGAA
AAATAGTGTATTTTCAGTGGAAAGGGTATTTTAGGCATTTTCTGTCAAAG
5 TTGTTATTGCAGGCTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATT
ATTATTCTGATTGCTTGTCTTTATCATTTTTTCTTAGCCTCTCGAAC
AGCTAGAAACCCTTTTAATCTTTTGATTTTCAATGACGAAATTTTCCCT
GTTACTCCATTTGATTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCT
CATCTGTTACTTCTTTTGATTGTTATTTTCATATCATGTTGTCTTTGAA
10 TCAAGCTTTTCCATTTTCAACCAGGGCAAAGGTCAAAGTAACCTACTT
TATGAGATCAAAAACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAAT
AGTTACAATTACCATTGTGATTAATAATTATAATATCTTGTATTAATTCA
TAAAAATTGGTACAGCACATATATGACATTTCAAAGGTTTTTGTGTTGACA
TATAATATGCCTCTGGCGTTTTCTTTATTGGACTTGCAGACCTCATTCCAA
15 AGTTTATACGGTGACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTTG
GTCTTTTCATAACTTTATCGAATTAGATGTGGAAGGTAATCATGATGTTA
AAAAGATTATCCATCCAGTGAGTTGCTGCAACTGCAAAGCTGGAAAAG
ATT.AATGTAAGGTGGTGTAAGGGTAGAGGAGGTATTTGAAACTGCATT
GGAAGCAGCAGGGAGAAATGGAATAGTGGAATTGGTTTTGATGAATCGT
20 CAC.AAACAACCTACTACTCTTGTCATCTTCCAAACCTTAGAGAAATG
AACTTATGGGGTCTAGATTGTCTGAGGTATATATGGAAGAGCAATCAGTG
GAC.AGCATTTGAGTTTCAAACCTAACAAAGAGTTGATATCTATAAATGTA
AAAGGTTAGAACATGTATTTACTAGTTCCATGGTTGGTAGTCTATCGCAA
CTCCAAGAGCTACATATATCCAACCTGCAGTGAGATGGAGGAGGTGATTGT
25 TAAGGATGCAGATGATTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATG
GGGAGACGAATAAGGAGATACTTGTGTTACCTCGTCTAAACTCCTTGATA
TTA.AGAGAACTTCCATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTT
TTC.ATTCCCATTATTGGATACTTTAAGAATTGAGGAATGCCAGCAATAA
CCACCTTCACCAAGGGAAATCCGCTACTCCACAGCTAAAAGAAATTGAA
30 ACACATTTTGGCTCGTTTTGTGCTGCAGGGGAAAAGACATCAACTCTCT
TAT.AAAGATCAAACAACAGGTAAATCAGATCTTTGTTGCTTTAATAATTC
TTAAACTACATTTGAAAAGCTTCATGCAAGTTTTTTTTGTTATATTGTCA
AAAACCGCAACCTACATTTTTCAGCTTTATATTTATGTACTTTATGCAGGA
GTTCAAACAAGACTCTGATTAATGTGAAGTAAATACTAAAGGTAAATTAT
35 ATTTTCATGTTCCTAGTTGCCTATTAATTAATTGCCTTTTAGTTTCATGAT
TTTTGGATGCATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCAT
TGTTTGGTTGAATGTTGACTCTATGTCTTGATGAATATTCAAGGGAAGAA
TTGTTTCATCATATGAAGGACATTAAGAAGAACATGGATGCTATGAAGAT
GTGGGAAAACAA

40

RG2B deduced polypeptide sequence (SEQ ID NO:90)

MSDPTGIAGAIINPIAQTALVPVTDHVGYMISCRKYVRVMQMKMTELNTSRISVEE
 HISRNTRNHLQIPSQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITE
 QIESLTRQLSLISWTDDPVPLGRVGSMNASTSASLSDDFPSREKTFTQALKALEPNQK
 5 FHMVALCGMGGVGVKTRMMQRLKKAEEKFLFNIVGAVIGEKTDPFAIQEAIADY
 LGIQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQ
 GVDKFKVLLTSRDSQVCTMMGVEANSIINVGLLTEAEAQSLFQQFVETSEPELQKIGE
 DIVRKCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQ
 EEETKSTFLMCGLFPEDFDIPEELMRYGWGLKLFDRVYTIREARLNTCIERLVQ
 10 TNLLIESDDVGCVKMHDLVRAFVLGMFSEVEHASIVNHGNMPGWPDENMIVHSC
 KRISLTCKGMIEIPVDLKFPKLTILKLMHGDKSLRFPQDFYEGMEKLVHVISYDKMKY
 PLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLFSANSHIEWLPSTVRNLK
 KLRLDLRFDGLRIEQGVKSFVKLEEFYIGDASGFIDDNCNEMAERSYNLSALEF
 AFFNKAEVKNMSFENLERFKISVGCSDENINMSSHSYENMLQLVTNKGDVLDLSDK
 15 LNGLFLKTEVLFVSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLHISKVELRYLFLK
 NLANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLFSLSQLPKLSSLCHN
 VNIIGLPHLVDLILKGIPGFTVIYPQNKLRRTSSLLKEGVVIPKLETLOIDDMENLEEIW
 PCELSGGEKVKLRAIKVSSCDKLVNLFPRNPMSELLHHLEELTVENCGSIESLFDNLDD
 CVGAIGEEDNKSLRSINVENLGLKREVWRIGADNSHLINGFQAVESIKIEKCKRFR
 20 NIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSCLMH
 SFHNLRLVLTLDNYEGVEVVFEIESESPTCRELVTTRNNQQPIILPYLDLYLRNMD
 NTSHVWKCNSWNKFFTLPKQQSESPFHNLTTINILCKSIKYLFSPLMAELLSNLKDI
 RISECDGIKEVVSNRDDEDEEMTTFTSTHTTTTLFPSLDSLTLFLENLKCIGGGGAK
 DEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEIVGCYALSSVIPCYAA
 25 GQMQL

RG2C polynucleotide sequence (SEQ ID NO:91)

ATAATATTACACAAAGGTAACGTCATTAATTAATTACGATACGAGACAGA
 CTTTTTCACTCGGACATNAACGGTCTATTCCTAACTTNANNTAATTNAAT
 30 GAATTTAGGATGTGCTAATATGCATGTAANATTCGCTACCGTCATCTTTC
 AAATGACCATATTTTTATGTATTTATAATGAATCAATGAAAAACCGGATT
 TCT.ATTTAAAATTCTTAAACTTCATCTTTTAAGCCAGGGTGAATACAAT
 TGCTAGATCCACTGTTAATTTCCATCGAATTATGCCTGATCAATTGTTGG
 CTGCCTACGATGCAGGTGCTACCACAAGAATATGGCCATGGAAACTGCTA
 35 ATGAAATTATAAAACAAGTTGTTCCAGTTCTCATGGTTCCTATTAACGAT
 TACCTACGCTACCTCGTTTCCCTGCAGAAAGTACATCAGTGACATGGATTT
 GAAAATGAAGGAATTAAGAAGCAAAAGACAATGTTGAAGAGCACAAAGA
 ATC.ATAACATTAGTAATCGTCTTGAGGTTCCAGCAGCTCAAGTCCAGAGC
 TGGTTGGAAGATGTAGAAAAGATCAATGCAAAAGTGGAAACTGTTCTTAA
 40 AGATGTCGGCTGTTGCTTCAATCTAAAGATTAGGTACAGGGCCGGAAGGG
 ATGCCTTCAATATAATTGAGGAGATCGACAGTGCATGAGACGACACTCT
 CTG.ATCACTTGGACCGATCATCCCATTCTTTGGGAAGAGTTGATTCCGT

GATGGCATCCACCTCTACGCTTCAACTGAACACAATGACTTCCAGTCAA
GAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACTTGAGGCCAACACATG
ATAGCCTTATGTGGAATGGGGGAGTGGGGAAGACCCACATGATGCAAAG
GCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTTGGTTATATCATCGAGG
5 CGGTTATAGGGGAAATATCGGACCCCATGCTATTCAGCAAGTTGTAGCA
GATTACCTATGCATAGAACTGAAAGAAAGCGATAAGAAAACAAGAGCTGA
GAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGATGGAGGTAACACTAAGT
TCCTCATAATATTGGATGATGTCTGGCAGTCCGTTGATCTAGAAGATATT
GGTTAAGCCCTTCTCCCAATCAAGGTGTGCGACTTCAAGGTCTTGTTGAC
10 TTCACGAGACGAACATGTTTGCTCAGTGATGGGGGTTGAAGCTAATTCAA
TTATTAACGTGGGACTTCTAATTGAAGCAGAAGCACAAAGATTGTTCCAG
CAATTTGTAGAACTTCTGAGCCCGAGCTCCACAAGATAGGAGAAGATAT
TGTTAGGAGGTGTTGCGGTCTACCCATTGCCATCAAACCATGGCGTGTA
CTCTAAGAAATAAAAGAAAGGATGCATGGAAGGATGCACTTCTCGTTTA
15 CAACACCATGACATTGGTAATGTTGCTACTGCAGTTTTTAGAACAGCTA
TGAGAATCTCCCGGACAAGGAGACAAAATCTGTTTTTTTATGATGTGTGGTT
TGTTTCCCGAAGACTTCAATATTCCTACCGAGGAGTTGATGAGGTATGGA
TGGGGCTTAAAGTTATTTGATAGAGTTTATACAATTATAGAAGCAAGAAA
CAGGCTCAACACCTGCATTGACCGACTGGTGCAGACAAATTTACTAATTG
20 GAAGTGATAATGGTGTACATGTCAAGATGCATGATCTGGTCCGTGCTTTT
GTTTTGGGTATGTATTCTGAAGTCGAGCAAGCTTCAATTGTCAACCATGG
TAAATATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCCTCTTGCA
AAAGAATTTCAATTAACATGCAAGGGTATGATTGAGTTTCCAGTAGACCTC
AAGTTTCCATAACTAACGATTTTGAAGCTTATGCATGGAGATAAATCGCT
25 AAAGTTTCCCTCAAGAATTTTATGAAGGAATGGAAAAGCTCCGGGTATAT
CATACCATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCAATGCTCC
ACC.AACATTCGGGTGCTTCATCTCACGGAATGTTTCAATTAAGATGTTTGA
TTGCTCGTGTATTGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCTA
ATTCTTGCATTGAGTGGTTACCTTCCACGGTCAGAAATTTAAAAAAGCTA
30 AGGTTACTTGATTTGAGATTGTGTTATGGTCTCCGTATAGAACAGGGTGT
CTTGAAAAGTTTGGTCAAACCTTGAAGAATTTTATATTGGAAATGCATATG
GGTTTATAGATGATAACTGCAAGGAGATGGCAGAGCGTTCCTTACAACCTT
TCTGCATTAGAATTCGCGTCTTTAATAACAAGGCTGAAGTGAAAAATAT
GTCATTTGAGAATCTTGAACGATTTAAGATCTCAGTGGGATGCTCTTTTG
35 ATGGAAATATCAATATGAGTAGCCACTCATAACGAAAACATGTTGCGATTG
GTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGGTATTTTT
GAAAACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAG
ATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTTTCATTCTGCAAT
TTAAAAGTCCTTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAA
40 ACTCAATGTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTA
AATGCAAGAATATGGAAGAACTCATACTACTGGGATTGGGGGTTGTGGA
GAAGAGACAATTACTTTCCCAAGCTGAAGTTTTTATCTTTGAGTCAACT
ACCGAAGTTATCAGGTTTGTGCCATAATGTCAACATAATTGGGCTACCAC

ATCTCGTAGACTTGAACTTAAGGGCATTCCAGGTTTCACAGTCATTTAT
CCGCAGAACAAGTTGCGAACATCTAGTTTGTGAAGGAAGAGGTAGATAT
ATGTTCTTTATGTTAATACAATTTAAACAATATTTTCAACCAAATTTTCA
TAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCT
5 ATTAAGGGATGATAATTTGCGAGTTGTGATTCCTAAGTTGGAGACTT
CAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACCTTAG
TGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAGTGAGTAGCTGTGATA
AGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTT
GAAGAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACAT
10 TGACTTGGATTGTGTGCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCT
TAAGAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGG
ATAAAAGGTGCAGATAACTCTCATCTCATCAATGGTTTTCAAGCTGTTGA
AAGCATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTA
TCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGT
15 TGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCATTTCACT
TTCTTAATTAATTANGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGT
GGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCAT
GAAACGCTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAA
AAATATGGCTTAAATTTTTTATATTTATGTATCAACATGATTTTTTCATT
20 AGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACTAA
TTCTAACTTTAGCTAATAAATCGTTATAAATGTAATAAATTACTTTTTAG
TGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCTTA
ACAAAAAAACTATTTGGTTCAGAAAACTGTAATTCAGATAACTAAAA
TAAAAATATTTGACATTCACTAAGAGCATTTTTTTCTAAATATGATTGCA
25 AATGAATAAAACTTAAATTTATACAGAAAAGATTTTTATATATGTTATAC
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG
GTATCACAAAGGGATATATAATAAATATTATTTTTCTGTAGTCATTTAT
AATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTA
AACTTTCATAATAAAAATTTATAATTATTATTTTAAATAAATTATT
30 AATTAAGAGATATATCAAAAATTTAAAGTTATTATAACTTCAAATTTAAC
ATATAATTAATAAATATATGATCATAACTTCCGCAACTCTTCTTTTGTA
TTAAATGACCAGAGAAGCTCTTAGTATATTTTCTAAATCAAAGTCACAA
AACTAATGAAGCATATAATTTGTGAAAATCAATTAGCATTAGGTTTTAA
GAGTCACCAAATTCAAAGAGTAATCCAATGCTTTCATTACCACTATGGAG
35 AAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTAATT
GTTGCTTATTAACCAAAGACCCATTACTTAGCCAAGAGTTTAACCAAAA
AAAATTACATTCATGTATCATTATTAATGACTAGATATATATGAATATGA
AGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTCATG
GAATTCCTCAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACC
40 AAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAATAAGGA
TTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTTGTT
CTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAATGCA
AAGGAGAGCCATTAATTCGTATGTATTGATCCCTTCAAAGCTGCACCA

ACCTCCCTTAAATAAACTCAAAGCAAAAATGACAAAATTGCCCTGAAG
GACCCTATGCGGGTGCCTTGCGCGGGTGGAGCTGAATATGAAAGGTCTTT
GGTCTTTGTGAGGGTGTGTTGTGCGGGTTAGCTTGTGCGCATGCTTCCGC
GCGGTTGCGGCACATGTGCACAGGTGATGCATGGTGTGTACGTTCTTGAC
5 TTTTGAGCCTCCGATGCTTAGTCCACTTGGCCCAATTCGAGTCCAATCAA
CTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTAAGCCCAATTTGCC
TTCTCCAAATCATCCATAACTTCACAGAATCGCCCGTTCATCTTAATCCC
GAATGAACAATTATTCTCCCGTCTTCATTTTAAGCAAGATACCACCTTCT
TCATGCTTCATCCATCAATAGTACACTTCATGTATCATCTCTACTAGTTA
10 TTTAGTCCACAGTCCCTGTTGTCCTCCAAATTTAATTATCTCATTAGTT
CCCGTTCGCTAGTTTCCTTAAAATTTGCAATTAAGCTCACAGAAATATT
AAGTACCCGAAATGGTCATAAAAATAACAGAAAAGGAAAATATGCATGAAGA
TAACTAAATGATGAACGAAATATGCTAAAATAGACTATAAAAATGAAGTA
AATAAAATGAAATTATCGCACTCCGACCACCCTTATAGGCTTGTAGTCCA
15 CCCACCCTTCATTCCTTGTACCAATATGGGATGGAAACATCATAATTA
GCCAAAAACTAACATATAAGGGGTGAGTGACAAAGGTAAGTACTAAAGA
TGAAAAAATCCATTTTTCTTGTATATACACAACACACACATAGGGGCAG
ACGTAGGATTCATAGTACAGATTGTTGGTGGCACATAAGTGTTGCTAGT
GACATTTTTTTTTCTTTTACGTAGTGGCACAACAGTARAAAAAACRAAA
20 AATTCGAAATTTTTACAATGTGCCTAAAAAAAACAGTGGTTGTTGGTGC
CACTATGGACACCAAAGTTGAACTGCCCTGCGCGGCACACACACACAC
ACATAAAGTTG
GGATGTGATACTTCTTTTGGGAAAATGGAGTTATATCTTTGATATTGTAT
TTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAAGTTTTATT
25 TATTTKGATATGAAAAAAAAGTCTTTTATACATTGGATTTAACATAAAA
ATCCAACAATATTAATCAAAAAGACCAAACATGTGGACAATTATGTATAT
AATTAATTCACAATAGTCTTTAGGAATAGNATTATATATATAATTAATTC
TCAATGGTCTTAGGAATAGTAAGTTCTTATATTTCAAACNTTTGCCACAN
TTCTTTGNTTACTTNGACACTTTYCTCTMWNNANWMWWTWATATATATAT
30 ATATATATATATAHAHAHAHAVACACACACACTAGATGTGTGCCMGC
AAGCAGTGACGTNNNGAGAANACTTTCTTAAGCATAAATAATTATTATA
TTTTTTATTGGGTATTATATAATAAAAAATTACAACTTTTAAATAAAATA
TTTATGTTTATACTTTATATTTATATTGCTTGTATACTATTAATATAATA
AATTAATATTTATGTCTAATTTATGAAATGTAAATTAATTTAAATACATG
35 AATTTAATATTTTTAAAATTTTCAGTTTGCTTCAAATTGAGTTTCTTAAT
TATTGACCAAACATGTGGACAATTATGTATATAATTAATTCACAATAGTC
TTTAGGAATAGTATTATATATATAATTAATTCATGCTTAGGAATA
GTAAGTTCTTATATTTCAAACTTTTGCCACAATTCTTTGCTTACTTTGAC
ACTTTTCCTTCCTAACTTTACATATATATATATATATTAAGCGCAAAGGTC
40 ATAGGAATATAATATTTTCTATTATCTACGTTTTGCCACAAAAGTTTGA
ACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTTCAATGTTTTGCGACA
AAAGTTCCAAAACTTTTGCCACTTTGATCATTCTCAACTTTTCACCGCAT
TAGTTTGTGGAGTTGGCAGTTTTGGTCCCTCTAACTTCGATATTCTCTAC

TGCTAGCCAAAAAGGGTTCAGAGTTTCACACTTTTGGTCCCTGACAGTA
ACCAAATGTGAGATGTCAAATTTTTGCCACATTAGTTTGTGGAGTTGTCC
CTTTTGGTCCCCCACATTTCGATATTCTACTATACGATCTTATTTTTCTC
AAATAACAACACGTATATTTAATTAATAATGATAGAAATAGATATCAAAT
5 AAAGTATTTGTAACACTGTGTAGAGTTTTTTTTTACAAGTTTGTATCAAA
TCATATCAAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAATGTAA
TTTATTCTTTGATTTTGATAATTTTTAATATTTTGTGTGATCTATGTAT
TAAAAGTAAACAACAAAGAACATAATCCAAAACCCTAAATTGCAAGTCT
CGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGTCGCT
10 CTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAAAAGT
TGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGTCAAA
TTTTTGATTTAGTTGATGGATTTGAGTAGAAGTTTGGGCAGAACGGGAAT
GATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATATATG
TAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATCTTTT
15 TAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACCAACA
ACTCTTAAAACTTGATTAATCAATTGTTTACTTCATCTTGATAACAAGT
GGAATGATTTTCTACTTGAAAAAAAAGGTCCATGTGCGTCTGGTGGATCT
GGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAGACACAAACACGTCA
CCATATCTTTTATTTTATTTTAAATTTCTTTTTTCCCTATTTCTTTCTTT
20 CTTGATCTCCAGATGGTATGTGGTGTGGATAATTTACACATAGAGATTGG
GAACGACTGTGATTTAGAGAGGACGTGGCTTGGGGTTGAGGATGGTTTAT
GGCTGGCCGAGTTTCATTTATATAAAACAAACAATATATAAAACAAGGGG
TAAATGGCCATCTTATATGTATTTAACCGTCCTCTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTGTAATTTAAGAAGGGGTATACCAGTGCAGC
25 CTCTTATTCCCAACCAGTCAAATAGGGACTTAGGTTGTTTGGAAACAGTT
CCGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAAACTTAACCCTT
CAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGAT
TCTTGTTTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGTTGCAT
AGGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATCCAAC
30 ATTTTAATCTGTTGACGTTTCCATCATTTGCAACTGTTTCTTGAAAAA
AAAATACCTAAAATCAAATAACCATTTTCAAATCCAAAATTATAAGAGA
GAATTGTAATGGACATGGAATCATAAATCATTAAACACAGTTCAGTAAAC
AAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATCTATCAGAGAA
AGAGACATTACAAGAAGCCACTGGCAGTATTCAAATCTTGTATTCCCAT
35 CCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGGATAAT
TATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAG
TAGAGAATTGGTAACAACCTACAATAACCAACAACAGCCTATTATACTTC
CCTACCTCCAGGAATTGTATCTAAGGAATATGGACAACACGAGTCATGTG
TGGAAGTGCAGCAACTGGAATAAATCTTCACTCTTCCAAAACAACAATC
40 AGAATCACCATTCCACAACCTCACAACCATAGAAATGAGATGGTGTGATG
GCTTTAGGTACTTGTTCGCCTCTCATGGCAGAACTCTTTCCAACCTA
AAGAAAGTCAAGATACTTGGGTGTGATGGTATTAAGAAGTTGTTTCAAA
CAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACAAAA

CCACCAACTTGTTCCCTCATCTTGATTCTCTCACTCTAAACCAACTGAAG
AATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGA
AATATCTTTCAATAATACCACTGCAACGACTGCTGTTCTTGATCAATTTG
AGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCTTTTTTTATTT
5 GCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAA
TTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTC
TAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGA
TGGGTAATATAGGCAATTTAAGTTTTATTTCTGTTAAAGCAGTATTTAGC
AAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGT
10 CATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGGTTA
TCAGGTGACAGATATTGTAGAATAGAACAATATGTAATATTACCCAAAAC
TATTTTTTCTAAGGTTGCTCTGTTAAATATGTGCTTTCTTGATTTCAATG
AATTTGCATTCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAA
TCCCGAAATTAATTAACAAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGA
15 GAGCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTT
TCTTATATAAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCATTTTTC
CATGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTGGAGCTTATG
CCAATACGCTAGAGAGATAAAAAATAGGCAACTGCCATGCATTGTCAAGTG
TGATTCCATGTTATGCAGCAGGACAAAATGCAAAAGCTTCAAGTGCTGAGA
20 GTAATGGCTTGCAATGGGATGAAGGAGGTATTTGAAACTCAATTAGGGAC
GAGCAGCAACAAAAACAACGAGAAGAGTGGTGTGAGGAAGGAATTCCAA
GAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTAAGTATT
GGA.AATTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAG
CCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTTGCTACAGAATGAAAG
25 TGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAACAACAACA
ACA.ACAACGAAGGGGGCATCTTCTTCTTCTTCTTCTAAGAAGGTGGT
GGTCTTTCCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGG
TAGGATTCTTCTTGGGGATGAATGAGTTCGGTTGCCTTCATTAGATAAA
CTT.ATCATCGAGAAATGCCCAAAAATGATGGTGTTCACAGCTGGTGGGTC
30 CACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTC
TTG.ATCAAGAATCTGGCCTTAACCTTTCATCAGGTACATATATATTCCTTT
AATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAGTAAATTA
CTTCAAACACATTCACACTAGTTTCAGTCCAAGTTTATGTTGTTCTAGGA
AGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGAGTATTTCAAGTGGAA
35 AGGGTATTTTAGGTATTTCTGTCAAAAATTGTTATTGCAGGCTTTTTAG
TACCTGGAAGAGCATGATTATTCTCGATTTGCTTGTTTCTTTATCATTTT
TCTTAGCCTAGCATGATTTTCAATGAAATCTTCCCTGTTACTCCATTTG
ATTGTTGTTCTTCATGGTTCTAAGTGAGTTAGTGGCTCATCTGTTACTTC
TTTTGATTGTTATTTTCATAGCATGTTGTCACTTGAATCAAGCTTTTCCA
40 TTTTCAACAAGGACAAAAGGTCAAAACTAACCTACTTTATGAGATCAAAA
ATAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATACTTACAATTACC
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC
AGC.ACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT

GGCGTTTTCTTTATTGGACATGCAGACTTCATTCCAAAGTTTATACGGTG
 ACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAAC
 TTTATCGAATTAGATGTGAAATCTAATCATGATGTTAAAAAGATTATTCC
 ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGTAAAGATTAATGTAATGT
 5 GGTGTAAGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG
 AGAAATGGAAATAGTGGAAATGGTGGTGGATGAATCGTCACAAACAAC
 CACTACTCTTGTCAATCTTCCAAACCTTGGAGAAATGAAGTTACGGGGTC
 TCGATTGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG
 TTTCCAAACCTAACAAGAGTTGAAATTTATGAATGTAATTCATTAGAACA
 10 TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG
 AGATTGGTTTGTGCAACCATATGGAGGTCGTGCATGTTTCAGGATGCAGAT
 GTTTCTGTAGAAGAAGACAAAGAGAAAGAAATCTGATGGCAAGATGAATAA
 GGAGATACTTGTGTTACCTCATCTAAAGTCATTGAAATTACTACTTCTTC
 AAAGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATT
 15 TTGGATACTTTGGAAATCTACGAATGCCAGCAATAACCACCTTCACCAA
 GGGAAATCCGCTACTCCACAGCTAAAAGAAATGGAAACAAATTTGGCT
 TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC
 AAACAACAGGTAAACCAGATCTTTGTTGCTTTAATAATTCTTAAACTACA
 TTTGAAAAGCTTCATGCAAGTTTTTTTTGTTATATTGTCAAAAACCGCAA
 20 CCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGATTTCAAACAA
 GACTCTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGT
 TCCTAGTTGCCTATTAATTAAGGCCTTTTAGTTTCGTGATTTTTGGATGT
 ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG
 AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA
 25 TATGAAGGACATTAAAGAACATGGTGCTAT

RG2C deduced polypeptide sequence (SEQ ID NO:92)

MAMETANEIHKQVVPVLMVPINDYLRYLVSCRKYISDMDLKMKEKAKDNVEEH
 KHNHISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAFNI
 30 IEEDSVMRHSLITWTDHPIPLGRVDSVMASTSTLSTEHNDFQSREVRFSEALKALE
 ANHMIALCGMGGVGKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQVVADY
 LCIELKESDKKTRAELRQGFKAASDGGNTKFLIILDDVWQSVLDLEDIGLSPSPNQG
 VDFKVLTSRDEHVCSVMGVEANSIINVGLLIEAEAQRLLFQQFVETSEPELHKIGEDI
 VRRCCGLPIAIKTMACTLRNKRKDAWKDALSRLOHHDIGNVATAVFRTSYENLPD
 35 KETKSVFLMCGLPEDFNIPTEELMRYGWGLKLFDRVYTIIEARNRLNTCIDRLVQT
 NLLIGSDNGVHVKMHDLVRAFLVGMYSVEVEQASIVNHGNMPGWPDENMIVHSC
 KRISLTCKGMIEFPVDLKFPKLTILKLMHGDKSLKFPQEFYEGMEKLRVISYHKMKY
 PLLPLAPQCSTNIRVLHLTECSLKMFDSCIGNLSNLEVLFSANSCIEWLPSTVRNLK
 KLRLDLRLCYGLRIEQVLSLVKLEEFYIGNAYGFIDNCKEMAERSYNLSALEF
 40 AFFNKAQVKNMSFENLERFKISVGCSEFDGNINMSSHYSYENMLRLVTNKGDLVDSK
 LNLGLFKTEVLFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFLK
 NVANTLSRLEHLEVCKCKNMEELIHTGIGGCGETITFPKLFKLSLSQLPKLSGLCH

NVNIIGLPHLVDLKLGIPGFTVIYPQNKLRRTSSLLKEEVVIPKLETLOIDDMENLEEI.
 WPCELSGGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELTVENCGSIESLFNID
 LDCVGAIGEEDNKSLRSINVENLGKLRVWRIKGADNSHLINGFQAVESIKIEKCK
 RFRNIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSC
 5 LMHSFHNLRVLTLDNYEGVEVVFEIESESPTSRELVTTHNNQQQPILPYLQELYLR
 NMDNTSHVWKCSNWNKFFTLPKQSES PFHNLTTIEMRWCHGFRYLFSPMAELL
 SNLKKVKILGCDGIKEVVSNRDDEDEEMTFTSTHKTTNLFPHLDSLTLNQLKNLK
 CIGGGGAKDEGSNEISFNNTTATTA VLDQFELSEAGGVSWSLCQYAREIKIGNCHAL
 SSVIPCYAAGQMOKLQVLRVMACNGMKEVFETQLGTSSNKNNEKSGCEEGIPRVN
 10 NNVIMLPNLKILSIGNCGGLEHIFTSALES LRQLQELTIKGCYRMKVIVKKEEDEY G
 EQTTTTTTTKGASSSSSSKVVVFPCLKSIVLVNLP ELVGGFFLGMNEFR LPSLDKLI
 EKCPKMMVFTAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGD TLGPAT
 SEGTTWSFHNFIELDVKS NHDVKKIIPSELLQLQKLVKINVMWCKRVEEVFETALE
 AAGRNGNSGIGFDESSQTTTTTLVNLPNLGEMKLRGLDCLRYIWKSNQWTA FEFPN
 15 LTRVEIYECNSLEHVFTSSMVGSLQLQELEIGLCNHMEVVHVQDADVSVEEDKEK
 ESDGKMNKEILVLP HLKSLKLLLLQSLKGFSLGKEDFSFPLD TLEIYECPAITFTK
 GNS.ATPQLKEMETNFGFFYAAGEKDINSSIIKIKQQDFKQDSD.

RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94)

20 ACGACCACTATAGGGCGAATTGGGCCCGACGTCGCATGCTCCCGGCCGCC
 ATGGCCGCGGGATGTAAAACGACGGCCAGTCAATCGTAACCGTTCGTAC
 GAG AATCGCTGTCCTCTCCTTCAACCATTTAATGTATATGAGCTAAATTG
 AAACATCTACTATCATGTTTAAATTTATAAACTTTTTCTTTAGATTAC
 TTGTCTGGATGTGTTAATAAAAACCCAATTTCCCACATGCGTAGAGATCA
 25 TAG.ATGTA ACTATTGTTAATCAATTTTGCCTGCCAAGTTTAAATAATTAT
 ACTTGGATATTAACAAA ACTTTATCTAACGACCAAGGTAATATTA AAAAT
 AGGTTATTATTCTTCATGCTAATTA AAAGATGGGTTGCAAAAGTGAGACC
 ATG.AAAACATTAACACGTTGATATTTTCAACTTTTATTCTTTCATATTCA
 CCA TATTTTTTACTTTTCGTATTGATTAATCATCTTTCAATCACAGGCTCC
 30 TTGGCAAAAAGTCAGATCTATTAACAAATACTTCCATGTGGTTGCAAATT
 ACAAGGATTTCAACATAATTACCAAACATAGCATTATCATAAGATCGAA
 TAATAATCAAATTCTTCTATAATATTACACAAAGGTAACGTCATTAATTA
 ATT.ACGATACGAGACAGACTTTTTCACTCGTGACATCAACGGTCTATTCT
 AACTTTACTTAATTAATGAATCTAGGATGTGCTCATATGCATGTAATAT
 35 TTGCTACCGTCATCTTTCAAATGACCATATTTTTATGTATTTATAATGAA
 TCA.ATGAAAAACCGGATTTCTATTTAAAATTCTTAAAACTTCATCTTTTA
 AGCCAGGGTGAATAACAATTGTAGATCCACTGTTAATTTCCATCGATTATG
 CGTGATCAATTGTTGGCTGCATACGATGCAGGTGCTACCACAAGAATATG
 GCC.ATGGAACTGCTAATGAAATTATAAAACAAGTTGTTCCAGTTCTCAT
 40 GGTTCCCTATTAACGATTACCTACGCTACGTCGTTTCCTGCAGAAAAGTACA
 TCAGTGACATGGATTTGAAAATGAAGGAATTA AAAAGAAGCAAAAGACAAT
 GTTGAAGAGCACAAAGAATCATAACATTAGTAATCGTCTTGAGGTTCCAGC

AGCTCAAGTCCAGAGCTGGTTGGAAGATGTAGAAAAGATCAATGCAAAAG
TGGAAACTGTTCCCTAAAGATGTCGGCTGTTGCTTCAATCTAAAGATTAGG
TACAGGGCCGGAAGGGATGCCTTCAATATAATTGAGGAGATCGACAGTGT
CATGAGACGACACTCTCTGATCACTTGGACCGATCATCCCATTCTTTGG
5 GAAGAGTTGATTCCGTGATGGCATCCACCTCTACGCTTCAACTGAACAC
AATGACTTCCAGTCAAGAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACT
TGAGGCCAACCACATGATAGCATTATGTGGAATGGGGAGAGTGGGGAAGA
CCCACATGATGCAAAGGCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTT
GGTTATATCATCGAGGCAGTTATAGGGGAAATATCGGACCCCATTTGCTAT
10 TCAGCAAGTTGTAGCAGATTACCTATGCATAGAGCTGAAAGAAAGCGATA
AGAAAACAAGAGCTGAGAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGAT
GGAGGTAACACTAAGTTCCTCATAATATTGGATGATGTCTGGCAGTCCGT
TGATCTAGAAGATATTGGTTAAGCCCTTCTCCCAATCAAGGTGTCGACT
TCAAGGTCTTGTGACTTCACGAGACGAACATGTTTGCTCAGTGATGGGG
15 GTTGAAGCTAATTCAATTATTAACGTGGGACTTCTAATTGAAGCAGAAGC
ACAAGATTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCACA
AGATAGGAGAAGATATTGTTAGGAGGTGTTGCGGTCTACCCATTGCCATC
AAAACCATGGCGTGTACTCTAAGAAATAAAAAGAAAGGATGCATGGAAGGA
TGC.ACTTTCTCGTTTACAACACCATGACATTGGTAATGTTGCTACTGCAG
20 TTTTTAGAACCAGCTATGAGAATCTCCCGGACAAGGAGACAAAATCTGTT
TTTTTGATGTGTGGTTTGTTCCTCGAAGACTTCAATATTCTACCGAGGA
GTTGATGAGGTATGGATGGGGCTTAAAGTATTTGATAGAGTTTATACAA
TTATAGAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGGTGCAG
GCAAATTTACTAATTGGAAGTGATAATGGTGTACACGTCAAGATGCATGA
25 TCTGGTCCGTGCTTTTGTTCCTGAAAGTATGATGCGAGCAAGCTT
CAATTGTCAACCATGGTAATATGCCTGGGTGGCCTGATGAAAATGATATG
ATCGTGCCTCTTGCAAAGAATTTTCAATTAACATGCAAGGGTATGATTGA
GATTCCAGTAGACCTCAAGTTTCCTAAACTAACGATTTTGAAACTTATGC
ATGGAGATAAGTCTCTAAAGTTTCCTCAAGAATTTTATGAAGGAATGGAA
30 AAGCTCCAGGTTATATCATAAGATAAAATGAAGTACCCATTGCTTCTTT
GGCACCTCAATGCTCCACCAACATTCGGGTGCTTCATCTCACTGAATGTT
CATTAAAGATGTTGATTGCTCTTCTATCGGAAATCTATCGAATCTGGAA
GTGCTGAGCTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAG
AAAATTAAGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCC
35 GTATAGAACAGGGTGTCTTGAAGTTTGGTCAAACCTGAAGAATTTTAT
ATTGAAATGCATATGGGTTTATAGATGATAACTGCAAGGACATGGCAGA
GCGTTCTTACAACCTTTCTGCATTAGAATTCGCGTTCTTTAATAACAAGG
CTGAAGTGAATAATGTCATTTGAGAATCTTGAACGATTCAAGATCTCA
GTGGGGTGCTCTTTTGTGATGGAATATCAGTATGAGTAGCCACTCATAACGA
40 AAACATGTTGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAAC
TTAATGGGTTATTTTGAAGACAGAGGTGCTTTTTTTAAGTGTGCATGGC
ATG.AATGATCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTC
CTCTTCATTCTGCAATTTAAAAGTCCGTATTATTTCAAAGTGTGTAGAGT

TGAGATACCTTTTCAAACCTCCATGTTGCCAAACACTTTGTCAAGCCTTGAG
CATCTAGAAGTTTGTGGATGCGAAAATATGGAAGAACTCATACTACTGG
GATTGGGGGTTGTGGAGAAGAGACAATTACTTTCCCAAGCTGAAGTCTT
TATCTTTGAGTCAACTACCGAAGTTATCAGGTTTGTGCCATAATGTCAAC
5 ATAATTGGGCTACCACATCTCGTAGACTTGAACTTAAGGGCATTCCAGG
TTTCACAGTCATTTATCCGCAGAACAAGTTGCGAACATCTAGTTTGTGTA
AGGAAGAGGTAGATATATGTTCTTTATGTTAATACAATTTAAATAATATT
TTCAACCAAATTTTCATAATATATCTGTAATTTGATTGTATGATGTGTTA
TTGTTTATATGTGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCC
10 TAAGTTGGAGACACTTCAAATTGATGGCATGGAGAAGTTAGAAGAAATAT
GGCCTTGTGAGCTTAGTGGAGGTGAGAAAAGTTAAGTTGAGAGAGATAAA
GTGAGTAGCTGTGATAAGCTTGTGAATCTATTTCCGCACAATCCCATGTC
TCTGTTGCATCATCTTGAAGAGCTTAAAGTCAAAAATTGTCGTTCCATTG
AGTCGTTATTCAACATCGACTTGGATTGTGTGTCAGTGCAATTGGAGAAGAA
15 GACAACAAGAGCATCTTAAGAAGAATCAAAGTGAAGAATTTAGGGAAGCT
AAGAGAGGTGTGGAGGATAAAAGGTGCAGATAACTCTCGTCCCCTCATCC
ATGGCTTCCAGCTGTTGAAAGCATAAGTATCTGGGGATGTAAGCGGTTT
AGAAATATATTCACACCTATCACCGCAATTTTGATCTGGTGGCACTTTT
GGAGATTCACATAGGAAATTACAGAGAAAATCATGAATCGGAAGAGCAGG
20 TAACGCTTTCAATTTCACTTTCTTACTTAATTAAGGACTAAGCTCTTGT
TTTTGAATAATAAAGAGGTGGGATGACTAACTTGGGCATCACAATTGTA
ACAAAATGTTACAAACCATGAACGTACAAACCATTTCTTGAATTAAGGTT
TCAATACAAGTCATTTACAAATATGGCTTAAGTTTTTTTATATTTATGTA
TCAACATTATTTTCATTAGAGGTCATTATTATAATAGTAAGTTTAAAGC
25 AATTTAAATTAGCACTAATTTTTTCATCATCTAACTTTAGCTAATAAATCG
TTATAAATGTCAATAGCTAAAATAAAAATATTTGACATTCCTGAGAGCA
ATTTTTTCTAAACATGATTGCAAATGATTAAACTTAAATTTAAACTAAA
AAGATTTTTATATATGTTATACAAAATTTACAAATTGAAATTGGATATGT
TAATTAACAGTTTATAATTATTGTATTACAAAGCGATATATAATAAAAATA
30 TTATTTTTCTGTAGTCATGTATAATTGTATATGTAAATGATTTTTTAAGA
TGGTAGAAGTGGAAACTAGTCAATCTCACTTAACTCATTGTCACACCAGT
TTTATATCCGTTTCTCTCTCTCTCTCTTCTTGCCTCCATCTTTTTTCAAC
TCATAACACATAAAAATAACATATTTTCCAACACATTTAAGTCACTACCA
CATCATTATTTTTAATTTAATTAATTAAGTAAATATAAAAATTAATAAAA
35 CATAACATTTTTTTATTAATAAAGGCACTAATACAAATAAAAAGATACACGG
TAAATAAAAAAACGATAATTAGAAAAAAAACATAATAAAAAAAGACAACA
TTAAAAATAWAAAGCGACAACATAAATTAACATAATGATCAAGAAAATTCT
AAAACCTCCACCATATTTTTCTGCAATTTGTCATTTATGTTCAAACACCA
TTCGCAGAATCCCTCCTATCAAGTGATCATGTTGATTGAGAAAAAACTGT
40 ATGTCTCTCATGTATCTCCAAGTCCAACAAGTTAGCTTTTCATTTCTTC
ATTTTCTCATGTAAGACGCAAATTTTCATCCCGATATTGTTTTCTATCTT
CCACCTCTACTTTATTCACAGTGTGGATGAAGGAGAGGACAGCGATTCTC
GTACGAACGGTTACGATTCGACTGGCCGTCGTTTTACAATCCCGCGGCCA

TGGCGGCCGGGAGCATGCGACGTCGGGCCCATTCGCCCTATAGTGGTCGT
AATACA (SEQ ID NO:93)

Sequence gap

5 TGAGCCTCCGATGCTTAGTCCACTTGGCACAGTTCAAGTCCAATCAACTT
ATAACCCATTTTTCTTCAAGTTGTCTTCAAGTTAAGCCCAATTTGCCTTC
TCCAAATCATCCATAACTTCATGGAATCGCCCCTTCATCTTAATCCCGAA
TGCACAATTATTCTCCCATCTTCATTTAAGCAAGAGGCCACCTTCTTCA
TGCTTCATCCATCAATAGTCTGTTGGAATAGTGTCTAAGGCTGCAACTAT
ATTAGACAAGTATTTGACCCGGTTGTGCATGGTCCTTTTGGGTTGCCTTC
10 ACCATAGCAACTTGATAGGATGATTTATTAAGAGAGAGTAAATATTATTA
ATATATTATGAGAATAATATAATGAATAATATATTTGTTATTTGATTAAT
ATAAGTCATAGAATTAATTAGAATTAATTTGGTGACTTAAAGAGATTAAT
TAAATAAAGGGGTATAAACTGTCAATTGTTTGATAGTTAAGCTTTAGACT
GTAAATCCATTTGGATATGGTATGGACGAATCCTAAGGGATTTAGGATAG
15 CTAAAATCGTCCATATGAGTTATCTAAGAAGGATTTGGATAGCCTTAAGA
GAAGATTATCTGATAGGGACTTATCTGTAATCCTTAAGGAGTCTACAAGT
ATAAATAGACCCTATGGCTGATGGAATTCGACACATCTCCTAAAGTAAGA
GAGCCTTGGCCGAATTCCTCCCCTCACCTCTCCTAAATCATTCTTCTT
GCT.ATTGGTGTTTGTAAGCCATTAGAGGAGTGACATTTGTGACTCTAGAA
20 TCTCCAAGACCTCAAGATCAACAAGGAATCAAAGGTATGATTCTAGATC
TGTTTCAATGTTGTTATTTGTCCTAATTAGTCATTAGAAGACTTGGATTC
AAAGCATGTTTATTAGAAAGCCTAGATCYGAGCAATAGGGTTTTGCATGC
GCACATAGGAAAGTTCTTATGGCTAAAACCCATCATAGTCCACTTCATGT
ATC.ATCTCTACTAGTTATTTAGTCCATAATCCTTGTTGTCCTCCAAGTTT
25 AATTACCTCCCTTAGTTCCTGTTCTGCTAGTTTCCTTAAAATTTGCTATT
AAGATCACAGAACTAGAGAGTACCCAAAATGGTTATAAAAATAACAAAAAG
GAA.AATATGCATGAAGATTAATAAATTATAAATGTAATATGCTAAAATA
AACTATAAAAAAAAAGTAAATAAAATGAACTATCACACTCCGACCACCC
TTATAGGCTTGTACTGCACCCACCCTTCATTCCTTGACCAATATGGGAT
30 GGAAACATTATTCATTAAGCCAAAAAATAACATTTAAGGGGTGAGTGAC
AAAGGTAAGTACTAAAGACAACAATAATCCATTTTTCTTGTACATACACA
ACACACACATAGGGGCGGACGTAGGATTTGTAGTATGTGTTGTGGGTGAC
ACATTTTTTCTTTTACGTAGTGACACAATAGTAGAGAAAACGAGAAATTC
CAATTTTTTACATTGTGTTGAAAAAATATACAGGGGTTGCTGGTGCTAC
35 TCTGGGCACCAAAGTGGAACCGCCCCTGCACACACACACATAGAGGGA
GAGAGAGAGGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATT
TGGGATGTGATACTTCTTTGGGAAAATGGAGCAATATCTTTAATATTGT
ATTTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAACTTTTA
GTTTTTTTTATTTAATCTGTATATTTAATCATTTCAGTTTATAAGTTTT
40 ATTTATTTTGGTATACCAGAAAAAAGTCTTTTATGTGTTGGATTTAAC
ATA.AAAATCTAACAATATTAATCAAAAAGACCAACATGTGGACAATTAT
GTATATAATTAATTCTCAATGGTCTTAGTGTAACGATATAAATTTCAAAA
CAATTTTTACATTAAAAAAAACACTTTCAGTCATAATTGTTATAAATTA

TCATTGTATCACAAAATCAGTTCATAACATCACATCCCAAGATCAATAAA
GTGTAAATACTCCTCATGTGTGTACTAATCAAGCCGACGCCTTCCCGCGA
TTCTCACTGGTACCTGAAACACGTAACATAACAACACTGTAAGCATAAATGC
TTAGTGAGTTCCCCAAAATACCACATACCACATATATGCCTTTCCAGGCC
5 ATA.ACTCTGTAGGATCTTCCGACCCAAGTGTCTCAGGGGACTTCCGTCCC
GAATCCCGGTAGACCTTCCGGTCCTACCCGATTGACCTTCCGGTCCGTA
TCATACATAACATAACATAACACATACATATCACATAACAACATATAGCAC
ATACATCTCATAACATAAAAGACCTTCCGGTCACATAAAGGTACCCTTCC
AGGTACAGTATAGTGAGAANACTCACCTCGTATGATGTCTAATACCTCAC
10 GTGCTCGATATCCCTGAATCTCGAAACAATGACCTAGCCCCGCCTACTCA
CATAAAGTAATTATTTCAAATCATTAAACGGCTCTCAAGGCTAGACTACAT
CCCTTTCTATAAATCCACAGAAGGGTAAAAGACCATTTTACCCCTCCTTG
ACCCAAAAGTCCAAATGTTGATCAAACCCCAAAAAGTCAACGAAAGACAA
TGGTCAACTTTGACCCTACTCGTGGAGTGCACAAAGGTGACTCGGCAAGT
15 ACATGCGGGTCTCTGAATCCTTTCAGTCTCTCTTGGCTCGTCGAGTCTT
TCTTCCACCCGACGAGTTACACCTGTCATGAATCGCGGGGCAACCCCGAC
TCG.ACTTGTCGAGTCCGCTCATGGACTCAACGAGTTCATTCCATGCTCAC
ACTCAAATGACCTCCTGAGGTGAGATCTGTTCCCTCTAATCCATAGATCTG
ACCTTCCCAAGCTCAATAAACACGTAAAGGTTCGAACTTGATACTCATGC
20 AACGTCCAAATGATTCTACTTGATGATTTAGCCCCAAATACAACATCCTA
AGTCCATACGACCTTATTTTTCTCAAATAACAACACATATATTTAATTAC
CAATGACAGTAATAGATATCATATAAAGTATTTGTAACACTTTGTAAGAA
CCTTGCTACTATAGGTAAAAAGAAACATTTCAAAGTACATGCCCTAATTA
GAAAAAAAGTTATAAAAAAATAATGACTAGGGGGCGTGTTTTTTTACTAG
25 TTTGTATCAAATTATATCAAATTTAAGGTGGAAAAGAATGACGACCACA
TTAACCAGAAATGTAATTATTTTTTTATTTGGTAATTTTTAATATTTGTT
GTG.ATCTATGTATTTAAAAGTAAATATCAAACAAGAACATAATCCAAACC
CTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGA
TGCGGTTACGTCGCTCTCTCACTTCCCTACAACCCATTGTTGCTACTAATT
30 A.CACTAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGAAATTGA
ACG.AATCTCGTCAAATTTTTTATTTTGTGATGGATTTGAGTGGAAGTTT
AGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACATGGGTGAAGA
TAAAATGGAGTTGTCGCCGTTGTATTATAGATCTCTTAGGGGTTTGATT
TGAGTTATTA.CTGTATACGTAGCCTCTTTACAACGACCATTCTTCCAAGT
35 ACC.ATTTGATCTTTTTAGAAATCCAGTTGTCTGAAACACCCTGATTTGGAT
CAAATATC.CCAACAACCTCTTAAGA.CTGGACTAATTAATTGTTTTCTTG
ATCTTGATAACAAGAGGAAACACGTCACCATATCTTTTATTTTAAATTTG
CTTTTGGTGTATTTTCTTTCTTCCCATTTCTTTCTTGATCTGTTCCAGAT
GGTATTTGGTGTGGATAATTTACACCTGGAGATTGTGAACGATGGGAAGG
40 GGT.ATGTGATTTACAGAGGATGTGGCTTGTGGTTGAGGATGGTTTATGGC
TGGCCGAGTCTAATTTATATTTATATAAACAATAAATATATAAAAACAAG
GGTAAAATATGTATTTAAGCGTCCTCTTTTAAATGGTGACAATTTTTACAG
TTT.ACTCTCTTTGTTTTTTAATTGTGATGCCACGATCGAACTCATTCAT

CCCCCCCCTTTTTTTTTTAAAATAAAAAATTAAGAAGGGGTACCACCAT
ATACCCGTGTCAGCTTCTTATTCCCAAGCAGTCAAATAGGGACTTAGGTT
GTATGGAAACAGTTCCGTGACTTGGATGGCAGATAAAATTTAGTAAACTTA
ACCCTTCAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAAGCTAAAT
5 TCTGATTCTTGTTGAAAATAAGTTGCATCTTTATTTTTGCATATTATCT
TGTTGCATAGGATCCTTAGCATCTTTAATAGTTTATTTGAAGCTGAAAG
ATCCAACCTAGTTTTGATCTGTTGGCATTTCATCATTTGCAACTGTTTC
TTGAAAAAAAATACCTAAAATCAAATAACCATTTTCAAATCCAAAATTA
TAAGAGAGAATTGTTAATGGACGTGGAATCATAAATCATTAAACACAGTTC
10 AGTACACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTAT
CAGAGAAAGAGACATTACAAGAAGTCACTGATACTAATATTTCTAATGAT
GTTGTATTATTTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAA
ACTTAAATTGGAAAATTATGAAGGAGTGGAGGTGGTGGTTTGAGATAGAGA
GTGAGAGTCCAACATGTAGAGAATTGGTAACAACCTACAATAACCAACAA
15 CAGCCTATTATACTTCCCAACCTCCAGGAATTGTATCTAAGGAATATGGA
CAACACGAGTCATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTC
TTCCAAAACAACAATCAGAATCACCATTCCACAACCTCACAACCATAGAA
ATGAGATGGTGTATGGCTTTAGGTACTTGTTTTCGCCTCTCATGGCAGA
ACTTCTTTCCAACCTAAAGAAAGTCAAGATACTTGGGTGTGATGGTATTG
20 AAGAAGTTGTTCAAACAGAGATGATGAGGATGAAGAAATGACTACATTT
ACATCTACCCACACAACCACCAACTTGTTCCTCATCTTGATTCTCTCAC
TCTAAAATACATGCACTGTCTGAAGTGTATTGGTGGAGGTGGTGCCAAGG
ATGAGGGGAGCAATGAAATATCTTTCAATAATACCACTACAACCTACCGAT
CAATTTAAGGTATGTTTGTACATATTTAATTATATATTTAATTTCCCTGT
25 TAATTTCCCTTTTCTTTGCAATATTCTATGCGAACTCAAGAATGGGATTG
GAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCTTTTATTTGTT
ATTTATCATTTTCATATCAAGTACCTATAACATTTCTTTTTTATTTTTCT
AATTAGAAGAGGTCCACATGTCTAATTAGGTTTTCCATTCTATGTGTAAC
CTCTATTCTCTCTGTAATCAAGCATCTTAGATTATTTATCCATTTTCATA
30 ATTGTTGTTATTTTTACAGTTTTTTTTTTTTATTTAATTTTAATAATTTAA
TTTTAATTTATTTATTTTTTTTTTTTTGGTAATTGCAACCTGTCATATAT
TCAAGTCTTAATGTAACATAATAATACATTTTATACCCACTATACTAAGA
TAATAATTACCTAAAGGGATGGATGCCATGCACTGCTACACTTCAGNAA
CTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAAATGATAATGGCATCTTT
35 TGATGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATT
AGCTAGTAGTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTCAAAATCT
GGTCATTGTACCCAGAAATTTAGTTAAATGTAACATTTTAGATATTAGGGG
TCATCAGGTGACAGATATTGTAGAATAGAACAATATGTAATATTACCCAA
AACTATTTTTCTAAGGTTGCTCTGTAAATATGTGCTTTCTTGATTCA
40 TTGAATTTGCATTCGTATATTTTAGGTGGTAAACTGATTGTCTCTTCAAT
AAATCCTGAAATTAATTAATAAAAAAAAAAAAAAAGTACATTTTTGATTT
GGAGAGCACTGGTATCATTTAGTATAGAAAAAACTAGATTTTGAATTAY
CTTTCTTATATAAAAGTTGTGTATATAGTTAATTAGTTTTACATCATTT

TTCTATGTGTTGTTGCAGTTGTCTGAAGCAGGTGGTGTGTTGTTGGAGCTT
ATGCCAATACTCTAGAGAGATAGAGATATATAGGTGTGATGCACTGTCAA
GTGTAATTCCATGTTACGCAGCAGGACAAATGCAAAAGCTGCAAGTGCTG
ACAGTCAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAAACTCAATTAGG
5 GACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTC
CAAGAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTGGAA
ATCTACGGTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGA
AAGCCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTACTACTCTTGTC
AATCTTCCAAACCTCAAAGAAATGAGGTTGGAGTGGCTAAGTAATCTGAG
10 GTATATATGGAAGAGCAATCAGTGGACAGCATTGAGTTTCCAAACCTAA
CAAGAGTTGAAATTTGTGAATGTAATTCATTAGAACATGTATTTACTAGT
TCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTACATATATTTAACTG
CAGTCTGATGGAGGAGGTAATTGTTAAGGATGCAGATGTTTCTGTAGAAG
AAGACAAAGAGAAAGAATCTGATGGCAAGACGAATAAGGAGATACTTGTG
15 TTACCTCATCTAAAGTCCTTCAAATTACAACCTTCTCGAAGTCTTAAGGG
GTTTAGCTTGGGGAAGGAGGATTTTTTCATTCCCATTATTGGATACTTTAG
AAATCAAAAGATGCCCAACAATAACCACCTTCACCAAAGGAAATCCGCT
ACTCCACAACATAAAAGAAATACAAACAAATTTTGGCTTCTTTTATGCTGC
AGGGGAAAAAGACATCAACTCTTTATAAAGATCAAACAACAGGTAATC
20 AGATCTTTGTTGCTTTAATAATTCTTAAACTACATTTGAAAAGCTTCATG
CAAGTTTTTTTTGTTATATTGTCAAAAACCGCAACCTACATTCAGCTTTAT
ATTTATGTACTTTATGCAGGATTTCAAACAAGACTCAGATTAATGTGAAG
TGAATATTAAGGTAATTTATATTTTCATGTTCCCTAGTTGCCTATTAATT
AATGGCCTTTTAGTTCATGATTTTTGGATGTATTCTTCATGATGATGTGA
25 ATCTTCTAATACCCCATTCATTGTTTGGTTGAATGTTGACTCTATGTCAG
GATGAATATTCAAGGGAAGAATTGTTTCATCAWATGAAGGACATTAAGAA
CATGGATGCTATGAAGATGTTGGGAAAACATATGTATCAAGTGGCAARCT
GCTTAATGATCTAAGTTTGTGGTTGANGATGTTGATTTTAATATTTCAA
ATTCATTGGTTATATGGGCTTATCAATAGTGTTAATGGGATAATGAGTGA
30 CTTAACCTAAATTATGTTGTTGGTAAATGTTGGACAAGTATGGAAAATTA
GGAATGACTTGTGAAAAAAAAAATAAAAAAAAAA (SEQ ID NO:94)

RG2D deduced polypeptide sequence (SEQ ID NO:95)

MAMETANEIKQVVPVLMVPINDYLRYVVSCKRYISDMDLKMKELKEAKDNVEE
35 HKNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAF
NIIIEIDSVMRRHSLITWTDHPIPLGRVDSVMASTLSTEHNDFQSREVRFSEALKA
LEANHMIALCGMGRVVKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQVVVA
DYLIELKESDKKTRAEKLRQGFKAASDGGNTKFLIILDDVWQSDLEDIGLSPSPN
QGVDFKVLVTSRDEHVCSVMGVEANSIINVGLLIEAEAQRLLFQFVETSEPELHKIG
40 EDIVRRCCLPIAKTMACTLRNKRKDAWKDALSRHQHDIGNVATAVFRTSYENL
PDKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKLFDRVYTIIEARNRLNTCIERLV
QANLLIGSDNGVHVKMHDLVRAFVLGMYSEVEQASIVNHGNMGPWPDENMIVH

SCKRISLTCKGMIEIPVDLKFPLTILKLMHGDKSLKFPQEFYEGMEKLQVISYDKM
 KYPLLPLAPQCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLFSFANSRIEWLPSTVRN
 LKKLRLLDLRFCDGLRIEQVLSLVKLEEFYIGNAYGFIDNCKDMAERSYNLSA
 LEFAFFNNKAEVKNMSFENLERFKISVGCSPDGNISMSSHSYENMLQLVTNKGVDL
 5 DSKLNGLFLKTEVLFSLVHGMNDLEDVEVKSTHPTQSSSFCNLKVRISKVELRYL
 FKLHVANTLSSLEHLEVCGCENMEELIHTGIGGCCGEETITFPKLKSLSQLPKLSGL
 CHNVNIIGLPHLVDLKLGIPGFTVIYPQNKLRRTSSLLKEEVVIPKLETQLIDGMENL
 EEIWPCELSGGEKVKLREIKVSSCDKLVNLFPHNPMSELLHHLEELKVKNCRSIESLF
 NIDLDCVSAIGEEDNKSILRRIKVKNLGKLEVVWRIKGADNSRPLIHGFPAVESISIW
 10 GCKRFRNIFTPIANFDLVALLEIHIGNYRENHESEEQIEILSEKETLQEVTDTNISND
 VVLFPSCLMHSFHNHKLKLENYEGVEVVFEIESESPTCRELVTTHNNQQPIILPN
 LQELYLRNMDNTSHVWKC SNWNKFFTLPKQQSESPFHNLTTIEMRWCHGFRYLF
 PLMAELLSNLKVKILGCDGIEEVVSNRDEDEEMTTFTSTHTTTNLFPHLDSLTLK
 YMHCLKCIGGGGAKDEGSNEISFNNTTTTTDQFKLSEAGGVCWSLCQYSREIEIYRC
 15 DALSSVIPCYAAGQMQLQVLTVSSCNGLKEVFETQLGTSSNKNNEKSGCEEGIPR
 VNNNVIMLPNLKILEIYCGGLEHIFTFSALESRLQLQELTIKGYITLVNLPNLKEM
 RLEWLSNLRWIWKSNOQTAFEPNLTRVEICECNSLEHVFTSSMVGSLQLQELHIF
 NCSLMEEVIVKDADVSVVEEDKEKESDGKTNKEILVPHLKSLLQLLRSKGFSLGK
 EDFSFPLDLEIKRCPTITTTFTKGN SATPQLKEIQTNFGFFYAAGEKDINSLIKIKQQ
 20 DFKQDSD.CEVNIK

RG2E polynucleotide sequence (SEQ ID NO:96)

TGGGAAGACACAATGATGCAAAGGTTGAAGAAGGTTGCTAAAGAAAATAGAAT
 GTTCAATTATATGGTTGAGGCAGTTATAGGGGAAAAGACAGACCCACTTGCTAT
 25 TCA.ACAAGCTGTAGCGGATTACCTTTGTATAGAGTTAAAAGAAAGCACTAAACC
 AGC.AAGAGCTGATAAGCTTCGTGAATGGTTTAAAGCCAACCTCTGGAGAAGGTA
 AGA.ATAAGTTCCTTGTAAATATTTGATGATGTTTGGCAGTCCGTTGATCTGGAAG
 ACATTGGTTTAAAGTCATTTTCCAAATCAAGGTGTGACTTCAAGGTCTTGTGTA
 CTTACGAGACGAACATGTTTGCACAGTAATGGGGGTTGAAGCTAATTCAATTC
 30 TTAATGTGGGACTTCTAGTAGAAGCAGAAGCACAAAGTTTGTTCAGCAATTTG
 TAGAACTTTTGGACCCGAGCTCCATAAGATAGGAGAAGATATCGTAAGGAAG
 TGTTGTGGTTTACCTATTGCCATTAACCATGGCATGTACTCTAAGAAATAAA
 AGAAAGGATGCATGGAAGGATGCACTTTTGCATTTAGAGTACCATGACATTAGC
 AGTGTGCGCCCAAAGTCTTTGAAACGAGCTACCATAATCTCCACAACAAGGAG
 35 ACTAAATCTGTGTTTTTGGATGTGTGGTTTTTTTCTGAAGACTTCAATATTCCAA
 TCGAGGAGTTGATGAGGTATGGATGGGGCTTAAAGATATTTGATAGAGTTTATA
 CTATTAGACAAGCAAGAATCAGGCTCAACACCTGCATTGAGCGACTGGTGCAG
 ACAAAATTTGTTAATAGAAAGTGATGATGGTGTGCACGTCAAGATGCATGATCTG
 GTCCGTGCTTTTCGTTTTGGTTATGTTTTCTGAAGTTGAACATGCTTCAATTATCA
 40 ACCATGGTAATATGCTTGGATGGCCTGAAAATTATATGACCAACTCTTGCAAAA
 CAATTTCAATTAACATGCAAGAGTATGTCTGAATTTCCGGGAGATCTCAAGTTTC
 CAAACCTAACGATTTTGAACCTCATGCATGGAGATAAGTTGCTAAGATATCCTC

AAGACTTTTATGAAGGAATGGAAAAGCTCTGGGTTATATCATATGATGAAATGA
 AGTATCCATTGCTTCCCTCGTTACCTCAATGCTCCATCAACCTTCGAGTGCTTCA
 CCTCCATCGATGCTCATTAAATGATGTTTGATTGCTCTTGTATTGGAAATATGTTG
 AATCTGGAAGTGCTTAGCTTTGTTAAATCTGGCATTGAATGGTTACCTTCCACA
 5 ATAGGAAATTTAAAGAAGCTAAGGTTACTTGATCTGAGAGATTGTTATGGTCTT
 CGTATAGAAAAAGGTGTCTTGAAAAATTTGGTGAAAATTGGAGGAATTTATATT
 GGTAGAGCAGATATTTTATAGAT

RG2E deduced polypeptide sequence (SEQ ID NO:97)

10 WEDTMMQRLKKVAKENRMFNYMVEAVIGEKTDP LAIQQAVADYLCIELKESTKP
 ARADKLREWFKANS GEGKNKFLVIFDDVWQSV DLEDIGLSHFNPQGVDFKVL LTS
 RDEHVCTVMGVEANSILNVGLLVEAEAQSLFQQFVETFEPELHKIGEDIVRKC CGL
 PIAIKTMACTLRNKRKDAWKDALLHLEYHDISSVAPKVFETS YHNLHNKETS VFL
 MCGFFPEDFNIPIEELMRYGWGLKIFDRVY TIRQARIRLNTCIERLVQTNLLIESDDG
 15 VHVKMHDLVRAFVLVMFSEVEHASIINHGNMLGWPENYMTNSCKTISLTCKSMSE
 FPGDLKFPNL TILKLMHGDKLLRYPQDFYEGMEKLWVISYDEMKYPLLPSLPQCSI
 NLRVLHLHRC SLMMFDCSCIGNMLNLEVL SFVKS GIEWLPSTIGNLKKLRLLDLRD
 CYGLRIEKGV LKNLVKIGGIYIGRADIL.

RG2F polynucleotide sequence (SEQ ID NO:98)

CTGTGGAAGACACAATGATGCAAAGGCTGAAAAAGGTTGTGCATGAAAAGAAA
 ATGTTTAACTTTATTGTTGAAGCAGTTATAGGGGAAAAGACAGACCCCGTTGCC
 ATTCAGGATGCTATAGCAGATTACCTAGGTGTAGAGCTCAATGAAAAATCTAAG
 CAAGCAAGAGCTGATAAGCTCCGTCAAGGATTCAAGGACAAATCAGATGGAGG
 25 CAAAATAAGTTCTTTGTAATACTTGACGATGTTTGGCAGTCTGTTGATCTGGA
 AGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGCGTCGACTTCAAGGTCTTGTT
 GAC.ATCACGAGACAGACATGTTTGCACAGTGATGGGGGTTGAAGCCAAATTA
 TTCTAAACGTGGGACTTCTAATTGAAGCTGAAGCACAAAGTTTGTTCACCAAT
 TTGTTGTCACTTCTGAGCCCGAGCTCCATAAGATAGGAGAAGATATTGTAAAGA
 30 AGTGTTCGGTCTGCCAATTGCCATCAAACCATGGCATGTACTCTACGACATA
 AAAGAAAGGATGCATGGAAGGATGCACTTTCACGTTTAGAGCACCATGACATT
 CAAAGTGTTGTGCCTAAAGTATTTGAAACGAGCTACAACAATCTCAAAGACAA
 GGAGACTAAATCCGTATTTTGTATGTGTGGTTGTTTCTGAAGACTTGGATAT
 ACCTATCGAGGAGTTGATGAGGTATGGATGGGGCTTAAGATTATTTGATAGAGT
 35 TAATACTATTACACAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGG
 TGCACACAAATTTGTTAATTGAAAGTGTTGATGGTGTGCATGTCAAGATGCATG
 ATCTGGTTCGTGCTTTTGT TTTGGGAATGTTTTCTGAAGTGGAGCATGCTTCAAT
 TGTCAACCATGGTAATATGCCCGAGTGGACTGAAAATGATATGACTGACTCTTG
 CAAACAAATTTCAATTAACATGCAAGAGTATGTTGGAGTTTCTGGAGACCTCAA
 40 GTTTCCAAACCTAAAGATTTTGAACCTTATGCATGGAGGTAAGTCACTAAGGTA
 TCCTCAAGACTTTTATCAAGGAATGGAAAAGCTGGAGGTTATATCATACGATGA
 AATGAAGTATCCATTGCTTCCCTCGTTGCCTCAATGTTCCACCATCCTTCGAGTG

CTTCATCTCCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTCAATCGGTAATC.
 TTTTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAGCATTGAATTGTTACCTTC
 CGTAATTGGAAATTTGAAGAAGTTGCGGCTGCTAGATTTGACAACTGTTATGG
 TGTTTCGTATAGAAAAGGATGTCTTGAAAAATTTGGTGAACTTGAAGAGCTTTA
 5 TATTAGGAATGGTCTACCAGTTTACAGAGGAT

RG2F deduced polypeptide sequence (SEQ ID NO:99)

VEDTMMQRLKKV VHEKMFNFIVEAVIGEKTPVAIQDAIADYLGVELNEKSKQA
 RADKLRQGFKDKSDGGKNKFFVILDDVWQSV DLEDIGLSPFPNQGVDFKVLLTSRD
 10 RHVCTVMGVEAKLILNVGLLIEAEAQSLFHQFVVTSEPELHKIGEDIVKKCFGLPIAI
 KTMACTLRHKRKDAWKDALSRLEHHDIQSVV PKVFETSYNNLKDKETKSVFLMCG
 LFPEDLDIPIEELMRYG WGLRFLFDRVNTITQARNRLNTCIERLVHTNLLIESVDGVH
 VKMHDLVRAFVLGMFSEVEHASIVNHGNMPEWTENDMTD SCKQISLTCKSMLEFP
 GDLKFPNLKILKLMHGGKSLRYPQDFYQGM EKLEVISYDEMKYPLLPSLPQCSTILR
 15 VLHLHECSLRMFDCCSIGNL FNMEVLSFANSSI ELLPSVIGNLKKLRLDLLTNCYGV
 RIEKDV LKNLVKLEELYIRNGLPVYRG

RG2G polynucleotide sequence (SEQ ID NO:100)

GAAGACACGATGATGAAGA ACTGAAGGAGGTCGTGGGACAAAAGAAATCATT C
 20 AATATTATTATTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCAATT CAG
 CAAGCTGTAGCAGATTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGC
 AAGAGCTGATAAGCTTCGTA AACGGTTTGAAGCCGATGGAGGAAAGAATAAGT
 TCCTTGTAATACTTGACGATGTATGGCAGTTTGTGCGATCTTGAAGATATTGGTTT
 AAGTCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAGA
 25 TTCACATGTTTGC ACTCTGATGGGAGCTGAAGCAAATTCAATTCTTAATATAAA
 AGTTTTAAAAGATGTAGAAGGACAAAGTTTGTTCGCCAGTTTGTCTAAAAATGC
 GGGTGATGATGACCTGGATCCTGCTTTCATGGGATAGCAGATAGTATTGCAAG
 TAGATGTCAAGGTTTGCCCATTC AAAACCATTCCTTAAGTCTTAAAGG
 TAGAAGCAAGTCTGCATGGGACGTTGCACTTCTCGTCTGGAGAATCATAAGAT
 30 TGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTACGACAATCTCCA
 AGATGAGGTTACTAAATCTATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTT
 GATATTCCTACTGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATA
 GAAGCAAAA ACTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCG
 GCTTAGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGTGTCAAGAT
 35 GCACGATGTGGTGCGTGATTTTGT TTTGCATATATTCTCAGAAGTCCAACACGC
 TTCAATTGTCAACCATGGTAACGTGT CAGAGTGGCTAGAGGAAAATCATAGCAT
 C TACTCTTG TAAAAGAATTTCA TTAACATGCAAGGGTATGTCTCAGTTTCCCAA
 AGACCTCAAATTTCCAACCTTTCAATTTGAAACTTATGCATGGAGATAAGTC
 ACTGAGCTTTCTGAAA ACTTTTATGGAAAAGATGGAAAAGGTT CAGGTAATATC
 40 ATATGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACCAA
 CGTTCGAGTGCTTCATCTTCA TTAAGGATGTTTGATTGCTCTTCA
 ATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTGAA

TGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACA
 AATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTTGGTCAAACCT
 GAAGAGCTTTATATGGGTGTTAATCGTCCGTATGGACAGGCCGTTAGCTTGACA
 GATGAAAA

5

RG2G deduced polypeptide sequence (SEQ ID NO:101)

RHDDEELKEVVGQKKSFNIIIQVVIGEKTNPQAVADYLSIELKENTKEARADKL
 RKRFEADGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTL
 MGAEANSILNIKVLKDVESLFRQFAKNAGDDLDPAFNGIADSIASRCQGLPIAI
 10 KTIALSLKGRSKSAWDVALSRLLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCAL
 FPEDFDIPEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVK
 MHDVVRDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSQFPKDL
 KFPNLSILKLMHGDKLSFPENFYGKMEKVQVISYDKLMPYLLPSSLECSTNVRVLH
 LHYCSLRMFDCCSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRID
 15 NGVLKNLVKLEELYMGVNRPYQAVSLTDE

RG2H polynucleotide sequence (SEQ ID NO:102)

TGAAGGAGGTTGTGGAACGAAAGAAAATGTTTCAGTATTATTGTTCAAGTG
 GTCATAGGAGAGAAGACAAACCTATTGCTATTCAGCAAGCTGTAGCAGA
 20 TTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATA
 AGCTTCGTAATGGTTCGAGGCCGATGGAGGAAAGAATAAGTTCCTTGTA
 ATACTTGACGATGTATGGCAGTTTGTGCGATCTTGAAGATATTGGTTAAG
 TCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAG
 ATTCACATGTTTGCCTCTGATGGGAGCCGAAGCCAATTCAATTCTCAAT
 25 ATAAAAGTTTTAACAGCTGTAGAAGGACAAAGTTTTGTTCCGCCAGTTTGC
 TAAAATGCGGGTGATGATGACCTGGATCCTGCTTCAATAGGATAGCAG
 ATAGTATTGCAAGTAGATGTCAAGGTTTGCCATTGCCATCAAAACCATT
 GCCTTAAGTCTTAAAGGTAGAAGCAAGCCTGCGTGGGACCATGCGCTTTC
 TCGTTTGGAGAACCATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTT
 30 TTAATAATTAGCTATGACAATCTCCAAGATGAGATTACTAAATCTATTTTT
 TTACTTTGTGCTTTATTTCCCTGAAGATTTTGATATTCCTACTGAGGAGTT
 GATGAGGTATGGATGGGGCTTCAAATTATTTATAGAAGCAAAAACCTATAA
 GAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTTAGGGAGACA
 AATTTGTTATTTGGAAGCGATGACATTGGATGCGTCAAGATGCACGATGT
 35 GGTGCGTGATTTGTTTTGCATATATTCTCAGAAGTCCAGCACGCTTCAA
 TTGTCAACCATGGTAACGTGTGAGAGTGGCTAGAGGAAAATCATAGCATC
 TACTCTTGTAAGAATTTTCAATTAACATGCAAGGGTATGTCTGAGTTTCC
 CAAAGACCTCAAATTTCAAACCTTTCAATTTTGAACTTATGCATGGAG
 ATAAGTCGCTGAGCTTTCCTGAAAACCTTTTATGGAAAGATGGAAAAGGTT
 40 CAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCCCTCATCACT
 TGAATGCTCCACTAACGTTTCGAGTGCTTCATCTCCATTATTGTTCAATTA
 GGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTC

AGCTTTGCTAATTCTAACATTGAATGGTTACCATCTACAATTGGAAATTT
GAAGAAGCTAAGGCTACTAGATTTGACAAATTGTAAAGGTCTTCGTATAG
ATAATGGTGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTTTATATGGGT
GTTAATCATCCGTATGGAC

5

RG2H deduced polypeptide sequence (SEQ ID NO:103)

KEVVERKKMFSIIVQVVIGEKTNPVIAIQQAVADYLSIELKENTKEARADKLRKWFEA
DGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTLMGAEAN
SILNIKVLTAVEGQSLFRQFAKNAGDDDLDPAFNRIADSIASRCQLPIAIKTIALSLK
10 GRSKPAWDHALSRLNHHKIGSEEVVREVFKISYDNLQDEITKSIFLLCALFPEDFDIP
TEELMRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVVR
DFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLSI
LKL.MHGDKSLSFPENFYGKMEKVQVISYDKLMPYLLPSSLECSTNVRVHLHLYCSL
RMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLDLTNCCKGLRIDNGVLKN
15 LVKLEELYMGVNHYPG

RG2I polynucleotide sequence (SEQ ID NO:104)

AAGAAGAGCTGAAGGAGGTTGTGGAACAAAAGAAAACGTTCAATATTATT
GTTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCTATTCAAGCAAGC
20 TGTAGCAGATCCCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAA
GAGCTGATAAGCTTCGTAAATGGTTCGAGGCTGATGGAGGAAAGAATAAG
TTCCTCGTNATACTTGACGATGTATGGCNGTTTGTGATCTTGAAGATAT
TGGTTTAAAGTCCATCAAATAAAGGTGTCANCTTCAAGGTCTTGTGGA
CGTCAAGAGATTCACATGTTTGCACCTCTGATGGGAGCTGAAGCCAATTCA
25 ATTCTCAATATAAAAAGTTTTAAAAGATGTAGAAGGAAAAAGTTTGTCCG
CCAGTTTGCTAAAAATGCGGGTGATGATGACCTGGATCCTGCTTTCATTG
GGATAGCAGATAGTATTGCAAGTAGATGTCAAGGTTTGCCATTGCCATC
AAAACCATTGCCTTAAGTCTTAAAGGTAGAAGCAAGTCTGCATGGGACGT
TGC.ACTTTCTCGTCTGGAGAATCATAAGATTGGTAGTGAAGAAGTTGTGC
30 GTGAAGTTTTTAAAATTAGCTATGACAATCTCCAAGATGAGGTTACTAAA
TCT.ATTTTTTACTTTGTGCTTTATTTCCCTGAAGATTTTGATATTCCTAC
TGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATAGAAGCAA
AAACTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTT
AGGGAGACAAATTTGTTATTTGGAAGTGTGACATTGGATGCGTCAAGAT
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAGC
ACGCTTCAATTGTCAACCATGGTAATGTGTCAGAGTGGCTAGAGGAAAAT
CATAGCATCTACTCTTGTAAGAATTTCATTAACATGCAAGGGTATGTC
TGAGTTTCCCAAAGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTA
TGC.ATGGAGATAAGTCGCTGAGCTTTCCTGAAAACCTTTTATGGAAAGATG
40 GAAAAGGTTTCAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCC
CTC.ATCACTTGAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT
GTTCAATTAAGGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATG

GAAGTGCTCAGCTTTGCTAATTCTGGCATTGAATGGTTACCATCTACAAT
 TGGAAATTTGAAGAAGCTAAGGCTACTGGATCTGACAGATTGTGGAGGTC
 TTCATATAGATAATGGCGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTT
 TATATGGGTGCTAATCGTCTGTTTGGAAAGTGCCAT

5

RG2I deduced polypeptide sequence (SEQ ID NO:105)

EELKEVVEQKKT FNIVQV VIG EKTNP IAIQQA VADSL SIELKENTKEARADKLRKWF
 EADGGKNKFLVILDDVW?FVDLEDIGLSPHPNKGV?FKVLLTSRDSHVCTLMGAEA
 NSILNIKVLK DVEGKSLFRQFAKNAGDDDLDPAFIGIADSIASRCQGLPIAKTIALSL
 10 KGRSKSAWDVALSRL ENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCALFPEDFDI
 PTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHV
 RDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLS
 ILKLMHGDKSLSFPENFYGKMEKVQVISYDKLMYPLLPSLE CSTNLRVHLHECSL
 RMFDCSSIGNLLNMEVLSFANS GIEWLPSTIGNLKKLRLLDLTDCGGLHIDNGVLKN
 15 LVKLEELYMGANR LFGKCH

RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107)

ATGTC CGACCCAACAGGGATTGTTGGTGCCATTATTAACCCAATTGCTCA
 AACGGCCTTGGTTCCCCTTACAGACCATGTAGGCTACATGATTCCTGCA
 20 GAAAATATGTGAGGGACATGCAAATGAAAATGACAGAGTTAAATACCTCA
 AGAATCAGTGCAGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCA
 GATTCCATCTCAAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAG
 CGAATGTTGCAAACCTTTCCAATTGATGTCATCAGTTGTTGTAGTCTCAGG
 ATCAGGCACAAGCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATCGA
 25 AAGTCTAACGAGACAAAATTCGCTGATTATCTGGACTGATGAACCTGTTC
 CCCTGGGAAGAGTTGGTTCCATGATTGCATCCACCTCTGCAGCATCAAGT
 GATCATCATGATGTCTTCCCCTCAAGAGAGCAAATTTTTAGGAAAGCACT
 AGAAGCACTTGAACCCGTCCAAAAATCCACATAATAGCCTTATGGGGGA
 TGGGCGGAGTGGGGAAGACCACGATGATGAAGAAGCTGAAAGAGGTCGTG
 30 GAACAAAAGAAAACGTGCAATATTATTGTTCAAGTGGTCATAGGAGAGAA
 GACAAACCCTATTGCTATCCAGCAAGCTGTAGCAGATTACCTCTCTATAG
 AGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTAAACGG
 TTCGAAGCCGATGGAGGAAAGAATAAGTTCCTTGTAATACTTGACGATGT
 ATGGCAGTTTTTCGATCTTGAAGATATTGGTTAAGTCCTCTGCCAAATA
 35 AAGGTGTCAACTTCAAGGTCTTGTGACGTCAAGAGATTCACATGTTTGC
 ACTCTGATGGGAGCTGAAGCCAATTCTATTCTCAATATAAAAAGTTTTAAA
 AGATGTAGAAGGAAAAAGTTTTGTTCCGCCAGTTTGCTAAAAATGCGGGTG
 ATGATGACCTGGATCCTGCTTTCATTGGGATAGCAGATAGTATTGCAAGT
 AGATGTCAAGGTTTGCCATTGCCATCAAACCATTGCCTTAAGTCTTAA
 40 AGGTAGAAGCAAGTCTGCATGGGACGTCGCACTTCTCGTCTGGAGAATC
 ATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTAT
 GACAATCTCCAAGATGAGGTTACTAAATCTATTTTTTTACTCTGTGCTTT

ATTCCTGAAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGT
GGGGCTTGAAATTATTTATAGAAGCAAAAACATAAGAGAAGCAAGAAAC
AGGCTCAACAACACTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGG
AAGTCATGACTTTGGGTGCGTCAAGATGCACGATGTGGTGCGTGATTTG
5 TTTTGCATATGTTTTCAGAAGTCAAGCATGCTTCAATTGTCAACCATGGT
AACATGTCAGAGTGGCCAGAGAAAAATGATACCAGCAACTCTTGTA AAAAG
AATTCATTAACATGCAAGGGTATGTCTAAGTTTCCTAAAGACATCAACT
ATCCAAACCTTTTGATTTTGAAACTTATGCATGGAGATAAGTCGCTGTGC
TTTCCTGAAAACCTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATA
10 TGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTA
ACGTTTCGAGTGCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGC
TCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTC
TAACATTGAATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGC
TACTAGATTTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTA
15 AAAAATTTGGTCAAACCTTGAAGAGCTTTATATGGGTGTTAATCGTCCGTA
TGGACAGGCCGTTAGCTTGACAGATGAAAACCTGCAATGAAATGGTAGAAG
GTTCCAAAAA ACTTCTTGCACTAGAATATGAGTTGTTTAAATACAATGCT
CAAGTGAAGAATATATCCTTCGAGAATCTTAAACGATTCAAGATCTCAGT
GGGATGTTCTTTACATGGATCTTTCAGTAAAAGCAGGCACTCATAACGAAA
20 ACACGTTGAAGTTGGCCATTGACAAAGGCCAACTATTGGAATCCC GAATG
AACGGGTTGTTTGAGAAAACGGAGGTTCTTTGTTTAAAGTGTGGGGGATAT
GTATCATCTTTCAGATGTTAAGGTGAAGTCTCTTCGTTCTACAATTTAA
GAGTCTTGTGCTTTTCAGAGTGTGCAGAGTTGAAACACCTCTTCACACTT
GGTGTGCAAATACTTTGTCAAAGCTTGAGCATCTTAAAGTCTACAAATG
25 CGATAATATGGAAGAACTCATAACATACCGGGGGTAGTGAAGGAGATACAA
TTACATTCCCCAAGCTGAAGCTTTTATATTTGCATGGGCTGCCAAACCTA
TTGGGTTTGTGTCTTAATGTCAACGCAATTGAGCTACCAAACTTGTGCA
AATGAAGCTTTACAGCATTCCGGGTTTCACAAGCATTATCCGCGGAACA
AGTTGGAAGCATCTAGTTTGTGAAAGAAGAGGTACATATACATATAGTT
30 TATGTTAATACATTTTAAACAATCTTTTCAACTAAAAGTTTCAGAATATA
TCTGTATTTTGATTGTATGATGTGTTAGTGTGTTGGATGTGGCTATTAAG
GATAATTATTTGGCAGGTTGTGATTCCCTAAGTTGGATATACTTGAAATTC
ATGACATGGAGAATTTAAAGGAAATATGGCCTAGTGAGCTTAGTAGAGGT
GAGAAAGTTAAGTTGAGAAAGATTAAGTGAGAAATTGTGATAAACTTGT
35 GAATCTATTTCCACACAATCCCATGTCTCTGCTGCATCATCTTGAAGAGC
TTATAGTCGAGAAATGTGGTTCATTGAAGAGTTGTTCAACATCGACTTG
GATTGTGCCAGTGTAATTGGAGAAGAAGACAACAACAGCAGCTTAAGAAA
CATCAATGTGGAGAATTCAATGAAGCTAAGAGAGGTGTGGAGGATAAAAAG
GTGCAGATAACTCTCGTCCCCTCTTTCGTGGCTTCAAGTTGTTGAAAAG
40 ATAATCATTACGAGATGTAAGAGGTTTACAAATGTATTCACACCTATCAC
CACAAATTTTGATCTGGGGGCACTTTTGGAGATTCAGTTGATTGTAGAG
GAAATGATGAATCAGACCAAAGTAACCAAGAGCAAGAGCAGGTATGGATT
TCAATTTTACTCTTTTACTTAATTAATGATTAAGCCCCTGCTTTTAAATA

AAAAGGGGACAAACCATTTCTTGACTTAATGTTGCAATACAAGTCATGTA
TAAGAGTGATTAACFTTTTTTTTATTTATAAAAATAACTACAAAACATGTTT
TTTCATTATAGATCATGTATAAATGTGACTAATTTTTTTTCATCGCCTAAC
TTTTGTTGATAAATCATTAGAAATGTCACTAATTACTTTTTAGTATTTAT
5 AAAATAACTACAAAACATGTTTTTTTCATTATAGATCATGTATATATCAAC
TAAAATATTATTCCCTTACACAAAAAAGGTTCAAGAAAGCCTGTA
TTTCGAAATAACTAAAAAGAAAATATTTGATATTCCTAAGAGAAATTTT
TTTCTAAACATGATCGCAAATGATTAAACTTAAATTAAACTAAAAAGA
TTTTTATATATGTTATNCAAAATTAAAATTTGAAATTAAGTTTATAATTC
10 TNGTNTCACAAAGGGATATATATAGTAAAATATTATTTTTTTTGCAGTCAT
GCATAGTTGTATTTTTAAATGATTTATTAACGTGGTAGGAGTGGAACCA
CTC.AATCTAGTAGACCCACTATCACATGTCACATCAGCTTTACATCTATT
TTTCTTTCTCCTTTTTTCATCTTTTTAACTCATAACACNTAAAANTANC
ATATTTTCCAACACACTNAACTCATTGTACATTATTATTTTTAATTTAA
15 TTA.AATTNGAAAATTAAAATTAANTAAANCNTAACATTTTTTAATTA
AAT.ATTAATCCAAATAAAAANTNCACGATAAATTAAAAANGTTTANTTTG
GAA.AAAAANCC (SEQ ID NO:106)

Sequence gap

ATA.ACCCTTTCAAGGGTCAACTCAAGTCCAAGTTAAAGTCAAGGTCAAAA
20 CCTTGGTTAAAGTCAACTTTGGTCAAAGTCAACATCTACTTGACTCACCT
CACCGAGTTGGTCCACCAACTTGTCTGAGTCCCTTAATCCACAACTTCAA
GAACTTCGATCCTACTCGTCGAGTCTTTCAAGAACTCTTCGAGTTTCCAT
TACACAGAATCGGGACCTTTTGCTCATGACTCGCCGAGTTCATCCTTGAA
CTTGTCGAGTCTAGCTTCATACGAGTTCGAGTGTTTAGTCCTTGACTCGT
25 CGAGTTCTTCCTTGAACCTCGTCGAGTCCATCTTCGTATAGTTGGGACATT
GCC TTGAACTCACCGAGTTCATCATTGAACTCATCGAGTCC TTCGATCTT
CAAGTCCATAATCCTGTCCATCTTGTTGAGTCCCTCTTAGACTCAACCA
GATTCCTCAGAAACAGAAAAGGTTAGGGAACCATTACCTGACTCGCCGAG
TCCCAAGAACGAATCCCCGAGTCCCCCAATGTCCATGACCATAACAATCGA
30 TTTTCGTTGGGCTCATTGCATCCAAAGCATAGATCTAACCTCCTAGGGTC
CAT.ATTACACGTAAAGCTACGAACTTGACGTCCATGCATGGGGGATTTGG
CTC.AAATGGCATTAAAATGGGGTTTATCTGATGCATGGGACTCCCATGGC
CAT.AAAGTTAACACCTTTATGCCATGGGAATCCTCAATGGTTCCATATCT
GAAGTTAACTCTACAATATGTTCTAAACCCGAAGGTGGCTTAGAAATG
35 CCCC AAAATGGCAAGATTCAAGCCTTAAAGGAGATCTAACAAATGATAAG
TCA.AGGTTCAAGCTTTTTACCTTGAATAAGCTGGAAATGAAGCAAAATCT
CTGGATCCACTTGCTTCTTCAAGAACCCCAAGCTTCCACTTCTTCCTTC
AAGTTTCAAACAACCTTTAAACTCAAAAATGGCTCAAGAACACTCAAAA
AGCTTTAGGGTTTCGAGTTAGGGCTTTTTGGAAGCGAGAGGGACGATGGG
40 GGCTGAAATGAGGCTAGAAAAAGTGTTTAAATAGGGGGCAAACCCTAAAT
ATT.AGGGTTTCATCCAGGCAGCCCTACTCGTCGAGTCCGGGCTCCCGACTC
GTCGAGTAGGTCACTTAAAACCCGCGTCCATAATCCAGTCTACTCGACGA
GTTGGGCCTCCAACCTCGTCGATTCCGAGTGCAAAACGTTCAATTAATAA

ATTTAAATATGTACCAGGAACCGGGTGTACAGTTGAGACTTTATACCTC
CATAAGATAGATCTAGGTGCACATAGCCTGGATCCACAAGCTCCATGTCA
ACAAGCGACTCTTCAAGAAGTTCATTCTCCTCCTTAAGCACCAAAAAAC
ACACAAAATCACCATGAAGCTCAAGAAATACTCAAATAGAGGATAGGGTT
5 TCGTTCGTAGGGTTAGAGAGGATGGAGGCTAGAGGAAATGAGGGATAGAG
GCGAGTTAAGGTCTTTAAATAGGGTCCAAGACCCTAAATTAGGGTTTTAA
TCTGGCCAGACGAACGCAGGGTGTCCCAAATGCATATGTGTCCAAATTC
TCGTGTGCGCCATGCGTACCTCCCTTGTACGCCATGTGTACCGGGTTTGG
TCCAAACCCTTCTAACTTCAAATGATCATAACTTGCACCCCTTATCTGTT
10 TTCGATGTTCTTTATATCCACGGAAAGGTAACAAGAAGCCCTATACTTCT
ATAAACTTTATTTAATCTGAAAACCAACCGAAATTAATCCAAAATTCAT
AAAAGTCCCGAACCAACACATTTACCGATACCCTTGGGCTCCAAAACACA
AATTGAAAACCCGGATCATCCAACTACATCATCCACCTCCAAATGAGCC
CAAACCTCAATTATTCAAGGGTCTAAGCCTGTTAATGCCACTCCTCGAT
15 TACCACCCCGCAATGGGAAACGATTCAAACAGGGCGTTACATAATTTGT
TGTGGTTTTGTATTTTTATTTCCGGTGAAGGTGAAAGATCCAACATTTT
TTAATCTGTTGGCATTTCATCATTTGCAACTGTTTCTTGAAAAAAAAA
TACCTAAAATCAAATAACCATTTTCAAATCCAAAATTATAAGAGAGAAT
TGTAAATGGACATGGAATCTTAAATCATTAACACAGTTCAGTACACAAGT
20 TGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAAGAG
ACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATCCTG
TCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAGTTA
AAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGTAGA
GAATTGGTAACAACCTACCATAACCAACAACAGCCTGTTATATTTCCCAA
25 CCTCCAGCATTTGGATCTAAGGGGTATGGACAACATGATTCGCGTGTGGA
AGTGCAGCAACTGGAATAAATCTTCACTCTTCCAAAACAACAATCAGAA
TCCCATTCCACAACCTCACAACCATAAATATTGATTTTTGCAGAAGCAT
TAAGTACTTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGA
AAGTCAATATAAAATGGTGTATGGTATTGAAGAAGTTGTTCAAACAGA
30 GATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAACCAC
CATCTTGTTCCCTCATCTTGATTCTCTCACTCTAAGTTTCCTGGAGAATC
TGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATA
TCTTTCAATAATAACCACTGCAACTACTGCTGTTCTTGATCAATTTGAGGT
ATGCTTTGTTTCATATTCAATTATTTATTTAATTTCCCTTTTTATTTGCAA
35 TATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAATTAC
CTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCTAGT
AAGGGCAGTTATGGAAGTTCAAATAAAATGATAATGGCATCTTTTGATGGG
TAAATATAGGCAATTTAAGTTTTATTTCTGTTAAAGCAGTATTTAGCAAGT
ACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATT
40 GTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAG
GTGACAGATATTGTAGAATAGAACAATATATAATATTACCCAAAACCTATT
TTTTCTAAGGTTTTCTGTAAATATGTGCTTTCTTGATTTCATTGAATT
TGCATTCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCC

GAAATTAATTAAAAAAAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGA
GCACTGGTATCATTTAGTATATAAAAAAAGTATTTTGAATTAAGTTTC
TTATATAAAAGCTGTGTATATAGTTTAAATTAGTTTACATCATTTTTCCA
TGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTCTTGGAGCTTATGCC
5 AAT.ACGCTAGAGAGATAAGTATAGAATTCTGCAATGCATTGTCAAGTGTG
ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGACAGT
CAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAAACTCAATTAAGGAGGA
GCAGCAACAAAAACAACGAGAAGAGTGGTTGTGATGAAGGAAATGGTGGA
ATTCCAAGAGTAAATAACAATGTTATTATGCTTCTGGTCTGAAGATATT
10 GGAAATCAGCTTTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCAC
TTGAAAGCCTGAGACAGCTCGAAGAGTTAACGATAATGAATTGCTGGTCA
ATG.AAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAC
AACAAACAACGAAGGGGACTTCTTCTTCTTCTTCTTCTTCTTCTTCTT
CTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT
15 TTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGGTAGG
ATTCTTCTTGGGGATGAATGAGTTCCGGTTGCCTTCATTAGATGAACTTA
TCA.TCGAGAAATGCCCAAAAATGATGGTGTACAGCTGGTGGGTCCACA
GCTCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTATTGA
TCA.AGAATCTGGCCTTAACTTTCATCAGGTATATATGTTTCTTTAATTGG
20 CATCATCTAATTAAGAAAGATATCATTCTGCCAAGTAAATTTACTTCAA
ACACATTCACACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGGAAGGCCA
AAA.TGGGAAAGCAAGATAGGGAAAAATAGTGTATTTCAAGTGGAAGGGTA
TTTTAGGTATTTTCTGTCAAAGTTGTTATTGCAGGCTTTTTAGTACCTG
GAATCGTGTGTGGGAGGAGCATTATTATTCTGATTGCTTGTTCCTTTAT
25 CATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTAATCTTTTGAT
TTT.AAATGACAAAATTTTTCCCTGTTACTCTATTTGATTGTTGTTCTTCA
TGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTGATTGTTATT
TTC.ATAGCATGTTAGTCACTTGAATCAAGCTTTTTCATTTTCAACCAGGG
CAA.AAGGTCAAAGTAACCTACTTTATGAGATCAAAAACAGCAACCCATC
30 GGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCAFTGTGATTAATA
ATT.ATAATATCCTGTATTAATTCATAAAAATTGGTACAGCACATATATGA
CATTTCAAAGGTTTTGTTTGACATATATATGCCTCTGGCGTTTTCTTTA
TTGGACTTGCAGACCTCATTCCAAAGTTTATACGGTGACACCTTGGGCCC
TGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAACTTGATTGAATTAG
35 ATGTGAAATTTAATAAGGATGTTAAAAAGATTATCCATCCAGTGAGTTG
CTGCAACTGCAAAGCTGGAAAAGATAAATATAAACAGTTGTGTTGGGGT
AG.AGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGGAGAAATGGAATA
GTGGAATTGGTTTTGATGAATCGTCACAAACAACCTACCACTACTCTTGTC
AATCTTCAAACCTTAGAGAAATGAACTTATGGGGTCTAGATTGTCTGAG
40 GTATATATGGAAGAGCAATCAGTGGACAGCATTGAGTTTCCAAAATAA
CA.AGAGTTGAAATTAGTAATTGCAACAGTTTAGAACATGTATTTACTAGT
TCCATGGTTGGTAGTCTATCGCAACTCCAAGAGCTACATATAAGTCAGTG
CA.AACTTATGGAGGAGGTGATTGTTAAGGATGCAGATGTTTCTGTAGAAG

AAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAAGGAGATACTTGCG
 TTACCTAGTCTAAAGTCCCTGAAATTAGAAAAGCTTACCATCTCTTGAGGG
 GTTTAGCTTGGGGAAGGAGGATTTTTTCATTCCCATTATTGGATACTTTAA
 GAATTGAGGAATGCCAGCAATAACCACCTTCACCAAGGGAAATTCCGCT
 5 ACTCCACAATAAGAGAAATAGAAAACAAGATTTGGCTCGGTTTATGCAGG
 GGAAGACATCAAATCCTCTATTATAAAGATCAAACAACAGGTAAATCAGA
 TCATTGTTGGTTAATAATTCTTAAACTACATTTGAAAAGTTTCATGTAA
 GTTTTTTATTATTGTCAAAGCCGCAACCTATATTTCAACTTTATATTT
 ATGTACTTTATGCAGGATTTCAAAAAGCCAGGACTCTATTTAATGTGA
 10 AGTAAATACTAGAAGAGGTAAATTCTATTTACATGTCTCCTGATTGCCTA
 TTAATTAATGGCCTTTCAGTTCATGGTTTTTGGATGTATTCTTCATGATG
 ACGTGAATGTTTAAATACCCCACTAGTTAATTGTTAGGTTGAATGTTGAT
 GACCAAAGGACTATATGTCGGGAAGAATATTCAAGGAAAGAATTGTTTCAT
 CATATGAAGGGCATTAAATTAAGAAGAACATGGATGCTATGAAGATGTTG
 15 GGAAAATATATGAATCAAATAACAAGCTACTCACTTATCTAAGTTTGTG
 GTTGAGGATGTTGATTTTAATATTTCAAATTCATTGGTATCATTATATGG
 GTTTATCAGTAGTGTTAATGGGATAATGAGCAACTTAACCTTAAATTATG
 CTGTTGGTAAATGTTGGACTCAAGTATGGAAAATTAGGAATAACTTGTGA
 AAAATATATGCAAAAAGTAGGATTGAGATTTTCAATGAAAAAATTATGAA
 20 ACTATACTACTATAGTATATAAATAAATTCAACTTACTGTTGGGTATATT
 GGAAGCACATATCATGAAAGTAACTAGAAGCAGAATTTGTTCCCATCTTC
 ATCTACTTATAGTTTCCATTTCTTACTTGTAATAATCTGATTAACTTTA
 GAGTTATTTCTATTTTTTACCAACCAAATTTTCATATAAAGGCCACAAG
 T (SEQ ID NO:107)

25

RG2J deduced polypeptide sequence (SEQ ID NO:108)

MSDPTGIVGAIINPIAQTALVPLTDHVGYMISCRKYVRDMQMKMTELNTSRISAEEH
 ISRNTRNHLQIPSIKDWLDQVEGIRANVANFPIDVISCCSLRIRHKLQKAFKITEQI
 ESLTRQNSLIHWTDPEVPLGRVGSMIASSTAASSDHHDFVPSREQIFRKALEALEPVQ
 30 KSHIALWGMGGVVKTTMMKKLKEVVEQKKTENIIVQV VIGEKTNP IAIQQAVADY
 LSIELKENTKEARADKLRKRFEADGGKNKFLVILDDVWQFFDLEDIGLSPLPNKGV
 NFKVLLTSRDSHVCTLMGAEANSILNIKVLKDVEGKSLFRQFAKNAGDDDLDPAFI
 GIADSIASRCQGLPIAIKTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYD
 NLQDEVTKSIFLLCALFPEDFDIPIEELVRYGWGLKLFIEAKTIREARNRLNNCTERL
 35 RETNLLFGSHDFGCVKMHDVVRDFVLHMFSEVKHASIVNHGNMSEWPEKNDTSN
 SCKRISLTCKGMSKFPKDINYPNLLILKLMHGDKSLCFPENFYGKMEKVQVISYDKL
 MYPLLPSSLECSTNVRVHLHLHYCSLRMFDCCSIGNLLNMEVLSFANSNIEWLPSTIG
 NLKKLRLLDLTNCKGLRIDNGVLKNLVKLEELYMGVNRPYGQAVSLTDENCNEM
 VEGSKLLALEYELFKYNAQVKNISFENLKRFKISVGC SLHGSF SKSRHSYENTLKL
 40 AIDKGELLESRMNGLFEKTEVLCLSVGDMYHLSVVKVSSSFYNLRVLVVSECAEL
 KHLFTLGVANTLSKLEHLKVYKCDNMEELIHTGGSEGDITTFPKLKL LYLHGLPNL
 LGLCLNVNAIELPKLVQMKLYSIPGFTSIYPRNKLEASSLLKEEVVIPEELIVEKCGSI
 EELFNIDLDCASVIGEEDNNSLRNINVENSMKLEVVWRIKGADNSRPLFRGFQVVE

KIIITRCKRFTNVFTPIITNFDFLGALLEISVDCRGNDESDQSNQEQEQIEILSEKETLQE
 ATDSISNVVFPSCLMHSFHNLQKLILNRVKGVEVVFEIESESPTSRELVTTHHNQQQP
 VIFPNLQHLLDRGMDNMIRVWKCSNWNKFFTLPKQQSESPFHNLTINIDFCRSIKY
 LFSPLMAELLSNLKKVNIKWCYGIEEVVSNRDEDEEMTTFTSTHTTTILFPHLDSL
 5 TLSFLENLKCIGGGGAKDEGSNEISFNNTTATTA VLDQFELSEAGGVSWSLCQYAR
 EISIEFCNALSSVIPCYAAGQMOKLQVLTVSSCNGLKEVFETQLRRSSNKNNEKSGC
 DEGNNGGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFALESRLRQLEELTIMNCWSMK
 VIVKKEEDEYGEQQT TTTTKGTSSSSSSSSSSSSSSPPSSSKKV VVFPCLKSIVLVNLP
 ELVGFFLGMNEFRLPSLDELIEKCPKMMVFTAGGSTAPQLKYIHTRLGKHTIDQES
 10 GLNFHQDIYMPLAFSLDLQTSFQSLYGDTLGPATSEGTTWSFHNLIELDVKFNKD
 VKKIIPSELLQLQKLEKININSCVGVVEVFETALEAAGRNGNSGIGFDESSQTTTTTL
 VNLPNLREMNLWGLDCLRYTWKSNQWTA FEFPKLTRVEISNCNSLEHVFTSSMVGS
 LSQLQELHISQCKLMEEVIVKDA DVSVVEEDKEKESDGKMNKEILALPSLKSLKLESL
 PSLEGFSLGKEDFSFPLDLTRIEECPAITFTTKGNSATPQLREIETRFSGSVYAGEDIKS
 15 SIIKIKQQDFKKAQDSI.CEVNTR

RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110)

TGGGATTCCATATATAAAAACATATATTTTTATAAAGTGGGATTCCATTG
 TTTATATAGATTTTTATTACCAATAGACAATAGATTAAAAAAGATATA
 20 AAAACATGTCGGCTTTTGACTAAAAATATAGATTTTTATGAATAGAATAT
 TCAATTTGCTTAACTCGTTTAAAAAAATGAAAAAGATGTCGATATAAAA
 TCTCATATGGGCCTTCTTTACCATTCAAATAGTAAAATAGTAAAAGATAC
 TTGTTTGGGGCATGAACTGACCATAGTCAAACCCATACAAAATCAAACGA
 ATCCACATGGATGATGACGATGGGGTCGCAGTAAATGTGTTTTGGTCCT
 25 TTTTTTTCGAGAGAACAGAAGCTTCTGCTCTTCATCTTCTTAGATTTTG
 GGGATTTTCTGGTTTCAGGGGTTGTGAGTGGAAACTAAATGAAGCAAA
 AAAGTATGGTATAATTGGTTGCTAGTGA AATTGATGCTTTCTACTAT
 CATCTTTAAAATTGTCAAACATTATGTATTA AATTATGAGATCGAAAGT
 GGTCTATGGGCCAAAGGTAATACAAGCTTACTCAATGAAATGAATCTAGG
 30 ATGCATCATGCATGTATTGGTTAGATTAAAGATTTTCATCAAATTTCTT
 TATCAAATTGTTGTATAACCATGTTATGTAGGTGCTACCACAAGCCATAAC
 ATCGAGCAATGGAGTGTATTACTGGCATCTTTAGCAACCCGTTTGCTCAG
 TGTCTCATCGCTCCTGTGAAAGAACACCTTTGCCTTCTGATTTTCTATAC
 ACAATATGTAGGGGATATGCTTACTGCAATGACGGAGTTGAATGCTGCAA
 35 AAGACATTGTTGAAGAGCGGAAGAATCAAACG TAGAAAAATGTTTTGAG
 GTTCCAAACCATGTCAACCGTTGGTTGGAAGATGTTCAAACAATCAACAG
 AAAAGTGGAACGTGTTCTTAACGATAATTGCAATTGGTTCAATCTATGTA
 ATAGGTACATGCTCGCAGTGAAAGCCTTGGAGATAACTCAGGAGATCGAT
 CATGCCATGAAACA ACTCTCTCGGATAGAATGGACTGATGATTCAGTTCC
 40 TTTGGGAAGAAATGATCCACAAAGGCATCCACCTTACACCATCAAGTG
 ATTACAATGACTTCGAGTCAAGAGAACACACTTTTAGGAAAGCACTTGAA
 GCACTTGATCCAACACACATCCACATGGTAGCCTTATGGGGGATGGG

TGGAGTTGGGAAGACCACGATGATGAAGAGGCTGAAAAATATTATTAAG
AAAAGAGGACGTTTCATTATATTGTTTTGGTGGTTATAAAGGAAAATATG
GATCTCATTTCATCCAGGATGCTGTAGCAGATTATCTGGATATGAAGCT
AACAGAAAAGCAATGAATCAGAAAGAGCCGATAAACTTCGTGAAGGGTTTC
5 AGGCCAAATCAGATGGAGGTAAGAATAGGTTCCATAATACTGGATGAT
GTATGGCAATCTGTTAATATGGAAGATATTGGTTTAAGTCCTTTCCGAA
TCAAGGTGTCGACTTCAAGGTCTTGTTGACCTCGGAAAACAAAGATGTTT
GTGCAAAAATGGGAGTTGAAGCTAATTTAATTTTCGACGTGAAATCTTA
ACAGAAGAAGAAGCACAAAGTTTGTATCAATTTGTAAAAGTTTCTGA
10 TACCCACCTTGATAAGATTGGAAAAGCTATTGTAAGAACTGTGGTGGTC
TACCCATTGCCATCAAACCATAGCCAATACTCTTAAAAATAGAAACAAG
GATGTATGGAAGGATGCACTTCTCGTATAGAGCATCATGACATTGAGAC
AATTGCACATGTTGTTTTCAAATGAGCTACGACAATCTCCAAAACGAAG
AAGCTCAATCCATTTTTTTGCTTTGTGGATTGTTTCCTGAAGACTTTGAT
15 ATTCCTACTGAGGAATTGGTGAGGTATGGATGGGGATTGAGAGTATTTAA
TGGAGTGTATACTATAGGAGAAGCAAGACACAGGTTGAACGCCTACATCG
AGCTGCTCAAGGATTCTAATTTATTGATTGAAAGTGATGATGTTCACTGC
ATC.AAGATGCATGATTTAGTTTCGTGCTTTTGTGGTGGATACGTTAATAG
ATTCAAGCATTCTTTGATTGTTAACCATGGTAATGGTGGTATGTTAGGGT
20 GGCCTGAAAATGATATGAGTGCCTCATCTTGCAAAAGAATTTCATTAATA
TGC.AAGGGCATGTCCGATTTTCTAGAGACGTAAAGTTTCCAAATCTCTT
GATTTTGAAACTTATGCATGCAGATAAGTCTTTGAAGTTTCTCAAGACT
TTTATGGAGAAATGAAGAAGCTTCAGGTTATATCATAACGATCACATGAAG
TATCCCTTGCTTCCAACATCACCTCAATGCTCCACCAACCTTCGTGTGCT
25 TCATCTTCATCAATGCTCATTGATGTTGATTGCTCTTCTATTGGAAATC
TGTTGAATCTGGAAGTGCTCAGCTTTGCTAATTCTGGTATTGAGTGGTTG
CCTTCCACAATCGGAAATTTGAAGGAGCTAAGGGTACTAGATTTGACAAA
TTGTGATGGTCTTCGTATAGATAATGGTGTCTAAAGAAATTGGTGAAC
TTG.AAGAGCTTTATATGAGAGTTGGTGGTCGATATCAAAGGCCATTAGC
30 TTC.ACTGATGAAAACCTGCAATGAAATGGCAGAGCGTTCAAAAAATCTTTC
TGC.ATTAGAATTTGAGTCTTCAAAAACAATGCTCAACCAAGAATATGT
CATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGTTATTTTAAG
GGAGATTTCCGGTAAGATCTTTCCTCTTTTGAACACGTTGCGGTTGGT
CACCAACAGAACTGAAGTCTTGAATCTAGGCTTAATGAGTTGTTGAGA
35 AAACAGATGTTCTTTATTTAAGTGTGGGAGATATGAATGATCTTGAAGAT
GTTGAGGTAAAGTTGGCACATCTTCTAAATCCTCTTCTTCCACAATTT
AAGAGTCCTTATCATTTCTGAGTGTATAGAGTTGAGATACCTTTTCACAC
TTG.ATGTTGCAAACACTTTGTCAAAGCTTGAGCATCTTCAAGTTTACGAA
TGCGATAATATGGAAGAAATCATAACATACAGAGGGTAGAGGAGAAGTGAC
40 AATTACATCCCAAAGCTGAAGTTTTTATCATTGTGTGGGCTACCAAATC
TGTTGGGTTTGTGTGGTAATGTGCACATAATTAATCTACCACAACCTCACA
GAGTTGAAACTTAATGGCATTCCAGGTTTCACAAGCATATATCCTGAAAA
AGATGTTGAAACATCTAGTTTTGTTGAATAAAGAGGTAATGTGTTTTATG

TTAATACAATACAATCTTTTCAATTAACCGTTTCAAAATATATTGTATGA
TTTATTTTTGTTTGGATGGGGTTATTAATGGGTGATTATTTCTCAGGTTG
TAATTCCTAATTTGGAGAACTTGATATTAGTTATATGAAGGATTTGAAA
GAGATATGGCCTTGTGAATTAGGGATGAGTCAGGAAGTTGATGTTTCTAC
5 GTTGAGAGTGATTAAAGTAAGCAGTTGTGATAATCTTGTGAATCTATTCC
CGTGCAATCCTATGCCATTGATACATCACCTTGAAGAGCTTCAAGTGATA
TTTTGTGGTTCCATTGAAGTGTTATTCAACATTGAGTTGGATTCTATTGG
TCAAATTGGAGAAGGCATCAACAATAGCAGCTTGAAGAATCATCCAATTGC
AGAACTTAGGGAAGCTAAGTGAGGTGTGGAGGATAAAAGGTGCGGATAAC
10 TCTAGTCTTCTCATCAGTGGCTTTCAAGGTGTTGAAAGCATTATCGTTAA
CAAATGCAAGATGTTTAGAAATGTATTACACCTACCACCACCAATTTTG
ATCTGGGGGCACCTTATGGAGATTCGGATACAAGATTGTGGAGAAAAGAGG
AGAAACAACGAATTGGTAGAGAGTAGCCAAGAGCAAGAGCAGGTATGGCT
TTCAATTTCACTTTCTTACTTAATGAAGGATTAAGCTCCTGCTTTTTTGAA
15 TAAAAAGTGGATGAATGACTAAATTCGGGAATGCCACCCGGAAAGTTATC
AACCATTTAGCTACACCATTTTTTTGAACTAATGTTGCAATAAATGCATAA
TATAATTAATAAATGGTCATTGATAAATGTAAACCAACCTTTTTTATTTA
TTAAAATGTCTACAATAAATGATTTTCTTTATTATATATCATTTTATAAC
AATAAGCTTAAAGATGTTTAAATAGCCAATGTCAGTTATAGATCGTAACT
20 AATTTTTTATTAAGTATTTTAGTTAAGATATCACTCATTATTATTTTTA
TAGAAAAAAGACAAGATTGGCTAATCCTCATAAGAATTTGGAAGATTTAA
GCAAATATAGAGCTTTTCCAAACATAGCCAATAGTTTCTTTTGCAGGTC
CCATCTACGAAATTATCAATAGATTTGCGATTTTTTTTTTGGCACCCGGGA
AATTTCCATTAATTAATAAATAAAGTTCAAGCCATTTTGTAGTTGGCACCTG
25 CAAAATGGTAGTTTGCACCTGCGGAAATCACCTTTCACCATTTTCGCATCT
ATGACTTGTGAAAATGTTAATTTGTGAAATGGTCATGTGCACCTCATGAG
AAATACGAAATGGTCAGTAATATGACTTTTTTATATAAATATGATGGTGG
CATATATTTATAGGAAAATATAGCTGCACGATATTAATTAATAGTGAAT
TAGTTAACTGTATACGATAAGTATACAAAATTTATATGTATGAAGTATAC
30 TCAATTTAGGACGACTCGGGCAATGAAATCATCATTTAATAGGAGCAATG
AAATCATTTTCGAAAAATGTTTACAAATGAATAAAAATATTAATTAAACT
TAAACATTTTGTTAGTAGTTTGAATTTACAAACTGAAATTTGTTGTAT
TTATTAACATTTATAAATGTTGTACTATGATTTTTTTCCTTGTGTGCAAAT
ATTCCTTAAAAATCCACCTAAAATCAAATAATTAATCTTTTTCAAGTTG
35 AAAAATGAAAATCGTATGATATAACCGTGTATGGATGTGGAATTATATAT
CAGTTACTAATTACATTTTTTTGTTGGGATATATGTGCGCAGATTGATATT
GCAATCCCATTCACTCTCACACACTCTTCCAAAACCTCCGTAAACTTGC
TTTGGAAAAGTATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTCCAA
CAAGTAGAGAATTGATAACAATTCACCATAATCAACAACCACTACTTCCC
40 AACCTTGAGTTATTGGATATAAGTTTTATGGACAGCATGAGTCATGTATG
GAAGTGCAACTGGAATAAATCTTTCATTCTTCAAAAACAACAGTCAGAAT
CCCCATTCTGTAATCTCACACCATACATATTCAATATTGCCAAAGCATT
AAGTACTTGTTTTCAACTCTCATGGCAAACTTCTTCCAACCTAAAGAA

GGTCGAGGTAAGAGAGTGTCATGGTATTGAAGAAGTTGTTTCGAACAGAG
ATGATGAAGATGAGGAAAAGACTACATTTACATCTACATCTTCTGAAAAA
AGC ACTAATTTGTTCCCTCGTCTTGAATCTCTCGCTCTTTATCAACTTCC
AAATCTCAAGTGATTGGTGGTGGTGGTCTGCCAACAGTGGGAACAATG
5 AAATATCTCTTGATAATCCACTACTACTACTTCTTTTGTGATCAATCT
AAGGTATGTTTTTTTTTTNGTTNCCCTT (SEQ ID NO:109)

Sequence gap

CCTCCCTAATAACATGTTATGCACACTATACTAACATATTAGACACGT
AAAGGATAAATGCTATGCCTCATATAACGTTATATTTATAATCTTTAA
10 ACAATCAAATTTATTAACAATAACTAAGTGTGAGCAAAGGCAGGTACC
CGACTAAATTGCCAAAACCAGTCTGGTGGTTCGTGGAATGTTGGGCCAG
GTCGTTAAAACGTCTACACACCGGTTCTTTAAATCACAGATCCGCTTCTC
ATACTGTGAACCCGGTTTTAATTTTAAAAGAAAATTCATTATAAAGTAA
ATGACTTAAACCATTACAAACAACAAAATTTACCATTACAATGTTGGAC
15 TATCATTATTTGCAACATAAACTGAAAATACACATATTTCCCTTCTGATA
TCAGCATGAGTGGCTGGTTGGCTAACCCAAAATCCATGCATTGTAGATG
TGTGTTACAACACATAGTATCAATGAAAGGCATATTTTTAGGCTAGAATT
TAACAATCTGTAATAATATCCCTAAAACATAATCATCATCAACCAACT
AATATAAAACCATTGGGTTTCGTCAATTTTAGGTACAAAACATAGATTTTTC
20 TAAGCTTGTTGTATTTAAACATATGCTTTCTAAACTTAATTGATTTTGCA
TTCCAAAATTTTAGGTTGTAAAGTGGTATGTCATTTGTTGTCTTTTCAAC
ATTAAATTGTACAAAACCAAACTACATAATTGATGTAGATATCATAACA
ATTGTGTTATTTAGTATATAAAAACATAATTTTGAATTGAATTTCTTATA
CAAAGTTGTGTCTATGTATACATGTTTATGTAGGTAATAGACAATTAGT
25 CTCTGTTAAGTATATGGAGTTTAAATTTTAGACTAATTTTCATGTGTTG
CAGTTTTATCAGGCAGGTGGCGTTTTTTGGACGTTATGCCAATACTCCAG
AGAGATAAATAAAGGGAGTGTATGCATTGTCAAGTGTAATTCCATGTT
ATGCAGCAGGACAGATGCAAAATGTTCAAGTGCTGAATATATACAGGTGC
AACTCAATGAAGGAGTTATTTGAACTCAAGGGATGAACAACAACAATGG
30 TGACAGTGGTTGTGATGAAGGAAATGGTTGTATACCAGCAATTCCAAGAC
TAAATAACGTTATTATGCTACCCAATCTAAAGATATTGAAGATTGAAGAT
TGTGGTCATCTGGAACATGTATTCACATTCTCTGCACTTGGAAAGCCTGAG
ACAGCTCGAAGAGTTAACGATAGAGAAATGCAAGGCAATGAAAGTGATAG
TGAAGGAAGAAGATGAATATGGAGAGCAAACAACAAGGCATCTTCGAAG
35 GAGGTTGTGGTCTTTCCTCGTCTCAAGTCCATTGAACTGGAAAATCTACA
AGAGCTCATGGGTTTCTACTTAGGGAAGAATGAGATTCAGTGGCCTTCAT
TGGATAAGGTTATGATCAAGAATTGCCAGAAATGATGGTGTGTTGCACCT
GGTGAGTCCACAGTTCCCAAGCGCAAGTATATAAATACAAGCTTTGGCAT
ATATGGGATGGAGGAGGTAAGTAACTCAAGGGATGAACAACAATAATG
40 ATGACAATTGTTGTGATGATGGAAATGGTGGAAATCCAAGACTAAATAAC
GTTATTATGTTTCCAAATATAAAGATATTGCAAATCAGCAATTGTGGCAG
TTTGGAACATATATTCACATTCTCTGCACTTGAAGCCTGATGCAGCTCA
AAGAGTTAACAATAGCGGATTGCAAGGCAATGAAAGTGATTGTGAAGGAG

GAATATGATGTAGAGCAAACAAGGGTATTGAAGGCTGTGGTATTTTCTTG
TCTAAAGTCCATTACACTATGCCATCTACCAGAGTTGGTGGGTTTCTTCT
TGGGGAAGAATGAGTTCTGGTGGCCTTCATTGGATAAGGTTACCATCATT
GATTGCCACAAATGATGGGGTTCACACCTGGTGGGTCAACAACCTCCCA
5 CCTCAAGTACATACTCAAGCTTAGGCAAACATACTCTTGAATGTGGCC
TTAATTTCAAGTCACAACACTGCATATCATCAGGTATAATTATTATTCT
TTNACACCATCTAATTATGGAATCATGACGCTAATTACAGTATTAACAC
(SEQ ID NO:110)

10 **RG2K deduced polypeptide sequence (SEQ ID NO:111)**

MECITGIFSNPFAQCLIAPVKEHLCLLIFYTQYVGDMLTAMTELNAAKDIVEERK
NQNVEKCFEVPNHVNRWLEDVQTINRKVERVLNDNCNWFNLCNRYMLAVKAL
EITQEIDHAMKQLSRIEWTDDSVPLGRNDSTKASTSTPSSDYNDFESREHTFRKAL
EALGSNHTSHMVALWGMGGVGGKTTMMKRLKNIIEKRTFHYYIVLVVIKENMDL
15 ISIQDAVADYLDMKLTESNESERADKLREGFQAKSDGGKNRFLIILDDVWQSVN
MEDIGLSPFPNQGVDFKVLITSENKDVCAKMGVEANLIFDVKFLTEEEAQLSFY
QFVKVSDTHLDKIGKAIVRNCGGLPIAKTIANLTKNRNKDVWKDALSRIEHHD
IETLAHVVFQMSYDNLQNEEAQSIFLLCGLFPEDFDIPEELVRYGWGLRVFNGV
YTIGEARHRLNAYIELLKDSNLLIESDDVHCIMHDLVRAFVLDTFNRFKHSLIV
20 NHGNGGMLGWPENDMSASSCKRISLICKGMSDFPRDVKFPNLLILKLMHADKS
LKFPQDFYEMKKLQVISYDHMKYPLLPTSPQCSTNLRVLHLHQCSLMFDCSSI
GNLLNLEVLFSANGIEWLPSTIGNLRELRLVLDLTNCDGLRIDNGVLKLVKLEELY
MRVGGRYQKAISFTDENCNEMAERSKNLSALEFEFFKNNAPKNMSEFENLERFKIS
VGCYFKGDFGKIFHSFENTLRLVTRTEVLESRLNELFEKTDVLYLSVGDMDNLED
25 VEVKLAHLPKSSSFHNLRLVLIHSECIELRYLFTLDVANTLSKLEHLQVYECDNMEEH
HTEGRGEVTITFPKLKFLSLCGLPNLLGLCGNVHIINLPQLTELKLNIGIPGFTSIYPEK
DVETSSLLNKEVVIPNLEKLDISYMKDLKEIWPCELGMSQEVVDVSTLRVIKVVSSCDN
LVNLFPCNPMLIHHLEELQVIFCGSIEVLFNIELDSIGQIGEGINNSSLRIQLQNLGK
LSEVWRIKGADNSSLLISGFQGVESIIVNKCKMFRNVFTPTTTNFDLGALMEIRIQDC
30 GEKRRNELVESSQEQQ

RG2L polynucleotide sequence (SEQ ID NO:112)

GGAAGACACAATGATGCAAAGACTGAAGAAGGTTGCCAAAGAAAATAGAA
TGTTTCAGTTACATGGTCGAGGCAGTTATAGGGGAAAAGACAGACCCAATT
35 GCTATTCAACAAGCTGTAGCCGATTACCTTCGTATACAGTTCAAAGAAAG
CACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCCACT
CTGNAGACGGTAAGAATAAGTTCCTCGTAATATTTGATGACGTCTGGCAG
TCCGTTGATCTGGAAGATATTGGNTTAAGTCCTTTTCCAAATCAAGGTGT
CGACTTCAAGGTCTTGTGACTTCACGAGACGAACACGTTTGACAATGA
40 TGGGGGTTGAAGCTAATTCAGTTATTAATGTGGGACTTCTAACTGAAGTA
GAAGCACAAAGTCTGTTCCAGCAATTTGTAGAACTTTTGAGCCCGAGCT
CTGTAAGATAGGAGAAGTTATCGTAAGAAAGTGTGCGGTCTACCTATTG

CCATCAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGG
 AAGGATGCACTTTCACGTATAGAGCACTATGACATTCGTAGTGTTGCGCC
 TAAAGTCTTTGAAACAAGCTATCACAATCTCCAAGACAGGGAGACTAAAT
 CCGTGTTTTTGATGTGTGGTTTTGTTTCCTGAAGACTTCAATATTCCTACC
 5 GAGGAGTTGATGAGGTATGGATGGGGCTTAAAGCTATTTGACAGAGTTTA
 TACAATTAGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTTG
 TGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATG
 CATGATCTGGTGCCTGCTTTTGTGTTTTGGGTATGTATTCTGAAGTCGAGCA
 TGCTTCAATTGTCAACCATGGTAATATGCATGGGTGGACTAAAAATGATA
 10 TGAACGACTCTTGCAAAACAGTTTCTTTAACATGCGAGAGTGTGTCTGAG
 TTTCCAGGAGACCTCAAGTTTCCAAACCTAAAGCTTTTGAAACTTATGCA
 TGGAGATAAGATGCTAAGGTTTTCTCAAGACTTTTATGAAGGAATGGAAA
 AGCTCCAGGTAATATCATAACCATAAAATGAAGTATCCATTGCTTCCCTCG
 TCACCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTTCATCGGTGTTT
 15 ATTACGGATGCTTGATTGCTCTTGATCGGAAATTTGACGAATCTGGAAG
 TGTTGAGCTTCGCTAATTCTGGCATTGAACGGATACCTTCAGCAATCGGA
 AATTTGAAGAAGCTTAGGCAACTTGATCTGAGAGGTCGTTATGGTCTTTG
 TATAGAACAGGGTGTCTTGAAAAATTTGGTCGAACTTGAAGAACTTTATA
 TTGGAAATGCATCTGCGTTTAGAGATTATAACTGCAATGAGATGGCAG
 20

RG2L deduced polypeptide sequence (SEQ ID NO:113)

EDTMMQRLKKVAKENRMFSYMVEAVIGEKTDPPIAQQAVADYLRIQFKESTKPAR
 ADKLRWFKAHS?DGKNKFLVIFDDVWQSVLDLEDIGLSPFPNQGVDFKVLTSRDE
 HVCTMMGVEANSVINVGLLTEVEAQSLFQQFVETFEPELCKIGEIVVRKCCGLPIAI
 25 KTMACTLRNKRKDAWKDALSRIEHYDIRSVAPKVFETSYHNLQDRETKSVFLMCG
 LFPEDFNIPTEELMRYGWGLKLFDRVYTIREARLNTCIERLVQTNLLIESDDVGC
 VKMHDLVRAFVLGMYSEVEHASIVNHGNMHGWTKNMNDSCKTVSLTCEVSEF
 PGDLKFPNLKLLKLMHGDKMLRFSQDFYEGMEKLQVISYHKMKYPLLSPSPQCST
 NLRVLHLHRCSLRMLDCSCIGNLTNLEVLSFANSIERIPSAIGNLKKLRQLDLRGR
 30 YGLCIEQGVLKNLVELEELYIGNASAFRDYCNEMA

RG2M polynucleotide sequence (SEQ ID NO:114)

GGGGAAGACACAATAGATGCAAAGGCTGAAGAAGTTGCCAAAGAAAAGAG
 AATGTTTCAGTTATATCATTGAGGCGGTTATAGGGGAAAAGACAGACCCCA
 35 TTTCCATTCAGGAAGCTATATCATATTACCTTGGTGTAGAGCTCAATGCA
 AATACTAAGTCAGTAAGAGCTGATATGCTTCGTCAAGGGTTCAAGGCCAA
 ATCTGATGTAGGTAAGGATAAATTCTTAATAATACTCGACGATGTATGGC
 AGTCTGTTGATTTGGAAGATAATTGGATTAAGTCCATTTCCAAATCAAGGT
 GTTAACTTCAAGGTCCTGTAAACATCACGAGACCGACATATTTGCACTGT
 40 GATGGGGGTTGAAGGTCATTTCGATTTTTAATGTGGGACTTCTCACAGAAG
 CAGAATCAAAAAGATTGTTCTGGCAGTTTGTAGAAGGTTCTGATCCTGAG
 CTCCATAAGATAGGAGAAGATATTGTAAGTAAGTGTGTGGTCTACCCAT

TGCCATTAAAACCATGGCATGTACACTTAGAGATAAAAAGTACGGATGCAT
 GGAAGGATGCACTGTCTCGTTTAGAGCATCATGACATTGAAAATGTTGCC
 TCTAAAGTTTTTAGAGCGAGCTATGACCATCTCCAAGACGAGGAGACTAA
 ATCCACTTTTTTCTATGTGGATTGTTCCAGAAGATTCCAATATTCCTA
 5 TGGAGGAGTTGGTGAGGTATGGGTGGGGATTGAAATTATTTAAAAAAGTG
 TATACCATAAGAGAAGCAAGAACTAGGCTCAACACTTGCATTGAGCGGCT
 CATCTATACCAATTTGTTGATAAAAAGTTGATGATGTTTCAGTGCATCAAGA
 TGCATGATCTCATCCGTTCTTTTGTGTTTGGATATGTTTTCTAAAGTTGAG
 CATGCTTCGATTGTCAACCATGGTAATACGCTAGAGTGGCCTGCAGATNA
 10 TNTGCACGACTCTGTAAAGGGCTTTCATTAACATGCAAGGGTANATGTG
 AGTTTTGTGGAGACCTNAANTTCCAACCCTAATGATTTTAAAACTTATG
 CATGGAGATAAATCGCTAAGGTTT

RG2M deduced polypeptide sequence (SEQ ID NO:115)

15 GEDTIDAKAEVAKKRMFSYIIEAVIGEKTDPISIQEAISSYYLGVELNANTKSVRAD
 MLRQGFKAASDVGKDKFLIILDDVWQSVLEDIGLSPFPNQGVNFKVLLTSRDRHI
 CTV.MGVEGHSIFNVGLLTEAESKRLFVQFVEGSDPELHKIGEDIVSKCCGLPIAIRT
 MACTLRDKSTDAWKDALSRLEHHDENVASKVFRASYDHLQDEETKSTFFLCGLFP
 EDSNIPMEELVRYGWGLKLFKKVYTIREARLNTCIERLIYTNLLIKVDDVQCIKM
 20 HDLIRSFVLDMFSKVEHASIVNHGNTLEWPAD??HDSCKGLSLTCKG?CEFCGDL?F
 PTLMILKLMHGDKSLRF

RG2N polynucleotide sequence (SEQ ID NO:116)

AGGTAATAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCG
 25 TGTTTTGTTGAATGAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGG
 TATATGACATATTTATAGTTACTGATAACAAATTATGATAATTTGGGTT
 TACRTAAGTTAGGATTCGTACTTCAACCAAATGTAATAGTTTTTGTGAGT
 CTATCTATGATTTGGGGAATCACATTAGCAACGGGATTGTAAGTAAT
 TCG.AAAAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTT
 30 TAGCGACATCTAATATTAATAAGAAATGTATCTGATATTGAATTAATGTCC
 TTAATGTGAACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTT
 CTAATCAATAAATTTTAATTTCTGTTTATGCTTCTAAGACAATAAAAAAT
 CCATGATTTACCTTTAAATATTAACAAAAATGACCATAAATAAATAAAAA
 ATT.AGGATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGAT
 35 GCTTTTGCTTTTCCCTCTTTTCCCTTGTTAGTCTATTATTCTGGAGAGTTT
 GAGAGAGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTA
 TTCTCTTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTACACGATCC
 ATGGTTTTTTGTGTATGTTTTTCAAATTGAAACTAGATTGGGACTTTTGC
 CCTTGATGATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAG
 40 TGGTGAATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATG
 ATGATGAGATAGAGATATGTTAAACTGGCTAGAAAATTGTTTTAATTTG
 AAATTTAGGTKGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTT

ATGCTAAWTAGTTATAAAGAACAACAAACTCTTAGTTTTTTTTTTCATGA
TTTTCAACCTCTTTGTACCAAATAAATTATAGCAAAATTGAATATCATT
CTCTGCAATCAATCTTAACCTTTTGTATTATCATCATGTCTAAAATTGCC
ACAAGTTTATTTTCAAAGTCATATTGGATTATGAAAGGACTATTTTTACC
5 AATTACATCTTTACTTTATGGGCCAAAGCTAATACAATCCGACTAAACTA
AAGGAATATGGGATGCATATAGTTTGCTTCCCGATTATAGATTTCTATCT
AATTTGTCTATTGTACTAATTTAGGTGCCACCACAAGTAAATTTGTAAA
TGGATATCGTTAATGCCATTCTTAAACCAGTTGTCGAGACTCTCATGGTA
CCCGTTAAGAAACACATAGGGTACCTCATTTCCCTGCAGGCAATATATGAG
10 GGAAATGGGTATCAAATGAGGGGATTGAATGCTACTAGACTTGGTGTCTG
AAGAGCATGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAA
GGCAGGGGTTGGTATGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAAAA
TTTTCTAGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGG
TCGGAAAGAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTATGAGA
15 GAACACTCTATCATCATCTGGAATGATCATTCCATTCTTCTAGGAAGAAT
TGATTCCACGAAAGCATCCACCTCAATACCATCAACCGATCATCATGATG
AGTTCAGTCAAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGAT
CCTAACCACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGG
GAAGACGACAATGATGCATCGGCTGAAAAGGTTGTGAAAGAAAAGAAAA
20 TGTTTAATTTTATTGTTGAGGCGTTGTAGGGGAAAAAACAGACCCCATT
GCTATTCAATCAGCTGTGGCAGATTACCTAGGTATAGAGCTCAATGAAA
AACTAAACCAGCAAGAAGTGAAGCTTCGTAAATGGTTTGTGGACAATT
CTGCTGGTAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGT
GATCTGAATGATATTGGTTTAAAGTCCTTTACCAAATCAAGGTGTGCACTT
25 CAAGGTGTTGTTGACATCACGAGACAAAGATGTTTGCCTGAGATGGGAG
CTGAAGTTAATCAACTTTTAAATGTGAAAATGTTAATAGAAACAGAAGCA
CAAAGTTTATTCCACCAATTTGTAGAAATTTCCGGATGATGTTGATCGTGA
GCTCCATAATATAGGAGTGAATATTGTAAGGAAGTGTGGCGGTCTACCCA
TTGTCATCAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCA
30 TGAAGAATGCACTTCTTCGTTTAGTGAACACTACAACATTGAAAATATAGT
GAATGGAGTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTA
AATCCACCTTTTTGCTTTGTGGAATGTTTCCCGAAGACTTTAATATTCCT
ACCGAGGAGTTGGTGAGGTATGGATGGGGTTGAAATTATTTAAAAAAGT
GTATACTATAGGAGAAGCAAGAATCAGGCTCAACACATGCATTGAGCGGC
35 TCATTACATACAAATTTGTTGATTGAAGTTGATGATGTTAGGTGCATCAAG
ATGCATGATCTTGTCCGTGCTTTTGTGTTTGGATATGTATTCTAAAGTCGA
GCATGCTTCCATTGTCAACCATGGTAATACTAGAGTGGCATGTGGATA
ATATGCACAACTCTTGTAAGAACTTTCATTAACATGCAAGGGTATGTCT
AAGTTTCTACAGACCTCAAGTTTCCAAACCTCTCGATTTTGAACTTAT
40 GCATGAAGATATATCATTGAGGTTTCCCAAAAACCTTTTATGAAGAAATGG
AGAAGCTTGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCC
TCATCACCGCAATGCTCCGTCAACCTTTGCGTGTTCATCTCCATAAATG
CTCGTTAGTGATGTTTACTGCTCTTGTATTGGAAATCTGTGCAATCTAG

AAGTGCTTAGCTTTGCTGATTCTGCCATTGACCTGTTGCCTTCCACAATC
GGAATTTTGAAGAAGCTAAGGCTACTGGATTGACAAATTGTTATGGTCT
TTGTATAGCTAATGGTGTCTTTAAAAAATTGGTCAAACCTGAAGAGCTCT
ATATGACAGTGGTTAATGGAGGAGTTCGAAAGGCGATCAGCCTCACTGAG
5 GATAACTGCAATGAGATGGCAGAACGTTCAAAAAGACCTTTCTGCATTAGA
ACTTGAGTTCTTTGAAAACAATGCTCAGCCAAAGAATATGTCATTTGAGA
AGCTACAACGATTCCAGATCTCAGTGGGGTGCTATTTATATGGAGCTTCC
ATAAAGAGCAGGCACTCGTATGAAAACACATTGAAGTTGGTTATTGACAA
AGGTGAATTTTGAATCTTGAATGAACGGCCTGTTTAAGAAAACAGAGG
10 TGTTATGTTTAAGTGTGGGAGATATGAATGATCTTGAAGATRTTGAGGTT
AAGTCATCCTCACACYTCTTCAATCTTCTTCGTTCAACAATTTAAGAGT
CCTTGTCGTTTCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTG
TTGCAAACACTTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGAT
AATATGGAAGAACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTAC
15 ATCCCCCAAGCTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGG
GTTTGTGCGATAATGTCAAATAATTGAGCTACCACAACTCATGGAGTTG
GAACCTGACGACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTT
TGAAACATTTAGTTTGTGAAGGAAGAGGTAATATAAATTTTAAATGCT
AATACATTACAAAGGATCTTTTCAGTTAAATCTTCAAATATATTGTAA
20 TTTGATTGTATGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTA
TCTTGCAGGTTCTGATTCCCTAAGTTAGAGAACTGCATGTTAGTAGTATG
TGAATCTGAAGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGT
TAAGTTCAGAGAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGT
TTCCGCACAAGCCCATATCTCTGCTGCGTCATCTTGAAGAGCTTAAAGTC
25 AAGAATTGTGGTTCATTGAATCGTTATTCAACATCCATTTGGATTGTGC
TGGTGCAACTGGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAG
TGATCAGTTGTGATAAGCTTGTGAATCTTTCCACACAATCCCATGTCT
ATACTGCATCATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCATTGA
ATCGTTATTCAACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAG
30 ACAACAGAAGCAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTA
AGAGAGGTGTGGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTCA
TGGCTTTCAATCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAGGTTTA
GAAATGTATTACACCTACCACCACAAATTTAATCTGGGGGCACTTTTG
GAGATTTCAATAGATGACTGCGGAGAAAACAGGGAAAATGACGAATCGGA
35 AGAGAGTAGCCATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTTTCKT
ACTTAATTAATGATTAAGCTCCTGCTTTTTRAATAAAAAAGGGACAAACC
ATTTTCATGACTTAATGTAGCAATACAAGTCATGTATAAGAGTGACCAACT
CTTTTTTATTTATAAAATGACTACAAAATATTTTTTTTTCATTAGAGATCA
TGTATAAATGTGACTAATTTTTCATCACCTAATTTAGTTGATAAATCTT
40 TATAAATGTCACTAGTTACTTTTCAGTAAAATAACAAATTTAATAAATTA
TCAACAAAAAGCATCAACTAAAAAATCCACAACCCGTAATAATTTAAA
ATAAAAGGATTTAACATCTAATACGAACAATTTTTTTTCTAAACATGATT
TGGACCAAATATCACCAGCAACTCAAGTTTGAATCGATTACGCTTAAAA

CTTGACCARCATAATTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATAT
AAGTTCGTTTCATCTTTTTCTTGATCTTGATAGCAAGTTGAATSATTTT
CTTCTTCAAATTGATAAAAATCTACATTATAAAGAGACTAGCTTGAAAA
AAAATGGTCTAGGTGGGTCTGGGTCTGGTAGATGAAGATGGAAGGGAGA
5 GTAGATTTCAAAGACACAAACACATCTTCATTTTATTTATTTATTTATTA
TTATTATTTTTGATATCTTGCTCATATTTGTTACAGATATGTGAGGTCT
ATTAATCTTTTTAAATATATAAAAAATAAATACATAAATGAGAAAATTAA
ATAAAGAATAAATTAATAAGGGCACAAATAGTCTTTTTTGGTAAGACAAGG
ACCAAAAGCGCAACAAAAGTAAACAGTAGGGACCATCCGATTTAAAAAAT
10 TAATTAGGGACCAAAAACATAAATTCACCAAAACCATAGGGACCATTCTGT
GTAATTTACTCTTGCTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTT
TTGTACATATCTAGGTAACGAACTTGTGAAAGTGTTACATCTACGATG
TGACCTACTACAACCGATCATAATGGTCATATATGAACACTTCCAACAAG
TTTGTATCTAGGTGTGTACAAAAAACGATAGTTACCATGATGTGAACA
15 TACCAAAAAATTAATTACCTTAGCAAGTTATTTTCCATTTAGGTTGTAT
GGAAACAGTTCCTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAAA
CTTAACCCTTCAATTAACCTACCTTTTTCTTATTAACTCAATTTCAAGCT
AAATTCTGATTCTTGTTGAAAGTAAGTTGCATCTTTATGTTTGTATTAT
CTTGTTGCATAGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAA
20 AGATCCAACATTTTTAATCTGTTGGCATTTCATCATTTGCAACTGTT
TCTTGAAAAAAA::TACCTAAAATCAAATAACCATTTTCATATCCAAAA
TTATAAGAGAGAATTGTTAACGGACATGGAATCATAAATCATTAAACACAG
TTCAGTACACAGGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTC
TATCAGAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATATT
25 GTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAAACTTAA
CTTGAACAGAGTTGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGA
GTCCAACAAGTAGAGAATTGGTAACAACCTACCATAACCAACAACAACCT
ATTATACTTCCCAACCTCCAGGAATTGATTCTATGGAATATGGACAACAT
GAGTCATGTGTGGAAGTGCGGCAACTGGAATAAATTTCTTCACTCTCCAA
30 AAGAACAATCAGAATCCCATTCCACAACCTCAGTAACATACATATTTAT
GAATGCAAAAGCATTAAAGTACTTGTTTTCACCTCTCATGGCAGAACTTCT
TTCCAACCTAAAGCATATCGAGATAAGAGAGTGTGATGGTATTGAAGAAG
TTGTTTCAAAAAGAGATGGTGAGGATGAAGACATGACTACATCTAC:::
:::GCACACAACCACCTTTTTCCCTCATCTTGATTCTCTCACTCTAAA
35 GCAACTGAAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGG
GGAGCAATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTT
GATCAATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCC
TTGTTAATTTCTTTTTCTTTGCAATATTCTATGAAAAAATCACCAAA
TCACAAATAAGAGATTTAACTTTTATTTACACCCATGCGGACTCAAGA
40 ATGGGATTTGGAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCA
TTTATTTGTTATTTATCATTTTCATATCATTTACTGATAACATTTCTTTT
TTACTTTTCTAATTAGAAAAGGTCCACATGTCTAATTAGGTTTTCCATTC
TATGTGAATCCTCTATTCTGTCTGTAATCAAGCATCTTAGATTATTTATC

CATTTTCATAATTGTGTTTATATTGACAGTTTTTTTTCTTTTTATAGTTGT
 AATTGCAACCTGTCATATWTTMWWKKCWWWATKYWMWWARTAATACATTT
 TATACCCWCTATACTAAGATA

5 **RG2N deduced polypeptide sequence (SEQ ID NO:117)**

LGKTTMMHRLKKVVKEKKMFNFIVEAVVGEKTDPIAIQSAVADYLGIELNEKTKPA
 RTEKLRKWFVDNSAGKKILVILDDVWQFVDLNDIGLSPLPNQGVDFKVLLTSRDKD
 VCTEMGAEVNSTFNVKMLIETEAQSLFHQFVEISDDVDRELHNIGVNIVRKCGGLPI
 VIKTMACTLRGKSKDAWKNALLRLVNYNIENIVNGVFKMSYDNLQDEETKSTFLL
 10 CGMPEDFNIPTEELVRYGWGLKLFKKVYTIGEARIRLNTCIERLIHTNLLIEVDDVR
 CIKMHDLVRAFVLDMYSKVEHASIVNHGNTLEWHVDNMHNSCKRSLTCKGMSK
 FPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLEVISYDKMKYPLLPSSPQCSVNL
 CVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDLLPSTIGILKKLRLDLTNCYGL
 CIANGVFKKLVKLEELYMTVVNGGVRKAISL

15

RG2O polynucleotide sequence (SEQ ID NO:118)

TTGTAAAACGACGGCCAGTCGAATCGTAACCGTTCGTACGAGAATCGCTG
 TCCTCTCCTTCATTTGAATCATGATATTTGAATATCGATACTTTTGACTG
 TAGCTTTTGGGTCGATTTTTTAGCAAGATACATAACTGGCCAAACCCATT
 20 GGCTATTTTAGCCCAAATATGAAATGGACTGGATTGTTTTTTCCTTTC
 TAACACGCACACATCTGGCGATCAGTATCACTCCATTATGAAGACCTAGT
 CAAATTCATTAACGTTTCAGTCGTTCCCTCAAAGTTTCAAAGTTCCAACCT
 CCAACTTCCCTCTTTTTTTTTTCTTTCCTCGATTCTGATTGAATCCGAT
 TCTGCGACGAAGGAGAGCTTGGTCAGAGGGCTGTGATTCTTGAGTCTTGA
 25 CCTCCGAATCTAGCTGGATTATTTTCGACACACCAGACCACGTATCAGGT
 TGCTCATCCCGAAATACTGCTTTGCAAACGTTGTATCATCGCCTAGGAA
 ATT.AAGTTTCTTTTTTGGCTCTGTTACTGAATCAGTAGCTTTGCAACTTG
 CTC.ATTATAAGCTGATCCATATTTTACATATCTTTTGAAGAATAATAGGT
 ACTGACTTTACCTTTCTGATGAGAGCGATTAAAGAGATACCTCTGTA AAA
 30 TCCATTTTTGTGAAGGGATCTGGGTTAGTTTTTAAAGGATTTGCTACAAC
 AGT.ATCCCAAAACGATCTATTTCCCATTTNACTCATCCGCTCAAGATCT
 ATCCACCTTTATATATGTTAATTGGGAGTCTTCCATGGTGCAATGAATCT
 AGGATGCATTTAGAAGCCCAATCCATTACAAGTTTTTCATCCAATTTCATG
 TGACAAGTTGTTGGTTACTATGTAGGTA CTCCACAATTAAGAATTTCCA
 35 GCAATGGATGTTGTTAATGCCATTCTTAAACCAGTTGCCGAGACACTTAT
 GGAACCTGTTAAGAAACATCTAGGCTACATCATTTCAGCACAAAACATG
 TGAGGGATATGAGTAACAAAATGAGGGAGTTGAACGCTGCAAGACATGCT
 GAAGAAGACCACTTGGACAGGAACATAAGA ACTCGTCTTGAGATTTCAA
 TCAAGTTAGGAGTTGGTTAGAAGAAGTAGAAAAGATCGATGCAAAAAGTAA
 40 AAGCCCTTCTAGTGATGTCACCGCTTGTGTCAGTCTCAAGATCAAACAT
 GAAGTCGGAAGGGAAGCCTTGAAGCTAATTGTGGAGATTGAAAGTGCCAC
 AAGACAACACTCTTTGATCACCTGGACTGATCATCCCATTCCTCTGGGAA

AAGTTGATTCCATGAAGGCATCGATGTCCACAGCATCAACCGATTACAAT
GACTTTCAGTCAAGAGAAAAAACTTTTACTCAAGCATTGAAAGCACTTGA
ACCAAACAACGCTTCCCACATGATAGCGTTATGTGGGATGGGTGGAGTGG
5 GGAAGACCACAATGATGCAAAGACTAAAAAAAGTTGCTAAACAAAATAGA
ATGTTTCAGTTATATGGTTGAGGCAGTTATAGGGGAAAAGACGGACCCAAT
TGCTATTCAACAAGCTGTAGCGGATTACCTTCGTATAGAGTTAAAAGAAA
GCACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTC AAGGCCAAC
TCTGGAGAAGGTAAGAATAAATTCCTTGTAATACTTGATGACGTCTGGCA
10 GTCTGTTGATCTAGAAGATATTGGTTTAAAGTCTTTTCCAAATCAAGGTG
TCGACTTCAAGGTCTTATTGACTTCACGAGACGAACATGTTTGCACAGTA
ATGGGAGTTGGATCTAATTCAATTCTTAATGTGGGACTTCTAATAGAAGC
AGAAGCACAAAGTTTGTTCACAATTTGTAGAAACTTCTGAGCCCGAGC
TCC.ATAAGATAGGAGAAGATATTGTAAGGAAGTGTTCGGTCTACCTATT
15 GCC.ATCAAACCATGGCATGTACTCTTAGAAAATAAAAGAAAGGATGCTTG
GAAGGATGCACTTTCGCGTATAGAGCACTATGACCTTCGCAATGTTGCGC
CTAAAGTCTTTGAAACGAGCTACCACAATCTCCATGACAAAGAGACTAAA
TCAGTGTTTTTGATGTGTGGTTTGTTCGGGAAGACTTCAATATTCCTAC
TGAGGAGTTGATGAGGTATGGATGGGGATTAAAGATATTTGATAGAGTCT
ATACATTTATAGAAGCAAGAAACAGGATCAACACCTGCATTGAGCGACTG
20 GTGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGAT
GCATGATCTGGTCCGTGCTTTTGTTTTAGGTATGTATTCTGAAGTAGAGC
ATGCTTCAGTTGTCAACCATGGTAATATACCTGGATGGACTGAAAATGAT
CCG.ACTGACTCTTGTAAGCAATTCATTAACATGCGAGAGTATGTCTGG
AAACATTCCAGGAGACTTCAAGTTTCCAAACCTAACGATTTTGAACCTA
25 TGC.ATGGAGATAAGTCGCTAAGATTTCCACAAGACTTTTATGAAGGAATG
GAAAAGCTCCAGGTTATATCATAACGATAAAAATGAAGTATCCAATGCTTCC
CTTGTCTCCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT
GTTCAATTAAGATGTTTGATTGCTCTTGTATTGGAAATATGGCGAATGTG
GAAGTGTGAGCTTTGCTAATTCTGGCATTGAAATGTTACCTTCCACTAT
30 CGGAAATTTAAAGAAGCTAAGGTTACTTGATTAAACAGATTGTCATGGTC
TTC.ATATAACACACGGTGTCTTAAACAATTTGGTCAAACCTGAAGAGTTG
TAT.ATGGGATTTTCTGATCGACCTGATCAAACCTCGTGGTAATATTAGCAT
GACAGATGTCAGCTACAATGAATTAGCAGAACGTTCAAAGGCCTTTCTG
CATTAGAGTTCCAGTTCTTTGAAAACAATGCCCAACCAAATAATATGTCG
35 TTTGGGAAACTTAAACGATTCAAGATCTCAATGGGATGCACTTTATATGG
AGGATCAGATTACTTTAAGAAAACGTATGCTGTCCAAAACACATTGAAGT
TGGTACTAACAAGGTGAACCTATTGGACTCTAGAATGAACGAGTTGTTT
GTTGAAACAGAAATGCTTTGTTTAAAGTGTGATGATATGAATGATCTTGG
TGATGTTTGTGTGAAGTCTCACGTTCTCCTCAACCTTCTGTGTTCAAAA
40 TTCTAAGAGTCTTTGTCGTTTCCAAGTGTGTTGAGTTGAGATACCTTTTC
ACA.ATTGGTGTAGCCAAGGATTTGTCAAATCTTGAGCATCTTGAAGTTGA
TTC.ATGTAATAATATGGAACAACCTCATATGTATTGAGAATGCTGGAAAAG
AGACAATTACATTCCTAAAGCTGAAGATTTTATCTTTGAGTGGGCTACCA

AAGCTTTCGGGTTTGTGCCAAAATGTCAACAACTTGAGCTACCACA
CATAGAGTTGAACTTAAGGGCATTCCAGGGTTCACATGCATTTATCCGC
AAAACAAGTTGGAAACATCTAGTTTGTGAAGGAAGAGGTAGATATATGT
TTTATGTTAATACAAGTTAAAAAATCTTTTAACTAAAAGTTTCAGTATA
5 TATATCTATATGTCTATAATTTGATTATATGATGTATTAGTGTGGATG
TGGCTATTAAGGGATGATTATTTTGCAGGTGTGATTCCTAAGTTGGAGA
CACTTCAAATTGATGAGATGGAGAATTTAAAGGAAATATGGCATTATAAA
GTTAGTAATGGTGAGAGAGTTAAGTTGAGAAAGATTGAAGTGAGTAACTG
TGATAAGCTTGTGAATCTATTTCCACACAACCCCATGTCTCTGCTGCATC
10 ATCTTGAAGAGCTTGAAGTCAAGAAATGTGGTTCATTGAATCGTTATTC
AACATCGACTTGGATTGTGTTGATGCCATAGGAGAAGAAGACAACATGAG
GAGCTTAAGAAACATTAAGTGAAGAATTCATGGAAGTTAAGAGAAGTGT
GGTGATAAAAAGGTGAAAATAACTCTTGCCCCCTGTTTCTGGCTTTCAA
GCTGTTGAAAGCATAAGCATTGAAAGTTGTAAGAGTTTAGAAATGTATT
15 CACACCTACCACCACCAATTTAATATGGGGGCACTTTTGGAGATATCAA
TAGATGACTGTGGAGAATACATGGAAAATGAAAATCGGAAAAGAGTAGC
CAAGAGCAAGAGCAGGTATGGATTTCAATTTCACTTTCTTACTTACTTAA
GGATTAAGCTTCTGTTTTTTGAATAAAAAAGGGACATCTTCTAATAATG
CACATCTTAAATTA AAAAGTATTTAATTGTTGCATAGCAGCGTATAACAT
20 CTTCTAATAATTTATCTGAAGGTGAAAGATCCA ACTACTTCTAATTTGTT
AACAAATTTCAATCATTGCAAATGTTCTTAAAAAATTAATTACCTGAAA
TCAAAACAATCTTCTTCAAATCCAAAATTATGAGACAGAATTGAGAAGGG
ATGTGAAATTATAAACCATTAACACAATTCCATGCTCACGTTACTAATTA
CATTTCTTGTTGGGATATATATGTACAGACTGATATTTTGTGAGAGGAAG
25 TGA AATTACAAGAAGTCACTGATACTATTTCTAATGTTGTATTACATCG
TGTCTCATACTCTTTTTATAACAACCTCCGTA AACTCAACTTGGAGAA
GTATGGAGGAGTTGAGGTTGTGTTTGAAGATAGAGAGTTCAACAAGTAGAG
AATTGGTAACAACATAACCATAAACAACAACAACAACAACCTATATTT
CCC AACCTTGAGGAATTATATCTATATTATATGGACAACATGAGTCATGT
30 ATGGAAGTGCAACA ACTGGAATAAATTTTACAACAATCAGAATCCCCAT
TCCACAACCTCACAACCATAACATGTCCGATTGCAA AAGCATTAAAGTAC
TTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGAGAATCAA
TATTGACGAGTGTGATGGTATTGAAGAAATTGTTTCAAAAAGAGATGATG
TGGATGAAGAA

35

RG2O deduced polypeptide sequence (SEQ ID NO:119)

MDV VNAILKPVAETLMEPVKKHLGYIISSTKHVRDMSNMRELNAARHAEEDHLD
RNIRTRLEISNQVRSWLEEVKIDAKVKALPSDVTACCSLKIKHEVGREALKLIVEIE
SATRQHSLITWTDHPIPLGKVDMSMKASMSTASTDYNDFQSREKFTQALKALEPNN
40 ASHMIALCGMGGVGKTTMMQRLKVKAKQNRMF SYMVEAVIGEKTDP IAIQQAVA
DYLRIELKESTKPARADKLREWFKANS GEGKNKFLVILDDVWQSV DLEDIGLSPFP
NQGVDFKVL LSRDEHVCTVMGVGSNSILNVGLLIEAEAQSLFQQFVETSEPELHKI

GEDIVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDLRNVAPKVFETSYHN
 LHDKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKIFDRVYTFIEARNRINTCIERL
 VQTNLLIESDDVGCVKMHDLVRAFVLGMYSVEHASVVNHGNIPGWTENDPTDSC
 KAISLTCESMSGNIPGDFKFPNLTILKLMHGDKSLRFPQDFYEGMEKLQVISYDKMK
 5 YPMLPLSPQCSTNLRVLHLHECSLKMFDSCSIGNMANVEVLSFANSNGIEMLPSTIGN
 LKKLRLDLTDCHGLHITHGVFNVLKLEELYMGFSDRPDQTRGNISMTDVSYNE
 LAERSKGLSALEFQFFENNAQPNNMSFGKLRFKISMGTLYGGSDYFKKTYAVQ
 NTLKLVTKGELLDSRMNELFVETEMLCLSVDDMNDLGDVCVKSSRSPQPSVFKIL
 RVFVVSCKVELRYLFTIGVAKDLSNLEHLEVDSCNNMEQLICIENAGKETITFLKLI
 10 LLSGLPKLSGLCQNVNKLLELPQLIELKLGIPGFTCIYPQNKLETSSLLKEEVVIPKL
 ETLQIDEMENLKEIWHYKVSNGERVKLRKIEVSNCDKLVNLFPHNPMSSLHHLEEL
 EVKKCGSIESLFNIDLDCVDAIGEEDNMRLRNKVKNSWKLREVWCIKGENNSCPL
 VSGFQAVESISIESCKRFRNVFTPTTTNFNMGALLEISIDDCGEYMENEKSEKSSQEQ
 EQTDILSEEVKLQEVTDTISNVVFTSCLHISFYNNLRKLNLEKYGGVEVVFEIESSTS
 15 RELVTTYHKQQQQQPIFPNLEELYLYMDNMSHVWKCNNWNKFLQQSESPFHN
 LTTIHMSDCKSIKYLFSPLMAELLSNLKRINIDECDGI

RG2P polynucleotide sequence (SEQ ID NO:120)

CCCATTGCTATTCAGGAAGCAGTAGCAGATTACCTCNGTATAGAGCTCAA
 20 AGAAAAAACTAAATCNGCAAGAGCTGATATGCTTCGTA AAAATGTTAGTTG
 CCAAGTCCGATGGTGGTAAAAATAAGTTCCTAGTAATACTTGACGATGTA
 TGGCAGTTTGTGATTTAGAAGATATCGGTTTAAGTCCTTTGCCAAATCA
 AGGTGTTAACTTCAAGGTCTTGCTAACATCACGGGATGTAGATGTTTGCA
 CTATGATGGGAGTCGAAGCCAATTCAATTCTCAACATGAAAATCTTACTA
 25 GATGAAGAAGCACAAAGTTTGTTCATGGAGTTTGTACAAATTCGAGTGA
 TGTTGATCCCAAGCTTCATAAGATAGGAGAAGATATTGTAAGAAAGTGT
 GTGGTTTGCCTATTGCCATCAAACCATGGCCCTTACTCTTAGAAATAAA
 AGCAAGGATGCATGGAGTGATGCACTTTCTCGTTTAGAGCATCATGACCT
 TCACAATTTTGTGAATGAAGTTTTTGAATTAGCTACGACTATCTTCAAG
 30 ACCAGGAGACTAAATATATCTTTTTGCTTTGTGGATTGTTTCCCGAAGAC
 TACAATATTCCTCCTGAGGAGTTAATGAGGTATGGATGGGGCTTAAATTT
 ATTTAAAAAAGTGTATACTATAAGAGAAGCAAGAGCCAGACTCAACACCT
 GCATTGAGCGGCTTATCCATACCAATTTGTTGATGGAAGGAGATGTTGTT
 GGGTGTGTAAGATGCATGATCTAGCACTTGCTTTTGTATGGATATGTT
 35 TTCTAAAGTGCAGGATGCTTCAATTGTCAACCATGGTAGCATGTCAGGGT
 GGCCTGAAAATGATGTGAGTGGCTCTTGCCAAAGAATTCATTAACATGC
 AAGGGTATGTCTGGGTTTCTATAGACCTCAACTTTCCAAACCTCACAAAT
 TTTAAAACCTTATGCATGGAGATAAGTTTCTCAAGTTTCTCCAGACTTTT
 ATGAACAAATGGAAAAGCTTCAAGTTGTATCGTTTCATGAAATGAAATAT
 40 CCGTTTCTTCCCTCGTCTCCTCAATATTGCTCCACCAACCTTCGAGTTCT
 TCATCTCCATCAATGCTCATTGATGTTTGATTGCTCTTGATTGGAAATC
 TGTTTAATCTGGAAGTGTGAGCTTTGCTAATTCTGGCATTGAATGGTTA

CCTTCCAGAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACAGA
 TTGTTTTGGTCTTCGTATAGATAAGGGTGTCTTAAAAAATTTGGTCAAAC
 TTGAAGAGGTTTATATGAGAGTTGCTGTTTGAAGCAAAAAGCCGGAAAT
 AGAAAAGCCATTAGCTTCACAGATGATAACTGCAATGAGATGGCAGAGCG
 5 TTC

RG2P deduced polypeptide sequence (SEQ ID NO:121)

PIAIQEAVADYL?IELKEKTKSARADMLRKMLVAKSDGGKNKFLVILDDVWQFVDL
 EDIGLSPLPNQGVNFKVLLTSRDVDVCTMMGVEANSILNMKILLDEEAQSLFMEFV
 10 QISSDVPKHLHKIGEDIVRKCCGLPIAKTMALTLRNKSKDAWSDALSRLHHDHLDHN
 FVNEVFGISYDYLQDQETKYIFLLCGLFPEDYNIPPEELMRYGWGLNLFKKVYTIRE
 ARARLNTCIERLIHTNLLMEGDVVGCVKMHDLALAFVMDMFSKVQDASIVNHGS
 MSGWPENDVSGSCQRISLTCKGMSGFPIDLNFPNLTKLMLHGDKFLKFPDFYEQ
 MEKLQVVSFHEMKYPFLPSPQYCSNLRVLHLHQCSLMFDCSCIGNLNFNLEVLFSF
 15 ANSGIEWLPSRIGNLKKLRLLDLTDCFLRIDKGVKLNLVKLEEVYMRVAVRSKKA
 GNRKAISFTDDNCNEMAERS

RG2Q polynucleotide sequence (SEQ ID NO:122)

TGGGGAAGACACAGTGATAGAAAARAAAAGAATGTTGTGGAAAAGAGGA
 20 AAATGTTTGATTATGCTGTTGTGGCGGTTATAGGGGAAAAGACGGACCCT
 ATTGCTCTTCAGAAAAGTGTGCGGATTACTTGCATATTGAGCTAAATGA
 AAGCACTAACTAGCAAGAGCAGATAAACTTTGCAAATGGTTCAAGGACA
 ACTCGGATGGAGGTAAGAAAAAGTTCCTCGTAATACTCGACGATGTTTGG
 CAATCTGTTGATTTGGAAGATATTGGTTTAAGTACTCCTTTTCAAATCA
 25 AGGTGTCAACTTCAAGGTTTTGTTGACATCACGAAAGAGAGAAAATTTGCA
 CAATGATGGGAGTTGAAGCTGATTTAATTCTCAATGTCAAAGTCTTAGAA
 GAAGAAGAAGCACAAAAGTTGTTCCCTCCAGTTTGTAGAAATTGGTGACCA
 ATACCACGAGCTTCATCAGATAGGGGTACATATAGTAAAGAAGTGTTATG
 GTTTACCCATTGCCATTA AAAACCATGGCTCTTACTTTAAGAAATAAAAAGA
 30 AAGGATTCATGGAAGGACGCACTCTCTCGTTTAGAGGACCATGACACTGA
 AAATGTTGCAAATGCAGTTTTCGAGATGAACTACCGCAATCTACAAGATG
 AGGAGACCAAAGCCATTTTTTTGCTTTGCGGTTTGTTCCTCCGAAGACTTT
 GATATTCCTACTGAGGAGTTGGTGAGGTATGGATGGGGCTTAAATCTATT
 TAAAAAAGTGTATACCATAAGAAAGGCAAGAACGAGATCGCATAACATGTA
 35 TTGAGCGACTCTTGGATTCAAATTTGTTGATTGAAAGTAACGATATTCGG
 TGCGTCAAGATACACGATCTGGTGCGCGCTTTTGTTTTGGATATGTATTG
 TAAAGTTGAGCATGCTTCAATTGTCAACCATGGTAATATGCGGACCGAAT
 ATAATATGGCTGACTCTTGCAAAACAATTCATTAACATACAAGAGTATG
 TCTGGGTTTGGAGTTTCCAGGAGACCTCAAGTTTCAAACCTAACAGTTTT
 40 GAAACTTATGCANGGAGATAAGTCTCTAAGGTTTCCCTCAAGACTTTTATC
 AATCAATGGAAAAGTTCGGGTTATATCATATGATAAAATGAAGTATCCA
 TTGCTTCCCTCATCACCTCAATGCTCCACTAACATCCGAGTGCTTCGTCT

CCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTGTATTGGAAAGCTAT
 TGAATTTGGAAGTCCTCAGCTTTTTTAATTCTAACATTGAATGGTTACCT
 TCCACAATCAGAAATTTAAAAAAGCTAAGGCTACTAGATTTGAGATATTG
 TGATCGTCTTCGTATAGAACAAGGTGTCTTGAAAAATTTGGTCAAACCTG
 5 AAGAACTTTATACTGGATATACATCAGCGTTTACAGA

RG2Q deduced polypeptide sequence (SEQ ID NO:123)

GEDTVIEKKKNVVEKRKMFDYAVVAVIGEKTDPIALQKTVADYLHIELNESTKLAR
 ADKLCCKWFKDNSDGGKKKFLVILDDVWQSVLEDIGLSTPFPNQGVNFKVLLTSR
 10 KREICTMMGVEADLILNVKVLVEEEEAQKLFQFVEIGDQYHELHQIGVHIVKKCYG
 LPIAKTMALTLRNKRKDSWKDALSRLLEDHDTENVANAVFEMNYRNLQDEETKAI
 FLLCGLFPEDFDIPTEELVRYGWGLNLFKKVYTIRKARTRSHTCIERLLDSNLLIESN
 DIRCVKIHDLVRAFVLDMYCKVEHASIVNHGNMRTEYNMADSCKTISLTYKSMMSG
 FEFPGLKFPNLTVLKLM?GDKSLRFPQDFYQSMEKLRVISYDKMKYPLLPSSPQCS
 15 TNIRVLRLHECSLRMFDCSCIGKLLNLEVLFFFNSNIEWLPSTIRNLKKLRLLDLRYC
 DRLRIEQVVKLVKLEELYTGYSAFTE

RG2S polynucleotide sequence (SEQ ID NO:124)

ATTTGGGGTTTTACATTTAATTTTTTGTGCATGAATGTGAAAATAGACTG
 20 CTTATTGATTCTTTGTGTTTCATTGAGTTGATTTTCATTATTACTACCTT
 ACAAAATTGCTCAGTGATAGATTTCCATTAATTTGCTAATTCGGTTGCTTC
 TAAATATGTAGGAGCTACTAAAAGCAAAAATATCGAGCAATGTCGGACCC
 AACGGGGATTGCTGGTGCCATTATTAACCCAATTGCTCAGAGGGCCTTGG
 TTCCCGTTACAGACCATGTAGGCTACATGATTTCCCTGCAGAAAATATGTG
 25 AGGGTCATGCAGACGAAAATGACAGAGTTGAATACCTCAAGAATCAGTGT
 AGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCAGATTCCATCTC
 AAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAGCAAATGTGGAA
 AACTTTCCGATTGATGTCATCACTTGTGTAGTCTCAGGATCAGGCACAA
 GCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATTGAAAGTCTAACAA
 30 GACAGCTCTCCCTGATCAGTTGGACTGATGATCCAGTTCCTCTAGGAAGA
 GTTGGTTCCATGAATGCATCCACCTCTGCATCATCAAGTGATGATTTCCC
 ATCAAGAGAGAAAACCTTTACACAAGCACTAAAAGCACTCGAACCCAACC
 AAC.AATTCCACATGGTAGCCTTGTGTGGGATGGGTGGAGTAGGGAAGACT
 AGAATGATGCAAAGGCTGAAGAAGGCCGCTGAAGAAAAGAAATTGTTTAA
 35 TTATATTGTTAGGGCAGTTATAGGGGAAAAGACGGACCCCTTTGCCATTC
 AAGAAGCTATAGCAGATTACCTCGGTATACTCAATGAAAAAACTAAG
 CCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAAAAGAATTCAGATGG
 AGGTAAGACTAAGTTCCTCATAGTACTTGACGATGTTTGGCAATTAGTTG
 ATCTTGAAGATATTGGGTTAAGTCCTTTTCCAAATCAAGGTGTCGACTTC
 40 AAGGTCTTGTGACATCACGAGACTCACAAAGTTTGCATATGATGGGGGT
 TGAAGCTAATTCAATTATTAACGTGGGCCTTCTAACTGAAGCAGAAGCTC
 AAAGTCTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCAGAAG

ATAGGAGAGGATATCGTAAGGAAGTGTTGCGGTCTACCTATTGCCATAAA
AACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCATGGAAGGATG
CACTTTCGCGCATAGAGCACTATGACATTCACAATGTTGCGCCCAAAGTC
TTTGAACGAGCTACCACAATCTCCAAGAAGAGGAGACTAAATCCACTTT
5 TTTAATGTGTGGTTTGTTCCTCGAAGACTTCGATATTCCTACTGAGGAGT
TGATGAGGTATGGATGGGGCTTGAAGCTATTTGATAGAGTTTATACGATT
AGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTGGTGCAGAC
AAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATGCATGATC
TGGTCCGTGCTTTTGTTCCTGGGTATGTTTTCTGAAGTCGAGCATGCTTCT
10 ATTGTCAACCATGGTAATATGCCCGAGTGGACTGAAAATGATATAACTGA
CTCTTGCAAAGAATTCATTAACATGCAAGAGTATGTCTAAGTTTCCAG
GAGATTTCAAGTTTCCAAACCTAATGATTTTGAAACTTATGCATGGAGAT
AAGTCGCTAAGGTTTCCCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCA
TGTTATATCATAACGATAAAATGAAGTACCCATTGCTTCCCTTGGCACCTC
15 GATGCTCCACCAACATTCGGGTGCTTCATCTCACTAAATGTTCAATTAAG
ATGTTTGATTGCTCTTGTATTGGAAATCTATCGAATCTGGAAGTGCTGAG
CTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAGAAATTTAA
AGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAA
CAGGGTGTCTTGAAAAGTTTAGTCAAACCTGAAGAATTTTATATTGGAAA
20 TGCATCTGGGTTTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTG
ACAACCTTCTGCATTAGAATTCGCGTTCCTTAATAACAAGGCTGAAGTG
AAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGACG
CTCTTTTGATGGAAATATCAATATGAGTAGCCACTCATAACGAAAACATGT
TGC.AATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAACTTAATGGG
25 TTAATTTTGAAAACAAAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGA
TCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCAT
TCTGCAATTTAAAAGTTCTTATTTTCAAAGTGTGTAGAGTTGAGATAC
CTTTTCAAACCTCAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGA
AGTTTGTGAATGCGAGAATATGGAAGAACTCATACTACTGGAATTTGTG
30 GAGAAGAGACAATTAATTTCCCTAAGCTGAAGTTTTTATCTTTGAGTCAA
CTACCGAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACC
ACATCTCGTAGACTTGATACTTAAGGGCATTCCAGGTTTACAGTCATTT
ATCCGCAGAACAAGTTGCGAACATCTAGTTTGTGGAAGGAAGAGGTAGAT
ATATGTTCTTTATGTTAATAACAATTTAAATAATATTTTCAACCAAATTT
35 CATAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGG
CTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCCTAAGTTGGAGACAC
TTC.AAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTT
AGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAGTGAGTAGCTGTGA
TAAGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATC
40 TTG.AAGAGCTTAAAGTCAAGAATTGCGGTTCCATTGAATCGTTATTCAAC
ATTGACTTGGATTGTGTTCGGTCAATTGGAGAAGAAGACAACAAGAGCCT
CTT.AAGAAGCATCAACATGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGA
GGATAAAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTT

GAAAGCATAAAGATTGAAAAATGTAAGAGGTTTAGCAATATATTCACACC
TATCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAG
GTTGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTC AATTTAA
CTTTCTTAAGTAATTAAGGACTAACCTCCTGTTTTTTGAATAATAAAGAG
5 GTGGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACC
ATGAAACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATT
AAAAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTTCA
TTAGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACT
AATTCTAACTTTAGCTAATAAATCGTTATAAATGTAATAAATTACTTTTT
10 AGTGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCC
TAACAAAAAAACTATTTGGTTT CAGAAGAACCGTAATTC AAGATAACTAA
AATAAAAAATTTGACATTCACTAAGAGCATTTTTTTTTTCTAAATATGAT
TGCAAATGAATAAAACTTAAATTTATACAGAAAAGATTTTTATATATGTT
ATACAAAATTTACAAATTGAAACTGGATATGTTAATTAACGGTTTATAAT
15 TCTGGTATCACAAAGGGATATATAATAAATATTATTTCTGTAGTCATT
TATAATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAG
TTAAACTTTTATAATAAAAAATTTATAATTATTATTTTAAATAAATT
ATT.AATTAAGAGATGTATCAAAAATTTAAAGTTATTATAACTTCAAATTT
AAC.ATATAATTAGAAAATATATGATCATAACTTTCCGCAACTCTTCTTTT
20 GTATTA AAATGCCAGAGAAGCTCTTAGTAYATTTTCTAAATCAAAGTCA
CAAACCTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTT
TAAGAGTCACCAAATTC AAAGAGTAATCCAATGCTTTCATTACCACTATG
GAG.AAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTC AAACTA
ATTGTTGCTTACTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAAACCA
25 AAA.AAAATTACATTCATGTATCATTATTCATGACTAGATATATATGAACA
TGA.AGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTC
ATGGAATTCCTCAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCA
ACC.AAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAA
GGATTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTT
30 GTTCTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAAT
GCA.AAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCA
CCA.ACCTCCCTTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTG
AAGGACCTATGCGGGTGCCTTGC GCGGGTGGAGCTGAATACGAAAGGTC
TTTGGTCTTTGTGAGGGTGTATGCTGTGCGGGTTAGCTTGTGCGCATGCTTC
35 CGCGCGGTTGCGGCACATGTGCACAAGTGTATGATGGTGTGTACGTTCTT
GAGTTTTGAGCCTCCGATGCTTAGTCCATTTGGCCCAATTCGAGTCCAAT
CAGCTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTATCTTCAAGTT
AAGCCCAAATTCCTTCTCAAATCATCCATAACTTCACAAAATCGCCCG
TTC.ATCTTAATCCCGAATGCACAATTATTCTCCTGTCTTCTTTTAAAGCA
40 AGATACCACCTTCTTCATGCTTCATCCATCAATAGTACACTTCATGTATC
ATCTCTACTAGTTATTTAGTCCACAATCCTTATTGTCCTCAAATTTAAT
TATCTCATTTAGTTCCCGTTCCACTAGTTTCTTAAATTTGCAATTAAG
CTC.ACACAAATATTAAGTACCTGAAATGGTCATAAAAATAACAAAAGGAA

AATATGTCATGAAGATTAATACTAAATGATGAACGAAATATGCTAAAATAGAC
 TATAAAATGAAGTAAATAAAATGAAATTATCGCACTCCGACCACCCTTAT
 AGGCTTGTAGTCCATCCACCCTTCATTCTTGTTACCAATATGGGATGGAA
 ACATCATTAATTAAGCCAAAAAATAACATATAAGGGGTGAGTGACAAAG
 5 GTA.AGTACTAAAGATGAAAATAATCCATTTTTYTTGTATATAACACAACAC
 ACACATAGGGGCAGACGTAGGATTCATAGTACAGATTGTTGGTGGCACA
 TAAGTGTGCTGGTGACACTTTTTTTTTCTTTTACGTAGTGGCACAACAG
 TAG.AAAAAACGAAAAATTGAAATTTTTTACAATGTGTSTAAAAAAAAYA
 GTGGTGTGGTGGCCTACTATGGACACCAAAGTTGAAGTGGCCCTGCGCGC
 10 RCACACACACACACATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
 ARAGWAWGRRRGAKAKARMCSMSYTTGGGATGTGATACTTCTTTTAGGAA
 AATGGAGTTATATCTTTGATATTGTATTTTTTTAATGTAATTTATATATT
 TAATCATTTTTAGTTTATAAGTTTTATTTATTTTGTATATGAAAAAAAGT
 CTTTTATACATTGGATTTAACATAAAAAATCCAACAATATTAATCAAAAAG
 15 ACC.AMACATGTGGACAMWTATGTATATAAWTAATTCACAATAGTCTTTAG
 GAATAGNATTATATATATAATTAATTCTCAATGGTCTTAGGAATAGTAAG
 TTCTTATATTTCAAACCTTNGCCACAATTCTTTGKTTACTTWGACACTTY
 CCTCTCTCTAATTATATATATATATATATATATATATATATATATACACA
 CAC.ACACACACACACTAGATGTGTGCCCGCGCAAAGCAGTGACGTNNNGG
 20 AGA.NACTTTCTTAAGCATAAATAATTATTATATTTTTTATTGGGTATTA
 TAT.AATAAAAAATTACAACCTTTAAATAAAAATATTTATGTTTATACTTTA
 TATTTATATTGCTTGTATACTATTAATAATAAATAAATTAATTTATGTCT
 AATTTATGAAATGTAAATTAATTTAAATACATGAATTTAATATTTTTAAA
 ATTTTCAGTTTGCTTCAAATTTAGATTTCTTAATTTTTTTTTAATTCAN
 25 GTATTCAAAATTTTGGTAAGTATTAAGAATTATTTATGCACAATTGATT
 TAT.ACAAAAAAATTTGTAAGTTATACATCTTAAAATTCAAGATATAACTA
 ACATGTTTTACAATATATATATATATANATATATATATATATATATATAT
 ATATATATATATATATAGTAAAGCGCANAGGTACATAGGNANAGANTATTT
 TCT.ATTATTCTACGTTTTGCCACAAAAGTTTGAACACTTTGCCACTTTTT
 30 GTCCCTCCTTAACCTTTCAATGTTTTGCGACAAAAGTTCCAAAATTTG
 CCACTTTGATCATTCTCAACTTTTCACCGCATTAGTTTGTGGAGTTGGC
 AGTTTTGGTCCCCCTAACTTCGATATTTTTCTCCTGCTAGCCAAAAGGGT
 TCC.AGAGTTTCACANTTTTGGTCCCTGACAATAACCAAATGTGAGATGTG
 AAATTTTTGCCACATTAGTTTGTGGAGTTGTCCCTTTTGGTCCCCCCACA
 35 TTCGATATTCTACTATACGACCTTATTTTTCTCAAATAACAACACGTATA
 TTTAATTACCAATGATAGAAATAGATATCAAATAAAGTATTTGTAACACC
 GTGTAAGAACGGTGCTACTATAGGTAAAAATAAACATTTCAAAGTACGAT
 GTCCTAATTGGAAAAAGAGTTTTAAAAAAAATAACAAGTGGGGCGAGTTT
 TTTTTACAAGTTTGTATCAAATCATATCAAATTTAAGGTGGAACGGTGA
 40 CCACATTAACCAGAAATGTAATTTATTCTTTGATTTTGATAATTTTTAAT
 ATTTTGTGTGATCTATGTATTTAAAAGTAAACAACAAGAACATAATCC
 AAAACCCTAAATTTGCAAGTCTCGCCAATTTCTCTATCACTAGTCGTCAC
 TTACGATGGCGTTACGTGCTCTCTCACTTCTTACAACCCTTTGTGTGCTA

CTCATTACAATAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGG
AATTGAACAAATCTCGTCAAATTTTTGATTTTGTGATGGATTTGAGTAG
AAGTTTGGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACTTGAT
TCTGAGTTATTACTATATATGTAGCCTCTTTACAACGACCAAGGTTTCTT
5 CCAGGTACCATTTGATCTTTTTAGAACCCAGTTGTCTGAAACACCCCTGAT
TTGGATCAAATATCACCAACAACCTCTTAAAACTTGATTAATCAATTGTT
TTCTTCATCTTGATAACAAGTGAATGATTTTCTACTTAGATTAACCTGA
AAAAAAGGTCCATGTGCGTCTGGTGGATCTGGTAAATGAAGATGGAAGG
GAGAGCTGACTTTAAAGACACAAACACGTCACCATATCTTTTATTTTATT
10 TTAATTTGCTTTTTTTCCTATTTCTTTCTTTCTTGATCTCCAGATGGTAT
GTGGTGTGGATAAATTACACATAGAGATTGGGAACGACTGTGTTTTAGAG
AGGACGTGGCTTGGGGTTGAGGATGGTTTATGGCTGGCCGAGTTTCATTT
ATATAAACAAACAAATATATAAAACAAGGGGTAAAATGGCCATCTTATAT
GTATTTAACCGTCCTTTTTTATTTTTTTTTTTTTTTTTTAAATTTAAGAAGG
15 GGTATACCAGTGTGAGCCTCTTATTCCCAACCAGGCAACCAGTCAAATAG
GGACTTAGGTTGTTTGGAAACAGTTCCGTGAGACCGTGACTTGGATGGTA
GATAAATTTAGTAACTTAACCCTTCAATTAACCTACCTTTTTCTTATTA
ACTCAATTTCAACCTAAATTCTGATTCTTGTTGAAAATAAGTTGCATCT
TTATGTTTGTATTATCCTGTTGCATAGGATCCTTAGCATCTTTAATAAT
20 TTATTTGAAGGTGAAAGATCCAACCTATTTTTTAGCTGTTGGCATTITCCA
TCATTTGCAACTGTTTCTTGAAAAAAAATACCTAAAATCAAATAACCA
TTTTCAAATCCAAAATTATAAGAGAGAATTGTTAATGGACGTGGAATCGT
AAATCATTAAACACAGTTCAGTACACAAGTTGCTAATTACATTTCTTGCTG
TGCAGATTGAAATTCTATCAGAGAAAGAGACATTACAAGAAGTCACTGAT
25 ACTAATATTTCTAATGATGTTGTATTATTCCCATCCTGTCTCATGCACTC
TTTTCATAACCTCCATAAACTTAAATTGGAGAGAGTTAAAGGAGTGGAGG
TGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGTAGAGAATTGGTAACA
ACTCACCATAACCAACAACATCCTATTATACTTCCCAACCTCCAGGAATT
GGATCTAAGTTTTATGGACAACATGAGTCATGTGTGGAAGTGCAGCAACT
30 GGAATAAATTCTTCACTCTTCCAAAACAACAATCAGAATCCCCATCCAC
AACCTCACAACCATAACACATGTTTCACTGTCAGAAGCATTAAAGTACTTGT
TTCGCCTCTCATGGCAGAACTTCTTTCCAACCTAAAGGATATCTGGATAA
GTGGGTGTAATGGTATTAAGAAGTTGTTTCAAAGAGAGATGATGAGGAT
GAAGAAATGACTACATTTACATCTACCCACACAACCACCTCTTGTTCCT
35 TCATCTTGATTCTCTCACTCTAAGACTACTGGAGAATCTGAAGTGTATTG
GTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATATCTTTCAATAAT
ACCCTGCAACTACTGCTGTTCTTGATCAATTTGAGGTATGCTTTGTACA
TATTCAATTAATTTAATTTTCTTTTTTCTTTGCAATATTCTATAAAT
AATACATTTTATACCCACTATACTAAGATAATAATTACCTAGAGGGATGG
40 ATGCTATGACACAGCTGCTACACTTCAGAACTCTAGTAAGGGCAGTTAT
GGAAGTTCAATAAAAATGATAATGGCATCTTTTGATGGGTAATATAGGCAA
TTAAGTTTTATTCTGTAAAGCAGTATTAGCAAGTACTGGCCAGTAG
GAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATTGTACCCAAGAAT

TTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAGGTGACAGATAT
TGTAGAATAGAACAATATATAATATTACCCAAAACATTTTTTCTAAGGT
TATTCTGTAAATATGTGCTTTCTTGATTTTCATTGAATTTGCATTCCTAT
ATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCCGAAATTAATTA
5 AAAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGAGCACTGGTATCA
TTTAGTATATAAAAAACTAGATTTTGAATTAAGTTTCTTATATAAAAGC
TGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCATGTGGTGTGCA
GTTGTCTGAAGCAGGTGGTGTCTTGGAGTTTATGCCAATACGCTAGAG
AGATAGAGATATCTAAGTGTAATGTATTGTCAAGTGTGATTCCATGTTAT
10 GCAGCAGGACAAATGCAAAGCTTCAAGTGCTGAGAGTAACGGGTTGTGA
TGGCATGAAGGAGGTATTTGAACTCAATTAGGGACGAGCAGCAACAAAA
ACAGAAAGGGTGGTGGTGAAGGAAATGGTGGAAATCCAAGAGTAAAT
AAC.AATGTTATTATGCTTCCCAATCTAAAGACATTGAAAATCTACATGTG
CGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAGCCTGACAC
15 AGCTCCAAGAGTTAAAGATAGTGGGTTGCTACGGAATGAAAGTGATTGTG
AAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACAACAAC
AACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTTCTAAGAAGGTTG
TGGTCTTTCCCGTCTAAAGTCCATTGAACTATTCAATCTACCAGAGCTG
GTAGGATTCTTCTTGGGGATGAATGAGTTCGGTTGCCTTCATTGGAAGA
20 AGTTACCATCAAGTATTGCTCAAAAATGATGGTGTGTTGCAGCTGGTGGGT
CCACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACT
CTTGATCAAGAATCTGGCCTTAACTTTCATCAGGTATATATATATTCCTT
TAA TTGGCATGATCTAATTAAGAAAGATATCATTCCCTGCCAAGTAAATTT
ACTTCAAACACATTCACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGG
25 AAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTCAGTGGA
AAGGGTATTTTAGGTATTTCTGTCAAAAGTTGTTATTGCAGGCTTTTTA
GTACCTGGAATCGTGTGTGGGAGGAGCGTTATTATTCTGATTTGCTTGT
TCTTTATCATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATC
TTTTGATTTTAAATGACAAAATTTTTCCCTGTTACTCTATTGATTGTTG
30 TTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGAT
TGTTATTTTCATATCATGTTGTCCTTTGAATCAAGCTTTTCCATTTTCAA
CCAGGGCAAAGGTCAAAGTAACCTACTTTATGAGATCAAAAACAGCAA
CCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGA
TTAATAATTATAATATCTTGTATTAATTCATTAATAATTGGTACAGCACAT
35 ATATGACATTTTAAAGGTTTGTGTTTGTGTTWGACATATATATGCCTCTGGC
GTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTGACA
CCTCGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAACTTG
ATCGAATTAGATATGGAATTAATTATGATGTTAAAAAGATTATCCATC
CAGTGAGTTGCTGCAACTGCAAAGCTGGAAAAGATTTCATGTGAGTAGTT
40 GTTATTGGGTAGAGGAGGTATTTGAACTGCATTGGAAGCAGCAGGGAGA
AATGGAAATAGTGGAAATTGGTTTTGATGAATCGTCACAACTACTACTAC
TACTACTCTTTTCAATCTTCGAAACCTCAGAGAAATGAAGTTGCATTTTC
TACGTGGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG

TTTCCAAACCTAACAAGAGTTCATATAAGTAGGTGTAGAAGGTTAGAACA
 TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG
 ATATTAGTTGGTGCAACCATATGGAGGAGGTGATTGTTAAGGATGCAGAT
 GTTCTGTTGAAGAAGACAAAGAGAGAGAATCTGATGGCAAGACGAATAA
 5 GGAGATACTTGTGTTACCTCGTCTAAAATCCTTGAAATTA AAAATGCCTTC
 CATGTCCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTTCATCCCATTA
 TTGGATACTTTAGAAATCTACAAATGCCAGCAATAACGACCTTCACCAA
 GGGAAATTCTGCTACTCCACAGCTAAAAGAAATAGAAACAAGATTTGGCT
 CGTTTTATGCAGGGGAAGACATCAACTCCTCTATTATAAAAAGATCAAAC
 10 AACAGGTAAATCAGATCTTTGTTGCTTTAATAATTCTTAAACTACATTTG
 AAAAGCTTCATGCAAGTTTTTTTTGTTATATTGTCAAAAACCGCAACCTA
 CATTTTCAGCTTTATATTTATGACTTTATGCAGGAGTTCAAACAAAAC
 CTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGTTCTT
 AGTTGCCTATTAATTAATGGCCTTTTAGTTCRTGATTTTTGGATGTAGTY
 15 WTCATGATGATGTGAATCTTCTAATACCCCATTCATTGTTTGGTTGAATG
 TTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCATATG
 AAGGACATTAAGAACATGGATGCTATGAAGATGTTGGAARAC

RG2S deduced polypeptide sequence (SEQ ID NO:125)

20 MSDPTGIAGAIINPIAQRALVPVTDHVGVMISCRKYVRVMQTKMTELNTSRISVEEH
 ISRNTRNHLQIPSQIKDWLDQVEGIRANVENFPIDVITCCSLRIRHKLGGQKAFKITEQI
 ESLTRQLSLISWTDDPVPLGRVGS MNASTSASSSDDFPSREKTFTQALKALEPNQQF
 HMAALCGMGGVVGKTRMMQRLKKA AEEKLKFNYIVRAVIGEKTDPF AIQEALADYL
 GIQLNEKTKPARADKLREWFKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQG
 25 VDFKVLLTSRDSQVCTMMGVEANSIINVGLL TEAEAQSLFQQFVETSEPELQKIGED
 IVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETS YHNLQE
 EETKSTFLMCGLFPEDFDIPTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQT
 NLLIESDDVGCVKMHDLVRAFVLGMFSEVEHASIVNHGNMPEWTENDITDSCKRIS
 LTCKSMSKFPDGFKFPNLMILKLMHGDKSLRFPQDFYEGMEKLVHVISYDKMKYPLL
 30 PLAPRCSTNIRVLHLTKCSLKMFD CSCIGNLSNLEVLSFANSRIEWLPSTVRNLKCLR
 LLDLRFCDGLRIEQGV LKSLVKLEEFYIGNASGFIDDNCNEMAERSDNL SALEFAFF
 NNKAEVKNMSFENLERFKISVGRSFDGNINMSSH SYENMLQLVTNKG DVLDSKLN
 GLFLKTKVLFVSVHGMNDLEDVEVKSTHPTQSSSFCNLKVL IISKCVELRYL FKLNL
 ANTLRLEHLEVCECENMEELIHTGICGEETITFPKLFLSLSQLPKLSSLCHNVNIIG
 35 LPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDDMENLEEIWPCELS
 GGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELKVKNCGSIESL FNIDLDCVGA
 IGEEDNKSLLRSINMENLGKLR EVWRKIGADNSHLINGFQAVESIKIECKRFSNIFT
 PITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEVTD TNISNDV VLFPSCLMH
 SFHNLHKLKLERVKGVEVVFEIESESPTSRELVTTHHNQQHPHILPNLQELDLSFMD
 40 NMSHVWKCSNWNKFFTLPKQQSESPFHNL TIHMFSCRSIKYLF SPLMAELLSNLK
 DIWISGCNGIKEVVSKRDEDEEMTFTSTHTTTILFPHLDSLTLR LLENLKCIGGGG
 AKDEGSNEISFNNTTATTA VLDQFELSEAGGVSWSLCQYAREIEISKCNV LSSVIPCY

AAGQMQLQVLRVTGCDGMKEVFETQLGTSSNKNRKGGGDEGNGGIPRVNNNVI
 MLPNLKTLKIYMCGGLEHIFTFSALESLTQLQELKIVGICYGMKVIVKKEEYGEQ
 QTTTTTTTKGASSSSSSSSKVVVFPRLKSIELFNLPELVGFFLGMNEFRLPSLEEV
 IKYCSKMMVFAAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTS
 5 TSEGTTWSFHNLIELDMELNYDVKKIIPSELLQLQKLEKIHVSSCYWVEEVFETAL
 EAAGRNGNSGIGFDESSQTTTTTFLNLRNLREMKLHFLRGLRYWKSQWTA
 FEF PNLTRVHISRCRRLEHVFTSSMVGSLQLQELDISWCNHMEEVIVK
 DADVSVEEDK ERES DGKT NKEILVLPRLKSLKLCPLCKGFS
 LKEDFSFPLD TLEIYKCPAITFT KGN SATPQLKEIETRF
 GSFYAGEDINSSIIKRSNNRSSNKTLINVK.ILK

10

RG2T polynucleotide sequence (SEQ ID NO:126)

GGAAGACGACAATGGTGCAACGGTTGAAGAAGGTTGTGAAAGATAAGAAG
 ATGTTCCATTATATTGTCGAGGTGGTTGTAGGGGCAAACACTGACCCAT
 TGCTATCCAGGATACTGTTGCAGATTACCTCAGCATAGA
 ACTGAAAGGAA ATACGAGAGATGCAAGGGCTTATAAGCTTCGTGAATGCTTTAAGGCCCTC
 15 TCTGGTGGAGGTAAGATGAAGTTCCTAGTAATTCTTGACGATGTATGGAG
 CCCTGTTGATCTGGATGATATCGGTTTAAGTTCCTTGCCAAATCAAGGTG
 TTGACTTCAAGGTCTTGCTGACATCACGCAACAGTGATATCTGCATGATG
 ATGGGAGCTAGTTAATTTTCAACCTCAATATGTTAACAGACGAGGAAGC
 20 ACATAATTTTTTCCGTCGATACGCAGAAATTTCTTATGATGCTGATCCCG
 AGCTTATTAAGATAGGAGAAGCTATTGTAGAGAAATGTGGTGGTTTACCC
 ATTGCCATCAAACTATGGCCGTTACTCTTAGAAATAAACGCAAAGATGC
 ATGGAAAGATGCACTTTCTCGTTT
 TAGAGCACCGTGACACTCATAATGTTG
 TGGCTGATGTTCTTAAATTGAGCTACAGCAATATCCAAGACGAGGAGACT
 25 CGGTCGATTTTTTTGCTATGTGGTTTGTTCCTGAAGACTTTGATATCC
 TACCGAAGACTTAGTGAGGTATGGATGGGGATTGAAAATATTTACCAGAG
 TGTATACTATGAGACATGCAAGAAAAAGGTTGGACACGTGCATTGAGCGG
 CTTATGCATGCCAACATGTTGATAAAAAGTGATAATGTTGGATTTGTCAA
 GATGCATGATCTGGTTCGTGCTTTTGT
 TTTGGGCATGTTATCTGAAGTCG
 30 AGCATGCATCAATTGTCAACCATGGGGATATGCCAGGGTGGTTTGAAACT
 GCAAATGATAAGAACAGCTTGTGCAAAAAGAAATTCATTAACATGCAAAGG
 TATGTCTGCGATTCTGAAGACCTCACGTTTCCAAACCTCTCGATCCTGA
 AATTAATGGATGGAGACGAGTCACTGAGGTTTCTGAAGGCTTTTATGGA
 GAAATGGAAAACCTT
 CAGGTTATATCATATGATAACATGAAGCAGCCATT
 35 TCTTCCACAATCACTTCAATGCTCCAATGTTTCGAGTGCTTCATCTCCATC
 ACTGCTCATTAAATGTTTGATTGCTCTTCTATTGGAAATCTTTTGAATCTC
 GAGGTGCTCAGCATTGCTAATTCTGCCATTAAATTGTTACCCTCCACTAT
 TGGAGATCTGAAGAAGCTAAGGCTCCTGGATTTGACAAATTGTGTTGGTC
 TCTGTATAGCTAATGGCGTCTTAGAAATTTGGTCAAACCTGAAGAGCTT
 40 TATATGAGAGTTGATGATCGAGATTCGTTTTTTGTGAAAGCTGATGACAG
 CAAGACCATTACCT

RG2T deduced polypeptide sequence (SEQ ID NO:127)

KTTMVQRLKKVVKDKKMFHYIVEVVVGANTDPIAIQDTVADYLSIELKGNTRDAR
 AYKLRECFKALSGGGKMKFLVILDDVWSPVDLDDIGLSSLPNQGVDFKVLLTSRNS
 DICMMM GASLIFNLNMLTDEEAHNFFRRYAEISYDADPELIKIGEAIVEKCGGLPIAI
 5 KTMAVTLRNKRKDAWKDALSRLEHRDTHNVVADVLKLSYSNIQDEETRSIFLLCG
 LFPEDFDIPTEDLVRYGWGLKIFTRVYTMRHARKRLDTCIERLMHANMLIKSDNVG
 FVKMHDLVRAFLGMLSEVEHASIVNHGDMPGWFETANDKNSLCKRISLTCKGMS
 AIPEDLTFPNLSILKLMDGDESLRFPFGFYGEMENLQVISYDNMKQPFLPQSLQCSN
 VRVLHLHHCSLMFDCSSIGNLLNLEVLSIANSIAIKLLPSTIGDLKKLRLDLLTNCVGL
 10 CIANGVFRNLVKLEEL YMRVDDRDSFFVKADDSKTTT

RG2U polynucleotide sequence (SEQ ID NO:128)

GCCTTGTGTGGGATGGGTGGAGTGGGAAAGACCACTGTGATGAAGAAGCT
 GAAGGAGGTTGTGGTAGGAAAGAACTGTTTAATCATTATGTTGAGGCGG
 15 TTATAGGGGAAAAGACAGACCCCATGCTATTCAACAAGCTGTTGCCGAG
 TACCTTGGTATAAGTCTAACCGAAACCACTAAACCAGCAAGAAGCTGATAA
 GCTCCGTACATGGTTTGCAAACAACCTCAAATGGAGGAAAGAAGAAGTTCC
 TGGTAATACTAGACGATGTATGGCAACCAGTTGATTTGGAAGATATTGGT
 TTAAGTCGTTTTCCAATCAAGATGTTGACTTCAAGGTCTTGATTACATC
 20 ACGGGACCAATCAGTTTGCCTGAGATGGGAGTTAAAGCTGATTTAGTTC
 TCAAGGTGAGTGTCTGGAGGAAGCGGAAGCACACAGTTTGTTCCTCCAA
 TTTTATAGAACCTTCTGATGATGTCGATCCTGAGCTCAATAAAATCGGAGA
 AGAAATTGTAAAGAAGTGTTCGAGACTACCCATTGCTATCAAAACCATGG
 CCTGAACTCTTAGAAGTAAAAGTAAGGATACATGGAAGAATGCCCTTCT
 25 CGTTTACAACACCATGACATTAACACAATTGCGTCTACTGTTTTCCAAC
 TAGCTATGACAATCTCGAAGACGAGGTGACTAAAGCTACTTTTTGCTTT
 GTGGTTTATTTCCGGAGGACTTCAATATTCCTACCGAGGACCTATTGAGG
 TATGGATGGGGATTGAAGTTATTCAAGGAAGTAGATACTATACGAGAAGC
 AAGATCCAAGTTGAAAGCCTGCATTGAGCGGCTCATGCATACCAATTTGT
 30 TGATCGAAGGTGATGATGTTAGGTACGTAAAGATGCATGATCTGGTGCGT
 GCTTTTGTTTGGATATGTTTTCTAAAGCCGAGCATGCATCTATTGTCAA
 CCATGGTAGTAGTAAGCCAAGGTGGCCTGAAACTGAAAGTGATGTGAGCT
 CCTCTTGCAAAGAATTCATTAACATGCAAGGGTNTG

35 RG2U deduced polypeptide sequence (SEQ ID NO:129)

ALCGMGGV GKTTVMKKLKEVVVGKLFNHYVEAVIGEKTDPPIAIQQAVA EYLGIS
 LTETTKPARTDKLRTW FANNSNGGKKKFLVILDDVWQPVDLEDIGLSRFPNQDVD
 FKVLITSRDQSVCTEMGVKADLV LKVSVLEEAEAHSLFLQFLEPSDDVDPELNKIGE
 EIVK KCCRLPIAIKTMA. TLRSKSKDTWKNALSRLQHHDINTIASTVFQTSYDNLEDE
 40 VTKATFLLCGLFPEDFNIPTEDLLRYGWGLKLFKEVDTIREARSKLKACIERLMHTN

LLIEGDDVRYVKMHDLVRAFVLDMFSKAEHASIVNHGSSKPRWPETESDVSSCKR
ISLTCKG?

RG2V polynucleotide sequence (SEQ ID NO:130)

5 CTGTGGAAGACACGAATGATSAAGAAGCTGAAGGAGGTCGTGGAACAAAA
GAAAATGTTCAATATTATTGTTCAAGTGGTCATAGGAGAGAAGACAAACC
CTATTGCTATTCAGCAAGCTGTAGCAGATTACCTCTCTATTGAGCTGAAA
GAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTNAATGGTTCGAGGA
CGATGGAGGAAAGAATAAGTTCCTTGTAATACTTGATGATGTATGGCAGT
10 TTGTCGATCTTGAAGATATTGGTTTAAAGTCCTCTGCCAAATAAAGGTGTC
AACTTCAAGGTCTTGTGACGTTAAGAGATTCACATGTTTGCACCTCTGAT
GGGAGCTGAAGCCAATTC AATTCTCAATATAAAAAGTTTTAAAAGATGTTN
AAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGCAGGTGATGATGAC
CTGGATCCTGCTTTCAATGGGATAGCAGATAGTATTGCAAGTAGATGTCA
15 AGGTTTGCCCATTTGCCATCAAACCATTGCCTTAAAGTCTTAAAGGTAGAA
GCAAGCCTGCGTGGGACCATGCGCTTTCGTTTTGGAGAACCATAAGATT
GGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTATGACAATCT
CCAAGATGAGGTTACTAAATCTATTTTTWTACTTTGTGCTTTATTTCTG
AAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGTGGGGCTTG
20 AAATTATTTATAGAAGCAAAAAC TATAAGAGAAGCAAGAAACAGGCTCAA
CACCTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGGAAGTGATG
ACATTGGATGCGTCAAGATGCACGATGTGGTGCGTGATTTTGTGTTGGTAT
ATATTCTCAGAAGTCCAGCACGCTTCAATTGTCAACCATGGTAATGTGTC
AGAGTGGCTAGAGGAAAATCATAGCATCTACTCTTGTAAGAATTTTCAT
25 TAACATGCAAGGGTATGTCTGAGTTTCCCAAAGACCTCAAATTTCCAAAC
CTTTCAATTTTGAAACTTATGCATGGAGATAAGTCGNTGAGCTTTCCTGA
AGACTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATATGATAAAT
TGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTAACGTTCTGA
GTGCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGCTCTTCAAT
30 TGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTG
AATGGTTACCATCTACAATTGGAATTTGAAGAAGCTAAGGCTACTAGAT
TTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTT
GGTCAAACCTGAAGAGCTTTATATGGGTGTTAATGTCCGTATGGACCAGG
CCGT

35

RG2V deduced polypeptide sequence (SEQ ID NO:131)

LWKTRM?KKLKEVVEQKKMFNIIQVQVIGEKTNPIAIQAVADYLSIELKENTKEAR
ADKLR?WFEDDGGKKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTLRDSH
VCTLMGAEANSILNIKVLKDV?GQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGL
40 PLIAIKTIALSLKGRSKPAWDHALSRLNHNKIGSEEVVREVKISYDNLQDEVTKSIF?L
CALFPEDFDIPIEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIG

CVKMHVVRDFVWYIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEF
PKDLKFPNLSILKLMHGDKS?SFPEDFYGKMEKVQVISYDKLMYPLLPSSLECSTNV
RVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLDLLTNCCKG
LRIDNGVLKNLVKLEELYMGVNVVRMDQAV

5

RG2W polynucleotide sequence (SEQ ID NO:132)

TTGGGAAAGAGACAATGATGAAGAATTGAAAGAGGTTGTGGTTGAAAAGA
AAATGTTTAATCATTATGTGGAGGCGTTATAGGGGAGAAGACGGACCCC
ATTGCTATTCAGCAAGCCGTTGCAGAGTACCTTGGTATAATTCTAACAGA
10 AACCCTAAGGCAGCAAGAACCGATAAGCTACGTGCATGGCTTTCTGACA
ATTCAGATGGAGGAAGAAAGAAGTTCCTAGTAATACTAGACGATGTATGG
CATCCGTTGATATGGAAGATATTGGTTAAGTCGTTTCCCAAATCAAGG
TGTCGACTTCAAGGTCTTGATTACATCACGGGACCAAGCTGTTTGCCTG
AGATGGGAGTTAAAGCTGATTCAAGTTATCAAGGTGAGTGTCTAGAGGAA
15 GCTGAAGCACAAAGCTTATTCTGCCAACTTTGGGAACCTTCTGATGATGT
CGATCCTGAGCTCCATCAGATTGGAGAAGAAATTGTAAGGAAGTGTGTG
GTTTACCCATTGCAATAAAAACCATGGCCTGCACTCTTAGAAGTAAAAGC
AAGGATACATGGAAGAATGCACTTTCTCGTTTACAACACCATGACATTAA
CACAGTCGCGCCTACTGTTTTTCAAACCAGCTATGACAATCTCCAAGATG
20 AGGTGACTGGAGATACTTTTTTCTGATGTGGTTTGTTCGGGAGGACTTC
GATATTCCTACTGAAGACTTATTGAAGTATGGATGGGGCTTAAAATTATT
CAAGGGAGTGGATTCTGTAAGAGAAGCAAGATACCAGTTGAACGCCTGCA
TTGAGCGGCTCGTGCATACCAATTTGTTGATTGAAAGTATGTTGTTGGG
TGCGTCAAGTTGCACGATCTGGTGCCTGCTTTTATTTTGGATATGTTTTG
25 TAAAGCGGAGCATGCTTCGATTGTCAACCATGGTAGTAGTAAGCCTGGGT
GGCCTGAAACTGAAAATGATGTGATCAGGACCTCCTGCAAAGAATCTCA
TTAACATGCAAGGGTATGATTGAGTTTTCTAGTGACCTCAAGTTTCCAAA
TGTCTTGATTTTAAACTTATGCATGGAGATAAGTCGCTAAGGTTT

30 RG2W deduced polypeptide sequence (SEQ ID NO:133)

WERDNDEELKEVVVEKMFNHYVEAVIGEKTDPQAIQQA VAEYLGILTETTKAAR
TDKLRWLSDNSDGGRRKFLVILDDVWHPVDMEDIGLSRFPNQGVDFKVLITSRD
QAVCTEMGVKADSVIKVSVLEEAQAQLFCQLWEPSSDDVDPELHQIGEEIVRCCG
LPIAKTMACTLRKSKDTWKNALSRLQHHINTVAPTQTSYDNLQDEVTGDTF
35 LLCGLFPEDFDIPTEDLLKYGWGLKLFKGVDSVREARYQLNACIERLVHTNLLIESD
VVGCVKLHDLVRAFILDMFCKAEHASIVNHGSSKPGWPETENDVIRTSCKRISLTCK
GMIEFSSDLKFPNVLILKLMHGDKSLRF

RG5 polynucleotide sequence (SEQ ID NO:134)

40 GGGGGGGTGGGGAAGNCGACTCTAGCCCAGAAGNTCTATAATGACCATAA
AATAAAAGGAAGCTTTAGTAAACAAGCATGGATCTGTGTTTCTCAACAAT

ATTCTGATATTTCAAGTTTTGAAAGAAGTCCTTCGGAACATCGGTGTTGAT
TATAAGCATGATGAAACTGTTGGAGAACTTAGCAGAAGGCTTGCAATAGC
TGTCGAAAATGCAAGTTTCTTTCTTGTGTTGGATGATATTTGGCAACATG
AGGTGTGGACTAATTTACTCAGAGCCCCATTAAACACTGCAGCTACAGGA
5 ATAATTCTAGTAACAACCTCGTAATGATACAGTTGCACGAGCAATTGGGGT
GGAAGATATTCATCGAGTAGAATTGATGTCAGATGAAGTAGGATGAAAT
TGCTTTTGAAGAGTATGAACATTAGCAAAGAAAGTGAAGTAGAAAACCTA
CGAGTTTTAGGGGTTGACATTGTTTCGTTTGTGTGGTGGCCTCCCCCTAGC
CTT

10

RG5 deduced polypeptide sequence (SEQ ID NO:135)

GGV GK T T L A Q K ? Y N D H K I K G S F S K Q A W I C V S Q Q Y S D I S V L K E V L R N I G V D Y K H D E T
V G E L S R R L A I A V E N A S F F L V L D D I W Q H E V W T N L L R A P L N T A A T G I I L V T T R N D T V A
R A I G V E D I H R V E L M S D E V G W K L L K S M N I S K E S E V E N L R V L G V D I V R L C G G L P L A L

15

RG7 polynucleotide sequence (SEQ ID NO:136)

GGTGGGGTTGGGAAGACAACGGGCACAAGGAGGCGACTGCCAATACTTCC
GACTTTTATTCATAGAGATGACGAGTCTTATTTTCTACTACTATAGGGA
GGATATTTGGTTGCGCGAGACGATTCATTGCGCGAAGGGATTCTATCCTT
20 CTTTTTTTCCGCGAAGACTTCGTTCCGGAGGACGGGCTATATTCCCTTA
ATATTAGTCTAGCCCAGTCTAGGCCAACCATATGGCGATGCGGTAGACCT
CCCAGAGATAGATACTTGATCTTAGAGGATTCACACGTTCAATGGTGGAA
ACTTAAGGAACCGGCTAAGAGTGACTAAACGGAAAAACCCTATTCATTCC
ATAGCCTCATCCGGTCGAGGCATTAACAATCCATCCAATCCTCTTTCC
25 TTTGGTCTACTCTAATGATGTGCCCGTTCGTTGGTGGGAATATCTCTTTAT
ACCGACGATTTATATGGGGATTGCCACTAGCGTTG

30

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2
5 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.
2. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising an leucine rich region (LRR).
10
3. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising a nucleotide binding site (NBS).
4. The nucleic acid construct of claim 1, wherein the polynucleotide is a full length
15 gene.
5. The nucleic acid construct of claim 1, wherein the further encodes a fusion protein.
6. The nucleic acid construct of claim 1, wherein the RG1 polypeptide is encoded by
20 an RG1 polynucleotide sequence.
7. The nucleic acid construct of claim 6, wherein the RG1 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5
25 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
8. The nucleic acid construct of claim 1, wherein the RG2 polypeptide is encoded by an RG2 polynucleotide sequence.
30
9. The nucleic acid construct of claim 8, wherein the RG2 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 (RG2A);

SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

10. The nucleic acid construct of claim 1, wherein the RG3 polypeptide is encoded by an RG3 polynucleotide sequence.

11. The nucleic acid construct of claim 10, wherein the RG3 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:68.

12. The nucleic acid construct of claim 1, wherein the RG4 polypeptide is encoded by an RG4 polynucleotide sequence.

13. The nucleic acid construct of claim 12, wherein the RG4 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:69.

14. The nucleic acid construct of claim 1, wherein the RG5 polypeptide is encoded by an RG5 polynucleotide sequence.

15. The nucleic acid construct of claim 14, wherein the RG5 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

16. The nucleic acid construct of claim 1, wherein the RG7 polypeptide is encoded by an RG7 polynucleotide sequence.
17. The nucleic acid construct of claim 16, wherein the RG7 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.
18. The nucleic acid construct of claim 1, further comprising a promoter operably linked to the RG polynucleotide.
19. The nucleic acid construct of claim 18, wherein the promoter is a plant promoter.
20. The nucleic acid construct of of claim 19, wherein the plant promoter is a disease resistance promoter.
21. The nucleic acid construct of claim 19, wherein the plant promoter is a lettuce promoter.
22. The nucleic acid construct of claim 18, wherein the promoter is a constitutive promoter.
23. The nucleic acid construct of claim 18, wherein the promoter is an inducible promoter.
24. The nucleic acid construct of claim 18, wherein the promoter is a tissue-specific promoter.
25. A nucleic acid construct comprising a promoter sequence from an RG gene linked to a heterologous polynucleotide.
26. A transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide.

27. The transgenic plant of claim 26, wherein the plant promoter is a plant promoter.
28. The transgenic plant of claim 26, wherein the plant promoter is a viral promoter.
- 5 29. The transgenic plant of claim 26, wherein the plant promoter is a heterologous promoter.
30. The transgenic plant of claim 26, wherein the plant is lettuce.
- 10 31. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
- 15 32. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:21 (RG2A); SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).
- 20 33. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:68 (RG3) and SEQ ID NO:69 (RG4).
- 25 30

34. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:134 (RG5).
35. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a
5 sequence as set forth in SEQ ID NO:136 (RG7).
36. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO: 13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ
10 ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), and SEQ ID NO:20 (RG1J).
37. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41
15 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ
20 ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID
25 NO:133 (RG2W).
38. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG3 polypeptide with a sequence as set forth by SEQ ID NO:138.
- 30 39. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG4 polypeptide with a sequence as set forth by SEQ ID NO:139.

40. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135.
41. A method of enhancing disease resistance in a plant, the method comprising
5 introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence.
42. The method of claim 41, wherein the plant is a lettuce plant.
- 10 43. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51
15 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O);
20 SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).
44. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide
25 selected from the group consisting of SEQ ID NO:138 (RG3); SEQ ID NO:139 (RG4); and SEQ ID NO:135 (RG5).
45. The method of claim 41, wherein the promoter is a tissue-specific promoter or a plant disease resistance promoter.

46. The method of claim 41, wherein the promoter is a constitutive promoter or an inducible promoter.
47. A method of detecting RG resistance genes in a nucleic acid sample, the method comprising:
- 5 contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and,
- wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample.
- 10
48. The method of claim 47, wherein the RG polynucleotide is an RG1 polynucleotide.
49. The method of claim 47, wherein the RG polynucleotide is an RG2 polynucleotide.
- 15
50. The method of claim 47, wherein the RG polynucleotide is an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide.
51. The method of claim 47, wherein the RG resistance gene is amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.
- 20
52. The method of claim 51, where the RG resistance gene is amplified by the polymerase chain reaction.
53. The method of claim 47, wherein the RG polynucleotide is labeled.
- 25
54. An RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER																				
IPC(6) : Please See Extra Sheet.																				
US CL : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205																				
According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols)																				
U.S. : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																				
APS, DIALOG																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
Y	PARAN et al. Development of Reliable PCR-Based Markers Linked to Downy Mildew Resistance Genes in Lettuce. Theor. Appl. Genet. 1993. Vol. 85, No. 8, pages 985-993, see entire article.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54																		
Y	KESSELI et al. Analysis of a Detailed Genetic Linkage Map of Lactuca sativa (Lettuce) Constructed From RFLP and RAPD Markers. Genetics. April 1994. Vol. 136, No. 4, pages 1435-1446, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54																		
Y	MICHELMORE, RW. Isolation of Disease Resistance Genes from Crop Plants. Current Opinion in Biotechnology. 1995. Vol. 6, No. 2, pages 145-152, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T*</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Δ*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Δ*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Δ*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search		Date of mailing of the international search report																		
14 MARCH 1998		13 APR 1998																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized/signed PHUONG BUI																		
Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PARAN et al. Recent Amplification of Triose Phosphate Isomerase Related Sequences in Lettuce. Genome. 1992. Vol. 35, No. 4, pages 627-635, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	PARAN et al. Identification of Restriction Fragment Length Polymorphism and Random Amplified Polymorphic DNA markers linked to Downy Mildew Resistance Genes in Lettuce, Using Near-Isogenic Lines. Genome. 1991. Vol. 34, No. 6, pages 1021-1027, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 7, 9, 11, 13, 15, 17, 31-40, 43-44
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

these claims are drawn to numerous sequences identified by SEQ ID NOs. However, since no computer readable form was submitted, no meaningful search could be carried out.

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

-
- The additional search fees were accompanied by the applicant's protest.
-
-
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A01H 1/00; C07H 21/04; C07K 14/00; C12N 5/04, 5/10; C12P 19/34; C12Q 1/68